C,CFLAG,ROWID,ID,ARMAN,TIME,NTIM,TAD,AMT,RATE,EVID,EXROUTN,TESTN,DV,BLQ,LLOQ,CMT,MDV,STUDYID,USUBJID,ARMA,VISIT,VISITNUM,TIMEPT,EXDUR,EXDOSE,EXDOSU,EXTDOSE,EXROUTE,EXSTDTC,EXENDTC,EXTRT,TEST,TESTCD,TESTLABL,TESTCAT,METHOD,DVOR,DVORU,SAMDTTM,AGE,AGEU,SEX,SEXN,RACE,RACEN,ETHNIC,ETHNICN,WGTBL,HGTBL,BMIBL,TARGETBL,BIOMARKERBL
C,PRE-DOSE,1,1,1,-42.77847222,0,.,.,.,0,0,1,80.7,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.7,mg/L,5/16/2017 15:29,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
C,PRE-DOSE,2,1,1,-42.77847222,0,.,.,.,0,0,4,116,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,116,u/ml,5/16/2017 15:29,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
C,PRE-DOSE,3,1,1,-42.77847222,0,.,.,.,0,0,5,187,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,187,u/ml,5/16/2017 15:29,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
C,PRE-DOSE,4,1,1,-42.77847222,0,.,.,.,0,0,6,94,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,94,u/ml,5/16/2017 15:29,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
C,PRE-DOSE,5,1,1,-0.845138889,-1,.,.,.,0,0,1,103,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,103,mg/L,6/27/2017 13:53,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
C,PRE-DOSE,6,1,1,-0.845138889,0,.,.,.,0,0,4,115,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,115,u/ml,6/27/2017 13:53,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
C,PRE-DOSE,7,1,1,-0.845138889,0,.,.,.,0,0,5,198,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,198,u/ml,6/27/2017 13:53,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
C,PRE-DOSE,8,1,1,-0.845138889,0,.,.,.,0,0,6,84,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,84,u/ml,6/27/2017 13:53,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
C,PRE-DOSE,9,1,1,-0.113888889,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,6/28/2017 7:26,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
C,PRE-DOSE,10,1,1,-0.113888889,0,.,.,.,0,0,1,94.6,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,94.6,mg/L,6/28/2017 7:26,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
C,PRE-DOSE,11,1,1,-0.113888889,0,.,.,.,0,0,4,122,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,122,u/ml,6/28/2017 7:26,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
C,PRE-DOSE,12,1,1,-0.113888889,0,.,.,.,0,0,5,214,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,214,u/ml,6/28/2017 7:26,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
C,PRE-DOSE,13,1,1,-0.113888889,0,.,.,.,0,0,6,81,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,81,u/ml,6/28/2017 7:26,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,14,1,1,0,.,.,70,1482.352941,1,2,0,.,.,.,2,1,StudyID,001-007,1 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.047222222,70,mg,70,INTRAVENOUS,1498644600,1498648680,Dupilumab,.,.,.,.,,.,.,.,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,15,1,1,0.047222222,0,.,.,.,0,0,2,3.540959324,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,34.5,mg/L,6/28/2017 11:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,16,1,1,0.047222222,0,.,.,.,0,0,1,87.5,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.5,mg/L,6/28/2017 11:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,17,1,1,0.047222222,0,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,6/28/2017 11:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,18,1,1,0.047222222,0,.,.,.,0,0,5,20,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,20,u/ml,6/28/2017 11:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,19,1,1,0.047222222,0,.,.,.,0,0,6,41,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,41,u/ml,6/28/2017 11:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,20,1,1,0.057638889,0.010416667,.,.,.,0,0,2,3.583518938,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,36,mg/L,6/28/2017 11:33,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,21,1,1,0.057638889,0.010416667,.,.,.,0,0,1,80.4,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.4,mg/L,6/28/2017 11:33,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,22,1,1,0.057638889,0.010416667,.,.,.,0,0,4,91,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,91,u/ml,6/28/2017 11:33,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,23,1,1,0.057638889,0.010416667,.,.,.,0,0,5,3,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,3,u/ml,6/28/2017 11:33,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,24,1,1,0.057638889,0.010416667,.,.,.,0,0,6,41,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,41,u/ml,6/28/2017 11:33,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,25,1,1,0.068055556,0.020833333,.,.,.,0,0,2,3.583518938,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,36,mg/L,6/28/2017 11:48,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,26,1,1,0.068055556,0.020833333,.,.,.,0,0,1,80.5,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.5,mg/L,6/28/2017 11:48,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,27,1,1,0.068055556,0.020833333,.,.,.,0,0,4,93,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,93,u/ml,6/28/2017 11:48,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,28,1,1,0.068055556,0.020833333,.,.,.,0,0,5,12,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,12,u/ml,6/28/2017 11:48,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,29,1,1,0.068055556,0.020833333,.,.,.,0,0,6,40,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,40,u/ml,6/28/2017 11:48,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,30,1,1,0.088888889,0.041666667,.,.,.,0,0,2,3.563882964,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,35.3,mg/L,6/28/2017 12:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,31,1,1,0.088888889,0.041666667,.,.,.,0,0,1,81.5,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.5,mg/L,6/28/2017 12:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,32,1,1,0.088888889,0.041666667,.,.,.,0,0,4,93,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,93,u/ml,6/28/2017 12:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,33,1,1,0.088888889,0.041666667,.,.,.,0,0,5,24,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,24,u/ml,6/28/2017 12:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,34,1,1,0.088888889,0.041666667,.,.,.,0,0,6,41,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,41,u/ml,6/28/2017 12:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,35,1,1,0.130555556,0.083333333,.,.,.,0,0,2,3.5085559,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,33.4,mg/L,6/28/2017 13:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,36,1,1,0.130555556,0.083333333,.,.,.,0,0,1,79.3,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.3,mg/L,6/28/2017 13:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,37,1,1,0.130555556,0.083333333,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,6/28/2017 13:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,38,1,1,0.130555556,0.083333333,.,.,.,0,0,5,11,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,11,u/ml,6/28/2017 13:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,39,1,1,0.130555556,0.083333333,.,.,.,0,0,6,39,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,39,u/ml,6/28/2017 13:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,40,1,1,0.213888889,0.166666667,.,.,.,0,0,2,3.5085559,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,33.4,mg/L,6/28/2017 15:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,41,1,1,0.213888889,0.166666667,.,.,.,0,0,1,92.1,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,92.1,mg/L,6/28/2017 15:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,42,1,1,0.213888889,0.166666667,.,.,.,0,0,4,90,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,90,u/ml,6/28/2017 15:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,43,1,1,0.213888889,0.166666667,.,.,.,0,0,5,40,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,40,u/ml,6/28/2017 15:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,44,1,1,0.213888889,0.166666667,.,.,.,0,0,6,42,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,42,u/ml,6/28/2017 15:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,45,1,1,0.380555556,0.333333333,.,.,.,0,0,2,3.449987546,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,31.5,mg/L,6/28/2017 19:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,46,1,1,0.380555556,0.333333333,.,.,.,0,0,1,90.1,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.1,mg/L,6/28/2017 19:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,47,1,1,0.380555556,0.333333333,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,6/28/2017 19:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,48,1,1,0.380555556,0.333333333,.,.,.,0,0,5,52,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,52,u/ml,6/28/2017 19:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,49,1,1,0.380555556,0.333333333,.,.,.,0,0,6,46,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,46,u/ml,6/28/2017 19:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,50,1,1,0.547222222,0.5,.,.,.,0,0,2,3.306886702,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,27.3,mg/L,6/28/2017 23:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,51,1,1,0.547222222,0.5,.,.,.,0,0,1,82,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82,mg/L,6/28/2017 23:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,52,1,1,0.547222222,0.5,.,.,.,0,0,4,100,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,100,u/ml,6/28/2017 23:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,53,1,1,0.547222222,0.5,.,.,.,0,0,5,32,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,32,u/ml,6/28/2017 23:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,54,1,1,0.547222222,0.5,.,.,.,0,0,6,48,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,48,u/ml,6/28/2017 23:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,55,1,1,1.047222222,1,.,.,.,0,0,2,3.222867846,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,25.1,mg/L,6/29/2017 11:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,56,1,1,1.047222222,1,.,.,.,0,0,1,79.8,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.8,mg/L,6/29/2017 11:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,57,1,1,1.047222222,1,.,.,.,0,0,4,93,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,93,u/ml,6/29/2017 11:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,58,1,1,1.047222222,1,.,.,.,0,0,5,107,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,107,u/ml,6/29/2017 11:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,59,1,1,1.047222222,1,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,6/29/2017 11:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,60,1,1,3.005555556,3,.,.,.,0,0,2,2.862200881,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,17.5,mg/L,7/1/2017 10:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,61,1,1,3.005555556,3,.,.,.,0,0,1,95,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,95,mg/L,7/1/2017 10:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,62,1,1,3.005555556,3,.,.,.,0,0,4,110,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,110,u/ml,7/1/2017 10:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,63,1,1,3.005555556,3,.,.,.,0,0,5,126,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,126,u/ml,7/1/2017 10:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,64,1,1,3.005555556,3,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,7/1/2017 10:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,65,1,1,7.136111111,7,.,.,.,0,0,2,2.228938553,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,9.29,mg/L,7/5/2017 13:26,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,66,1,1,7.136111111,7,.,.,.,0,0,1,90.9,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.9,mg/L,7/5/2017 13:26,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,67,1,1,7.136111111,14,.,.,.,0,0,4,98,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,98,u/ml,7/5/2017 13:26,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,68,1,1,7.136111111,14,.,.,.,0,0,5,157,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,157,u/ml,7/5/2017 13:26,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,69,1,1,7.136111111,14,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,7/5/2017 13:26,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,70,1,1,15.12916667,14,.,.,.,0,0,2,1.08180517,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.95,mg/L,7/13/2017 13:16,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,71,1,1,15.12916667,14,.,.,.,0,0,1,96.1,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,96.1,mg/L,7/13/2017 13:16,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,72,1,1,15.12916667,28,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,7/13/2017 13:16,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,73,1,1,15.12916667,28,.,.,.,0,0,5,178,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,178,u/ml,7/13/2017 13:16,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,74,1,1,15.12916667,28,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,7/13/2017 13:16,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,75,1,1,21.14305556,21,.,.,.,0,0,2,0.431782416,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.54,mg/L,7/19/2017 13:36,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,76,1,1,21.14305556,21,.,.,.,0,0,1,88.3,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88.3,mg/L,7/19/2017 13:36,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,77,1,1,21.14305556,42,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,7/19/2017 13:36,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,78,1,1,21.14305556,42,.,.,.,0,0,5,185,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,185,u/ml,7/19/2017 13:36,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,79,1,1,21.14305556,42,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,7/19/2017 13:36,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,80,1,1,28.13055556,28,.,.,.,0,0,2,-0.202116184,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.817,mg/L,7/26/2017 13:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,81,1,1,28.13055556,28,.,.,.,0,0,1,88.5,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88.5,mg/L,7/26/2017 13:18,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,82,1,1,28.13055556,56,.,.,.,0,0,4,112,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,112,u/ml,7/26/2017 13:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,83,1,1,28.13055556,56,.,.,.,0,0,5,200,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,200,u/ml,7/26/2017 13:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,84,1,1,28.13055556,56,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,7/26/2017 13:18,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,85,1,1,42.14513889,42,.,.,.,0,0,2,-1.237874356,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.29,mg/L,8/9/2017 13:39,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,86,1,1,42.14513889,42,.,.,.,0,0,1,90.2,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.2,mg/L,8/9/2017 13:39,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,87,1,1,42.14513889,84,.,.,.,0,0,4,114,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,114,u/ml,8/9/2017 13:39,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,88,1,1,42.14513889,84,.,.,.,0,0,5,209,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,209,u/ml,8/9/2017 13:39,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,89,1,1,42.14513889,84,.,.,.,0,0,6,76,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,76,u/ml,8/9/2017 13:39,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,90,1,1,56.14305556,56,.,.,.,0,0,2,-2.095570924,1,0.078,2,0,StudyID,001-007,1 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.123,mg/L,8/23/2017 13:36,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,91,1,1,56.14305556,56,.,.,.,0,0,1,87,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87,mg/L,8/23/2017 13:36,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,92,1,1,56.14305556,112,.,.,.,0,0,4,120,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,120,u/ml,8/23/2017 13:36,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,93,1,1,56.14305556,112,.,.,.,0,0,5,248,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,248,u/ml,8/23/2017 13:36,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,94,1,1,56.14305556,112,.,.,.,0,0,6,75,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,75,u/ml,8/23/2017 13:36,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,95,1,1,84.15416667,84,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-007,1 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/20/2017 13:52,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,96,1,1,84.15416667,84,.,.,.,0,0,1,91.7,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,91.7,mg/L,9/20/2017 13:52,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,97,1,1,84.15416667,168,.,.,.,0,0,4,124,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,124,u/ml,9/20/2017 13:52,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,98,1,1,84.15416667,168,.,.,.,0,0,5,269,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,269,u/ml,9/20/2017 13:52,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,99,1,1,84.15416667,168,.,.,.,0,0,6,88,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,88,u/ml,9/20/2017 13:52,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,100,1,1,98.1375,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-007,1 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/4/2017 13:28,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,101,1,1,98.1375,98,.,.,.,0,0,1,103,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,103,mg/L,10/4/2017 13:28,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,102,1,1,98.1375,196,.,.,.,0,0,4,120,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,120,u/ml,10/4/2017 13:28,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,103,1,1,98.1375,196,.,.,.,0,0,5,237,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,237,u/ml,10/4/2017 13:28,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,104,1,1,98.1375,196,.,.,.,0,0,6,87,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,87,u/ml,10/4/2017 13:28,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,105,1,1,112.1458333,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-007,1 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/18/2017 13:40,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,106,1,1,112.1458333,112,.,.,.,0,0,1,96.9,0,0.0078,0,0,StudyID,001-007,1 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,96.9,mg/L,10/18/2017 13:40,.,.,.,.,.,.,.,.,69.5,.,.,94.6,214
.,.,107,1,1,112.1458333,224,.,.,.,0,0,4,111,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,111,u/ml,10/18/2017 13:40,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,108,1,1,112.1458333,224,.,.,.,0,0,5,192,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,192,u/ml,10/18/2017 13:40,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
.,.,109,1,1,112.1458333,224,.,.,.,0,0,6,80,.,.,0,0,StudyID,001-007,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,80,u/ml,10/18/2017 13:40,30,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.5,169,24.3,94.6,214
C,PRE-DOSE,110,2,1,-48.83541667,0,.,.,.,0,0,1,97.1,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,97.1,mg/L,5/23/2017 13:57,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
C,PRE-DOSE,111,2,1,-48.83541667,0,.,.,.,0,0,4,102,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,102,u/ml,5/23/2017 13:57,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
C,PRE-DOSE,112,2,1,-48.83541667,0,.,.,.,0,0,5,395,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,395,u/ml,5/23/2017 13:57,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
C,PRE-DOSE,113,2,1,-48.83541667,0,.,.,.,0,0,6,108,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,108,u/ml,5/23/2017 13:57,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
C,PRE-DOSE,114,2,1,-0.824305556,-1,.,.,.,0,0,1,83.8,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.8,mg/L,7/10/2017 14:13,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
C,PRE-DOSE,115,2,1,-0.824305556,0,.,.,.,0,0,4,104,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,104,u/ml,7/10/2017 14:13,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
C,PRE-DOSE,116,2,1,-0.824305556,0,.,.,.,0,0,5,358,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,358,u/ml,7/10/2017 14:13,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
C,PRE-DOSE,117,2,1,-0.824305556,0,.,.,.,0,0,6,71,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,71,u/ml,7/10/2017 14:13,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
C,PRE-DOSE,118,2,1,-0.11875,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,7/11/2017 7:09,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
C,PRE-DOSE,119,2,1,-0.11875,0,.,.,.,0,0,1,85.4,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.4,mg/L,7/11/2017 7:09,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
C,PRE-DOSE,120,2,1,-0.11875,0,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,7/11/2017 7:09,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
C,PRE-DOSE,121,2,1,-0.11875,0,.,.,.,0,0,5,393,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,393,u/ml,7/11/2017 7:09,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
C,PRE-DOSE,122,2,1,-0.11875,0,.,.,.,0,0,6,77,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,77,u/ml,7/11/2017 7:09,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,123,2,1,0,.,.,55,1200,1,2,0,.,.,.,2,1,StudyID,001-013,1 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045833333,55,mg,55,INTRAVENOUS,1499767200,1499771160,Dupilumab,.,.,.,.,,.,.,.,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,124,2,1,0.045833333,0,.,.,.,0,0,2,3.335769576,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.1,mg/L,7/11/2017 11:06,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,125,2,1,0.045833333,0,.,.,.,0,0,1,68.4,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.4,mg/L,7/11/2017 11:06,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,126,2,1,0.045833333,0,.,.,.,0,0,4,77,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,77,u/ml,7/11/2017 11:06,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,127,2,1,0.045833333,0,.,.,.,0,0,5,222,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,222,u/ml,7/11/2017 11:06,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,128,2,1,0.045833333,0,.,.,.,0,0,6,43,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,43,u/ml,7/11/2017 11:06,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,129,2,1,0.05625,0.010416667,.,.,.,0,0,2,3.471966453,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,32.2,mg/L,7/11/2017 11:21,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,130,2,1,0.05625,0.010416667,.,.,.,0,0,1,66.7,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.7,mg/L,7/11/2017 11:21,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,131,2,1,0.05625,0.010416667,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,7/11/2017 11:21,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,132,2,1,0.05625,0.010416667,.,.,.,0,0,5,209,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,209,u/ml,7/11/2017 11:21,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,133,2,1,0.05625,0.010416667,.,.,.,0,0,6,43,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,43,u/ml,7/11/2017 11:21,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,134,2,1,0.066666667,0.020833333,.,.,.,0,0,2,3.360375387,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.8,mg/L,7/11/2017 11:36,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,135,2,1,0.066666667,0.020833333,.,.,.,0,0,1,67.8,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.8,mg/L,7/11/2017 11:36,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,136,2,1,0.066666667,0.020833333,.,.,.,0,0,4,89,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,89,u/ml,7/11/2017 11:36,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,137,2,1,0.066666667,0.020833333,.,.,.,0,0,5,192,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,192,u/ml,7/11/2017 11:36,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,138,2,1,0.066666667,0.020833333,.,.,.,0,0,6,42,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,42,u/ml,7/11/2017 11:36,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,139,2,1,0.088194444,0.041666667,.,.,.,0,0,2,3.478158423,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,32.4,mg/L,7/11/2017 12:07,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,140,2,1,0.088194444,0.041666667,.,.,.,0,0,1,75.5,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.5,mg/L,7/11/2017 12:07,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,141,2,1,0.088194444,0.041666667,.,.,.,0,0,4,91,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,91,u/ml,7/11/2017 12:07,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,142,2,1,0.088194444,0.041666667,.,.,.,0,0,5,220,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,220,u/ml,7/11/2017 12:07,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,143,2,1,0.088194444,0.041666667,.,.,.,0,0,6,45,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,45,u/ml,7/11/2017 12:07,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,144,2,1,0.136111111,0.083333333,.,.,.,0,0,2,3.360375387,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.8,mg/L,7/11/2017 13:16,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,145,2,1,0.136111111,0.083333333,.,.,.,0,0,1,69.9,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.9,mg/L,7/11/2017 13:16,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,146,2,1,0.136111111,0.083333333,.,.,.,0,0,4,89,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,89,u/ml,7/11/2017 13:16,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,147,2,1,0.136111111,0.083333333,.,.,.,0,0,5,221,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,221,u/ml,7/11/2017 13:16,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,148,2,1,0.136111111,0.083333333,.,.,.,0,0,6,48,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,48,u/ml,7/11/2017 13:16,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,149,2,1,0.221527778,0.166666667,.,.,.,0,0,2,3.33220451,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28,mg/L,7/11/2017 15:19,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,150,2,1,0.221527778,0.166666667,.,.,.,0,0,1,70.2,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.2,mg/L,7/11/2017 15:19,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,151,2,1,0.221527778,0.166666667,.,.,.,0,0,4,81,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,81,u/ml,7/11/2017 15:19,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,152,2,1,0.221527778,0.166666667,.,.,.,0,0,5,280,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,280,u/ml,7/11/2017 15:19,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,153,2,1,0.221527778,0.166666667,.,.,.,0,0,6,48,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,48,u/ml,7/11/2017 15:19,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,154,2,1,0.379166667,0.333333333,.,.,.,0,0,2,3.306886702,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,27.3,mg/L,7/11/2017 19:06,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,155,2,1,0.379166667,0.333333333,.,.,.,0,0,1,78.8,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.8,mg/L,7/11/2017 19:06,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,156,2,1,0.379166667,0.333333333,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,7/11/2017 19:06,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,157,2,1,0.379166667,0.333333333,.,.,.,0,0,5,281,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,281,u/ml,7/11/2017 19:06,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,158,2,1,0.379166667,0.333333333,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,7/11/2017 19:06,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,159,2,1,0.545833333,0.5,.,.,.,0,0,2,3.198673118,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,24.5,mg/L,7/11/2017 23:06,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,160,2,1,0.545833333,0.5,.,.,.,0,0,1,77.8,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.8,mg/L,7/11/2017 23:06,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,161,2,1,0.545833333,0.5,.,.,.,0,0,4,101,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,101,u/ml,7/11/2017 23:06,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,162,2,1,0.545833333,0.5,.,.,.,0,0,5,280,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,280,u/ml,7/11/2017 23:06,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,163,2,1,0.545833333,0.5,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,7/11/2017 23:06,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,164,2,1,1.048611111,1,.,.,.,0,0,2,3.025291076,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,20.6,mg/L,7/12/2017 11:10,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,165,2,1,1.048611111,1,.,.,.,0,0,1,78.7,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.7,mg/L,7/12/2017 11:10,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,166,2,1,1.048611111,1,.,.,.,0,0,4,91,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,91,u/ml,7/12/2017 11:10,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,167,2,1,1.048611111,1,.,.,.,0,0,5,299,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,299,u/ml,7/12/2017 11:10,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,168,2,1,1.048611111,1,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,7/12/2017 11:10,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,169,2,1,3.004166667,3,.,.,.,0,0,2,2.674148649,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,14.5,mg/L,7/14/2017 10:06,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,170,2,1,3.004166667,3,.,.,.,0,0,1,92.9,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,92.9,mg/L,7/14/2017 10:06,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,171,2,1,3.004166667,3,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,7/14/2017 10:06,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,172,2,1,3.004166667,3,.,.,.,0,0,5,403,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,403,u/ml,7/14/2017 10:06,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,173,2,1,3.004166667,3,.,.,.,0,0,6,79,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,79,u/ml,7/14/2017 10:06,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,174,2,1,7.142361111,7,.,.,.,0,0,2,2.039920784,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,7.69,mg/L,7/18/2017 13:25,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,175,2,1,7.142361111,7,.,.,.,0,0,1,73.5,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.5,mg/L,7/18/2017 13:25,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,176,2,1,7.142361111,14,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,7/18/2017 13:25,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,177,2,1,7.142361111,14,.,.,.,0,0,5,365,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,365,u/ml,7/18/2017 13:25,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,178,2,1,7.142361111,14,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,7/18/2017 13:25,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,179,2,1,14.14236111,14,.,.,.,0,0,2,1.17557333,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.24,mg/L,7/25/2017 13:25,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,180,2,1,14.14236111,14,.,.,.,0,0,1,88.4,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88.4,mg/L,7/25/2017 13:25,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,181,2,1,14.14236111,28,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,7/25/2017 13:25,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,182,2,1,14.14236111,28,.,.,.,0,0,5,303,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,303,u/ml,7/25/2017 13:25,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,183,2,1,14.14236111,28,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,7/25/2017 13:25,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,184,2,1,21.1375,21,.,.,.,0,0,2,0.343589704,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.41,mg/L,8/1/2017 13:18,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,185,2,1,21.1375,21,.,.,.,0,0,1,87.3,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.3,mg/L,8/1/2017 13:18,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,186,2,1,21.1375,42,.,.,.,0,0,4,100,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,100,u/ml,8/1/2017 13:18,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,187,2,1,21.1375,42,.,.,.,0,0,5,348,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,348,u/ml,8/1/2017 13:18,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,188,2,1,21.1375,42,.,.,.,0,0,6,77,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,77,u/ml,8/1/2017 13:18,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,189,2,1,28.13680556,28,.,.,.,0,0,2,-0.215671536,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.806,mg/L,8/8/2017 13:17,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,190,2,1,28.13680556,28,.,.,.,0,0,1,85.3,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.3,mg/L,8/8/2017 13:17,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,191,2,1,28.13680556,56,.,.,.,0,0,4,102,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,102,u/ml,8/8/2017 13:17,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,192,2,1,28.13680556,56,.,.,.,0,0,5,369,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,369,u/ml,8/8/2017 13:17,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,193,2,1,28.13680556,56,.,.,.,0,0,6,72,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,72,u/ml,8/8/2017 13:17,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,194,2,1,42.15625,42,.,.,.,0,0,2,-1.370421012,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.254,mg/L,8/22/2017 13:45,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,195,2,1,42.15625,42,.,.,.,0,0,1,90.5,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.5,mg/L,8/22/2017 13:45,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,196,2,1,42.15625,84,.,.,.,0,0,4,112,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,112,u/ml,8/22/2017 13:45,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,197,2,1,42.15625,84,.,.,.,0,0,5,379,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,379,u/ml,8/22/2017 13:45,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,198,2,1,42.15625,84,.,.,.,0,0,6,76,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,76,u/ml,8/22/2017 13:45,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,199,2,1,56.14166667,56,.,.,.,0,0,2,-2.373007557,1,0.078,2,0,StudyID,001-013,1 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.0932,mg/L,9/5/2017 13:24,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,200,2,1,56.14166667,56,.,.,.,0,0,1,90.9,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.9,mg/L,9/5/2017 13:24,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,201,2,1,56.14166667,112,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,9/5/2017 13:24,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,202,2,1,56.14166667,112,.,.,.,0,0,5,408,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,408,u/ml,9/5/2017 13:24,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,203,2,1,56.14166667,112,.,.,.,0,0,6,73,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,73,u/ml,9/5/2017 13:24,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,204,2,1,84.14930556,84,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-013,1 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/3/2017 13:35,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,205,2,1,84.14930556,84,.,.,.,0,0,1,90.1,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.1,mg/L,10/3/2017 13:35,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,206,2,1,84.14930556,168,.,.,.,0,0,4,104,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,104,u/ml,10/3/2017 13:35,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,207,2,1,84.14930556,168,.,.,.,0,0,5,405,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,405,u/ml,10/3/2017 13:35,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,208,2,1,84.14930556,168,.,.,.,0,0,6,90,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,90,u/ml,10/3/2017 13:35,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,209,2,1,98.13958333,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-013,1 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/17/2017 13:21,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,210,2,1,98.13958333,98,.,.,.,0,0,1,85.2,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.2,mg/L,10/17/2017 13:21,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,211,2,1,98.13958333,196,.,.,.,0,0,4,89,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,89,u/ml,10/17/2017 13:21,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,212,2,1,98.13958333,196,.,.,.,0,0,5,376,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,376,u/ml,10/17/2017 13:21,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,213,2,1,98.13958333,196,.,.,.,0,0,6,83,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,83,u/ml,10/17/2017 13:21,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,214,2,1,112.1388889,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-013,1 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/31/2017 13:20,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,215,2,1,112.1388889,112,.,.,.,0,0,1,92,0,0.0078,0,0,StudyID,001-013,1 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,92,mg/L,10/31/2017 13:20,.,.,.,.,.,.,.,.,54.3,.,.,85.4,393
.,.,216,2,1,112.1388889,224,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,10/31/2017 13:20,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,217,2,1,112.1388889,224,.,.,.,0,0,5,377,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,377,u/ml,10/31/2017 13:20,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
.,.,218,2,1,112.1388889,224,.,.,.,0,0,6,86,.,.,0,0,StudyID,001-013,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,86,u/ml,10/31/2017 13:20,37,YEARS,F,2,OTHER,7,Not Hispanic or Latino,.,54.3,155,22.6,85.4,393
C,PRE-DOSE,219,3,1,-48.81597222,0,.,.,.,0,0,1,76.7,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.7,mg/L,5/23/2017 14:45,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
C,PRE-DOSE,220,3,1,-48.81597222,0,.,.,.,0,0,4,104,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,104,u/ml,5/23/2017 14:45,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
C,PRE-DOSE,221,3,1,-48.81597222,0,.,.,.,0,0,5,182,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,182,u/ml,5/23/2017 14:45,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
C,PRE-DOSE,222,3,1,-48.81597222,0,.,.,.,0,0,6,89,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,89,u/ml,5/23/2017 14:45,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
C,PRE-DOSE,223,3,1,-0.827083333,-1,.,.,.,0,0,1,79.7,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.7,mg/L,7/10/2017 14:29,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
C,PRE-DOSE,224,3,1,-0.827083333,0,.,.,.,0,0,4,114,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,114,u/ml,7/10/2017 14:29,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
C,PRE-DOSE,225,3,1,-0.827083333,0,.,.,.,0,0,5,246,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,246,u/ml,7/10/2017 14:29,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
C,PRE-DOSE,226,3,1,-0.827083333,0,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,7/10/2017 14:29,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
C,PRE-DOSE,227,3,1,-0.1125,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,7/11/2017 7:38,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
C,PRE-DOSE,228,3,1,-0.1125,0,.,.,.,0,0,1,82.5,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.5,mg/L,7/11/2017 7:38,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
C,PRE-DOSE,229,3,1,-0.1125,0,.,.,.,0,0,4,114,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,114,u/ml,7/11/2017 7:38,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
C,PRE-DOSE,230,3,1,-0.1125,0,.,.,.,0,0,5,227,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,227,u/ml,7/11/2017 7:38,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
C,PRE-DOSE,231,3,1,-0.1125,0,.,.,.,0,0,6,66,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,66,u/ml,7/11/2017 7:38,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,232,3,1,0,.,.,95,2072.727273,1,2,0,.,.,.,2,1,StudyID,001-014,1 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045833333,95,mg,95,INTRAVENOUS,1499768400,1499772360,Dupilumab,.,.,.,.,,.,.,.,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,233,3,1,0.046527778,0,.,.,.,0,0,2,3.310543013,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,27.4,mg/L,7/11/2017 11:27,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,234,3,1,0.046527778,0,.,.,.,0,0,1,64.7,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.7,mg/L,7/11/2017 11:27,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,235,3,1,0.046527778,0,.,.,.,0,0,4,98,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,98,u/ml,7/11/2017 11:27,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,236,3,1,0.046527778,0,.,.,.,0,0,5,84,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,84,u/ml,7/11/2017 11:27,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,237,3,1,0.046527778,0,.,.,.,0,0,6,41,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,41,u/ml,7/11/2017 11:27,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,238,3,1,0.05625,0.010416667,.,.,.,0,0,2,3.356897123,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.7,mg/L,7/11/2017 11:41,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,239,3,1,0.05625,0.010416667,.,.,.,0,0,1,68.1,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.1,mg/L,7/11/2017 11:41,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,240,3,1,0.05625,0.010416667,.,.,.,0,0,4,103,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,103,u/ml,7/11/2017 11:41,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,241,3,1,0.05625,0.010416667,.,.,.,0,0,5,62,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,62,u/ml,7/11/2017 11:41,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,242,3,1,0.05625,0.010416667,.,.,.,0,0,6,42,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,42,u/ml,7/11/2017 11:41,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,243,3,1,0.066666667,0.020833333,.,.,.,0,0,2,3.377587516,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,29.3,mg/L,7/11/2017 11:56,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,244,3,1,0.066666667,0.020833333,.,.,.,0,0,1,70.2,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.2,mg/L,7/11/2017 11:56,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,245,3,1,0.066666667,0.020833333,.,.,.,0,0,4,102,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,102,u/ml,7/11/2017 11:56,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,246,3,1,0.066666667,0.020833333,.,.,.,0,0,5,88,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,88,u/ml,7/11/2017 11:56,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,247,3,1,0.066666667,0.020833333,.,.,.,0,0,6,45,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,45,u/ml,7/11/2017 11:56,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,248,3,1,0.0875,0.041666667,.,.,.,0,0,2,3.391147046,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,29.7,mg/L,7/11/2017 12:26,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,249,3,1,0.0875,0.041666667,.,.,.,0,0,1,71,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71,mg/L,7/11/2017 12:26,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,250,3,1,0.0875,0.041666667,.,.,.,0,0,4,104,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,104,u/ml,7/11/2017 12:26,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,251,3,1,0.0875,0.041666667,.,.,.,0,0,5,100,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,100,u/ml,7/11/2017 12:26,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,252,3,1,0.0875,0.041666667,.,.,.,0,0,6,45,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,45,u/ml,7/11/2017 12:26,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,253,3,1,0.129166667,0.083333333,.,.,.,0,0,2,3.238678452,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,25.5,mg/L,7/11/2017 13:26,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,254,3,1,0.129166667,0.083333333,.,.,.,0,0,1,69.3,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.3,mg/L,7/11/2017 13:26,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,255,3,1,0.129166667,0.083333333,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,7/11/2017 13:26,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,256,3,1,0.129166667,0.083333333,.,.,.,0,0,5,83,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,83,u/ml,7/11/2017 13:26,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,257,3,1,0.129166667,0.083333333,.,.,.,0,0,6,42,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,42,u/ml,7/11/2017 13:26,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,258,3,1,0.214583333,0.166666667,.,.,.,0,0,2,3.363841595,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.9,mg/L,7/11/2017 15:29,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,259,3,1,0.214583333,0.166666667,.,.,.,0,0,1,72.2,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.2,mg/L,7/11/2017 15:29,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,260,3,1,0.214583333,0.166666667,.,.,.,0,0,4,98,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,98,u/ml,7/11/2017 15:29,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,261,3,1,0.214583333,0.166666667,.,.,.,0,0,5,101,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,101,u/ml,7/11/2017 15:29,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,262,3,1,0.214583333,0.166666667,.,.,.,0,0,6,47,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,47,u/ml,7/11/2017 15:29,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,263,3,1,0.379166667,0.333333333,.,.,.,0,0,2,3.148453361,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,23.3,mg/L,7/11/2017 19:26,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,264,3,1,0.379166667,0.333333333,.,.,.,0,0,1,65.4,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.4,mg/L,7/11/2017 19:26,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,265,3,1,0.379166667,0.333333333,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,7/11/2017 19:26,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,266,3,1,0.379166667,0.333333333,.,.,.,0,0,5,136,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,136,u/ml,7/11/2017 19:26,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,267,3,1,0.379166667,0.333333333,.,.,.,0,0,6,46,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,46,u/ml,7/11/2017 19:26,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,268,3,1,0.547222222,0.5,.,.,.,0,0,2,3.020424886,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,20.5,mg/L,7/11/2017 23:28,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,269,3,1,0.547222222,0.5,.,.,.,0,0,1,64.8,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.8,mg/L,7/11/2017 23:28,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,270,3,1,0.547222222,0.5,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,7/11/2017 23:28,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,271,3,1,0.547222222,0.5,.,.,.,0,0,5,126,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,126,u/ml,7/11/2017 23:28,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,272,3,1,0.547222222,0.5,.,.,.,0,0,6,50,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,50,u/ml,7/11/2017 23:28,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,273,3,1,1.045833333,1,.,.,.,0,0,2,3.039749159,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,20.9,mg/L,7/12/2017 11:26,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,274,3,1,1.045833333,1,.,.,.,0,0,1,68.7,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.7,mg/L,7/12/2017 11:26,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,275,3,1,1.045833333,1,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,7/12/2017 11:26,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,276,3,1,1.045833333,1,.,.,.,0,0,5,182,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,182,u/ml,7/12/2017 11:26,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,277,3,1,1.045833333,1,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,7/12/2017 11:26,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,278,3,1,3.045138889,3,.,.,.,0,0,2,2.509599262,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,12.3,mg/L,7/14/2017 11:25,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,279,3,1,3.045138889,3,.,.,.,0,0,1,72.9,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.9,mg/L,7/14/2017 11:25,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,280,3,1,3.045138889,3,.,.,.,0,0,4,102,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,102,u/ml,7/14/2017 11:25,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,281,3,1,3.045138889,3,.,.,.,0,0,5,208,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,208,u/ml,7/14/2017 11:25,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,282,3,1,3.045138889,3,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,7/14/2017 11:25,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,283,3,1,7.145138889,7,.,.,.,0,0,2,1.819698838,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,6.17,mg/L,7/18/2017 13:49,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,284,3,1,7.145138889,7,.,.,.,0,0,1,76.7,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.7,mg/L,7/18/2017 13:49,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,285,3,1,7.145138889,14,.,.,.,0,0,4,104,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,104,u/ml,7/18/2017 13:49,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,286,3,1,7.145138889,14,.,.,.,0,0,5,214,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,214,u/ml,7/18/2017 13:49,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,287,3,1,7.145138889,14,.,.,.,0,0,6,69,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,69,u/ml,7/18/2017 13:49,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,288,3,1,14.15694444,14,.,.,.,0,0,2,0.792992516,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.21,mg/L,7/25/2017 14:06,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,289,3,1,14.15694444,14,.,.,.,0,0,1,71.7,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.7,mg/L,7/25/2017 14:06,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,290,3,1,14.15694444,28,.,.,.,0,0,4,110,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,110,u/ml,7/25/2017 14:06,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,291,3,1,14.15694444,28,.,.,.,0,0,5,233,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,233,u/ml,7/25/2017 14:06,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,292,3,1,14.15694444,28,.,.,.,0,0,6,66,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,66,u/ml,7/25/2017 14:06,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,293,3,1,21.13194444,21,.,.,.,0,0,2,-0.002002003,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.998,mg/L,8/1/2017 13:30,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,294,3,1,21.13194444,21,.,.,.,0,0,1,78.8,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.8,mg/L,8/1/2017 13:30,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,295,3,1,21.13194444,42,.,.,.,0,0,4,113,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,113,u/ml,8/1/2017 13:30,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,296,3,1,21.13194444,42,.,.,.,0,0,5,213,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,213,u/ml,8/1/2017 13:30,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,297,3,1,21.13194444,42,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,8/1/2017 13:30,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,298,3,1,28.14861111,28,.,.,.,0,0,2,-0.830113036,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.436,mg/L,8/8/2017 13:54,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,299,3,1,28.14861111,28,.,.,.,0,0,1,74.6,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.6,mg/L,8/8/2017 13:54,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,300,3,1,28.14861111,56,.,.,.,0,0,4,103,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,103,u/ml,8/8/2017 13:54,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,301,3,1,28.14861111,56,.,.,.,0,0,5,191,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,191,u/ml,8/8/2017 13:54,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,302,3,1,28.14861111,56,.,.,.,0,0,6,62,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,62,u/ml,8/8/2017 13:54,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,303,3,1,42.14861111,42,.,.,.,0,0,2,-2.032557956,1,0.078,2,0,StudyID,001-014,1 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.131,mg/L,8/22/2017 13:54,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,304,3,1,42.14861111,42,.,.,.,0,0,1,87.4,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.4,mg/L,8/22/2017 13:54,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,305,3,1,42.14861111,84,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,8/22/2017 13:54,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,306,3,1,42.14861111,84,.,.,.,0,0,5,277,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,277,u/ml,8/22/2017 13:54,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,307,3,1,42.14861111,84,.,.,.,0,0,6,71,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,71,u/ml,8/22/2017 13:54,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,308,3,1,59.12152778,56,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-014,1 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/8/2017 13:15,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,309,3,1,59.12152778,56,.,.,.,0,0,1,82.6,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.6,mg/L,9/8/2017 13:15,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,310,3,1,59.12152778,112,.,.,.,0,0,4,113,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,113,u/ml,9/8/2017 13:15,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,311,3,1,59.12152778,112,.,.,.,0,0,5,302,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,302,u/ml,9/8/2017 13:15,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,312,3,1,59.12152778,112,.,.,.,0,0,6,74,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,74,u/ml,9/8/2017 13:15,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,313,3,1,84.14027778,84,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-014,1 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/3/2017 13:42,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,314,3,1,84.14027778,84,.,.,.,0,0,1,80.2,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.2,mg/L,10/3/2017 13:42,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,315,3,1,84.14027778,168,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,10/3/2017 13:42,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,316,3,1,84.14027778,168,.,.,.,0,0,5,272,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,272,u/ml,10/3/2017 13:42,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,317,3,1,84.14027778,168,.,.,.,0,0,6,78,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,78,u/ml,10/3/2017 13:42,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,318,3,1,98.16944444,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-014,1 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/17/2017 14:24,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,319,3,1,98.16944444,98,.,.,.,0,0,1,78.6,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.6,mg/L,10/17/2017 14:24,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,320,3,1,98.16944444,196,.,.,.,0,0,4,90,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,90,u/ml,10/17/2017 14:24,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,321,3,1,98.16944444,196,.,.,.,0,0,5,240,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,240,u/ml,10/17/2017 14:24,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,322,3,1,98.16944444,196,.,.,.,0,0,6,73,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,73,u/ml,10/17/2017 14:24,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,323,3,1,112.1340278,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-014,1 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/31/2017 13:33,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,324,3,1,112.1340278,112,.,.,.,0,0,1,101,0,0.0078,0,0,StudyID,001-014,1 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,101,mg/L,10/31/2017 13:33,.,.,.,.,.,.,.,.,93.1,.,.,82.5,227
.,.,325,3,1,112.1340278,224,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,10/31/2017 13:33,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,326,3,1,112.1340278,224,.,.,.,0,0,5,174,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,174,u/ml,10/31/2017 13:33,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
.,.,327,3,1,112.1340278,224,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-014,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,10/31/2017 13:33,33,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,93.1,187,26.6,82.5,227
C,PRE-DOSE,328,4,1,-45.81319444,0,.,.,.,0,0,1,84.3,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.3,mg/L,5/26/2017 14:40,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
C,PRE-DOSE,329,4,1,-45.81319444,0,.,.,.,0,0,4,86,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,86,u/ml,5/26/2017 14:40,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
C,PRE-DOSE,330,4,1,-45.81319444,0,.,.,.,0,0,5,137,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,137,u/ml,5/26/2017 14:40,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
C,PRE-DOSE,331,4,1,-45.81319444,0,.,.,.,0,0,6,62,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,62,u/ml,5/26/2017 14:40,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
C,PRE-DOSE,332,4,1,-0.826388889,-1,.,.,.,0,0,1,96.9,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,96.9,mg/L,7/10/2017 14:21,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
C,PRE-DOSE,333,4,1,-0.826388889,0,.,.,.,0,0,4,103,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,103,u/ml,7/10/2017 14:21,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
C,PRE-DOSE,334,4,1,-0.826388889,0,.,.,.,0,0,5,186,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,186,u/ml,7/10/2017 14:21,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
C,PRE-DOSE,335,4,1,-0.826388889,0,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,7/10/2017 14:21,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
C,PRE-DOSE,336,4,1,-0.11875,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,7/11/2017 7:20,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
C,PRE-DOSE,337,4,1,-0.11875,0,.,.,.,0,0,1,99.1,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,99.1,mg/L,7/11/2017 7:20,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
C,PRE-DOSE,338,4,1,-0.11875,0,.,.,.,0,0,4,113,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,113,u/ml,7/11/2017 7:20,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
C,PRE-DOSE,339,4,1,-0.11875,0,.,.,.,0,0,5,215,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,215,u/ml,7/11/2017 7:20,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
C,PRE-DOSE,340,4,1,-0.11875,0,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,7/11/2017 7:20,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,341,4,1,0,.,.,55,1182.089552,1,2,0,.,.,.,2,1,StudyID,001-020,1 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.046527778,55,mg,55,INTRAVENOUS,1499767860,1499771880,Dupilumab,.,.,.,.,,.,.,.,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,342,4,1,0.046527778,0,.,.,.,0,0,2,3.356897123,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.7,mg/L,7/11/2017 11:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,343,4,1,0.046527778,0,.,.,.,0,0,1,79.4,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.4,mg/L,7/11/2017 11:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,344,4,1,0.046527778,0,.,.,.,0,0,4,73,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,73,u/ml,7/11/2017 11:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,345,4,1,0.046527778,0,.,.,.,0,0,5,33,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,33,u/ml,7/11/2017 11:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,346,4,1,0.046527778,0,.,.,.,0,0,6,30,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,30,u/ml,7/11/2017 11:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,347,4,1,0.056944444,0.010416667,.,.,.,0,0,2,3.394508394,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,29.8,mg/L,7/11/2017 11:33,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,348,4,1,0.056944444,0.010416667,.,.,.,0,0,1,85,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85,mg/L,7/11/2017 11:33,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,349,4,1,0.056944444,0.010416667,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,7/11/2017 11:33,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,350,4,1,0.056944444,0.010416667,.,.,.,0,0,5,42,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,42,u/ml,7/11/2017 11:33,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,351,4,1,0.056944444,0.010416667,.,.,.,0,0,6,31,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,31,u/ml,7/11/2017 11:33,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,352,4,1,0.067361111,0.020833333,.,.,.,0,0,2,3.33220451,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28,mg/L,7/11/2017 11:48,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,353,4,1,0.067361111,0.020833333,.,.,.,0,0,1,84.6,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.6,mg/L,7/11/2017 11:48,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,354,4,1,0.067361111,0.020833333,.,.,.,0,0,4,76,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,76,u/ml,7/11/2017 11:48,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,355,4,1,0.067361111,0.020833333,.,.,.,0,0,5,39,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,39,u/ml,7/11/2017 11:48,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,356,4,1,0.067361111,0.020833333,.,.,.,0,0,6,30,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,30,u/ml,7/11/2017 11:48,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,357,4,1,0.088194444,0.041666667,.,.,.,0,0,2,3.360375387,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.8,mg/L,7/11/2017 12:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,358,4,1,0.088194444,0.041666667,.,.,.,0,0,1,83.6,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.6,mg/L,7/11/2017 12:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,359,4,1,0.088194444,0.041666667,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,7/11/2017 12:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,360,4,1,0.088194444,0.041666667,.,.,.,0,0,5,36,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,36,u/ml,7/11/2017 12:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,361,4,1,0.088194444,0.041666667,.,.,.,0,0,6,32,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,32,u/ml,7/11/2017 12:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,362,4,1,0.129861111,0.083333333,.,.,.,0,0,2,3.299533728,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,27.1,mg/L,7/11/2017 13:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,363,4,1,0.129861111,0.083333333,.,.,.,0,0,1,85.8,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.8,mg/L,7/11/2017 13:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,364,4,1,0.129861111,0.083333333,.,.,.,0,0,4,71,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,71,u/ml,7/11/2017 13:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,365,4,1,0.129861111,0.083333333,.,.,.,0,0,5,32,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,32,u/ml,7/11/2017 13:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,366,4,1,0.129861111,0.083333333,.,.,.,0,0,6,31,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,31,u/ml,7/11/2017 13:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,367,4,1,0.215972222,0.166666667,.,.,.,0,0,2,3.295836866,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,27,mg/L,7/11/2017 15:22,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,368,4,1,0.215972222,0.166666667,.,.,.,0,0,1,83.6,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.6,mg/L,7/11/2017 15:22,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,369,4,1,0.215972222,0.166666667,.,.,.,0,0,4,91,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,91,u/ml,7/11/2017 15:22,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,370,4,1,0.215972222,0.166666667,.,.,.,0,0,5,54,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,54,u/ml,7/11/2017 15:22,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,371,4,1,0.215972222,0.166666667,.,.,.,0,0,6,32,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,32,u/ml,7/11/2017 15:22,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,372,4,1,0.379861111,0.333333333,.,.,.,0,0,2,3.265759411,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,26.2,mg/L,7/11/2017 19:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,373,4,1,0.379861111,0.333333333,.,.,.,0,0,1,81.1,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.1,mg/L,7/11/2017 19:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,374,4,1,0.379861111,0.333333333,.,.,.,0,0,4,90,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,90,u/ml,7/11/2017 19:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,375,4,1,0.379861111,0.333333333,.,.,.,0,0,5,83,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,83,u/ml,7/11/2017 19:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,376,4,1,0.379861111,0.333333333,.,.,.,0,0,6,35,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,35,u/ml,7/11/2017 19:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,377,4,1,0.546527778,0.5,.,.,.,0,0,2,3.165475048,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,23.7,mg/L,7/11/2017 23:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,378,4,1,0.546527778,0.5,.,.,.,0,0,1,81.8,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.8,mg/L,7/11/2017 23:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,379,4,1,0.546527778,0.5,.,.,.,0,0,4,87,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,87,u/ml,7/11/2017 23:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,380,4,1,0.546527778,0.5,.,.,.,0,0,5,73,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,73,u/ml,7/11/2017 23:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,381,4,1,0.546527778,0.5,.,.,.,0,0,6,36,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,36,u/ml,7/11/2017 23:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,382,4,1,1.046527778,1,.,.,.,0,0,2,3.054001182,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,21.2,mg/L,7/12/2017 11:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,383,4,1,1.046527778,1,.,.,.,0,0,1,90,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90,mg/L,7/12/2017 11:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,384,4,1,1.046527778,1,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,7/12/2017 11:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,385,4,1,1.046527778,1,.,.,.,0,0,5,83,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,83,u/ml,7/12/2017 11:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,386,4,1,1.046527778,1,.,.,.,0,0,6,43,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,43,u/ml,7/12/2017 11:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,387,4,1,3.004861111,3,.,.,.,0,0,2,2.646174797,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,14.1,mg/L,7/14/2017 10:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,388,4,1,3.004861111,3,.,.,.,0,0,1,90.1,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.1,mg/L,7/14/2017 10:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,389,4,1,3.004861111,3,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,7/14/2017 10:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,390,4,1,3.004861111,3,.,.,.,0,0,5,94,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,94,u/ml,7/14/2017 10:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,391,4,1,3.004861111,3,.,.,.,0,0,6,48,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,48,u/ml,7/14/2017 10:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,392,4,1,7.136805556,7,.,.,.,0,0,2,2.174751721,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,8.8,mg/L,7/18/2017 13:28,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,393,4,1,7.136805556,7,.,.,.,0,0,1,90.4,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.4,mg/L,7/18/2017 13:28,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,394,4,1,7.136805556,14,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,7/18/2017 13:28,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,395,4,1,7.136805556,14,.,.,.,0,0,5,160,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,160,u/ml,7/18/2017 13:28,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,396,4,1,7.136805556,14,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,7/18/2017 13:28,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,397,4,1,14.12986111,14,.,.,.,0,0,2,1.205970807,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.34,mg/L,7/25/2017 13:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,398,4,1,14.12986111,14,.,.,.,0,0,1,84.2,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.2,mg/L,7/25/2017 13:18,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,399,4,1,14.12986111,28,.,.,.,0,0,4,82,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,82,u/ml,7/25/2017 13:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,400,4,1,14.12986111,28,.,.,.,0,0,5,133,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,133,u/ml,7/25/2017 13:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,401,4,1,14.12986111,28,.,.,.,0,0,6,48,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,48,u/ml,7/25/2017 13:18,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,402,4,1,21.12847222,21,.,.,.,0,0,2,0.444685821,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.56,mg/L,8/1/2017 13:16,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,403,4,1,21.12847222,21,.,.,.,0,0,1,104,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,104,mg/L,8/1/2017 13:16,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,404,4,1,21.12847222,42,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,8/1/2017 13:16,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,405,4,1,21.12847222,42,.,.,.,0,0,5,222,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,222,u/ml,8/1/2017 13:16,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,406,4,1,21.12847222,42,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,8/1/2017 13:16,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,407,4,1,28.13611111,28,.,.,.,0,0,2,-0.223143551,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.8,mg/L,8/8/2017 13:27,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,408,4,1,28.13611111,28,.,.,.,0,0,1,85.3,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.3,mg/L,8/8/2017 13:27,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,409,4,1,28.13611111,56,.,.,.,0,0,4,86,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,86,u/ml,8/8/2017 13:27,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,410,4,1,28.13611111,56,.,.,.,0,0,5,178,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,178,u/ml,8/8/2017 13:27,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,411,4,1,28.13611111,56,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,8/8/2017 13:27,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,412,4,1,42.14930556,42,.,.,.,0,0,2,-1.439695138,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.237,mg/L,8/22/2017 13:46,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,413,4,1,42.14930556,42,.,.,.,0,0,1,84.6,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.6,mg/L,8/22/2017 13:46,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,414,4,1,42.14930556,84,.,.,.,0,0,4,77,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,77,u/ml,8/22/2017 13:46,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,415,4,1,42.14930556,84,.,.,.,0,0,5,191,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,191,u/ml,8/22/2017 13:46,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,416,4,1,42.14930556,84,.,.,.,0,0,6,52,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,52,u/ml,8/22/2017 13:46,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,417,4,1,56.13819444,56,.,.,.,0,0,2,-2.424752727,1,0.078,2,0,StudyID,001-020,1 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.0885,mg/L,9/5/2017 13:30,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,418,4,1,56.13819444,56,.,.,.,0,0,1,74,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74,mg/L,9/5/2017 13:30,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,419,4,1,56.13819444,112,.,.,.,0,0,4,74,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,74,u/ml,9/5/2017 13:30,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,420,4,1,56.13819444,112,.,.,.,0,0,5,176,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,176,u/ml,9/5/2017 13:30,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,421,4,1,56.13819444,112,.,.,.,0,0,6,48,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,48,u/ml,9/5/2017 13:30,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,422,4,1,84.15277778,84,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-020,1 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/3/2017 13:51,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,423,4,1,84.15277778,84,.,.,.,0,0,1,74.8,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.8,mg/L,10/3/2017 13:51,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,424,4,1,84.15277778,168,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,10/3/2017 13:51,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,425,4,1,84.15277778,168,.,.,.,0,0,5,227,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,227,u/ml,10/3/2017 13:51,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,426,4,1,84.15277778,168,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,10/3/2017 13:51,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,427,4,1,98.13055556,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-020,1 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/17/2017 13:19,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,428,4,1,98.13055556,98,.,.,.,0,0,1,65.4,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.4,mg/L,10/17/2017 13:19,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,429,4,1,98.13055556,196,.,.,.,0,0,4,73,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,73,u/ml,10/17/2017 13:19,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,430,4,1,98.13055556,196,.,.,.,0,0,5,136,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,136,u/ml,10/17/2017 13:19,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,431,4,1,98.13055556,196,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,10/17/2017 13:19,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,432,4,1,112.1368056,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-020,1 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/31/2017 13:28,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,433,4,1,112.1368056,112,.,.,.,0,0,1,89.3,0,0.0078,0,0,StudyID,001-020,1 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,89.3,mg/L,10/31/2017 13:28,.,.,.,.,.,.,.,.,53.4,.,.,99.1,215
.,.,434,4,1,112.1368056,224,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,10/31/2017 13:28,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,435,4,1,112.1368056,224,.,.,.,0,0,5,147,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,147,u/ml,10/31/2017 13:28,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
.,.,436,4,1,112.1368056,224,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-020,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,10/31/2017 13:28,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,53.4,154,22.5,99.1,215
C,PRE-DOSE,437,5,2,-49.78125,0,.,.,.,0,0,1,94.5,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,94.5,mg/L,6/13/2017 15:15,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
C,PRE-DOSE,438,5,2,-49.78125,0,.,.,.,0,0,4,97,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,97,u/ml,6/13/2017 15:15,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
C,PRE-DOSE,439,5,2,-49.78125,0,.,.,.,0,0,5,223,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,223,u/ml,6/13/2017 15:15,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
C,PRE-DOSE,440,5,2,-49.78125,0,.,.,.,0,0,6,105,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,105,u/ml,6/13/2017 15:15,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
C,PRE-DOSE,441,5,2,-0.845833333,-1,.,.,.,0,0,1,87.9,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.9,mg/L,8/1/2017 13:42,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
C,PRE-DOSE,442,5,2,-0.845833333,0,.,.,.,0,0,4,83,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,83,u/ml,8/1/2017 13:42,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
C,PRE-DOSE,443,5,2,-0.845833333,0,.,.,.,0,0,5,217,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,217,u/ml,8/1/2017 13:42,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
C,PRE-DOSE,444,5,2,-0.845833333,0,.,.,.,0,0,6,78,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,78,u/ml,8/1/2017 13:42,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
C,PRE-DOSE,445,5,2,-0.105555556,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,8/2/2017 7:28,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
C,PRE-DOSE,446,5,2,-0.105555556,0,.,.,.,0,0,1,91.6,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,91.6,mg/L,8/2/2017 7:28,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
C,PRE-DOSE,447,5,2,-0.105555556,0,.,.,.,0,0,4,85,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,85,u/ml,8/2/2017 7:28,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
C,PRE-DOSE,448,5,2,-0.105555556,0,.,.,.,0,0,5,216,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,216,u/ml,8/2/2017 7:28,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
C,PRE-DOSE,449,5,2,-0.105555556,0,.,.,.,0,0,6,73,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,73,u/ml,8/2/2017 7:28,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,450,5,2,0,.,.,230,5018.181818,1,2,0,.,.,.,2,1,StudyID,001-024,3 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045833333,230,mg,230,INTRAVENOUS,1501668000,1501671960,Dupilumab,.,.,.,.,,.,.,.,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,451,5,2,0.046527778,0,.,.,.,0,0,2,4.415219602,0,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,82.7,mg/L,8/2/2017 11:07,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,452,5,2,0.046527778,0,.,.,.,0,0,1,79.9,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.9,mg/L,8/2/2017 11:07,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,453,5,2,0.046527778,0,.,.,.,0,0,4,27,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,27,u/ml,8/2/2017 11:07,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,454,5,2,0.046527778,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/2/2017 11:07,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,455,5,2,0.046527778,0,.,.,.,0,0,6,15,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,15,u/ml,8/2/2017 11:07,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,456,5,2,0.05625,0.010416667,.,.,.,0,0,2,4.464758032,0,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,86.9,mg/L,8/2/2017 11:21,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,457,5,2,0.05625,0.010416667,.,.,.,0,0,1,82.8,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.8,mg/L,8/2/2017 11:21,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,458,5,2,0.05625,0.010416667,.,.,.,0,0,4,26,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,26,u/ml,8/2/2017 11:21,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,459,5,2,0.05625,0.010416667,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,8/2/2017 11:21,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,460,5,2,0.05625,0.010416667,.,.,.,0,0,6,17,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,17,u/ml,8/2/2017 11:21,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,461,5,2,0.066666667,0.020833333,.,.,.,0,0,2,4.409155302,0,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,82.2,mg/L,8/2/2017 11:36,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,462,5,2,0.066666667,0.020833333,.,.,.,0,0,1,78.9,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.9,mg/L,8/2/2017 11:36,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,463,5,2,0.066666667,0.020833333,.,.,.,0,0,4,27,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,27,u/ml,8/2/2017 11:36,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,464,5,2,0.066666667,0.020833333,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,8/2/2017 11:36,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,465,5,2,0.066666667,0.020833333,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,8/2/2017 11:36,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,466,5,2,0.0875,0.041666667,.,.,.,0,0,2,4.469350463,0,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,87.3,mg/L,8/2/2017 12:06,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,467,5,2,0.0875,0.041666667,.,.,.,0,0,1,76.2,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.2,mg/L,8/2/2017 12:06,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,468,5,2,0.0875,0.041666667,.,.,.,0,0,4,31,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,31,u/ml,8/2/2017 12:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,469,5,2,0.0875,0.041666667,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,8/2/2017 12:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,470,5,2,0.0875,0.041666667,.,.,.,0,0,6,17,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,17,u/ml,8/2/2017 12:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,471,5,2,0.129166667,0.083333333,.,.,.,0,0,2,4.378269586,0,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,79.7,mg/L,8/2/2017 13:06,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,472,5,2,0.129166667,0.083333333,.,.,.,0,0,1,72.8,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.8,mg/L,8/2/2017 13:06,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,473,5,2,0.129166667,0.083333333,.,.,.,0,0,4,26,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,26,u/ml,8/2/2017 13:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,474,5,2,0.129166667,0.083333333,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,8/2/2017 13:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,475,5,2,0.129166667,0.083333333,.,.,.,0,0,6,15,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,15,u/ml,8/2/2017 13:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,476,5,2,0.213888889,0.166666667,.,.,.,0,0,2,4.356708827,0,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,78,mg/L,8/2/2017 15:08,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,477,5,2,0.213888889,0.166666667,.,.,.,0,0,1,79.3,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.3,mg/L,8/2/2017 15:08,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,478,5,2,0.213888889,0.166666667,.,.,.,0,0,4,37,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,37,u/ml,8/2/2017 15:08,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,479,5,2,0.213888889,0.166666667,.,.,.,0,0,5,2,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,2,u/ml,8/2/2017 15:08,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,480,5,2,0.213888889,0.166666667,.,.,.,0,0,6,18,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,18,u/ml,8/2/2017 15:08,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,481,5,2,0.379166667,0.333333333,.,.,.,0,0,2,4.275276265,1,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,71.9,mg/L,8/2/2017 19:06,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,482,5,2,0.379166667,0.333333333,.,.,.,0,0,1,78,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78,mg/L,8/2/2017 19:06,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,483,5,2,0.379166667,0.333333333,.,.,.,0,0,4,30,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,30,u/ml,8/2/2017 19:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,484,5,2,0.379166667,0.333333333,.,.,.,0,0,5,3,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,3,u/ml,8/2/2017 19:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,485,5,2,0.379166667,0.333333333,.,.,.,0,0,6,19,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,19,u/ml,8/2/2017 19:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,486,5,2,0.545833333,0.5,.,.,.,0,0,2,4.222444565,1,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,68.2,mg/L,8/2/2017 23:06,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,487,5,2,0.545833333,0.5,.,.,.,0,0,1,75,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75,mg/L,8/2/2017 23:06,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,488,5,2,0.545833333,0.5,.,.,.,0,0,4,33,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,33,u/ml,8/2/2017 23:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,489,5,2,0.545833333,0.5,.,.,.,0,0,5,3,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,3,u/ml,8/2/2017 23:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,490,5,2,0.545833333,0.5,.,.,.,0,0,6,20,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,20,u/ml,8/2/2017 23:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,491,5,2,1.047222222,1,.,.,.,0,0,2,4.171305603,1,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,64.8,mg/L,8/3/2017 11:08,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,492,5,2,1.047222222,1,.,.,.,0,0,1,85.4,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.4,mg/L,8/3/2017 11:08,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,493,5,2,1.047222222,1,.,.,.,0,0,4,44,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,44,u/ml,8/3/2017 11:08,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,494,5,2,1.047222222,1,.,.,.,0,0,5,8,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,8,u/ml,8/3/2017 11:08,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,495,5,2,1.047222222,1,.,.,.,0,0,6,24,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,24,u/ml,8/3/2017 11:08,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,496,5,2,3.004166667,3,.,.,.,0,0,2,3.881563798,1,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,48.5,mg/L,8/5/2017 10:06,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,497,5,2,3.004166667,3,.,.,.,0,0,1,92.2,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,92.2,mg/L,8/5/2017 10:06,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,498,5,2,3.004166667,3,.,.,.,0,0,4,49,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,49,u/ml,8/5/2017 10:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,499,5,2,3.004166667,3,.,.,.,0,0,5,64,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,64,u/ml,8/5/2017 10:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,500,5,2,3.004166667,3,.,.,.,0,0,6,39,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,39,u/ml,8/5/2017 10:06,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,501,5,2,7.159722222,7,.,.,.,0,0,2,3.404525172,1,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,30.1,mg/L,8/9/2017 13:50,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,502,5,2,7.159722222,7,.,.,.,0,0,1,90.3,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.3,mg/L,8/9/2017 13:50,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,503,5,2,7.159722222,14,.,.,.,0,0,4,72,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,72,u/ml,8/9/2017 13:50,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,504,5,2,7.159722222,14,.,.,.,0,0,5,168,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,168,u/ml,8/9/2017 13:50,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,505,5,2,7.159722222,14,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,8/9/2017 13:50,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,506,5,2,14.15,14,.,.,.,0,0,2,2.912350665,1,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,18.4,mg/L,8/16/2017 13:36,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,507,5,2,14.15,14,.,.,.,0,0,1,98.8,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,98.8,mg/L,8/16/2017 13:36,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,508,5,2,14.15,28,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,8/16/2017 13:36,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,509,5,2,14.15,28,.,.,.,0,0,5,208,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,208,u/ml,8/16/2017 13:36,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,510,5,2,14.15,28,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,8/16/2017 13:36,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,511,5,2,21.13680556,21,.,.,.,0,0,2,2.191653532,1,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,8.95,mg/L,8/23/2017 13:17,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,512,5,2,21.13680556,21,.,.,.,0,0,1,98.1,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,98.1,mg/L,8/23/2017 13:17,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,513,5,2,21.13680556,42,.,.,.,0,0,4,83,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,83,u/ml,8/23/2017 13:17,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,514,5,2,21.13680556,42,.,.,.,0,0,5,213,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,213,u/ml,8/23/2017 13:17,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,515,5,2,21.13680556,42,.,.,.,0,0,6,64,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,64,u/ml,8/23/2017 13:17,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,516,5,2,28.14930556,28,.,.,.,0,0,2,1.677096561,1,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,5.35,mg/L,8/30/2017 13:35,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,517,5,2,28.14930556,28,.,.,.,0,0,1,95.3,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,95.3,mg/L,8/30/2017 13:35,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,518,5,2,28.14930556,56,.,.,.,0,0,4,90,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,90,u/ml,8/30/2017 13:35,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,519,5,2,28.14930556,56,.,.,.,0,0,5,252,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,252,u/ml,8/30/2017 13:35,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,520,5,2,28.14930556,56,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,8/30/2017 13:35,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,521,5,2,42.15486111,42,.,.,.,0,0,2,0.722705983,1,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.06,mg/L,9/13/2017 13:43,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,522,5,2,42.15486111,42,.,.,.,0,0,1,89,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,89,mg/L,9/13/2017 13:43,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,523,5,2,42.15486111,84,.,.,.,0,0,4,86,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,86,u/ml,9/13/2017 13:43,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,524,5,2,42.15486111,84,.,.,.,0,0,5,231,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,231,u/ml,9/13/2017 13:43,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,525,5,2,42.15486111,84,.,.,.,0,0,6,80,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,80,u/ml,9/13/2017 13:43,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,526,5,2,56.1375,56,.,.,.,0,0,2,-0.077961541,1,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.925,mg/L,9/27/2017 13:18,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,527,5,2,56.1375,56,.,.,.,0,0,1,101,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,101,mg/L,9/27/2017 13:18,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,528,5,2,56.1375,112,.,.,.,0,0,4,89,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,89,u/ml,9/27/2017 13:18,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,529,5,2,56.1375,112,.,.,.,0,0,5,250,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,250,u/ml,9/27/2017 13:18,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,530,5,2,56.1375,112,.,.,.,0,0,6,86,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,86,u/ml,9/27/2017 13:18,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,531,5,2,84.13125,84,.,.,.,0,0,2,-1.452434164,1,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.234,mg/L,10/25/2017 13:09,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,532,5,2,84.13125,84,.,.,.,0,0,1,105,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,105,mg/L,10/25/2017 13:09,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,533,5,2,84.13125,168,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,10/25/2017 13:09,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,534,5,2,84.13125,168,.,.,.,0,0,5,235,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,235,u/ml,10/25/2017 13:09,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,535,5,2,84.13125,168,.,.,.,0,0,6,86,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,86,u/ml,10/25/2017 13:09,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,536,5,2,98.14722222,98,.,.,.,0,0,2,-2.063568193,1,0.078,2,0,StudyID,001-024,3 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.127,mg/L,11/8/2017 13:32,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,537,5,2,98.14722222,98,.,.,.,0,0,1,153,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,153,mg/L,11/8/2017 13:32,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,538,5,2,98.14722222,196,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,11/8/2017 13:32,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,539,5,2,98.14722222,196,.,.,.,0,0,5,201,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,201,u/ml,11/8/2017 13:32,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,540,5,2,98.14722222,196,.,.,.,0,0,6,92,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,92,u/ml,11/8/2017 13:32,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,541,5,2,112.1541667,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-024,3 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/22/2017 13:42,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,542,5,2,112.1541667,112,.,.,.,0,0,1,95.5,0,0.0078,0,0,StudyID,001-024,3 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,95.5,mg/L,11/22/2017 13:42,.,.,.,.,.,.,.,.,75.6,.,.,91.6,216
.,.,543,5,2,112.1541667,224,.,.,.,0,0,4,85,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,85,u/ml,11/22/2017 13:42,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,544,5,2,112.1541667,224,.,.,.,0,0,5,239,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,239,u/ml,11/22/2017 13:42,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
.,.,545,5,2,112.1541667,224,.,.,.,0,0,6,82,.,.,0,0,StudyID,001-024,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,82,u/ml,11/22/2017 13:42,47,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,75.6,164,28.1,91.6,216
C,PRE-DOSE,546,6,2,-49.83472222,0,.,.,.,0,0,1,103,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,103,mg/L,6/20/2017 13:58,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
C,PRE-DOSE,547,6,2,-49.83472222,0,.,.,.,0,0,4,120,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,120,u/ml,6/20/2017 13:58,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
C,PRE-DOSE,548,6,2,-49.83472222,0,.,.,.,0,0,5,249,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,249,u/ml,6/20/2017 13:58,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
C,PRE-DOSE,549,6,2,-49.83472222,0,.,.,.,0,0,6,80,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,80,u/ml,6/20/2017 13:58,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
C,PRE-DOSE,550,6,2,-0.843055556,-1,.,.,.,0,0,1,99.5,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,99.5,mg/L,8/8/2017 13:46,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
C,PRE-DOSE,551,6,2,-0.843055556,0,.,.,.,0,0,4,129,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,129,u/ml,8/8/2017 13:46,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
C,PRE-DOSE,552,6,2,-0.843055556,0,.,.,.,0,0,5,261,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,261,u/ml,8/8/2017 13:46,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
C,PRE-DOSE,553,6,2,-0.843055556,0,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,8/8/2017 13:46,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
C,PRE-DOSE,554,6,2,-0.113194444,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,8/9/2017 7:17,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
C,PRE-DOSE,555,6,2,-0.113194444,0,.,.,.,0,0,1,87.1,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.1,mg/L,8/9/2017 7:17,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
C,PRE-DOSE,556,6,2,-0.113194444,0,.,.,.,0,0,4,126,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,126,u/ml,8/9/2017 7:17,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
C,PRE-DOSE,557,6,2,-0.113194444,0,.,.,.,0,0,5,239,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,239,u/ml,8/9/2017 7:17,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
C,PRE-DOSE,558,6,2,-0.113194444,0,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,8/9/2017 7:17,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,559,6,2,0,.,.,210,4581.818182,1,2,0,.,.,.,2,1,StudyID,001-039,3 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045833333,210,mg,210,INTRAVENOUS,1502272800,1502276760,Dupilumab,.,.,.,.,,.,.,.,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,560,6,2,0.045833333,0,.,.,.,0,0,2,4.384523515,0,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,80.2,mg/L,8/9/2017 11:06,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,561,6,2,0.045833333,0,.,.,.,0,0,1,75.6,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.6,mg/L,8/9/2017 11:06,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,562,6,2,0.045833333,0,.,.,.,0,0,4,85,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,85,u/ml,8/9/2017 11:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,563,6,2,0.045833333,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/9/2017 11:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,564,6,2,0.045833333,0,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,8/9/2017 11:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,565,6,2,0.05625,0.010416667,.,.,.,0,0,2,4.42604352,0,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,83.6,mg/L,8/9/2017 11:21,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,566,6,2,0.05625,0.010416667,.,.,.,0,0,1,79.1,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.1,mg/L,8/9/2017 11:21,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,567,6,2,0.05625,0.010416667,.,.,.,0,0,4,87,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,87,u/ml,8/9/2017 11:21,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,568,6,2,0.05625,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/9/2017 11:21,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,569,6,2,0.05625,0.010416667,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,8/9/2017 11:21,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,570,6,2,0.066666667,0.020833333,.,.,.,0,0,2,4.412798293,0,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,82.5,mg/L,8/9/2017 11:36,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,571,6,2,0.066666667,0.020833333,.,.,.,0,0,1,78.3,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.3,mg/L,8/9/2017 11:36,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,572,6,2,0.066666667,0.020833333,.,.,.,0,0,4,93,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,93,u/ml,8/9/2017 11:36,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,573,6,2,0.066666667,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/9/2017 11:36,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,574,6,2,0.066666667,0.020833333,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,8/9/2017 11:36,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,575,6,2,0.0875,0.041666667,.,.,.,0,0,2,4.405498991,0,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,81.9,mg/L,8/9/2017 12:06,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,576,6,2,0.0875,0.041666667,.,.,.,0,0,1,81.4,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.4,mg/L,8/9/2017 12:06,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,577,6,2,0.0875,0.041666667,.,.,.,0,0,4,85,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,85,u/ml,8/9/2017 12:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,578,6,2,0.0875,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/9/2017 12:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,579,6,2,0.0875,0.041666667,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,8/9/2017 12:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,580,6,2,0.129861111,0.083333333,.,.,.,0,0,2,4.368181228,0,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,78.9,mg/L,8/9/2017 13:07,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,581,6,2,0.129861111,0.083333333,.,.,.,0,0,1,78.9,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.9,mg/L,8/9/2017 13:07,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,582,6,2,0.129861111,0.083333333,.,.,.,0,0,4,85,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,85,u/ml,8/9/2017 13:07,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,583,6,2,0.129861111,0.083333333,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,8/9/2017 13:07,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,584,6,2,0.129861111,0.083333333,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,8/9/2017 13:07,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,585,6,2,0.213888889,0.166666667,.,.,.,0,0,2,4.361823927,0,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,78.4,mg/L,8/9/2017 15:08,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,586,6,2,0.213888889,0.166666667,.,.,.,0,0,1,76.8,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.8,mg/L,8/9/2017 15:08,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,587,6,2,0.213888889,0.166666667,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,8/9/2017 15:08,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,588,6,2,0.213888889,0.166666667,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,8/9/2017 15:08,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,589,6,2,0.213888889,0.166666667,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,8/9/2017 15:08,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,590,6,2,0.379166667,0.333333333,.,.,.,0,0,2,4.282206299,1,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,72.4,mg/L,8/9/2017 19:06,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,591,6,2,0.379166667,0.333333333,.,.,.,0,0,1,79,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79,mg/L,8/9/2017 19:06,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,592,6,2,0.379166667,0.333333333,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,8/9/2017 19:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,593,6,2,0.379166667,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/9/2017 19:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,594,6,2,0.379166667,0.333333333,.,.,.,0,0,6,13,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,13,u/ml,8/9/2017 19:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,595,6,2,0.545833333,0.5,.,.,.,0,0,2,4.188138442,1,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,65.9,mg/L,8/9/2017 23:06,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,596,6,2,0.545833333,0.5,.,.,.,0,0,1,74.5,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.5,mg/L,8/9/2017 23:06,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,597,6,2,0.545833333,0.5,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,8/9/2017 23:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,598,6,2,0.545833333,0.5,.,.,.,0,0,5,2,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,2,u/ml,8/9/2017 23:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,599,6,2,0.545833333,0.5,.,.,.,0,0,6,13,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,13,u/ml,8/9/2017 23:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,600,6,2,1.045833333,1,.,.,.,0,0,2,4.166665224,1,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,64.5,mg/L,8/10/2017 11:06,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,601,6,2,1.045833333,1,.,.,.,0,0,1,82.8,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.8,mg/L,8/10/2017 11:06,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,602,6,2,1.045833333,1,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,8/10/2017 11:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,603,6,2,1.045833333,1,.,.,.,0,0,5,2,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,2,u/ml,8/10/2017 11:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,604,6,2,1.045833333,1,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,8/10/2017 11:06,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,605,6,2,3.176388889,3,.,.,.,0,0,2,3.744787086,1,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,42.3,mg/L,8/12/2017 14:14,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,606,6,2,3.176388889,3,.,.,.,0,0,1,91.6,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,91.6,mg/L,8/12/2017 14:14,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,607,6,2,3.176388889,3,.,.,.,0,0,4,118,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,118,u/ml,8/12/2017 14:14,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,608,6,2,3.176388889,3,.,.,.,0,0,5,85,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,85,u/ml,8/12/2017 14:14,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,609,6,2,3.176388889,3,.,.,.,0,0,6,34,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,34,u/ml,8/12/2017 14:14,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,610,6,2,7.161111111,7,.,.,.,0,0,2,3.295836866,1,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,27,mg/L,8/16/2017 13:52,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,611,6,2,7.161111111,7,.,.,.,0,0,1,92.5,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,92.5,mg/L,8/16/2017 13:52,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,612,6,2,7.161111111,14,.,.,.,0,0,4,122,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,122,u/ml,8/16/2017 13:52,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,613,6,2,7.161111111,14,.,.,.,0,0,5,176,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,176,u/ml,8/16/2017 13:52,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,614,6,2,7.161111111,14,.,.,.,0,0,6,47,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,47,u/ml,8/16/2017 13:52,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,615,6,2,14.15138889,14,.,.,.,0,0,2,2.57261223,1,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,13.1,mg/L,8/23/2017 13:38,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,616,6,2,14.15138889,14,.,.,.,0,0,1,91.3,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,91.3,mg/L,8/23/2017 13:38,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,617,6,2,14.15138889,28,.,.,.,0,0,4,119,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,119,u/ml,8/23/2017 13:38,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,618,6,2,14.15138889,28,.,.,.,0,0,5,258,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,258,u/ml,8/23/2017 13:38,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,619,6,2,14.15138889,28,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,8/23/2017 13:38,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,620,6,2,21.16111111,21,.,.,.,0,0,2,1.870262531,1,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,6.49,mg/L,8/30/2017 13:52,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,621,6,2,21.16111111,21,.,.,.,0,0,1,90.9,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.9,mg/L,8/30/2017 13:52,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,622,6,2,21.16111111,42,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,8/30/2017 13:52,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,623,6,2,21.16111111,42,.,.,.,0,0,5,241,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,241,u/ml,8/30/2017 13:52,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,624,6,2,21.16111111,42,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,8/30/2017 13:52,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,625,6,2,28.14652778,28,.,.,.,0,0,2,1.272565596,1,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.57,mg/L,9/6/2017 13:31,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,626,6,2,28.14652778,28,.,.,.,0,0,1,83.9,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.9,mg/L,9/6/2017 13:31,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,627,6,2,28.14652778,56,.,.,.,0,0,4,117,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,117,u/ml,9/6/2017 13:31,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,628,6,2,28.14652778,56,.,.,.,0,0,5,224,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,224,u/ml,9/6/2017 13:31,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,629,6,2,28.14652778,56,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,9/6/2017 13:31,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,630,6,2,42.19791667,42,.,.,.,0,0,2,0.418710335,1,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.52,mg/L,9/20/2017 14:45,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,631,6,2,42.19791667,42,.,.,.,0,0,1,93.1,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,93.1,mg/L,9/20/2017 14:45,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,632,6,2,42.19791667,84,.,.,.,0,0,4,133,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,133,u/ml,9/20/2017 14:45,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,633,6,2,42.19791667,84,.,.,.,0,0,5,232,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,232,u/ml,9/20/2017 14:45,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,634,6,2,42.19791667,84,.,.,.,0,0,6,64,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,64,u/ml,9/20/2017 14:45,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,635,6,2,56.15416667,56,.,.,.,0,0,2,-0.484508315,1,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.616,mg/L,10/4/2017 13:42,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,636,6,2,56.15416667,56,.,.,.,0,0,1,99.4,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,99.4,mg/L,10/4/2017 13:42,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,637,6,2,56.15416667,112,.,.,.,0,0,4,128,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,128,u/ml,10/4/2017 13:42,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,638,6,2,56.15416667,112,.,.,.,0,0,5,277,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,277,u/ml,10/4/2017 13:42,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,639,6,2,56.15416667,112,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,10/4/2017 13:42,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,640,6,2,84.14444444,84,.,.,.,0,0,2,-1.897119985,1,0.078,2,0,StudyID,001-039,3 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.15,mg/L,11/1/2017 13:28,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,641,6,2,84.14444444,84,.,.,.,0,0,1,96.7,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,96.7,mg/L,11/1/2017 13:28,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,642,6,2,84.14444444,168,.,.,.,0,0,4,131,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,131,u/ml,11/1/2017 13:28,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,643,6,2,84.14444444,168,.,.,.,0,0,5,195,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,195,u/ml,11/1/2017 13:28,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,644,6,2,84.14444444,168,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,11/1/2017 13:28,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,645,6,2,98.15,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-039,3 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/15/2017 13:36,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,646,6,2,98.15,98,.,.,.,0,0,1,105,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,105,mg/L,11/15/2017 13:36,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,647,6,2,98.15,196,.,.,.,0,0,4,134,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,134,u/ml,11/15/2017 13:36,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,648,6,2,98.15,196,.,.,.,0,0,5,204,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,204,u/ml,11/15/2017 13:36,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,649,6,2,98.15,196,.,.,.,0,0,6,64,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,64,u/ml,11/15/2017 13:36,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,650,6,2,112.1569444,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-039,3 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/29/2017 13:46,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,651,6,2,112.1569444,112,.,.,.,0,0,1,107,0,0.0078,0,0,StudyID,001-039,3 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,107,mg/L,11/29/2017 13:46,.,.,.,.,.,.,.,.,70.2,.,.,87.1,239
.,.,652,6,2,112.1569444,224,.,.,.,0,0,4,133,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,133,u/ml,11/29/2017 13:46,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,653,6,2,112.1569444,224,.,.,.,0,0,5,174,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,174,u/ml,11/29/2017 13:46,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
.,.,654,6,2,112.1569444,224,.,.,.,0,0,6,62,.,.,0,0,StudyID,001-039,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,62,u/ml,11/29/2017 13:46,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,70.2,173,23.5,87.1,239
C,PRE-DOSE,655,7,2,-41.92013889,0,.,.,.,0,0,1,23.9,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,23.9,mg/L,6/26/2017 11:55,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
C,PRE-DOSE,656,7,2,-41.92013889,0,.,.,.,0,0,4,72,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,72,u/ml,6/26/2017 11:55,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
C,PRE-DOSE,657,7,2,-41.92013889,0,.,.,.,0,0,5,184,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,184,u/ml,6/26/2017 11:55,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
C,PRE-DOSE,658,7,2,-41.92013889,0,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,6/26/2017 11:55,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
C,PRE-DOSE,659,7,2,-0.855555556,-1,.,.,.,0,0,1,25.9,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,25.9,mg/L,8/6/2017 13:28,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
C,PRE-DOSE,660,7,2,-0.855555556,0,.,.,.,0,0,4,75,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,75,u/ml,8/6/2017 13:28,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
C,PRE-DOSE,661,7,2,-0.855555556,0,.,.,.,0,0,5,216,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,216,u/ml,8/6/2017 13:28,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
C,PRE-DOSE,662,7,2,-0.855555556,0,.,.,.,0,0,6,44,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,44,u/ml,8/6/2017 13:28,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
C,PRE-DOSE,663,7,2,-0.119444444,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,8/7/2017 7:08,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
C,PRE-DOSE,664,7,2,-0.119444444,0,.,.,.,0,0,1,27.3,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,27.3,mg/L,8/7/2017 7:08,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
C,PRE-DOSE,665,7,2,-0.119444444,0,.,.,.,0,0,4,103,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,103,u/ml,8/7/2017 7:08,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
C,PRE-DOSE,666,7,2,-0.119444444,0,.,.,.,0,0,5,220,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,220,u/ml,8/7/2017 7:08,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
C,PRE-DOSE,667,7,2,-0.119444444,0,.,.,.,0,0,6,47,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,47,u/ml,8/7/2017 7:08,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,668,7,2,0,.,.,180,3927.272727,1,2,0,.,.,.,2,1,StudyID,001-047,3 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045833333,180,mg,180,INTRAVENOUS,1502100000,1502103960,Dupilumab,.,.,.,.,,.,.,.,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,669,7,2,0.045833333,0,.,.,.,0,0,2,4.434381865,0,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,84.3,mg/L,8/7/2017 11:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,670,7,2,0.045833333,0,.,.,.,0,0,1,23.7,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,23.7,mg/L,8/7/2017 11:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,671,7,2,0.045833333,0,.,.,.,0,0,4,14,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,14,u/ml,8/7/2017 11:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,672,7,2,0.045833333,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/7/2017 11:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,673,7,2,0.045833333,0,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,8/7/2017 11:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,674,7,2,0.05625,0.010416667,.,.,.,0,0,2,4.440295543,0,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,84.8,mg/L,8/7/2017 11:21,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,675,7,2,0.05625,0.010416667,.,.,.,0,0,1,22.9,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,22.9,mg/L,8/7/2017 11:21,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,676,7,2,0.05625,0.010416667,.,.,.,0,0,4,30,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,30,u/ml,8/7/2017 11:21,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,677,7,2,0.05625,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/7/2017 11:21,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,678,7,2,0.05625,0.010416667,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,8/7/2017 11:21,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,679,7,2,0.066666667,0.020833333,.,.,.,0,0,2,4.421247348,0,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,83.2,mg/L,8/7/2017 11:36,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,680,7,2,0.066666667,0.020833333,.,.,.,0,0,1,24.1,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,24.1,mg/L,8/7/2017 11:36,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,681,7,2,0.066666667,0.020833333,.,.,.,0,0,4,10,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,10,u/ml,8/7/2017 11:36,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,682,7,2,0.066666667,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/7/2017 11:36,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,683,7,2,0.066666667,0.020833333,.,.,.,0,0,6,6,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,6,u/ml,8/7/2017 11:36,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,684,7,2,0.0875,0.041666667,.,.,.,0,0,2,4.513054897,0,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,91.2,mg/L,8/7/2017 12:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,685,7,2,0.0875,0.041666667,.,.,.,0,0,1,24.9,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,24.9,mg/L,8/7/2017 12:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,686,7,2,0.0875,0.041666667,.,.,.,0,0,4,20,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,20,u/ml,8/7/2017 12:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,687,7,2,0.0875,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/7/2017 12:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,688,7,2,0.0875,0.041666667,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,8/7/2017 12:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,689,7,2,0.129166667,0.083333333,.,.,.,0,0,2,4.396915247,0,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,81.2,mg/L,8/7/2017 13:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,690,7,2,0.129166667,0.083333333,.,.,.,0,0,1,23.8,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,23.8,mg/L,8/7/2017 13:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,691,7,2,0.129166667,0.083333333,.,.,.,0,0,4,33,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,33,u/ml,8/7/2017 13:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,692,7,2,0.129166667,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/7/2017 13:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,693,7,2,0.129166667,0.083333333,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,8/7/2017 13:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,694,7,2,0.2125,0.166666667,.,.,.,0,0,2,4.302712828,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,73.9,mg/L,8/7/2017 15:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,695,7,2,0.2125,0.166666667,.,.,.,0,0,1,25.6,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,25.6,mg/L,8/7/2017 15:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,696,7,2,0.2125,0.166666667,.,.,.,0,0,4,16,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,16,u/ml,8/7/2017 15:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,697,7,2,0.2125,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/7/2017 15:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,698,7,2,0.2125,0.166666667,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,8/7/2017 15:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,699,7,2,0.379166667,0.333333333,.,.,.,0,0,2,4.295923936,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,73.4,mg/L,8/7/2017 19:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,700,7,2,0.379166667,0.333333333,.,.,.,0,0,1,26.2,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,26.2,mg/L,8/7/2017 19:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,701,7,2,0.379166667,0.333333333,.,.,.,0,0,4,12,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,12,u/ml,8/7/2017 19:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,702,7,2,0.379166667,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/7/2017 19:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,703,7,2,0.379166667,0.333333333,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,8/7/2017 19:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,704,7,2,0.545833333,0.5,.,.,.,0,0,2,4.198704578,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,66.6,mg/L,8/7/2017 23:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,705,7,2,0.545833333,0.5,.,.,.,0,0,1,26.5,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,26.5,mg/L,8/7/2017 23:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,706,7,2,0.545833333,0.5,.,.,.,0,0,4,30,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,30,u/ml,8/7/2017 23:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,707,7,2,0.545833333,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/7/2017 23:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,708,7,2,0.545833333,0.5,.,.,.,0,0,6,8,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,8,u/ml,8/7/2017 23:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,709,7,2,1.045833333,1,.,.,.,0,0,2,4.210645018,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,67.4,mg/L,8/8/2017 11:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,710,7,2,1.045833333,1,.,.,.,0,0,1,30.5,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,30.5,mg/L,8/8/2017 11:06,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,711,7,2,1.045833333,1,.,.,.,0,0,4,27,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,27,u/ml,8/8/2017 11:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,712,7,2,1.045833333,1,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,8/8/2017 11:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,713,7,2,1.045833333,1,.,.,.,0,0,6,9,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,9,u/ml,8/8/2017 11:06,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,714,7,2,3.04375,3,.,.,.,0,0,2,3.815512105,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,45.4,mg/L,8/10/2017 11:03,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,715,7,2,3.04375,3,.,.,.,0,0,1,33.8,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,33.8,mg/L,8/10/2017 11:03,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,716,7,2,3.04375,3,.,.,.,0,0,4,27,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,27,u/ml,8/10/2017 11:03,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,717,7,2,3.04375,3,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,8/10/2017 11:03,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,718,7,2,3.04375,3,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,8/10/2017 11:03,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,719,7,2,7.161111111,7,.,.,.,0,0,2,3.586292865,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,36.1,mg/L,8/14/2017 13:52,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,720,7,2,7.161111111,7,.,.,.,0,0,1,32.3,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,32.3,mg/L,8/14/2017 13:52,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,721,7,2,7.161111111,14,.,.,.,0,0,4,24,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,24,u/ml,8/14/2017 13:52,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,722,7,2,7.161111111,14,.,.,.,0,0,5,6,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,6,u/ml,8/14/2017 13:52,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,723,7,2,7.161111111,14,.,.,.,0,0,6,13,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,13,u/ml,8/14/2017 13:52,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,724,7,2,14.14791667,14,.,.,.,0,0,2,3.210843653,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,24.8,mg/L,8/21/2017 13:33,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,725,7,2,14.14791667,14,.,.,.,0,0,1,31.5,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,31.5,mg/L,8/21/2017 13:33,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,726,7,2,14.14791667,28,.,.,.,0,0,4,49,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,49,u/ml,8/21/2017 13:33,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,727,7,2,14.14791667,28,.,.,.,0,0,5,39,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,39,u/ml,8/21/2017 13:33,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,728,7,2,14.14791667,28,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,8/21/2017 13:33,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,729,7,2,21.14930556,21,.,.,.,0,0,2,2.734367509,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,15.4,mg/L,8/28/2017 13:35,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,730,7,2,21.14930556,21,.,.,.,0,0,1,25.8,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,25.8,mg/L,8/28/2017 13:35,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,731,7,2,21.14930556,42,.,.,.,0,0,4,34,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,34,u/ml,8/28/2017 13:35,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,732,7,2,21.14930556,42,.,.,.,0,0,5,82,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,82,u/ml,8/28/2017 13:35,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,733,7,2,21.14930556,42,.,.,.,0,0,6,20,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,20,u/ml,8/28/2017 13:35,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,734,7,2,28.13888889,28,.,.,.,0,0,2,2.341805806,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,10.4,mg/L,9/4/2017 13:20,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,735,7,2,28.13888889,28,.,.,.,0,0,1,31.8,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,31.8,mg/L,9/4/2017 13:20,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,736,7,2,28.13888889,56,.,.,.,0,0,4,86,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,86,u/ml,9/4/2017 13:20,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,737,7,2,28.13888889,56,.,.,.,0,0,5,166,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,166,u/ml,9/4/2017 13:20,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,738,7,2,28.13888889,56,.,.,.,0,0,6,34,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,34,u/ml,9/4/2017 13:20,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,739,7,2,42.15347222,42,.,.,.,0,0,2,1.481604541,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,4.4,mg/L,9/18/2017 13:41,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,740,7,2,42.15347222,42,.,.,.,0,0,1,31.1,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,31.1,mg/L,9/18/2017 13:41,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,741,7,2,42.15347222,84,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,9/18/2017 13:41,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,742,7,2,42.15347222,84,.,.,.,0,0,5,196,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,196,u/ml,9/18/2017 13:41,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,743,7,2,42.15347222,84,.,.,.,0,0,6,45,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,45,u/ml,9/18/2017 13:41,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,744,7,2,56.16527778,56,.,.,.,0,0,2,0.688134639,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.99,mg/L,10/2/2017 13:58,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,745,7,2,56.16527778,56,.,.,.,0,0,1,36.2,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,36.2,mg/L,10/2/2017 13:58,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,746,7,2,56.16527778,112,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,10/2/2017 13:58,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,747,7,2,56.16527778,112,.,.,.,0,0,5,217,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,217,u/ml,10/2/2017 13:58,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,748,7,2,56.16527778,112,.,.,.,0,0,6,52,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,52,u/ml,10/2/2017 13:58,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,749,7,2,84.15902778,84,.,.,.,0,0,2,-0.785262469,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.456,mg/L,10/30/2017 13:49,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,750,7,2,84.15902778,84,.,.,.,0,0,1,42.3,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,42.3,mg/L,10/30/2017 13:49,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,751,7,2,84.15902778,168,.,.,.,0,0,4,74,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,74,u/ml,10/30/2017 13:49,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,752,7,2,84.15902778,168,.,.,.,0,0,5,137,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,137,u/ml,10/30/2017 13:49,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,753,7,2,84.15902778,168,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,10/30/2017 13:49,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,754,7,2,98.15763889,98,.,.,.,0,0,2,-1.276543497,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.279,mg/L,11/13/2017 13:47,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,755,7,2,98.15763889,98,.,.,.,0,0,1,35.4,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,35.4,mg/L,11/13/2017 13:47,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,756,7,2,98.15763889,196,.,.,.,0,0,4,68,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,68,u/ml,11/13/2017 13:47,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,757,7,2,98.15763889,196,.,.,.,0,0,5,242,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,242,u/ml,11/13/2017 13:47,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,758,7,2,98.15763889,196,.,.,.,0,0,6,52,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,52,u/ml,11/13/2017 13:47,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,759,7,2,112.1840278,112,.,.,.,0,0,2,-1.777856564,1,0.078,2,0,StudyID,001-047,3 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.169,mg/L,11/27/2017 14:25,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,760,7,2,112.1840278,112,.,.,.,0,0,1,33.1,0,0.0078,0,0,StudyID,001-047,3 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,33.1,mg/L,11/27/2017 14:25,.,.,.,.,.,.,.,.,57.8,.,.,27.3,220
.,.,761,7,2,112.1840278,224,.,.,.,0,0,4,46,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,46,u/ml,11/27/2017 14:25,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,762,7,2,112.1840278,224,.,.,.,0,0,5,215,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,215,u/ml,11/27/2017 14:25,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
.,.,763,7,2,112.1840278,224,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-047,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,11/27/2017 14:25,28,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,57.8,161,22.3,27.3,220
C,PRE-DOSE,764,8,2,-41.78194444,0,.,.,.,0,0,1,69.1,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.1,mg/L,6/28/2017 15:24,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
C,PRE-DOSE,765,8,2,-41.78194444,0,.,.,.,0,0,4,73,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,73,u/ml,6/28/2017 15:24,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
C,PRE-DOSE,766,8,2,-41.78194444,0,.,.,.,0,0,5,283,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,283,u/ml,6/28/2017 15:24,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
C,PRE-DOSE,767,8,2,-41.78194444,0,.,.,.,0,0,6,78,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,78,u/ml,6/28/2017 15:24,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
C,PRE-DOSE,768,8,2,-0.860416667,-1,.,.,.,0,0,1,94.5,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,94.5,mg/L,8/8/2017 13:31,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
C,PRE-DOSE,769,8,2,-0.860416667,0,.,.,.,0,0,4,104,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,104,u/ml,8/8/2017 13:31,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
C,PRE-DOSE,770,8,2,-0.860416667,0,.,.,.,0,0,5,460,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,460,u/ml,8/8/2017 13:31,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
C,PRE-DOSE,771,8,2,-0.860416667,0,.,.,.,0,0,6,93,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,93,u/ml,8/8/2017 13:31,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
C,PRE-DOSE,772,8,2,-0.113888889,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,8/9/2017 7:26,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
C,PRE-DOSE,773,8,2,-0.113888889,0,.,.,.,0,0,1,92.4,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,92.4,mg/L,8/9/2017 7:26,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
C,PRE-DOSE,774,8,2,-0.113888889,0,.,.,.,0,0,4,109,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,109,u/ml,8/9/2017 7:26,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
C,PRE-DOSE,775,8,2,-0.113888889,0,.,.,.,0,0,5,389,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,389,u/ml,8/9/2017 7:26,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
C,PRE-DOSE,776,8,2,-0.113888889,0,.,.,.,0,0,6,87,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,87,u/ml,8/9/2017 7:26,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,777,8,2,0,.,.,220,4800,1,2,0,.,.,.,2,1,StudyID,001-050,3 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045833333,220,mg,220,INTRAVENOUS,1502273400,1502277360,Dupilumab,.,.,.,.,,.,.,.,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,778,8,2,0.045833333,0,.,.,.,0,0,2,4.355425953,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,77.9,mg/L,8/9/2017 11:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,779,8,2,0.045833333,0,.,.,.,0,0,1,74,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74,mg/L,8/9/2017 11:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,780,8,2,0.045833333,0,.,.,.,0,0,4,34,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,34,u/ml,8/9/2017 11:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,781,8,2,0.045833333,0,.,.,.,0,0,5,40,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,40,u/ml,8/9/2017 11:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,782,8,2,0.045833333,0,.,.,.,0,0,6,17,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,17,u/ml,8/9/2017 11:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,783,8,2,0.05625,0.010416667,.,.,.,0,0,2,4.472780998,0,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,87.6,mg/L,8/9/2017 11:31,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,784,8,2,0.05625,0.010416667,.,.,.,0,0,1,78.2,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.2,mg/L,8/9/2017 11:31,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,785,8,2,0.05625,0.010416667,.,.,.,0,0,4,28,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,28,u/ml,8/9/2017 11:31,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,786,8,2,0.05625,0.010416667,.,.,.,0,0,5,40,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,40,u/ml,8/9/2017 11:31,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,787,8,2,0.05625,0.010416667,.,.,.,0,0,6,17,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,17,u/ml,8/9/2017 11:31,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,788,8,2,0.066666667,0.020833333,.,.,.,0,0,2,4.437934267,0,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,84.6,mg/L,8/9/2017 11:46,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,789,8,2,0.066666667,0.020833333,.,.,.,0,0,1,74.5,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.5,mg/L,8/9/2017 11:46,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,790,8,2,0.066666667,0.020833333,.,.,.,0,0,4,31,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,31,u/ml,8/9/2017 11:46,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,791,8,2,0.066666667,0.020833333,.,.,.,0,0,5,43,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,43,u/ml,8/9/2017 11:46,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,792,8,2,0.066666667,0.020833333,.,.,.,0,0,6,17,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,17,u/ml,8/9/2017 11:46,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,793,8,2,0.0875,0.041666667,.,.,.,0,0,2,4.427238977,0,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,83.7,mg/L,8/9/2017 12:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,794,8,2,0.0875,0.041666667,.,.,.,0,0,1,78,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78,mg/L,8/9/2017 12:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,795,8,2,0.0875,0.041666667,.,.,.,0,0,4,48,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,48,u/ml,8/9/2017 12:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,796,8,2,0.0875,0.041666667,.,.,.,0,0,5,51,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,51,u/ml,8/9/2017 12:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,797,8,2,0.0875,0.041666667,.,.,.,0,0,6,18,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,18,u/ml,8/9/2017 12:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,798,8,2,0.129861111,0.083333333,.,.,.,0,0,2,4.395682961,0,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,81.1,mg/L,8/9/2017 13:17,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,799,8,2,0.129861111,0.083333333,.,.,.,0,0,1,72.2,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.2,mg/L,8/9/2017 13:17,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,800,8,2,0.129861111,0.083333333,.,.,.,0,0,4,17,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,17,u/ml,8/9/2017 13:17,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,801,8,2,0.129861111,0.083333333,.,.,.,0,0,5,45,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,45,u/ml,8/9/2017 13:17,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,802,8,2,0.129861111,0.083333333,.,.,.,0,0,6,17,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,17,u/ml,8/9/2017 13:17,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,803,8,2,0.2125,0.166666667,.,.,.,0,0,2,4.338597077,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,76.6,mg/L,8/9/2017 15:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,804,8,2,0.2125,0.166666667,.,.,.,0,0,1,73.2,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.2,mg/L,8/9/2017 15:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,805,8,2,0.2125,0.166666667,.,.,.,0,0,4,21,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,21,u/ml,8/9/2017 15:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,806,8,2,0.2125,0.166666667,.,.,.,0,0,5,48,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,48,u/ml,8/9/2017 15:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,807,8,2,0.2125,0.166666667,.,.,.,0,0,6,18,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,18,u/ml,8/9/2017 15:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,808,8,2,0.379166667,0.333333333,.,.,.,0,0,2,4.254193263,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,70.4,mg/L,8/9/2017 19:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,809,8,2,0.379166667,0.333333333,.,.,.,0,0,1,76,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76,mg/L,8/9/2017 19:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,810,8,2,0.379166667,0.333333333,.,.,.,0,0,4,32,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,32,u/ml,8/9/2017 19:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,811,8,2,0.379166667,0.333333333,.,.,.,0,0,5,57,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,57,u/ml,8/9/2017 19:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,812,8,2,0.379166667,0.333333333,.,.,.,0,0,6,19,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,19,u/ml,8/9/2017 19:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,813,8,2,0.545833333,0.5,.,.,.,0,0,2,4.210645018,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,67.4,mg/L,8/9/2017 23:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,814,8,2,0.545833333,0.5,.,.,.,0,0,1,74.7,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.7,mg/L,8/9/2017 23:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,815,8,2,0.545833333,0.5,.,.,.,0,0,4,36,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,36,u/ml,8/9/2017 23:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,816,8,2,0.545833333,0.5,.,.,.,0,0,5,54,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,54,u/ml,8/9/2017 23:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,817,8,2,0.545833333,0.5,.,.,.,0,0,6,20,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,20,u/ml,8/9/2017 23:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,818,8,2,1.045833333,1,.,.,.,0,0,2,4.119037175,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,61.5,mg/L,8/10/2017 11:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,819,8,2,1.045833333,1,.,.,.,0,0,1,82.8,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.8,mg/L,8/10/2017 11:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,820,8,2,1.045833333,1,.,.,.,0,0,4,15,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,15,u/ml,8/10/2017 11:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,821,8,2,1.045833333,1,.,.,.,0,0,5,96,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,96,u/ml,8/10/2017 11:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,822,8,2,1.045833333,1,.,.,.,0,0,6,22,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,22,u/ml,8/10/2017 11:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,823,8,2,3.045833333,3,.,.,.,0,0,2,3.772760938,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,43.5,mg/L,8/12/2017 11:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,824,8,2,3.045833333,3,.,.,.,0,0,1,77.4,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.4,mg/L,8/12/2017 11:16,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,825,8,2,3.045833333,3,.,.,.,0,0,4,24,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,24,u/ml,8/12/2017 11:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,826,8,2,3.045833333,3,.,.,.,0,0,5,150,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,150,u/ml,8/12/2017 11:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,827,8,2,3.045833333,3,.,.,.,0,0,6,33,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,33,u/ml,8/12/2017 11:16,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,828,8,2,7.15,7,.,.,.,0,0,2,3.36729583,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,29,mg/L,8/16/2017 13:46,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,829,8,2,7.15,7,.,.,.,0,0,1,68.9,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.9,mg/L,8/16/2017 13:46,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,830,8,2,7.15,14,.,.,.,0,0,4,44,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,44,u/ml,8/16/2017 13:46,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,831,8,2,7.15,14,.,.,.,0,0,5,225,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,225,u/ml,8/16/2017 13:46,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,832,8,2,7.15,14,.,.,.,0,0,6,51,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,51,u/ml,8/16/2017 13:46,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,833,8,2,14.13263889,14,.,.,.,0,0,2,2.727852828,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,15.3,mg/L,8/23/2017 13:21,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,834,8,2,14.13263889,14,.,.,.,0,0,1,74,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74,mg/L,8/23/2017 13:21,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,835,8,2,14.13263889,28,.,.,.,0,0,4,69,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,69,u/ml,8/23/2017 13:21,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,836,8,2,14.13263889,28,.,.,.,0,0,5,228,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,228,u/ml,8/23/2017 13:21,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,837,8,2,14.13263889,28,.,.,.,0,0,6,61,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,61,u/ml,8/23/2017 13:21,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,838,8,2,21.15,21,.,.,.,0,0,2,1.985130862,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,7.28,mg/L,8/30/2017 13:46,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,839,8,2,21.15,21,.,.,.,0,0,1,63.9,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,63.9,mg/L,8/30/2017 13:46,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,840,8,2,21.15,42,.,.,.,0,0,4,68,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,68,u/ml,8/30/2017 13:46,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,841,8,2,21.15,42,.,.,.,0,0,5,245,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,245,u/ml,8/30/2017 13:46,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,842,8,2,21.15,42,.,.,.,0,0,6,61,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,61,u/ml,8/30/2017 13:46,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,843,8,2,28.13402778,28,.,.,.,0,0,2,1.358409158,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.89,mg/L,9/6/2017 13:23,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,844,8,2,28.13402778,28,.,.,.,0,0,1,72.2,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.2,mg/L,9/6/2017 13:23,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,845,8,2,28.13402778,56,.,.,.,0,0,4,75,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,75,u/ml,9/6/2017 13:23,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,846,8,2,28.13402778,56,.,.,.,0,0,5,296,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,296,u/ml,9/6/2017 13:23,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,847,8,2,28.13402778,56,.,.,.,0,0,6,69,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,69,u/ml,9/6/2017 13:23,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,848,8,2,42.14236111,42,.,.,.,0,0,2,0.412109651,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.51,mg/L,9/20/2017 13:35,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,849,8,2,42.14236111,42,.,.,.,0,0,1,65.9,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.9,mg/L,9/20/2017 13:35,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,850,8,2,42.14236111,84,.,.,.,0,0,4,83,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,83,u/ml,9/20/2017 13:35,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,851,8,2,42.14236111,84,.,.,.,0,0,5,296,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,296,u/ml,9/20/2017 13:35,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,852,8,2,42.14236111,84,.,.,.,0,0,6,75,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,75,u/ml,9/20/2017 13:35,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,853,8,2,56.14097222,56,.,.,.,0,0,2,-0.603306477,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.547,mg/L,10/4/2017 13:33,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,854,8,2,56.14097222,56,.,.,.,0,0,1,82.2,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.2,mg/L,10/4/2017 13:33,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,855,8,2,56.14097222,112,.,.,.,0,0,4,80,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,80,u/ml,10/4/2017 13:33,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,856,8,2,56.14097222,112,.,.,.,0,0,5,287,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,287,u/ml,10/4/2017 13:33,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,857,8,2,56.14097222,112,.,.,.,0,0,6,85,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,85,u/ml,10/4/2017 13:33,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,858,8,2,84.13055556,84,.,.,.,0,0,2,-1.958995389,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.141,mg/L,11/1/2017 13:18,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,859,8,2,84.13055556,84,.,.,.,0,0,1,72.5,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.5,mg/L,11/1/2017 13:18,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,860,8,2,84.13055556,168,.,.,.,0,0,4,56,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,56,u/ml,11/1/2017 13:18,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,861,8,2,84.13055556,168,.,.,.,0,0,5,348,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,348,u/ml,11/1/2017 13:18,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,862,8,2,84.13055556,168,.,.,.,0,0,6,74,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,74,u/ml,11/1/2017 13:18,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,863,8,2,98.1375,98,.,.,.,0,0,2,-2.520741103,1,0.078,2,0,StudyID,001-050,3 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.0804,mg/L,11/15/2017 13:28,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,864,8,2,98.1375,98,.,.,.,0,0,1,71.1,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.1,mg/L,11/15/2017 13:28,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,865,8,2,98.1375,196,.,.,.,0,0,4,39,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,39,u/ml,11/15/2017 13:28,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,866,8,2,98.1375,196,.,.,.,0,0,5,327,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,327,u/ml,11/15/2017 13:28,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,867,8,2,98.1375,196,.,.,.,0,0,6,69,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,69,u/ml,11/15/2017 13:28,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,868,8,2,112.1625,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-050,3 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/29/2017 14:04,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,869,8,2,112.1625,112,.,.,.,0,0,1,108,0,0.0078,0,0,StudyID,001-050,3 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,108,mg/L,11/29/2017 14:04,.,.,.,.,.,.,.,.,73.1,.,.,92.4,389
.,.,870,8,2,112.1625,224,.,.,.,0,0,4,67,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,67,u/ml,11/29/2017 14:04,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,871,8,2,112.1625,224,.,.,.,0,0,5,305,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,305,u/ml,11/29/2017 14:04,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
.,.,872,8,2,112.1625,224,.,.,.,0,0,6,81,.,.,0,0,StudyID,001-050,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,81,u/ml,11/29/2017 14:04,22,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,73.1,182,22.1,92.4,389
C,PRE-DOSE,873,9,1,-11.82083333,0,.,.,.,0,0,1,78.2,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.2,mg/L,6/29/2017 14:50,.,.,.,.,.,.,.,.,87,.,.,68.2,162
C,PRE-DOSE,874,9,1,-11.82083333,0,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,6/29/2017 14:50,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
C,PRE-DOSE,875,9,1,-11.82083333,0,.,.,.,0,0,5,198,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,198,u/ml,6/29/2017 14:50,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
C,PRE-DOSE,876,9,1,-11.82083333,0,.,.,.,0,0,6,51,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,51,u/ml,6/29/2017 14:50,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
C,PRE-DOSE,877,9,1,-0.828472222,-1,.,.,.,0,0,1,67.7,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.7,mg/L,7/10/2017 14:39,.,.,.,.,.,.,.,.,87,.,.,68.2,162
C,PRE-DOSE,878,9,1,-0.828472222,0,.,.,.,0,0,4,101,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,101,u/ml,7/10/2017 14:39,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
C,PRE-DOSE,879,9,1,-0.828472222,0,.,.,.,0,0,5,171,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,171,u/ml,7/10/2017 14:39,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
C,PRE-DOSE,880,9,1,-0.828472222,0,.,.,.,0,0,6,51,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,51,u/ml,7/10/2017 14:39,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
C,PRE-DOSE,881,9,1,-0.10625,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,7/11/2017 7:59,.,.,.,.,.,.,.,.,87,.,.,68.2,162
C,PRE-DOSE,882,9,1,-0.10625,0,.,.,.,0,0,1,68.2,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.2,mg/L,7/11/2017 7:59,.,.,.,.,.,.,.,.,87,.,.,68.2,162
C,PRE-DOSE,883,9,1,-0.10625,0,.,.,.,0,0,4,85,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,85,u/ml,7/11/2017 7:59,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
C,PRE-DOSE,884,9,1,-0.10625,0,.,.,.,0,0,5,162,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,162,u/ml,7/11/2017 7:59,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
C,PRE-DOSE,885,9,1,-0.10625,0,.,.,.,0,0,6,48,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,48,u/ml,7/11/2017 7:59,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,886,9,1,0,.,.,85,1854.545455,1,2,0,.,.,.,2,1,StudyID,001-052,1 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045833333,85,mg,85,INTRAVENOUS,1499769120,1499773080,Dupilumab,.,.,.,.,,.,.,.,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,887,9,1,0.045833333,0,.,.,.,0,0,2,3.254242969,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,25.9,mg/L,7/11/2017 11:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,888,9,1,0.045833333,0,.,.,.,0,0,1,56.5,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,56.5,mg/L,7/11/2017 11:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,889,9,1,0.045833333,0,.,.,.,0,0,4,67,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,67,u/ml,7/11/2017 11:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,890,9,1,0.045833333,0,.,.,.,0,0,5,12,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,12,u/ml,7/11/2017 11:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,891,9,1,0.045833333,0,.,.,.,0,0,6,19,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,19,u/ml,7/11/2017 11:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,892,9,1,0.05625,0.010416667,.,.,.,0,0,2,3.370738174,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,29.1,mg/L,7/11/2017 11:53,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,893,9,1,0.05625,0.010416667,.,.,.,0,0,1,61.8,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,61.8,mg/L,7/11/2017 11:53,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,894,9,1,0.05625,0.010416667,.,.,.,0,0,4,72,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,72,u/ml,7/11/2017 11:53,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,895,9,1,0.05625,0.010416667,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,7/11/2017 11:53,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,896,9,1,0.05625,0.010416667,.,.,.,0,0,6,19,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,19,u/ml,7/11/2017 11:53,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,897,9,1,0.066666667,0.020833333,.,.,.,0,0,2,3.314186005,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,27.5,mg/L,7/11/2017 12:08,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,898,9,1,0.066666667,0.020833333,.,.,.,0,0,1,63.2,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,63.2,mg/L,7/11/2017 12:08,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,899,9,1,0.066666667,0.020833333,.,.,.,0,0,4,74,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,74,u/ml,7/11/2017 12:08,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,900,9,1,0.066666667,0.020833333,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,7/11/2017 12:08,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,901,9,1,0.066666667,0.020833333,.,.,.,0,0,6,20,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,20,u/ml,7/11/2017 12:08,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,902,9,1,0.0875,0.041666667,.,.,.,0,0,2,3.342861805,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.3,mg/L,7/11/2017 12:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,903,9,1,0.0875,0.041666667,.,.,.,0,0,1,59.8,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,59.8,mg/L,7/11/2017 12:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,904,9,1,0.0875,0.041666667,.,.,.,0,0,4,76,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,76,u/ml,7/11/2017 12:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,905,9,1,0.0875,0.041666667,.,.,.,0,0,5,3,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,3,u/ml,7/11/2017 12:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,906,9,1,0.0875,0.041666667,.,.,.,0,0,6,21,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,21,u/ml,7/11/2017 12:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,907,9,1,0.129166667,0.083333333,.,.,.,0,0,2,3.335769576,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.1,mg/L,7/11/2017 13:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,908,9,1,0.129166667,0.083333333,.,.,.,0,0,1,59.4,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,59.4,mg/L,7/11/2017 13:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,909,9,1,0.129166667,0.083333333,.,.,.,0,0,4,75,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,75,u/ml,7/11/2017 13:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,910,9,1,0.129166667,0.083333333,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,7/11/2017 13:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,911,9,1,0.129166667,0.083333333,.,.,.,0,0,6,21,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,21,u/ml,7/11/2017 13:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,912,9,1,0.2125,0.166666667,.,.,.,0,0,2,3.325036021,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,27.8,mg/L,7/11/2017 15:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,913,9,1,0.2125,0.166666667,.,.,.,0,0,1,68.6,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.6,mg/L,7/11/2017 15:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,914,9,1,0.2125,0.166666667,.,.,.,0,0,4,77,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,77,u/ml,7/11/2017 15:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,915,9,1,0.2125,0.166666667,.,.,.,0,0,5,8,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,8,u/ml,7/11/2017 15:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,916,9,1,0.2125,0.166666667,.,.,.,0,0,6,23,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,23,u/ml,7/11/2017 15:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,917,9,1,0.379166667,0.333333333,.,.,.,0,0,2,3.169685581,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,23.8,mg/L,7/11/2017 19:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,918,9,1,0.379166667,0.333333333,.,.,.,0,0,1,60.5,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,60.5,mg/L,7/11/2017 19:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,919,9,1,0.379166667,0.333333333,.,.,.,0,0,4,72,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,72,u/ml,7/11/2017 19:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,920,9,1,0.379166667,0.333333333,.,.,.,0,0,5,21,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,21,u/ml,7/11/2017 19:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,921,9,1,0.379166667,0.333333333,.,.,.,0,0,6,24,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,24,u/ml,7/11/2017 19:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,922,9,1,0.545833333,0.5,.,.,.,0,0,2,3.091042453,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,22,mg/L,7/11/2017 23:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,923,9,1,0.545833333,0.5,.,.,.,0,0,1,60.9,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,60.9,mg/L,7/11/2017 23:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,924,9,1,0.545833333,0.5,.,.,.,0,0,4,77,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,77,u/ml,7/11/2017 23:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,925,9,1,0.545833333,0.5,.,.,.,0,0,5,10,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,10,u/ml,7/11/2017 23:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,926,9,1,0.545833333,0.5,.,.,.,0,0,6,28,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,28,u/ml,7/11/2017 23:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,927,9,1,1.045833333,1,.,.,.,0,0,2,2.985681938,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,19.8,mg/L,7/12/2017 11:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,928,9,1,1.045833333,1,.,.,.,0,0,1,67.2,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.2,mg/L,7/12/2017 11:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,929,9,1,1.045833333,1,.,.,.,0,0,4,83,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,83,u/ml,7/12/2017 11:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,930,9,1,1.045833333,1,.,.,.,0,0,5,81,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,81,u/ml,7/12/2017 11:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,931,9,1,1.045833333,1,.,.,.,0,0,6,35,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,35,u/ml,7/12/2017 11:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,932,9,1,3.004166667,3,.,.,.,0,0,2,2.740840024,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,15.5,mg/L,7/14/2017 10:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,933,9,1,3.004166667,3,.,.,.,0,0,1,77.5,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.5,mg/L,7/14/2017 10:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,934,9,1,3.004166667,3,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,7/14/2017 10:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,935,9,1,3.004166667,3,.,.,.,0,0,5,165,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,165,u/ml,7/14/2017 10:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,936,9,1,3.004166667,3,.,.,.,0,0,6,46,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,46,u/ml,7/14/2017 10:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,937,9,1,7.113194444,7,.,.,.,0,0,2,2.00148,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,7.4,mg/L,7/18/2017 13:15,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,938,9,1,7.113194444,7,.,.,.,0,0,1,77.8,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.8,mg/L,7/18/2017 13:15,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,939,9,1,7.113194444,14,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,7/18/2017 13:15,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,940,9,1,7.113194444,14,.,.,.,0,0,5,199,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,199,u/ml,7/18/2017 13:15,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,941,9,1,7.113194444,14,.,.,.,0,0,6,50,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,50,u/ml,7/18/2017 13:15,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,942,9,1,13.07638889,14,.,.,.,0,0,2,1.269760545,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.56,mg/L,7/24/2017 12:22,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,943,9,1,13.07638889,14,.,.,.,0,0,1,72.7,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.7,mg/L,7/24/2017 12:22,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,944,9,1,13.07638889,28,.,.,.,0,0,4,90,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,90,u/ml,7/24/2017 12:22,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,945,9,1,13.07638889,28,.,.,.,0,0,5,138,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,138,u/ml,7/24/2017 12:22,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,946,9,1,13.07638889,28,.,.,.,0,0,6,45,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,45,u/ml,7/24/2017 12:22,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,947,9,1,21.11875,21,.,.,.,0,0,2,0.412109651,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.51,mg/L,8/1/2017 13:23,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,948,9,1,21.11875,21,.,.,.,0,0,1,90.8,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.8,mg/L,8/1/2017 13:23,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,949,9,1,21.11875,42,.,.,.,0,0,4,110,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,110,u/ml,8/1/2017 13:23,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,950,9,1,21.11875,42,.,.,.,0,0,5,203,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,203,u/ml,8/1/2017 13:23,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,951,9,1,21.11875,42,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,8/1/2017 13:23,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,952,9,1,28.13055556,28,.,.,.,0,0,2,-0.387134151,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.679,mg/L,8/8/2017 13:40,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,953,9,1,28.13055556,28,.,.,.,0,0,1,75.2,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.2,mg/L,8/8/2017 13:40,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,954,9,1,28.13055556,56,.,.,.,0,0,4,87,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,87,u/ml,8/8/2017 13:40,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,955,9,1,28.13055556,56,.,.,.,0,0,5,164,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,164,u/ml,8/8/2017 13:40,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,956,9,1,28.13055556,56,.,.,.,0,0,6,47,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,47,u/ml,8/8/2017 13:40,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,957,9,1,42.14027778,42,.,.,.,0,0,2,-1.509592577,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.221,mg/L,8/22/2017 13:54,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,958,9,1,42.14027778,42,.,.,.,0,0,1,81.8,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.8,mg/L,8/22/2017 13:54,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,959,9,1,42.14027778,84,.,.,.,0,0,4,98,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,98,u/ml,8/22/2017 13:54,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,960,9,1,42.14027778,84,.,.,.,0,0,5,45,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,45,u/ml,8/22/2017 13:54,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,961,9,1,42.14027778,84,.,.,.,0,0,6,45,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,45,u/ml,8/22/2017 13:54,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,962,9,1,56.12916667,56,.,.,.,0,0,2,-2.48410697,1,0.078,2,0,StudyID,001-052,1 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.0834,mg/L,9/5/2017 13:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,963,9,1,56.12916667,56,.,.,.,0,0,1,85.6,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.6,mg/L,9/5/2017 13:38,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,964,9,1,56.12916667,112,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,9/5/2017 13:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,965,9,1,56.12916667,112,.,.,.,0,0,5,63,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,63,u/ml,9/5/2017 13:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,966,9,1,56.12916667,112,.,.,.,0,0,6,49,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,49,u/ml,9/5/2017 13:38,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,967,9,1,84.14305556,84,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-052,1 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/3/2017 13:58,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,968,9,1,84.14305556,84,.,.,.,0,0,1,77.7,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.7,mg/L,10/3/2017 13:58,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,969,9,1,84.14305556,168,.,.,.,0,0,4,106,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,106,u/ml,10/3/2017 13:58,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,970,9,1,84.14305556,168,.,.,.,0,0,5,77,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,77,u/ml,10/3/2017 13:58,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,971,9,1,84.14305556,168,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,10/3/2017 13:58,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,972,9,1,98.12430556,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-052,1 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/17/2017 13:31,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,973,9,1,98.12430556,98,.,.,.,0,0,1,84.2,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.2,mg/L,10/17/2017 13:31,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,974,9,1,98.12430556,196,.,.,.,0,0,4,106,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,106,u/ml,10/17/2017 13:31,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,975,9,1,98.12430556,196,.,.,.,0,0,5,212,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,212,u/ml,10/17/2017 13:31,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,976,9,1,98.12430556,196,.,.,.,0,0,6,62,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,62,u/ml,10/17/2017 13:31,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,977,9,1,112.1423611,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-052,1 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/31/2017 13:57,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,978,9,1,112.1423611,112,.,.,.,0,0,1,79.5,0,0.0078,0,0,StudyID,001-052,1 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.5,mg/L,10/31/2017 13:57,.,.,.,.,.,.,.,.,87,.,.,68.2,162
.,.,979,9,1,112.1423611,224,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,10/31/2017 13:57,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,980,9,1,112.1423611,224,.,.,.,0,0,5,191,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,191,u/ml,10/31/2017 13:57,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
.,.,981,9,1,112.1423611,224,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-052,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,10/31/2017 13:57,37,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,87,173,29.1,68.2,162
C,PRE-DOSE,982,10,2,-42.80347222,0,.,.,.,0,0,1,67.7,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.7,mg/L,7/11/2017 14:51,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
C,PRE-DOSE,983,10,2,-42.80347222,0,.,.,.,0,0,4,80,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,80,u/ml,7/11/2017 14:51,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
C,PRE-DOSE,984,10,2,-42.80347222,0,.,.,.,0,0,5,211,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,211,u/ml,7/11/2017 14:51,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
C,PRE-DOSE,985,10,2,-42.80347222,0,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,7/11/2017 14:51,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
C,PRE-DOSE,986,10,2,-0.855555556,-1,.,.,.,0,0,1,64,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64,mg/L,8/22/2017 13:36,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
C,PRE-DOSE,987,10,2,-0.855555556,0,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,8/22/2017 13:36,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
C,PRE-DOSE,988,10,2,-0.855555556,0,.,.,.,0,0,5,170,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,170,u/ml,8/22/2017 13:36,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
C,PRE-DOSE,989,10,2,-0.855555556,0,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,8/22/2017 13:36,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
C,PRE-DOSE,990,10,2,-0.125694444,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,8/23/2017 7:07,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
C,PRE-DOSE,991,10,2,-0.125694444,0,.,.,.,0,0,1,64.3,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.3,mg/L,8/23/2017 7:07,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
C,PRE-DOSE,992,10,2,-0.125694444,0,.,.,.,0,0,4,103,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,103,u/ml,8/23/2017 7:07,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
C,PRE-DOSE,993,10,2,-0.125694444,0,.,.,.,0,0,5,132,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,132,u/ml,8/23/2017 7:07,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
C,PRE-DOSE,994,10,2,-0.125694444,0,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,8/23/2017 7:07,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,995,10,2,0,.,.,170,3653.731343,1,2,0,.,.,.,2,1,StudyID,001-055,3 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.046527778,170,mg,170,INTRAVENOUS,1503482880,1503486900,Dupilumab,.,.,.,.,,.,.,.,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,996,10,2,0.046527778,0,.,.,.,0,0,2,4.188138442,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,65.9,mg/L,8/23/2017 11:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,997,10,2,0.046527778,0,.,.,.,0,0,1,55.1,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,55.1,mg/L,8/23/2017 11:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,998,10,2,0.046527778,0,.,.,.,0,0,4,25,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,25,u/ml,8/23/2017 11:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,999,10,2,0.046527778,0,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,8/23/2017 11:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1000,10,2,0.046527778,0,.,.,.,0,0,6,15,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,15,u/ml,8/23/2017 11:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1001,10,2,0.056944444,0.010416667,.,.,.,0,0,2,4.185098925,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,65.7,mg/L,8/23/2017 11:30,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1002,10,2,0.056944444,0.010416667,.,.,.,0,0,1,55.1,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,55.1,mg/L,8/23/2017 11:30,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1003,10,2,0.056944444,0.010416667,.,.,.,0,0,4,25,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,25,u/ml,8/23/2017 11:30,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1004,10,2,0.056944444,0.010416667,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,8/23/2017 11:30,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1005,10,2,0.056944444,0.010416667,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,8/23/2017 11:30,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1006,10,2,0.067361111,0.020833333,.,.,.,0,0,2,4.241326753,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,69.5,mg/L,8/23/2017 11:45,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1007,10,2,0.067361111,0.020833333,.,.,.,0,0,1,55.6,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,55.6,mg/L,8/23/2017 11:45,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1008,10,2,0.067361111,0.020833333,.,.,.,0,0,4,36,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,36,u/ml,8/23/2017 11:45,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1009,10,2,0.067361111,0.020833333,.,.,.,0,0,5,2,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,2,u/ml,8/23/2017 11:45,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1010,10,2,0.067361111,0.020833333,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,8/23/2017 11:45,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1011,10,2,0.088194444,0.041666667,.,.,.,0,0,2,4.147885329,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,63.3,mg/L,8/23/2017 12:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1012,10,2,0.088194444,0.041666667,.,.,.,0,0,1,56.1,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,56.1,mg/L,8/23/2017 12:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1013,10,2,0.088194444,0.041666667,.,.,.,0,0,4,24,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,24,u/ml,8/23/2017 12:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1014,10,2,0.088194444,0.041666667,.,.,.,0,0,5,3,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,3,u/ml,8/23/2017 12:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1015,10,2,0.088194444,0.041666667,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,8/23/2017 12:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1016,10,2,0.129861111,0.083333333,.,.,.,0,0,2,4.130355,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,62.2,mg/L,8/23/2017 13:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1017,10,2,0.129861111,0.083333333,.,.,.,0,0,1,56.1,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,56.1,mg/L,8/23/2017 13:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1018,10,2,0.129861111,0.083333333,.,.,.,0,0,4,21,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,21,u/ml,8/23/2017 13:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1019,10,2,0.129861111,0.083333333,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,8/23/2017 13:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1020,10,2,0.129861111,0.083333333,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,8/23/2017 13:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1021,10,2,0.213194444,0.166666667,.,.,.,0,0,2,4.154184563,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,63.7,mg/L,8/23/2017 15:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1022,10,2,0.213194444,0.166666667,.,.,.,0,0,1,55.6,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,55.6,mg/L,8/23/2017 15:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1023,10,2,0.213194444,0.166666667,.,.,.,0,0,4,42,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,42,u/ml,8/23/2017 15:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1024,10,2,0.213194444,0.166666667,.,.,.,0,0,5,3,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,3,u/ml,8/23/2017 15:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1025,10,2,0.213194444,0.166666667,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,8/23/2017 15:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1026,10,2,0.379861111,0.333333333,.,.,.,0,0,2,4.041295341,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,56.9,mg/L,8/23/2017 19:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1027,10,2,0.379861111,0.333333333,.,.,.,0,0,1,54.9,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,54.9,mg/L,8/23/2017 19:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1028,10,2,0.379861111,0.333333333,.,.,.,0,0,4,26,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,26,u/ml,8/23/2017 19:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1029,10,2,0.379861111,0.333333333,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,8/23/2017 19:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1030,10,2,0.379861111,0.333333333,.,.,.,0,0,6,17,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,17,u/ml,8/23/2017 19:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1031,10,2,0.546527778,0.5,.,.,.,0,0,2,4.041295341,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,56.9,mg/L,8/23/2017 23:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1032,10,2,0.546527778,0.5,.,.,.,0,0,1,58.7,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,58.7,mg/L,8/23/2017 23:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1033,10,2,0.546527778,0.5,.,.,.,0,0,4,37,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,37,u/ml,8/23/2017 23:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1034,10,2,0.546527778,0.5,.,.,.,0,0,5,3,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,3,u/ml,8/23/2017 23:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1035,10,2,0.546527778,0.5,.,.,.,0,0,6,19,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,19,u/ml,8/23/2017 23:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1036,10,2,1.046527778,1,.,.,.,0,0,2,3.90197267,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,49.5,mg/L,8/24/2017 11:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1037,10,2,1.046527778,1,.,.,.,0,0,1,60.4,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,60.4,mg/L,8/24/2017 11:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1038,10,2,1.046527778,1,.,.,.,0,0,4,34,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,34,u/ml,8/24/2017 11:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1039,10,2,1.046527778,1,.,.,.,0,0,5,2,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,2,u/ml,8/24/2017 11:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1040,10,2,1.046527778,1,.,.,.,0,0,6,20,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,20,u/ml,8/24/2017 11:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1041,10,2,3.046527778,3,.,.,.,0,0,2,3.569532696,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,35.5,mg/L,8/26/2017 11:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1042,10,2,3.046527778,3,.,.,.,0,0,1,63.7,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,63.7,mg/L,8/26/2017 11:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1043,10,2,3.046527778,3,.,.,.,0,0,4,53,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,53,u/ml,8/26/2017 11:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1044,10,2,3.046527778,3,.,.,.,0,0,5,15,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,15,u/ml,8/26/2017 11:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1045,10,2,3.046527778,3,.,.,.,0,0,6,35,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,35,u/ml,8/26/2017 11:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1046,10,2,7.163194444,7,.,.,.,0,0,2,3.100092289,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,22.2,mg/L,8/30/2017 14:03,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1047,10,2,7.163194444,7,.,.,.,0,0,1,68.3,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.3,mg/L,8/30/2017 14:03,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1048,10,2,7.163194444,14,.,.,.,0,0,4,82,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,82,u/ml,8/30/2017 14:03,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1049,10,2,7.163194444,14,.,.,.,0,0,5,31,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,31,u/ml,8/30/2017 14:03,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1050,10,2,7.163194444,14,.,.,.,0,0,6,47,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,47,u/ml,8/30/2017 14:03,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1051,10,2,14.12986111,14,.,.,.,0,0,2,2.302585093,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,10,mg/L,9/6/2017 13:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1052,10,2,14.12986111,14,.,.,.,0,0,1,54.6,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,54.6,mg/L,9/6/2017 13:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1053,10,2,14.12986111,28,.,.,.,0,0,4,72,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,72,u/ml,9/6/2017 13:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1054,10,2,14.12986111,28,.,.,.,0,0,5,50,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,50,u/ml,9/6/2017 13:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1055,10,2,14.12986111,28,.,.,.,0,0,6,46,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,46,u/ml,9/6/2017 13:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1056,10,2,21.13888889,21,.,.,.,0,0,2,1.665818246,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,5.29,mg/L,9/13/2017 13:28,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1057,10,2,21.13888889,21,.,.,.,0,0,1,50.9,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,50.9,mg/L,9/13/2017 13:28,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1058,10,2,21.13888889,42,.,.,.,0,0,4,70,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,70,u/ml,9/13/2017 13:28,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1059,10,2,21.13888889,42,.,.,.,0,0,5,53,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,53,u/ml,9/13/2017 13:28,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1060,10,2,21.13888889,42,.,.,.,0,0,6,51,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,51,u/ml,9/13/2017 13:28,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1061,10,2,28.14861111,28,.,.,.,0,0,2,1.187843422,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.28,mg/L,9/20/2017 13:42,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1062,10,2,28.14861111,28,.,.,.,0,0,1,58.6,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,58.6,mg/L,9/20/2017 13:42,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1063,10,2,28.14861111,56,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,9/20/2017 13:42,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1064,10,2,28.14861111,56,.,.,.,0,0,5,160,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,160,u/ml,9/20/2017 13:42,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1065,10,2,28.14861111,56,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,9/20/2017 13:42,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1066,10,2,42.15138889,42,.,.,.,0,0,2,0.165514438,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.18,mg/L,10/4/2017 13:46,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1067,10,2,42.15138889,42,.,.,.,0,0,1,55.6,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,55.6,mg/L,10/4/2017 13:46,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1068,10,2,42.15138889,84,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,10/4/2017 13:46,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1069,10,2,42.15138889,84,.,.,.,0,0,5,165,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,165,u/ml,10/4/2017 13:46,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1070,10,2,42.15138889,84,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,10/4/2017 13:46,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1071,10,2,56.15902778,56,.,.,.,0,0,2,-0.776528789,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.46,mg/L,10/18/2017 13:57,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1072,10,2,56.15902778,56,.,.,.,0,0,1,54,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,54,mg/L,10/18/2017 13:57,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1073,10,2,56.15902778,112,.,.,.,0,0,4,75,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,75,u/ml,10/18/2017 13:57,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1074,10,2,56.15902778,112,.,.,.,0,0,5,182,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,182,u/ml,10/18/2017 13:57,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1075,10,2,56.15902778,112,.,.,.,0,0,6,62,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,62,u/ml,10/18/2017 13:57,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1076,10,2,84.14513889,84,.,.,.,0,0,2,-2.282782466,1,0.078,2,0,StudyID,001-055,3 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.102,mg/L,11/15/2017 13:37,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1077,10,2,84.14513889,84,.,.,.,0,0,1,84.6,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.6,mg/L,11/15/2017 13:37,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1078,10,2,84.14513889,168,.,.,.,0,0,4,115,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,115,u/ml,11/15/2017 13:37,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1079,10,2,84.14513889,168,.,.,.,0,0,5,297,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,297,u/ml,11/15/2017 13:37,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1080,10,2,84.14513889,168,.,.,.,0,0,6,83,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,83,u/ml,11/15/2017 13:37,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1081,10,2,98.17152778,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-055,3 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/29/2017 14:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1082,10,2,98.17152778,98,.,.,.,0,0,1,80.9,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.9,mg/L,11/29/2017 14:15,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1083,10,2,98.17152778,196,.,.,.,0,0,4,87,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,87,u/ml,11/29/2017 14:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1084,10,2,98.17152778,196,.,.,.,0,0,5,239,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,239,u/ml,11/29/2017 14:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1085,10,2,98.17152778,196,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,11/29/2017 14:15,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1086,10,2,112.1555556,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-055,3 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,12/13/2017 13:52,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1087,10,2,112.1555556,112,.,.,.,0,0,1,67.7,0,0.0078,0,0,StudyID,001-055,3 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.7,mg/L,12/13/2017 13:52,.,.,.,.,.,.,.,.,56.1,.,.,64.3,132
.,.,1088,10,2,112.1555556,224,.,.,.,0,0,4,69,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,69,u/ml,12/13/2017 13:52,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1089,10,2,112.1555556,224,.,.,.,0,0,5,183,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,183,u/ml,12/13/2017 13:52,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
.,.,1090,10,2,112.1555556,224,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-055,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,12/13/2017 13:52,33,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.1,162,21.4,64.3,132
C,PRE-DOSE,1091,11,1,-68.87152778,0,.,.,.,0,0,1,94,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 997,997,U1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,94,mg/L,5/10/2017 13:55,.,.,.,.,.,.,.,.,62.1,.,.,82,178
C,PRE-DOSE,1092,11,1,-4.869444444,0,.,.,.,0,0,4,97,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,97,u/ml,7/13/2017 13:58,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
C,PRE-DOSE,1093,11,1,-4.869444444,0,.,.,.,0,0,5,237,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,237,u/ml,7/13/2017 13:58,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
C,PRE-DOSE,1094,11,1,-4.869444444,0,.,.,.,0,0,6,72,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,72,u/ml,7/13/2017 13:58,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
C,PRE-DOSE,1095,11,1,-0.891666667,-1,.,.,.,0,0,1,88.9,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88.9,mg/L,7/17/2017 13:26,.,.,.,.,.,.,.,.,62.1,.,.,82,178
C,PRE-DOSE,1096,11,1,-0.891666667,0,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,7/17/2017 13:26,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
C,PRE-DOSE,1097,11,1,-0.891666667,0,.,.,.,0,0,5,228,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,228,u/ml,7/17/2017 13:26,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
C,PRE-DOSE,1098,11,1,-0.891666667,0,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,7/17/2017 13:26,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
C,PRE-DOSE,1099,11,1,-0.108333333,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,7/18/2017 8:14,.,.,.,.,.,.,.,.,62.1,.,.,82,178
C,PRE-DOSE,1100,11,1,-0.108333333,0,.,.,.,0,0,1,82,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82,mg/L,7/18/2017 8:14,.,.,.,.,.,.,.,.,62.1,.,.,82,178
C,PRE-DOSE,1101,11,1,-0.108333333,0,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,7/18/2017 8:14,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
C,PRE-DOSE,1102,11,1,-0.108333333,0,.,.,.,0,0,5,178,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,178,u/ml,7/18/2017 8:14,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
C,PRE-DOSE,1103,11,1,-0.108333333,0,.,.,.,0,0,6,61,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,61,u/ml,7/18/2017 8:14,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1104,11,1,0,.,.,60,1309.090909,1,2,0,.,.,.,2,1,StudyID,001-056,1 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045833333,60,mg,60,INTRAVENOUS,1500375000,1500378960,Dupilumab,.,.,.,.,,.,.,.,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1105,11,1,0.045833333,0,.,.,.,0,0,2,3.36729583,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,29,mg/L,7/18/2017 11:56,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1106,11,1,0.045833333,0,.,.,.,0,0,1,75.2,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.2,mg/L,7/18/2017 11:56,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1107,11,1,0.045833333,0,.,.,.,0,0,4,79,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,79,u/ml,7/18/2017 11:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1108,11,1,0.045833333,0,.,.,.,0,0,5,57,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,57,u/ml,7/18/2017 11:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1109,11,1,0.045833333,0,.,.,.,0,0,6,42,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,42,u/ml,7/18/2017 11:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1110,11,1,0.05625,0.010416667,.,.,.,0,0,2,3.295836866,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,27,mg/L,7/18/2017 12:11,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1111,11,1,0.05625,0.010416667,.,.,.,0,0,1,78.1,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.1,mg/L,7/18/2017 12:11,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1112,11,1,0.05625,0.010416667,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,7/18/2017 12:11,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1113,11,1,0.05625,0.010416667,.,.,.,0,0,5,42,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,42,u/ml,7/18/2017 12:11,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1114,11,1,0.05625,0.010416667,.,.,.,0,0,6,42,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,42,u/ml,7/18/2017 12:11,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1115,11,1,0.066666667,0.020833333,.,.,.,0,0,2,3.246490992,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,25.7,mg/L,7/18/2017 12:26,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1116,11,1,0.066666667,0.020833333,.,.,.,0,0,1,76.1,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.1,mg/L,7/18/2017 12:26,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1117,11,1,0.066666667,0.020833333,.,.,.,0,0,4,98,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,98,u/ml,7/18/2017 12:26,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1118,11,1,0.066666667,0.020833333,.,.,.,0,0,5,47,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,47,u/ml,7/18/2017 12:26,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1119,11,1,0.066666667,0.020833333,.,.,.,0,0,6,44,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,44,u/ml,7/18/2017 12:26,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1120,11,1,0.0875,0.041666667,.,.,.,0,0,2,3.269568939,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,26.3,mg/L,7/18/2017 12:56,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1121,11,1,0.0875,0.041666667,.,.,.,0,0,1,71.2,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.2,mg/L,7/18/2017 12:56,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1122,11,1,0.0875,0.041666667,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,7/18/2017 12:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1123,11,1,0.0875,0.041666667,.,.,.,0,0,5,65,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,65,u/ml,7/18/2017 12:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1124,11,1,0.0875,0.041666667,.,.,.,0,0,6,44,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,44,u/ml,7/18/2017 12:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1125,11,1,0.130555556,0.083333333,.,.,.,0,0,2,3.210843653,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,24.8,mg/L,7/18/2017 13:58,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1126,11,1,0.130555556,0.083333333,.,.,.,0,0,1,74.1,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.1,mg/L,7/18/2017 13:58,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1127,11,1,0.130555556,0.083333333,.,.,.,0,0,4,91,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,91,u/ml,7/18/2017 13:58,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1128,11,1,0.130555556,0.083333333,.,.,.,0,0,5,24,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,24,u/ml,7/18/2017 13:58,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1129,11,1,0.130555556,0.083333333,.,.,.,0,0,6,42,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,42,u/ml,7/18/2017 13:58,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1130,11,1,0.214583333,0.166666667,.,.,.,0,0,2,3.299533728,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,27.1,mg/L,7/18/2017 15:59,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1131,11,1,0.214583333,0.166666667,.,.,.,0,0,1,75.5,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.5,mg/L,7/18/2017 15:59,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1132,11,1,0.214583333,0.166666667,.,.,.,0,0,4,83,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,83,u/ml,7/18/2017 15:59,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1133,11,1,0.214583333,0.166666667,.,.,.,0,0,5,67,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,67,u/ml,7/18/2017 15:59,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1134,11,1,0.214583333,0.166666667,.,.,.,0,0,6,47,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,47,u/ml,7/18/2017 15:59,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1135,11,1,0.379861111,0.333333333,.,.,.,0,0,2,3.186352633,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,24.2,mg/L,7/18/2017 19:57,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1136,11,1,0.379861111,0.333333333,.,.,.,0,0,1,72.5,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.5,mg/L,7/18/2017 19:57,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1137,11,1,0.379861111,0.333333333,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,7/18/2017 19:57,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1138,11,1,0.379861111,0.333333333,.,.,.,0,0,5,74,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,74,u/ml,7/18/2017 19:57,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1139,11,1,0.379861111,0.333333333,.,.,.,0,0,6,49,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,49,u/ml,7/18/2017 19:57,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1140,11,1,0.545833333,0.5,.,.,.,0,0,2,3.157000421,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,23.5,mg/L,7/18/2017 23:56,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1141,11,1,0.545833333,0.5,.,.,.,0,0,1,69,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69,mg/L,7/18/2017 23:56,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1142,11,1,0.545833333,0.5,.,.,.,0,0,4,74,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,74,u/ml,7/18/2017 23:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1143,11,1,0.545833333,0.5,.,.,.,0,0,5,93,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,93,u/ml,7/18/2017 23:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1144,11,1,0.545833333,0.5,.,.,.,0,0,6,48,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,48,u/ml,7/18/2017 23:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1145,11,1,1.045833333,1,.,.,.,0,0,2,3.08190997,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,21.8,mg/L,7/19/2017 11:56,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1146,11,1,1.045833333,1,.,.,.,0,0,1,79,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79,mg/L,7/19/2017 11:56,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1147,11,1,1.045833333,1,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,7/19/2017 11:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1148,11,1,1.045833333,1,.,.,.,0,0,5,139,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,139,u/ml,7/19/2017 11:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1149,11,1,1.045833333,1,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,7/19/2017 11:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1150,11,1,3.004166667,3,.,.,.,0,0,2,2.687847494,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,14.7,mg/L,7/21/2017 10:56,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1151,11,1,3.004166667,3,.,.,.,0,0,1,101,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,101,mg/L,7/21/2017 10:56,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1152,11,1,3.004166667,3,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,7/21/2017 10:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1153,11,1,3.004166667,3,.,.,.,0,0,5,210,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,210,u/ml,7/21/2017 10:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1154,11,1,3.004166667,3,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,7/21/2017 10:56,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1155,11,1,7.111111111,7,.,.,.,0,0,2,2.084429083,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,8.04,mg/L,7/25/2017 13:30,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1156,11,1,7.111111111,7,.,.,.,0,0,1,83,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83,mg/L,7/25/2017 13:30,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1157,11,1,7.111111111,14,.,.,.,0,0,4,78,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,78,u/ml,7/25/2017 13:30,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1158,11,1,7.111111111,14,.,.,.,0,0,5,225,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,225,u/ml,7/25/2017 13:30,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1159,11,1,7.111111111,14,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,7/25/2017 13:30,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1160,11,1,14.10972222,14,.,.,.,0,0,2,1.311031877,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.71,mg/L,8/1/2017 13:28,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1161,11,1,14.10972222,14,.,.,.,0,0,1,93.8,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,93.8,mg/L,8/1/2017 13:28,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1162,11,1,14.10972222,28,.,.,.,0,0,4,104,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,104,u/ml,8/1/2017 13:28,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1163,11,1,14.10972222,28,.,.,.,0,0,5,239,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,239,u/ml,8/1/2017 13:28,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1164,11,1,14.10972222,28,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,8/1/2017 13:28,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1165,11,1,21.12222222,21,.,.,.,0,0,2,0.593326845,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.81,mg/L,8/8/2017 13:46,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1166,11,1,21.12222222,21,.,.,.,0,0,1,74.9,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.9,mg/L,8/8/2017 13:46,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1167,11,1,21.12222222,42,.,.,.,0,0,4,104,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,104,u/ml,8/8/2017 13:46,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1168,11,1,21.12222222,42,.,.,.,0,0,5,245,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,245,u/ml,8/8/2017 13:46,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1169,11,1,21.12222222,42,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,8/8/2017 13:46,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1170,11,1,28.11458333,28,.,.,.,0,0,2,-0.149660775,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.861,mg/L,8/15/2017 13:35,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1171,11,1,28.11458333,28,.,.,.,0,0,1,80.9,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.9,mg/L,8/15/2017 13:35,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1172,11,1,28.11458333,56,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,8/15/2017 13:35,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1173,11,1,28.11458333,56,.,.,.,0,0,5,234,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,234,u/ml,8/15/2017 13:35,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1174,11,1,28.11458333,56,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,8/15/2017 13:35,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1175,11,1,42.12013889,42,.,.,.,0,0,2,-1.358679194,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.257,mg/L,8/29/2017 13:43,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1176,11,1,42.12013889,42,.,.,.,0,0,1,90.9,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.9,mg/L,8/29/2017 13:43,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1177,11,1,42.12013889,84,.,.,.,0,0,4,102,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,102,u/ml,8/29/2017 13:43,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1178,11,1,42.12013889,84,.,.,.,0,0,5,76,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,76,u/ml,8/29/2017 13:43,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1179,11,1,42.12013889,84,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,8/29/2017 13:43,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1180,11,1,56.09791667,56,.,.,.,0,0,2,-2.42249539,1,0.078,2,0,StudyID,001-056,1 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.0887,mg/L,9/12/2017 13:11,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1181,11,1,56.09791667,56,.,.,.,0,0,1,87.1,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.1,mg/L,9/12/2017 13:11,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1182,11,1,56.09791667,112,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,9/12/2017 13:11,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1183,11,1,56.09791667,112,.,.,.,0,0,5,58,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,58,u/ml,9/12/2017 13:11,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1184,11,1,56.09791667,112,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,9/12/2017 13:11,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1185,11,1,84.1,84,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-056,1 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/10/2017 13:14,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1186,11,1,84.1,84,.,.,.,0,0,1,78.2,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.2,mg/L,10/10/2017 13:14,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1187,11,1,84.1,168,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,10/10/2017 13:14,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1188,11,1,84.1,168,.,.,.,0,0,5,57,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,57,u/ml,10/10/2017 13:14,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1189,11,1,84.1,168,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,10/10/2017 13:14,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1190,11,1,98.10069444,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-056,1 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/24/2017 13:15,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1191,11,1,98.10069444,98,.,.,.,0,0,1,92.1,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,92.1,mg/L,10/24/2017 13:15,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1192,11,1,98.10069444,196,.,.,.,0,0,4,102,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,102,u/ml,10/24/2017 13:15,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1193,11,1,98.10069444,196,.,.,.,0,0,5,176,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,176,u/ml,10/24/2017 13:15,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1194,11,1,98.10069444,196,.,.,.,0,0,6,75,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,75,u/ml,10/24/2017 13:15,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1195,11,1,112.0993056,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-056,1 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/7/2017 13:13,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1196,11,1,112.0993056,112,.,.,.,0,0,1,76.1,0,0.0078,0,0,StudyID,001-056,1 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.1,mg/L,11/7/2017 13:13,.,.,.,.,.,.,.,.,62.1,.,.,82,178
.,.,1197,11,1,112.0993056,224,.,.,.,0,0,4,98,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,98,u/ml,11/7/2017 13:13,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1198,11,1,112.0993056,224,.,.,.,0,0,5,201,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,201,u/ml,11/7/2017 13:13,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
.,.,1199,11,1,112.0993056,224,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-056,1 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,11/7/2017 13:13,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.1,156,25.5,82,178
C,PRE-DOSE,1200,12,3,-53.825,0,.,.,.,0,0,1,74.1,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.1,mg/L,7/19/2017 15:22,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
C,PRE-DOSE,1201,12,3,-53.825,0,.,.,.,0,0,4,87,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,87,u/ml,7/19/2017 15:22,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
C,PRE-DOSE,1202,12,3,-53.825,0,.,.,.,0,0,5,223,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,223,u/ml,7/19/2017 15:22,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
C,PRE-DOSE,1203,12,3,-53.825,0,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,7/19/2017 15:22,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
C,PRE-DOSE,1204,12,3,-0.868055556,-1,.,.,.,0,0,1,77.1,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.1,mg/L,9/10/2017 14:20,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
C,PRE-DOSE,1205,12,3,-0.868055556,0,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,9/10/2017 14:20,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
C,PRE-DOSE,1206,12,3,-0.868055556,0,.,.,.,0,0,5,149,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,149,u/ml,9/10/2017 14:20,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
C,PRE-DOSE,1207,12,3,-0.868055556,0,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,9/10/2017 14:20,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
C,PRE-DOSE,1208,12,3,-0.154861111,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/11/2017 7:27,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
C,PRE-DOSE,1209,12,3,-0.154861111,0,.,.,.,0,0,1,79.1,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.1,mg/L,9/11/2017 7:27,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
C,PRE-DOSE,1210,12,3,-0.154861111,0,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,9/11/2017 7:27,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
C,PRE-DOSE,1211,12,3,-0.154861111,0,.,.,.,0,0,5,188,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,188,u/ml,9/11/2017 7:27,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
C,PRE-DOSE,1212,12,3,-0.154861111,0,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,9/11/2017 7:27,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1213,12,3,0,.,.,300,.,1,1,0,.,.,.,1,1,StudyID,001-057,300 mg SC,VISIT 4 (DAY 1) BASELINE,1,.,0,300,mg,300,SUBCUTANEOUS,1505128200,1505128200,Dupilumab,.,.,.,.,,.,.,.,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1214,12,3,0,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/11/2017 11:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1215,12,3,0,0,.,.,.,0,0,1,74,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74,mg/L,9/11/2017 11:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1216,12,3,0,0,.,.,.,0,0,4,106,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,106,u/ml,9/11/2017 11:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1217,12,3,0,0,.,.,.,0,0,5,199,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,199,u/ml,9/11/2017 11:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1218,12,3,0,0,.,.,.,0,0,6,51,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,51,u/ml,9/11/2017 11:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1219,12,3,0.010416667,0.010416667,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/11/2017 11:25,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1220,12,3,0.010416667,0.010416667,.,.,.,0,0,1,70.9,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.9,mg/L,9/11/2017 11:25,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1221,12,3,0.010416667,0.010416667,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,9/11/2017 11:25,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1222,12,3,0.010416667,0.010416667,.,.,.,0,0,5,123,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,123,u/ml,9/11/2017 11:25,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1223,12,3,0.010416667,0.010416667,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,9/11/2017 11:25,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1224,12,3,0.020833333,0.020833333,.,.,.,0,0,2,-2.390324007,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.0916,mg/L,9/11/2017 11:40,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1225,12,3,0.020833333,0.020833333,.,.,.,0,0,1,80.2,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.2,mg/L,9/11/2017 11:40,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1226,12,3,0.020833333,0.020833333,.,.,.,0,0,4,117,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,117,u/ml,9/11/2017 11:40,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1227,12,3,0.020833333,0.020833333,.,.,.,0,0,5,142,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,142,u/ml,9/11/2017 11:40,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1228,12,3,0.020833333,0.020833333,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,9/11/2017 11:40,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1229,12,3,0.041666667,0.041666667,.,.,.,0,0,2,-2.079441542,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.125,mg/L,9/11/2017 12:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1230,12,3,0.041666667,0.041666667,.,.,.,0,0,1,80.8,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.8,mg/L,9/11/2017 12:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1231,12,3,0.041666667,0.041666667,.,.,.,0,0,4,117,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,117,u/ml,9/11/2017 12:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1232,12,3,0.041666667,0.041666667,.,.,.,0,0,5,142,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,142,u/ml,9/11/2017 12:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1233,12,3,0.041666667,0.041666667,.,.,.,0,0,6,50,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,50,u/ml,9/11/2017 12:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1234,12,3,0.083333333,0.083333333,.,.,.,0,0,2,-0.865122445,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.421,mg/L,9/11/2017 13:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1235,12,3,0.083333333,0.083333333,.,.,.,0,0,1,73.2,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.2,mg/L,9/11/2017 13:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1236,12,3,0.083333333,0.083333333,.,.,.,0,0,4,114,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,114,u/ml,9/11/2017 13:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1237,12,3,0.083333333,0.083333333,.,.,.,0,0,5,101,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,101,u/ml,9/11/2017 13:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1238,12,3,0.083333333,0.083333333,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,9/11/2017 13:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1239,12,3,0.166666667,0.166666667,.,.,.,0,0,2,0.722705983,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.06,mg/L,9/11/2017 15:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1240,12,3,0.166666667,0.166666667,.,.,.,0,0,1,75.8,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.8,mg/L,9/11/2017 15:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1241,12,3,0.166666667,0.166666667,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,9/11/2017 15:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1242,12,3,0.166666667,0.166666667,.,.,.,0,0,5,153,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,153,u/ml,9/11/2017 15:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1243,12,3,0.166666667,0.166666667,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,9/11/2017 15:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1244,12,3,0.333333333,0.333333333,.,.,.,0,0,2,1.887069649,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,6.6,mg/L,9/11/2017 19:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1245,12,3,0.333333333,0.333333333,.,.,.,0,0,1,71.4,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.4,mg/L,9/11/2017 19:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1246,12,3,0.333333333,0.333333333,.,.,.,0,0,4,90,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,90,u/ml,9/11/2017 19:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1247,12,3,0.333333333,0.333333333,.,.,.,0,0,5,173,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,173,u/ml,9/11/2017 19:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1248,12,3,0.333333333,0.333333333,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,9/11/2017 19:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1249,12,3,0.5,0.5,.,.,.,0,0,2,2.233235015,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,9.33,mg/L,9/11/2017 23:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1250,12,3,0.5,0.5,.,.,.,0,0,1,69.6,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.6,mg/L,9/11/2017 23:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1251,12,3,0.5,0.5,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,9/11/2017 23:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1252,12,3,0.5,0.5,.,.,.,0,0,5,87,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,87,u/ml,9/11/2017 23:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1253,12,3,0.5,0.5,.,.,.,0,0,6,49,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,49,u/ml,9/11/2017 23:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1254,12,3,1,1,.,.,.,0,0,2,2.833213344,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,17,mg/L,9/12/2017 11:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1255,12,3,1,1,.,.,.,0,0,1,72.9,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.9,mg/L,9/12/2017 11:10,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1256,12,3,1,1,.,.,.,0,0,4,90,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,90,u/ml,9/12/2017 11:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1257,12,3,1,1,.,.,.,0,0,5,142,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,142,u/ml,9/12/2017 11:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1258,12,3,1,1,.,.,.,0,0,6,50,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,50,u/ml,9/12/2017 11:10,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1259,12,3,2.993055556,3,.,.,.,0,0,2,3.360375387,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.8,mg/L,9/14/2017 11:00,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1260,12,3,2.993055556,3,.,.,.,0,0,1,71.8,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.8,mg/L,9/14/2017 11:00,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1261,12,3,2.993055556,3,.,.,.,0,0,4,89,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,89,u/ml,9/14/2017 11:00,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1262,12,3,2.993055556,3,.,.,.,0,0,5,78,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,78,u/ml,9/14/2017 11:00,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1263,12,3,2.993055556,3,.,.,.,0,0,6,38,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,38,u/ml,9/14/2017 11:00,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1264,12,3,5.889583333,7,.,.,.,0,0,2,3.671224519,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,39.3,mg/L,9/17/2017 8:31,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1265,12,3,5.889583333,7,.,.,.,0,0,1,84.4,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.4,mg/L,9/17/2017 8:31,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1266,12,3,5.889583333,14,.,.,.,0,0,4,109,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,109,u/ml,9/17/2017 8:31,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1267,12,3,5.889583333,14,.,.,.,0,0,5,125,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,125,u/ml,9/17/2017 8:31,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1268,12,3,5.889583333,14,.,.,.,0,0,6,42,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,42,u/ml,9/17/2017 8:31,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1269,12,3,14.08263889,14,.,.,.,0,0,2,3.218875825,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,25,mg/L,9/25/2017 13:09,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1270,12,3,14.08263889,14,.,.,.,0,0,1,89.9,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,89.9,mg/L,9/25/2017 13:09,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1271,12,3,14.08263889,28,.,.,.,0,0,4,98,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,98,u/ml,9/25/2017 13:09,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1272,12,3,14.08263889,28,.,.,.,0,0,5,157,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,157,u/ml,9/25/2017 13:09,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1273,12,3,14.08263889,28,.,.,.,0,0,6,50,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,50,u/ml,9/25/2017 13:09,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1274,12,3,21.12847222,21,.,.,.,0,0,2,2.557227311,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,12.9,mg/L,10/2/2017 14:15,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1275,12,3,21.12847222,21,.,.,.,0,0,1,86.2,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,86.2,mg/L,10/2/2017 14:15,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1276,12,3,21.12847222,42,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,10/2/2017 14:15,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1277,12,3,21.12847222,42,.,.,.,0,0,5,203,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,203,u/ml,10/2/2017 14:15,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1278,12,3,21.12847222,42,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,10/2/2017 14:15,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1279,12,3,28.09722222,28,.,.,.,0,0,2,2.084429083,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,8.04,mg/L,10/9/2017 13:30,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1280,12,3,28.09722222,28,.,.,.,0,0,1,81,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81,mg/L,10/9/2017 13:30,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1281,12,3,28.09722222,56,.,.,.,0,0,4,77,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,77,u/ml,10/9/2017 13:30,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1282,12,3,28.09722222,56,.,.,.,0,0,5,89,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,89,u/ml,10/9/2017 13:30,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1283,12,3,28.09722222,56,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,10/9/2017 13:30,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1284,12,3,42.29861111,42,.,.,.,0,0,2,0.966983846,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.63,mg/L,10/23/2017 18:20,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1285,12,3,42.29861111,42,.,.,.,0,0,1,93.3,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,93.3,mg/L,10/23/2017 18:20,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1286,12,3,42.29861111,84,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,10/23/2017 18:20,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1287,12,3,42.29861111,84,.,.,.,0,0,5,219,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,219,u/ml,10/23/2017 18:20,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1288,12,3,42.29861111,84,.,.,.,0,0,6,50,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,50,u/ml,10/23/2017 18:20,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1289,12,3,56.12986111,56,.,.,.,0,0,2,-0.424647928,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.654,mg/L,11/6/2017 14:17,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1290,12,3,56.12986111,56,.,.,.,0,0,1,82.9,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.9,mg/L,11/6/2017 14:17,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1291,12,3,56.12986111,112,.,.,.,0,0,4,91,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,91,u/ml,11/6/2017 14:17,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1292,12,3,56.12986111,112,.,.,.,0,0,5,182,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,182,u/ml,11/6/2017 14:17,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1293,12,3,56.12986111,112,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,11/6/2017 14:17,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1294,12,3,84.09166667,84,.,.,.,0,0,2,-1.5945493,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.203,mg/L,12/4/2017 13:22,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1295,12,3,84.09166667,84,.,.,.,0,0,1,86.2,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,86.2,mg/L,12/4/2017 13:22,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1296,12,3,84.09166667,168,.,.,.,0,0,4,80,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,80,u/ml,12/4/2017 13:22,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1297,12,3,84.09166667,168,.,.,.,0,0,5,204,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,204,u/ml,12/4/2017 13:22,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1298,12,3,84.09166667,168,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,12/4/2017 13:22,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1299,12,3,98.12430556,98,.,.,.,0,0,2,-2.3892329,1,0.078,2,0,StudyID,001-057,300 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.0917,mg/L,12/18/2017 14:09,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1300,12,3,98.12430556,98,.,.,.,0,0,1,91.6,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,91.6,mg/L,12/18/2017 14:09,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1301,12,3,98.12430556,196,.,.,.,0,0,4,81,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,81,u/ml,12/18/2017 14:09,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1302,12,3,98.12430556,196,.,.,.,0,0,5,182,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,182,u/ml,12/18/2017 14:09,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1303,12,3,98.12430556,196,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,12/18/2017 14:09,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1304,12,3,113.1145833,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-057,300 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,1/2/2018 13:55,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1305,12,3,113.1145833,112,.,.,.,0,0,1,68.9,0,0.0078,0,0,StudyID,001-057,300 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.9,mg/L,1/2/2018 13:55,.,.,.,.,.,.,.,.,72.1,.,.,79.1,188
.,.,1306,12,3,113.1145833,224,.,.,.,0,0,4,89,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,89,u/ml,1/2/2018 13:55,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1307,12,3,113.1145833,224,.,.,.,0,0,5,204,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,204,u/ml,1/2/2018 13:55,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
.,.,1308,12,3,113.1145833,224,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-057,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,1/2/2018 13:55,19,YEARS,M,1,ASIAN,3,Not Hispanic or Latino,.,72.1,176,23.3,79.1,188
C,PRE-DOSE,1309,13,3,-47.84861111,0,.,.,.,0,0,1,66.1,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.1,mg/L,8/1/2017 14:38,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
C,PRE-DOSE,1310,13,3,-47.84861111,0,.,.,.,0,0,4,121,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,121,u/ml,8/1/2017 14:38,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
C,PRE-DOSE,1311,13,3,-47.84861111,0,.,.,.,0,0,5,230,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,230,u/ml,8/1/2017 14:38,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
C,PRE-DOSE,1312,13,3,-47.84861111,0,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,8/1/2017 14:38,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
C,PRE-DOSE,1313,13,3,-0.877083333,-1,.,.,.,0,0,1,80.1,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.1,mg/L,9/17/2017 13:57,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
C,PRE-DOSE,1314,13,3,-0.877083333,0,.,.,.,0,0,4,116,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,116,u/ml,9/17/2017 13:57,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
C,PRE-DOSE,1315,13,3,-0.877083333,0,.,.,.,0,0,5,212,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,212,u/ml,9/17/2017 13:57,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
C,PRE-DOSE,1316,13,3,-0.877083333,0,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,9/17/2017 13:57,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
C,PRE-DOSE,1317,13,3,-0.160416667,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/18/2017 7:09,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
C,PRE-DOSE,1318,13,3,-0.160416667,0,.,.,.,0,0,1,75.2,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.2,mg/L,9/18/2017 7:09,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
C,PRE-DOSE,1319,13,3,-0.160416667,0,.,.,.,0,0,4,114,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,114,u/ml,9/18/2017 7:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
C,PRE-DOSE,1320,13,3,-0.160416667,0,.,.,.,0,0,5,230,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,230,u/ml,9/18/2017 7:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
C,PRE-DOSE,1321,13,3,-0.160416667,0,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,9/18/2017 7:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1322,13,3,0,.,.,300,.,1,1,0,.,.,.,1,1,StudyID,001-069,300 mg SC,VISIT 4 (DAY 1) BASELINE,1,.,0,300,mg,300,SUBCUTANEOUS,1505732400,1505732400,Dupilumab,.,.,.,.,,.,.,.,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1323,13,3,0.000694444,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/18/2017 11:01,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1324,13,3,0.000694444,0,.,.,.,0,0,1,72.5,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.5,mg/L,9/18/2017 11:01,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1325,13,3,0.000694444,0,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,9/18/2017 11:01,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1326,13,3,0.000694444,0,.,.,.,0,0,5,215,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,215,u/ml,9/18/2017 11:01,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1327,13,3,0.000694444,0,.,.,.,0,0,6,52,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,52,u/ml,9/18/2017 11:01,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1328,13,3,0.010416667,0.010416667,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/18/2017 11:15,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1329,13,3,0.010416667,0.010416667,.,.,.,0,0,1,71.7,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.7,mg/L,9/18/2017 11:15,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1330,13,3,0.010416667,0.010416667,.,.,.,0,0,4,117,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,117,u/ml,9/18/2017 11:15,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1331,13,3,0.010416667,0.010416667,.,.,.,0,0,5,194,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,194,u/ml,9/18/2017 11:15,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1332,13,3,0.010416667,0.010416667,.,.,.,0,0,6,51,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,51,u/ml,9/18/2017 11:15,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1333,13,3,0.020833333,0.020833333,.,.,.,0,0,2,-1.62455155,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.197,mg/L,9/18/2017 11:30,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1334,13,3,0.020833333,0.020833333,.,.,.,0,0,1,71.2,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.2,mg/L,9/18/2017 11:30,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1335,13,3,0.020833333,0.020833333,.,.,.,0,0,4,100,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,100,u/ml,9/18/2017 11:30,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1336,13,3,0.020833333,0.020833333,.,.,.,0,0,5,192,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,192,u/ml,9/18/2017 11:30,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1337,13,3,0.020833333,0.020833333,.,.,.,0,0,6,51,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,51,u/ml,9/18/2017 11:30,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1338,13,3,0.041666667,0.041666667,.,.,.,0,0,2,0.609765572,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.84,mg/L,9/18/2017 12:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1339,13,3,0.041666667,0.041666667,.,.,.,0,0,1,74.9,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.9,mg/L,9/18/2017 12:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1340,13,3,0.041666667,0.041666667,.,.,.,0,0,4,113,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,113,u/ml,9/18/2017 12:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1341,13,3,0.041666667,0.041666667,.,.,.,0,0,5,214,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,214,u/ml,9/18/2017 12:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1342,13,3,0.041666667,0.041666667,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,9/18/2017 12:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1343,13,3,0.083333333,0.083333333,.,.,.,0,0,2,1.451613827,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,4.27,mg/L,9/18/2017 13:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1344,13,3,0.083333333,0.083333333,.,.,.,0,0,1,65.9,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.9,mg/L,9/18/2017 13:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1345,13,3,0.083333333,0.083333333,.,.,.,0,0,4,131,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,131,u/ml,9/18/2017 13:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1346,13,3,0.083333333,0.083333333,.,.,.,0,0,5,178,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,178,u/ml,9/18/2017 13:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1347,13,3,0.083333333,0.083333333,.,.,.,0,0,6,49,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,49,u/ml,9/18/2017 13:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1348,13,3,0.166666667,0.166666667,.,.,.,0,0,2,2.073171929,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,7.95,mg/L,9/18/2017 15:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1349,13,3,0.166666667,0.166666667,.,.,.,0,0,1,69.9,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.9,mg/L,9/18/2017 15:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1350,13,3,0.166666667,0.166666667,.,.,.,0,0,4,93,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,93,u/ml,9/18/2017 15:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1351,13,3,0.166666667,0.166666667,.,.,.,0,0,5,183,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,183,u/ml,9/18/2017 15:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1352,13,3,0.166666667,0.166666667,.,.,.,0,0,6,49,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,49,u/ml,9/18/2017 15:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1353,13,3,0.333333333,0.333333333,.,.,.,0,0,2,2.501435952,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,12.2,mg/L,9/18/2017 19:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1354,13,3,0.333333333,0.333333333,.,.,.,0,0,1,63.6,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,63.6,mg/L,9/18/2017 19:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1355,13,3,0.333333333,0.333333333,.,.,.,0,0,4,89,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,89,u/ml,9/18/2017 19:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1356,13,3,0.333333333,0.333333333,.,.,.,0,0,5,173,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,173,u/ml,9/18/2017 19:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1357,13,3,0.333333333,0.333333333,.,.,.,0,0,6,45,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,45,u/ml,9/18/2017 19:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1358,13,3,0.5,0.5,.,.,.,0,0,2,2.701361213,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,14.9,mg/L,9/18/2017 23:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1359,13,3,0.5,0.5,.,.,.,0,0,1,63.4,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,63.4,mg/L,9/18/2017 23:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1360,13,3,0.5,0.5,.,.,.,0,0,4,110,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,110,u/ml,9/18/2017 23:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1361,13,3,0.5,0.5,.,.,.,0,0,5,137,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,137,u/ml,9/18/2017 23:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1362,13,3,0.5,0.5,.,.,.,0,0,6,38,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,38,u/ml,9/18/2017 23:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1363,13,3,1,1,.,.,.,0,0,2,3.39785848,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,29.9,mg/L,9/19/2017 11:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1364,13,3,1,1,.,.,.,0,0,1,69.7,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.7,mg/L,9/19/2017 11:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1365,13,3,1,1,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,9/19/2017 11:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1366,13,3,1,1,.,.,.,0,0,5,114,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,114,u/ml,9/19/2017 11:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1367,13,3,1,1,.,.,.,0,0,6,31,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,31,u/ml,9/19/2017 11:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1368,13,3,3,3,.,.,.,0,0,2,3.790984677,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,44.3,mg/L,9/21/2017 11:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1369,13,3,3,3,.,.,.,0,0,1,71.5,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.5,mg/L,9/21/2017 11:00,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1370,13,3,3,3,.,.,.,0,0,4,52,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,52,u/ml,9/21/2017 11:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1371,13,3,3,3,.,.,.,0,0,5,38,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,38,u/ml,9/21/2017 11:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1372,13,3,3,3,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,9/21/2017 11:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1373,13,3,7.101388889,7,.,.,.,0,0,2,3.60004824,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,36.6,mg/L,9/25/2017 13:26,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1374,13,3,7.101388889,7,.,.,.,0,0,1,72.4,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.4,mg/L,9/25/2017 13:26,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1375,13,3,7.101388889,14,.,.,.,0,0,4,59,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,59,u/ml,9/25/2017 13:26,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1376,13,3,7.101388889,14,.,.,.,0,0,5,63,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,63,u/ml,9/25/2017 13:26,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1377,13,3,7.101388889,14,.,.,.,0,0,6,23,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,23,u/ml,9/25/2017 13:26,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1378,13,3,14.11736111,14,.,.,.,0,0,2,3.091042453,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,22,mg/L,10/2/2017 13:49,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1379,13,3,14.11736111,14,.,.,.,0,0,1,74.2,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.2,mg/L,10/2/2017 13:49,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1380,13,3,14.11736111,28,.,.,.,0,0,4,89,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,89,u/ml,10/2/2017 13:49,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1381,13,3,14.11736111,28,.,.,.,0,0,5,177,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,177,u/ml,10/2/2017 13:49,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1382,13,3,14.11736111,28,.,.,.,0,0,6,44,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,44,u/ml,10/2/2017 13:49,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1383,13,3,21.12013889,21,.,.,.,0,0,2,2.270061901,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,9.68,mg/L,10/9/2017 13:53,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1384,13,3,21.12013889,21,.,.,.,0,0,1,80.2,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.2,mg/L,10/9/2017 13:53,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1385,13,3,21.12013889,42,.,.,.,0,0,4,84,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,84,u/ml,10/9/2017 13:53,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1386,13,3,21.12013889,42,.,.,.,0,0,5,194,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,194,u/ml,10/9/2017 13:53,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1387,13,3,21.12013889,42,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,10/9/2017 13:53,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1388,13,3,28.12361111,28,.,.,.,0,0,2,1.472472057,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,4.36,mg/L,10/16/2017 13:58,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1389,13,3,28.12361111,28,.,.,.,0,0,1,87.2,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.2,mg/L,10/16/2017 13:58,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1390,13,3,28.12361111,56,.,.,.,0,0,4,109,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,109,u/ml,10/16/2017 13:58,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1391,13,3,28.12361111,56,.,.,.,0,0,5,232,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,232,u/ml,10/16/2017 13:58,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1392,13,3,28.12361111,56,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,10/16/2017 13:58,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1393,13,3,42.14375,42,.,.,.,0,0,2,0.173953307,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.19,mg/L,10/30/2017 14:27,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1394,13,3,42.14375,42,.,.,.,0,0,1,83.6,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.6,mg/L,10/30/2017 14:27,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1395,13,3,42.14375,84,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,10/30/2017 14:27,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1396,13,3,42.14375,84,.,.,.,0,0,5,215,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,215,u/ml,10/30/2017 14:27,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1397,13,3,42.14375,84,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,10/30/2017 14:27,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1398,13,3,56.13125,56,.,.,.,0,0,2,-1.046969056,1,0.078,2,0,StudyID,001-069,300 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.351,mg/L,11/13/2017 14:09,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1399,13,3,56.13125,56,.,.,.,0,0,1,86.8,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,86.8,mg/L,11/13/2017 14:09,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1400,13,3,56.13125,112,.,.,.,0,0,4,101,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,101,u/ml,11/13/2017 14:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1401,13,3,56.13125,112,.,.,.,0,0,5,224,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,224,u/ml,11/13/2017 14:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1402,13,3,56.13125,112,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,11/13/2017 14:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1403,13,3,84.11666667,84,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-069,300 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,12/11/2017 13:48,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1404,13,3,84.11666667,84,.,.,.,0,0,1,98.7,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,98.7,mg/L,12/11/2017 13:48,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1405,13,3,84.11666667,168,.,.,.,0,0,4,126,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,126,u/ml,12/11/2017 13:48,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1406,13,3,84.11666667,168,.,.,.,0,0,5,323,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,323,u/ml,12/11/2017 13:48,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1407,13,3,84.11666667,168,.,.,.,0,0,6,62,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,62,u/ml,12/11/2017 13:48,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1408,13,3,96.12777778,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-069,300 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,12/23/2017 14:04,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1409,13,3,96.12777778,98,.,.,.,0,0,1,67.2,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.2,mg/L,12/23/2017 14:04,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1410,13,3,96.12777778,196,.,.,.,0,0,4,101,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,101,u/ml,12/23/2017 14:04,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1411,13,3,96.12777778,196,.,.,.,0,0,5,234,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,234,u/ml,12/23/2017 14:04,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1412,13,3,96.12777778,196,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,12/23/2017 14:04,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1413,13,3,112.1222222,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-069,300 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,1/8/2018 13:56,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1414,13,3,112.1222222,112,.,.,.,0,0,1,66.3,0,0.0078,0,0,StudyID,001-069,300 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.3,mg/L,1/8/2018 13:56,.,.,.,.,.,.,.,.,63.9,.,.,75.2,230
.,.,1415,13,3,112.1222222,224,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,1/8/2018 13:56,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1416,13,3,112.1222222,224,.,.,.,0,0,5,256,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,256,u/ml,1/8/2018 13:56,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
.,.,1417,13,3,112.1222222,224,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-069,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,1/8/2018 13:56,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,63.9,175,20.9,75.2,230
C,PRE-DOSE,1418,14,4,-53.93333333,0,.,.,.,0,0,1,80.4,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.4,mg/L,8/4/2017 11:56,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
C,PRE-DOSE,1419,14,4,-53.93333333,0,.,.,.,0,0,4,124,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,124,u/ml,8/4/2017 11:56,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
C,PRE-DOSE,1420,14,4,-53.93333333,0,.,.,.,0,0,5,254,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,254,u/ml,8/4/2017 11:56,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
C,PRE-DOSE,1421,14,4,-53.93333333,0,.,.,.,0,0,6,71,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,71,u/ml,8/4/2017 11:56,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
C,PRE-DOSE,1422,14,4,-0.819444444,-1,.,.,.,0,0,1,85.1,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.1,mg/L,9/26/2017 14:40,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
C,PRE-DOSE,1423,14,4,-0.819444444,0,.,.,.,0,0,4,109,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,109,u/ml,9/26/2017 14:40,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
C,PRE-DOSE,1424,14,4,-0.819444444,0,.,.,.,0,0,5,175,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,175,u/ml,9/26/2017 14:40,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
C,PRE-DOSE,1425,14,4,-0.819444444,0,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,9/26/2017 14:40,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
C,PRE-DOSE,1426,14,4,-0.114583333,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/27/2017 7:35,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
C,PRE-DOSE,1427,14,4,-0.114583333,0,.,.,.,0,0,1,80.2,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.2,mg/L,9/27/2017 7:35,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
C,PRE-DOSE,1428,14,4,-0.114583333,0,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,9/27/2017 7:35,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
C,PRE-DOSE,1429,14,4,-0.114583333,0,.,.,.,0,0,5,199,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,199,u/ml,9/27/2017 7:35,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
C,PRE-DOSE,1430,14,4,-0.114583333,0,.,.,.,0,0,6,71,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,71,u/ml,9/27/2017 7:35,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1431,14,4,0,.,.,600,13292.30769,1,2,0,.,.,.,2,1,StudyID,001-074,10 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045138889,600,mg,600,INTRAVENOUS,1506507600,1506511500,Dupilumab,.,.,.,.,,.,.,.,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1432,14,4,0.047222222,0,.,.,.,0,0,2,5.726847748,0,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,307,mg/L,9/27/2017 11:28,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1433,14,4,0.047222222,0,.,.,.,0,0,1,78.2,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.2,mg/L,9/27/2017 11:28,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1434,14,4,0.047222222,0,.,.,.,0,0,4,38,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,38,u/ml,9/27/2017 11:28,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1435,14,4,0.047222222,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,9/27/2017 11:28,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1436,14,4,0.047222222,0,.,.,.,0,0,6,6,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,6,u/ml,9/27/2017 11:28,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1437,14,4,0.055555556,0.010416667,.,.,.,0,0,2,5.713732806,0,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,303,mg/L,9/27/2017 11:40,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1438,14,4,0.055555556,0.010416667,.,.,.,0,0,1,78.7,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.7,mg/L,9/27/2017 11:40,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1439,14,4,0.055555556,0.010416667,.,.,.,0,0,4,29,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,29,u/ml,9/27/2017 11:40,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1440,14,4,0.055555556,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,9/27/2017 11:40,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1441,14,4,0.055555556,0.010416667,.,.,.,0,0,6,6,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,6,u/ml,9/27/2017 11:40,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1442,14,4,0.065972222,0.020833333,.,.,.,0,0,2,5.579729826,0,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,265,mg/L,9/27/2017 11:55,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1443,14,4,0.065972222,0.020833333,.,.,.,0,0,1,69.4,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.4,mg/L,9/27/2017 11:55,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1444,14,4,0.065972222,0.020833333,.,.,.,0,0,4,29,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,29,u/ml,9/27/2017 11:55,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1445,14,4,0.065972222,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,9/27/2017 11:55,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1446,14,4,0.065972222,0.020833333,.,.,.,0,0,6,6,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,6,u/ml,9/27/2017 11:55,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1447,14,4,0.086805556,0.041666667,.,.,.,0,0,2,5.762051383,0,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,318,mg/L,9/27/2017 12:25,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1448,14,4,0.086805556,0.041666667,.,.,.,0,0,1,74.3,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.3,mg/L,9/27/2017 12:25,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1449,14,4,0.086805556,0.041666667,.,.,.,0,0,4,26,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,26,u/ml,9/27/2017 12:25,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1450,14,4,0.086805556,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,9/27/2017 12:25,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1451,14,4,0.086805556,0.041666667,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,9/27/2017 12:25,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1452,14,4,0.127083333,0.083333333,.,.,.,0,0,2,5.602118821,0,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,271,mg/L,9/27/2017 13:23,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1453,14,4,0.127083333,0.083333333,.,.,.,0,0,1,75.3,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.3,mg/L,9/27/2017 13:23,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1454,14,4,0.127083333,0.083333333,.,.,.,0,0,4,29,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,29,u/ml,9/27/2017 13:23,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1455,14,4,0.127083333,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,9/27/2017 13:23,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1456,14,4,0.127083333,0.083333333,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,9/27/2017 13:23,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1457,14,4,0.211805556,0.166666667,.,.,.,0,0,2,5.620400866,0,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,276,mg/L,9/27/2017 15:25,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1458,14,4,0.211805556,0.166666667,.,.,.,0,0,1,74.4,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.4,mg/L,9/27/2017 15:25,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1459,14,4,0.211805556,0.166666667,.,.,.,0,0,4,26,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,26,u/ml,9/27/2017 15:25,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1460,14,4,0.211805556,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,9/27/2017 15:25,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1461,14,4,0.211805556,0.166666667,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,9/27/2017 15:25,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1462,14,4,0.379861111,0.333333333,.,.,.,0,0,2,5.80814249,0,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,333,mg/L,9/27/2017 19:27,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1463,14,4,0.379861111,0.333333333,.,.,.,0,0,1,76.6,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.6,mg/L,9/27/2017 19:27,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1464,14,4,0.379861111,0.333333333,.,.,.,0,0,4,40,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,40,u/ml,9/27/2017 19:27,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1465,14,4,0.379861111,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,9/27/2017 19:27,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1466,14,4,0.379861111,0.333333333,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,9/27/2017 19:27,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1467,14,4,0.547222222,0.5,.,.,.,0,0,2,5.713732806,0,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,303,mg/L,9/27/2017 23:28,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1468,14,4,0.547222222,0.5,.,.,.,0,0,1,78.3,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.3,mg/L,9/27/2017 23:28,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1469,14,4,0.547222222,0.5,.,.,.,0,0,4,30,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,30,u/ml,9/27/2017 23:28,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1470,14,4,0.547222222,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,9/27/2017 23:28,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1471,14,4,0.547222222,0.5,.,.,.,0,0,6,8,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,8,u/ml,9/27/2017 23:28,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1472,14,4,1.047222222,1,.,.,.,0,0,2,5.602118821,0,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,271,mg/L,9/28/2017 11:28,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1473,14,4,1.047222222,1,.,.,.,0,0,1,82.4,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.4,mg/L,9/28/2017 11:28,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1474,14,4,1.047222222,1,.,.,.,0,0,4,34,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,34,u/ml,9/28/2017 11:28,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1475,14,4,1.047222222,1,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,9/28/2017 11:28,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1476,14,4,1.047222222,1,.,.,.,0,0,6,8,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,8,u/ml,9/28/2017 11:28,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1477,14,4,3.045138889,3,.,.,.,0,0,2,5.036952602,0,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,154,mg/L,9/30/2017 11:25,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1478,14,4,3.045138889,3,.,.,.,0,0,1,93.9,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,93.9,mg/L,9/30/2017 11:25,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1479,14,4,3.045138889,3,.,.,.,0,0,4,31,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,31,u/ml,9/30/2017 11:25,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1480,14,4,3.045138889,3,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,9/30/2017 11:25,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1481,14,4,3.045138889,3,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,9/30/2017 11:25,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1482,14,4,7.161805556,7,.,.,.,0,0,2,4.844187086,0,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,127,mg/L,10/4/2017 14:13,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1483,14,4,7.161805556,7,.,.,.,0,0,1,108,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,108,mg/L,10/4/2017 14:13,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1484,14,4,7.161805556,14,.,.,.,0,0,4,66,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,66,u/ml,10/4/2017 14:13,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1485,14,4,7.161805556,14,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,10/4/2017 14:13,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1486,14,4,7.161805556,14,.,.,.,0,0,6,19,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,19,u/ml,10/4/2017 14:13,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1487,14,4,14.13680556,14,.,.,.,0,0,2,4.356708827,0,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,78,mg/L,10/11/2017 13:37,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1488,14,4,14.13680556,14,.,.,.,0,0,1,131,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,131,mg/L,10/11/2017 13:37,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1489,14,4,14.13680556,28,.,.,.,0,0,4,75,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,75,u/ml,10/11/2017 13:37,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1490,14,4,14.13680556,28,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/11/2017 13:37,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1491,14,4,14.13680556,28,.,.,.,0,0,6,21,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,21,u/ml,10/11/2017 13:37,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1492,14,4,21.15902778,21,.,.,.,0,0,2,3.841600541,1,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,46.6,mg/L,10/18/2017 14:09,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1493,14,4,21.15902778,21,.,.,.,0,0,1,117,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,117,mg/L,10/18/2017 14:09,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1494,14,4,21.15902778,42,.,.,.,0,0,4,100,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,100,u/ml,10/18/2017 14:09,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1495,14,4,21.15902778,42,.,.,.,0,0,5,108,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,108,u/ml,10/18/2017 14:09,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1496,14,4,21.15902778,42,.,.,.,0,0,6,45,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,45,u/ml,10/18/2017 14:09,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1497,14,4,28.15,28,.,.,.,0,0,2,3.280911216,1,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,26.6,mg/L,10/25/2017 13:56,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1498,14,4,28.15,28,.,.,.,0,0,1,96.1,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,96.1,mg/L,10/25/2017 13:56,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1499,14,4,28.15,56,.,.,.,0,0,4,111,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,111,u/ml,10/25/2017 13:56,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1500,14,4,28.15,56,.,.,.,0,0,5,169,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,169,u/ml,10/25/2017 13:56,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1501,14,4,28.15,56,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,10/25/2017 13:56,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1502,14,4,42.14722222,42,.,.,.,0,0,2,3.663561646,1,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,39,mg/L,11/8/2017 13:52,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1503,14,4,42.14722222,42,.,.,.,0,0,1,99.9,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,99.9,mg/L,11/8/2017 13:52,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1504,14,4,42.14722222,84,.,.,.,0,0,4,114,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,114,u/ml,11/8/2017 13:52,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1505,14,4,42.14722222,84,.,.,.,0,0,5,183,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,183,u/ml,11/8/2017 13:52,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1506,14,4,42.14722222,84,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,11/8/2017 13:52,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1507,14,4,56.16111111,56,.,.,.,0,0,2,1.398716881,1,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,4.05,mg/L,11/22/2017 14:12,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1508,14,4,56.16111111,56,.,.,.,0,0,1,86.5,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,86.5,mg/L,11/22/2017 14:12,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1509,14,4,56.16111111,112,.,.,.,0,0,4,106,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,106,u/ml,11/22/2017 14:12,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1510,14,4,56.16111111,112,.,.,.,0,0,5,179,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,179,u/ml,11/22/2017 14:12,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1511,14,4,56.16111111,112,.,.,.,0,0,6,61,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,61,u/ml,11/22/2017 14:12,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1512,14,4,84.15694444,84,.,.,.,0,0,2,-0.28103753,1,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.755,mg/L,12/20/2017 14:06,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1513,14,4,84.15694444,84,.,.,.,0,0,1,83.2,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.2,mg/L,12/20/2017 14:06,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1514,14,4,84.15694444,168,.,.,.,0,0,4,130,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,130,u/ml,12/20/2017 14:06,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1515,14,4,84.15694444,168,.,.,.,0,0,5,247,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,247,u/ml,12/20/2017 14:06,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1516,14,4,84.15694444,168,.,.,.,0,0,6,71,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,71,u/ml,12/20/2017 14:06,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1517,14,4,98.17847222,98,.,.,.,0,0,2,-0.780886095,1,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.458,mg/L,1/3/2018 14:37,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1518,14,4,98.17847222,98,.,.,.,0,0,1,71.6,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.6,mg/L,1/3/2018 14:37,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1519,14,4,98.17847222,196,.,.,.,0,0,4,115,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,115,u/ml,1/3/2018 14:37,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1520,14,4,98.17847222,196,.,.,.,0,0,5,219,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,219,u/ml,1/3/2018 14:37,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1521,14,4,98.17847222,196,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,1/3/2018 14:37,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1522,14,4,112.1715278,112,.,.,.,0,0,2,-1.482805262,1,0.078,2,0,StudyID,001-074,10 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.227,mg/L,1/17/2018 14:27,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1523,14,4,112.1715278,112,.,.,.,0,0,1,63.1,0,0.0078,0,0,StudyID,001-074,10 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,63.1,mg/L,1/17/2018 14:27,.,.,.,.,.,.,.,.,61.2,.,.,80.2,199
.,.,1524,14,4,112.1715278,224,.,.,.,0,0,4,112,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,112,u/ml,1/17/2018 14:27,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1525,14,4,112.1715278,224,.,.,.,0,0,5,206,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,206,u/ml,1/17/2018 14:27,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
.,.,1526,14,4,112.1715278,224,.,.,.,0,0,6,64,.,.,0,0,StudyID,001-074,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,64,u/ml,1/17/2018 14:27,44,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,61.2,166,22.2,80.2,199
C,PRE-DOSE,1527,15,3,-51.84236111,0,.,.,.,0,0,1,66.3,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.3,mg/L,8/4/2017 14:57,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
C,PRE-DOSE,1528,15,3,-51.84236111,0,.,.,.,0,0,4,76,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,76,u/ml,8/4/2017 14:57,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
C,PRE-DOSE,1529,15,3,-51.84236111,0,.,.,.,0,0,5,272,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,272,u/ml,8/4/2017 14:57,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
C,PRE-DOSE,1530,15,3,-51.84236111,0,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,8/4/2017 14:57,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
C,PRE-DOSE,1531,15,3,-0.900694444,-1,.,.,.,0,0,1,78,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78,mg/L,9/24/2017 13:33,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
C,PRE-DOSE,1532,15,3,-0.900694444,0,.,.,.,0,0,4,75,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,75,u/ml,9/24/2017 13:33,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
C,PRE-DOSE,1533,15,3,-0.900694444,0,.,.,.,0,0,5,235,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,235,u/ml,9/24/2017 13:33,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
C,PRE-DOSE,1534,15,3,-0.900694444,0,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,9/24/2017 13:33,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
C,PRE-DOSE,1535,15,3,-0.158333333,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/25/2017 7:22,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
C,PRE-DOSE,1536,15,3,-0.158333333,0,.,.,.,0,0,1,79.5,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.5,mg/L,9/25/2017 7:22,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
C,PRE-DOSE,1537,15,3,-0.158333333,0,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,9/25/2017 7:22,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
C,PRE-DOSE,1538,15,3,-0.158333333,0,.,.,.,0,0,5,247,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,247,u/ml,9/25/2017 7:22,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
C,PRE-DOSE,1539,15,3,-0.158333333,0,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,9/25/2017 7:22,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1540,15,3,0,.,.,300,.,1,1,0,.,.,.,1,1,StudyID,001-075,300 mg SC,VISIT 4 (DAY 1) BASELINE,1,.,0,300,mg,300,SUBCUTANEOUS,1506337800,1506337800,Dupilumab,.,.,.,.,,.,.,.,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1541,15,3,0.000694444,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/25/2017 11:11,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1542,15,3,0.000694444,0,.,.,.,0,0,1,73.4,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.4,mg/L,9/25/2017 11:11,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1543,15,3,0.000694444,0,.,.,.,0,0,4,75,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,75,u/ml,9/25/2017 11:11,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1544,15,3,0.000694444,0,.,.,.,0,0,5,210,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,210,u/ml,9/25/2017 11:11,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1545,15,3,0.000694444,0,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,9/25/2017 11:11,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1546,15,3,0.010416667,0.010416667,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/25/2017 11:25,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1547,15,3,0.010416667,0.010416667,.,.,.,0,0,1,67.2,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.2,mg/L,9/25/2017 11:25,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1548,15,3,0.010416667,0.010416667,.,.,.,0,0,4,66,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,66,u/ml,9/25/2017 11:25,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1549,15,3,0.010416667,0.010416667,.,.,.,0,0,5,196,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,196,u/ml,9/25/2017 11:25,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1550,15,3,0.010416667,0.010416667,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,9/25/2017 11:25,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1551,15,3,0.020833333,0.020833333,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/25/2017 11:40,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1552,15,3,0.020833333,0.020833333,.,.,.,0,0,1,68.5,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.5,mg/L,9/25/2017 11:40,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1553,15,3,0.020833333,0.020833333,.,.,.,0,0,4,65,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,65,u/ml,9/25/2017 11:40,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1554,15,3,0.020833333,0.020833333,.,.,.,0,0,5,216,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,216,u/ml,9/25/2017 11:40,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1555,15,3,0.020833333,0.020833333,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,9/25/2017 11:40,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1556,15,3,0.041666667,0.041666667,.,.,.,0,0,2,-2.111964733,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.121,mg/L,9/25/2017 12:10,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1557,15,3,0.041666667,0.041666667,.,.,.,0,0,1,70.8,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.8,mg/L,9/25/2017 12:10,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1558,15,3,0.041666667,0.041666667,.,.,.,0,0,4,69,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,69,u/ml,9/25/2017 12:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1559,15,3,0.041666667,0.041666667,.,.,.,0,0,5,199,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,199,u/ml,9/25/2017 12:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1560,15,3,0.041666667,0.041666667,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,9/25/2017 12:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1561,15,3,0.083333333,0.083333333,.,.,.,0,0,2,-0.531028331,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.588,mg/L,9/25/2017 13:10,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1562,15,3,0.083333333,0.083333333,.,.,.,0,0,1,73.6,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.6,mg/L,9/25/2017 13:10,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1563,15,3,0.083333333,0.083333333,.,.,.,0,0,4,72,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,72,u/ml,9/25/2017 13:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1564,15,3,0.083333333,0.083333333,.,.,.,0,0,5,187,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,187,u/ml,9/25/2017 13:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1565,15,3,0.083333333,0.083333333,.,.,.,0,0,6,52,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,52,u/ml,9/25/2017 13:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1566,15,3,0.167361111,0.166666667,.,.,.,0,0,2,0.783901544,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.19,mg/L,9/25/2017 15:11,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1567,15,3,0.167361111,0.166666667,.,.,.,0,0,1,70.8,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.8,mg/L,9/25/2017 15:11,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1568,15,3,0.167361111,0.166666667,.,.,.,0,0,4,72,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,72,u/ml,9/25/2017 15:11,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1569,15,3,0.167361111,0.166666667,.,.,.,0,0,5,185,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,185,u/ml,9/25/2017 15:11,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1570,15,3,0.167361111,0.166666667,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,9/25/2017 15:11,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1571,15,3,0.333333333,0.333333333,.,.,.,0,0,2,1.932969638,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,6.91,mg/L,9/25/2017 19:10,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1572,15,3,0.333333333,0.333333333,.,.,.,0,0,1,62.7,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,62.7,mg/L,9/25/2017 19:10,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1573,15,3,0.333333333,0.333333333,.,.,.,0,0,4,62,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,62,u/ml,9/25/2017 19:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1574,15,3,0.333333333,0.333333333,.,.,.,0,0,5,180,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,180,u/ml,9/25/2017 19:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1575,15,3,0.333333333,0.333333333,.,.,.,0,0,6,52,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,52,u/ml,9/25/2017 19:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1576,15,3,0.5,0.5,.,.,.,0,0,2,2.351375257,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,10.5,mg/L,9/25/2017 23:10,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1577,15,3,0.5,0.5,.,.,.,0,0,1,60.3,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,60.3,mg/L,9/25/2017 23:10,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1578,15,3,0.5,0.5,.,.,.,0,0,4,43,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,43,u/ml,9/25/2017 23:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1579,15,3,0.5,0.5,.,.,.,0,0,5,132,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,132,u/ml,9/25/2017 23:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1580,15,3,0.5,0.5,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,9/25/2017 23:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1581,15,3,1,1,.,.,.,0,0,2,3.144152279,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,23.2,mg/L,9/26/2017 11:10,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1582,15,3,1,1,.,.,.,0,0,1,68,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68,mg/L,9/26/2017 11:10,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1583,15,3,1,1,.,.,.,0,0,4,35,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,35,u/ml,9/26/2017 11:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1584,15,3,1,1,.,.,.,0,0,5,123,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,123,u/ml,9/26/2017 11:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1585,15,3,1,1,.,.,.,0,0,6,50,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,50,u/ml,9/26/2017 11:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1586,15,3,3,3,.,.,.,0,0,2,3.793239469,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,44.4,mg/L,9/28/2017 11:10,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1587,15,3,3,3,.,.,.,0,0,1,80.5,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.5,mg/L,9/28/2017 11:10,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1588,15,3,3,3,.,.,.,0,0,4,42,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,42,u/ml,9/28/2017 11:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1589,15,3,3,3,.,.,.,0,0,5,25,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,25,u/ml,9/28/2017 11:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1590,15,3,3,3,.,.,.,0,0,6,33,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,33,u/ml,9/28/2017 11:10,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1591,15,3,7.109722222,7,.,.,.,0,0,2,3.862832761,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,47.6,mg/L,10/2/2017 13:48,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1592,15,3,7.109722222,7,.,.,.,0,0,1,76.5,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.5,mg/L,10/2/2017 13:48,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1593,15,3,7.109722222,14,.,.,.,0,0,4,67,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,67,u/ml,10/2/2017 13:48,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1594,15,3,7.109722222,14,.,.,.,0,0,5,84,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,84,u/ml,10/2/2017 13:48,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1595,15,3,7.109722222,14,.,.,.,0,0,6,44,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,44,u/ml,10/2/2017 13:48,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1596,15,3,14.11944444,14,.,.,.,0,0,2,3.18221184,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,24.1,mg/L,10/9/2017 14:02,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1597,15,3,14.11944444,14,.,.,.,0,0,1,76.6,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.6,mg/L,10/9/2017 14:02,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1598,15,3,14.11944444,28,.,.,.,0,0,4,87,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,87,u/ml,10/9/2017 14:02,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1599,15,3,14.11944444,28,.,.,.,0,0,5,184,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,184,u/ml,10/9/2017 14:02,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1600,15,3,14.11944444,28,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,10/9/2017 14:02,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1601,15,3,21.09097222,21,.,.,.,0,0,2,2.442347035,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,11.5,mg/L,10/16/2017 13:21,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1602,15,3,21.09097222,21,.,.,.,0,0,1,74.5,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.5,mg/L,10/16/2017 13:21,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1603,15,3,21.09097222,42,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,10/16/2017 13:21,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1604,15,3,21.09097222,42,.,.,.,0,0,5,225,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,225,u/ml,10/16/2017 13:21,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1605,15,3,21.09097222,42,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,10/16/2017 13:21,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1606,15,3,28.11736111,28,.,.,.,0,0,2,1.790091412,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,5.99,mg/L,10/23/2017 13:59,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1607,15,3,28.11736111,28,.,.,.,0,0,1,74.2,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.2,mg/L,10/23/2017 13:59,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1608,15,3,28.11736111,56,.,.,.,0,0,4,89,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,89,u/ml,10/23/2017 13:59,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1609,15,3,28.11736111,56,.,.,.,0,0,5,225,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,225,u/ml,10/23/2017 13:59,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1610,15,3,28.11736111,56,.,.,.,0,0,6,52,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,52,u/ml,10/23/2017 13:59,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1611,15,3,42.11180556,42,.,.,.,0,0,2,0.524728529,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.69,mg/L,11/6/2017 13:51,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1612,15,3,42.11180556,42,.,.,.,0,0,1,64.3,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.3,mg/L,11/6/2017 13:51,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1613,15,3,42.11180556,84,.,.,.,0,0,4,60,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,60,u/ml,11/6/2017 13:51,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1614,15,3,42.11180556,84,.,.,.,0,0,5,231,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,231,u/ml,11/6/2017 13:51,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1615,15,3,42.11180556,84,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,11/6/2017 13:51,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1616,15,3,56.12152778,56,.,.,.,0,0,2,-0.393042588,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.675,mg/L,11/20/2017 14:05,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1617,15,3,56.12152778,56,.,.,.,0,0,1,70.4,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.4,mg/L,11/20/2017 14:05,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1618,15,3,56.12152778,112,.,.,.,0,0,4,60,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,60,u/ml,11/20/2017 14:05,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1619,15,3,56.12152778,112,.,.,.,0,0,5,229,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,229,u/ml,11/20/2017 14:05,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1620,15,3,56.12152778,112,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,11/20/2017 14:05,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1621,15,3,84.14097222,84,.,.,.,0,0,2,-2.002480501,1,0.078,2,0,StudyID,001-075,300 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.135,mg/L,12/18/2017 14:33,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1622,15,3,84.14097222,84,.,.,.,0,0,1,66.1,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.1,mg/L,12/18/2017 14:33,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1623,15,3,84.14097222,168,.,.,.,0,0,4,56,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,56,u/ml,12/18/2017 14:33,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1624,15,3,84.14097222,168,.,.,.,0,0,5,193,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,193,u/ml,12/18/2017 14:33,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1625,15,3,84.14097222,168,.,.,.,0,0,6,47,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,47,u/ml,12/18/2017 14:33,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1626,15,3,99.11805556,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-075,300 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,1/2/2018 14:00,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1627,15,3,99.11805556,98,.,.,.,0,0,1,61,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,61,mg/L,1/2/2018 14:00,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1628,15,3,99.11805556,196,.,.,.,0,0,4,66,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,66,u/ml,1/2/2018 14:00,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1629,15,3,99.11805556,196,.,.,.,0,0,5,184,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,184,u/ml,1/2/2018 14:00,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1630,15,3,99.11805556,196,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,1/2/2018 14:00,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1631,15,3,112.2506944,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-075,300 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,1/15/2018 17:11,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1632,15,3,112.2506944,112,.,.,.,0,0,1,66.4,0,0.0078,0,0,StudyID,001-075,300 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.4,mg/L,1/15/2018 17:11,.,.,.,.,.,.,.,.,68.1,.,.,79.5,247
.,.,1633,15,3,112.2506944,224,.,.,.,0,0,4,85,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,85,u/ml,1/15/2018 17:11,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1634,15,3,112.2506944,224,.,.,.,0,0,5,242,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,242,u/ml,1/15/2018 17:11,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
.,.,1635,15,3,112.2506944,224,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-075,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,1/15/2018 17:11,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,68.1,171,23.3,79.5,247
C,PRE-DOSE,1636,16,3,-44.95138889,0,.,.,.,0,0,1,83.6,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.6,mg/L,8/11/2017 12:30,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
C,PRE-DOSE,1637,16,3,-44.95138889,0,.,.,.,0,0,4,125,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,125,u/ml,8/11/2017 12:30,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
C,PRE-DOSE,1638,16,3,-44.95138889,0,.,.,.,0,0,5,246,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,246,u/ml,8/11/2017 12:30,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
C,PRE-DOSE,1639,16,3,-44.95138889,0,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,8/11/2017 12:30,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
C,PRE-DOSE,1640,16,3,-0.902083333,-1,.,.,.,0,0,1,85.4,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.4,mg/L,9/24/2017 13:41,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
C,PRE-DOSE,1641,16,3,-0.902083333,0,.,.,.,0,0,4,117,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,117,u/ml,9/24/2017 13:41,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
C,PRE-DOSE,1642,16,3,-0.902083333,0,.,.,.,0,0,5,255,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,255,u/ml,9/24/2017 13:41,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
C,PRE-DOSE,1643,16,3,-0.902083333,0,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,9/24/2017 13:41,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
C,PRE-DOSE,1644,16,3,-0.154861111,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/25/2017 7:37,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
C,PRE-DOSE,1645,16,3,-0.154861111,0,.,.,.,0,0,1,83.8,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.8,mg/L,9/25/2017 7:37,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
C,PRE-DOSE,1646,16,3,-0.154861111,0,.,.,.,0,0,4,115,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,115,u/ml,9/25/2017 7:37,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
C,PRE-DOSE,1647,16,3,-0.154861111,0,.,.,.,0,0,5,216,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,216,u/ml,9/25/2017 7:37,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
C,PRE-DOSE,1648,16,3,-0.154861111,0,.,.,.,0,0,6,64,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,64,u/ml,9/25/2017 7:37,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1649,16,3,0,.,.,300,.,1,1,0,.,.,.,1,1,StudyID,001-081,300 mg SC,VISIT 4 (DAY 1) BASELINE,1,.,0.000694444,300,mg,300,SUBCUTANEOUS,1506338400,1506338460,Dupilumab,.,.,.,.,,.,.,.,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1650,16,3,0.000694444,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/25/2017 11:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1651,16,3,0.000694444,0,.,.,.,0,0,1,79.2,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.2,mg/L,9/25/2017 11:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1652,16,3,0.000694444,0,.,.,.,0,0,4,116,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,116,u/ml,9/25/2017 11:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1653,16,3,0.000694444,0,.,.,.,0,0,5,268,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,268,u/ml,9/25/2017 11:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1654,16,3,0.000694444,0,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,9/25/2017 11:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1655,16,3,0.011111111,0.010416667,.,.,.,0,0,2,-2.253794929,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.105,mg/L,9/25/2017 11:36,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1656,16,3,0.011111111,0.010416667,.,.,.,0,0,1,82.4,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.4,mg/L,9/25/2017 11:36,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1657,16,3,0.011111111,0.010416667,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,9/25/2017 11:36,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1658,16,3,0.011111111,0.010416667,.,.,.,0,0,5,254,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,254,u/ml,9/25/2017 11:36,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1659,16,3,0.011111111,0.010416667,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,9/25/2017 11:36,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1660,16,3,0.021527778,0.020833333,.,.,.,0,0,2,-2.055725015,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.128,mg/L,9/25/2017 11:51,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1661,16,3,0.021527778,0.020833333,.,.,.,0,0,1,86.9,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,86.9,mg/L,9/25/2017 11:51,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1662,16,3,0.021527778,0.020833333,.,.,.,0,0,4,115,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,115,u/ml,9/25/2017 11:51,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1663,16,3,0.021527778,0.020833333,.,.,.,0,0,5,236,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,236,u/ml,9/25/2017 11:51,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1664,16,3,0.021527778,0.020833333,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,9/25/2017 11:51,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1665,16,3,0.042361111,0.041666667,.,.,.,0,0,2,-1.883874758,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.152,mg/L,9/25/2017 12:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1666,16,3,0.042361111,0.041666667,.,.,.,0,0,1,87.6,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.6,mg/L,9/25/2017 12:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1667,16,3,0.042361111,0.041666667,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,9/25/2017 12:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1668,16,3,0.042361111,0.041666667,.,.,.,0,0,5,266,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,266,u/ml,9/25/2017 12:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1669,16,3,0.042361111,0.041666667,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,9/25/2017 12:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1670,16,3,0.084027778,0.083333333,.,.,.,0,0,2,-0.8603831,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.423,mg/L,9/25/2017 13:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1671,16,3,0.084027778,0.083333333,.,.,.,0,0,1,81.8,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.8,mg/L,9/25/2017 13:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1672,16,3,0.084027778,0.083333333,.,.,.,0,0,4,106,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,106,u/ml,9/25/2017 13:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1673,16,3,0.084027778,0.083333333,.,.,.,0,0,5,253,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,253,u/ml,9/25/2017 13:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1674,16,3,0.084027778,0.083333333,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,9/25/2017 13:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1675,16,3,0.167361111,0.166666667,.,.,.,0,0,2,0.223143551,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.25,mg/L,9/25/2017 15:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1676,16,3,0.167361111,0.166666667,.,.,.,0,0,1,81.2,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.2,mg/L,9/25/2017 15:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1677,16,3,0.167361111,0.166666667,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,9/25/2017 15:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1678,16,3,0.167361111,0.166666667,.,.,.,0,0,5,247,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,247,u/ml,9/25/2017 15:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1679,16,3,0.167361111,0.166666667,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,9/25/2017 15:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1680,16,3,0.334027778,0.333333333,.,.,.,0,0,2,1.036736885,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.82,mg/L,9/25/2017 19:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1681,16,3,0.334027778,0.333333333,.,.,.,0,0,1,87.2,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.2,mg/L,9/25/2017 19:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1682,16,3,0.334027778,0.333333333,.,.,.,0,0,4,109,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,109,u/ml,9/25/2017 19:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1683,16,3,0.334027778,0.333333333,.,.,.,0,0,5,253,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,253,u/ml,9/25/2017 19:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1684,16,3,0.334027778,0.333333333,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,9/25/2017 19:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1685,16,3,0.500694444,0.5,.,.,.,0,0,2,1.406096988,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,4.08,mg/L,9/25/2017 23:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1686,16,3,0.500694444,0.5,.,.,.,0,0,1,73.4,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.4,mg/L,9/25/2017 23:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1687,16,3,0.500694444,0.5,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,9/25/2017 23:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1688,16,3,0.500694444,0.5,.,.,.,0,0,5,186,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,186,u/ml,9/25/2017 23:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1689,16,3,0.500694444,0.5,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,9/25/2017 23:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1690,16,3,1.000694444,1,.,.,.,0,0,2,2.045108863,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,7.73,mg/L,9/26/2017 11:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1691,16,3,1.000694444,1,.,.,.,0,0,1,79.1,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.1,mg/L,9/26/2017 11:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1692,16,3,1.000694444,1,.,.,.,0,0,4,110,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,110,u/ml,9/26/2017 11:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1693,16,3,1.000694444,1,.,.,.,0,0,5,222,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,222,u/ml,9/26/2017 11:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1694,16,3,1.000694444,1,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,9/26/2017 11:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1695,16,3,3.000694444,3,.,.,.,0,0,2,3.005682604,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,20.2,mg/L,9/28/2017 11:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1696,16,3,3.000694444,3,.,.,.,0,0,1,81.7,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.7,mg/L,9/28/2017 11:21,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1697,16,3,3.000694444,3,.,.,.,0,0,4,113,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,113,u/ml,9/28/2017 11:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1698,16,3,3.000694444,3,.,.,.,0,0,5,191,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,191,u/ml,9/28/2017 11:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1699,16,3,3.000694444,3,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,9/28/2017 11:21,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1700,16,3,7.097222222,7,.,.,.,0,0,2,3.580737295,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,35.9,mg/L,10/2/2017 13:40,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1701,16,3,7.097222222,7,.,.,.,0,0,1,79.4,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.4,mg/L,10/2/2017 13:40,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1702,16,3,7.097222222,14,.,.,.,0,0,4,115,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,115,u/ml,10/2/2017 13:40,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1703,16,3,7.097222222,14,.,.,.,0,0,5,133,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,133,u/ml,10/2/2017 13:40,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1704,16,3,7.097222222,14,.,.,.,0,0,6,47,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,47,u/ml,10/2/2017 13:40,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1705,16,3,14.09166667,14,.,.,.,0,0,2,3.015534901,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,20.4,mg/L,10/9/2017 13:32,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1706,16,3,14.09166667,14,.,.,.,0,0,1,82.9,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.9,mg/L,10/9/2017 13:32,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1707,16,3,14.09166667,28,.,.,.,0,0,4,114,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,114,u/ml,10/9/2017 13:32,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1708,16,3,14.09166667,28,.,.,.,0,0,5,184,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,184,u/ml,10/9/2017 13:32,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1709,16,3,14.09166667,28,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,10/9/2017 13:32,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1710,16,3,21.09097222,21,.,.,.,0,0,2,2.360854001,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,10.6,mg/L,10/16/2017 13:31,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1711,16,3,21.09097222,21,.,.,.,0,0,1,82.2,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.2,mg/L,10/16/2017 13:31,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1712,16,3,21.09097222,42,.,.,.,0,0,4,114,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,114,u/ml,10/16/2017 13:31,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1713,16,3,21.09097222,42,.,.,.,0,0,5,190,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,190,u/ml,10/16/2017 13:31,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1714,16,3,21.09097222,42,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,10/16/2017 13:31,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1715,16,3,28.11805556,28,.,.,.,0,0,2,2.002830439,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,7.41,mg/L,10/23/2017 14:10,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1716,16,3,28.11805556,28,.,.,.,0,0,1,81,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81,mg/L,10/23/2017 14:10,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1717,16,3,28.11805556,56,.,.,.,0,0,4,112,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,112,u/ml,10/23/2017 14:10,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1718,16,3,28.11805556,56,.,.,.,0,0,5,236,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,236,u/ml,10/23/2017 14:10,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1719,16,3,28.11805556,56,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,10/23/2017 14:10,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1720,16,3,42.10833333,42,.,.,.,0,0,2,0.765467842,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.15,mg/L,11/6/2017 13:56,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1721,16,3,42.10833333,42,.,.,.,0,0,1,85.2,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.2,mg/L,11/6/2017 13:56,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1722,16,3,42.10833333,84,.,.,.,0,0,4,120,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,120,u/ml,11/6/2017 13:56,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1723,16,3,42.10833333,84,.,.,.,0,0,5,234,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,234,u/ml,11/6/2017 13:56,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1724,16,3,42.10833333,84,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,11/6/2017 13:56,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1725,16,3,56.08472222,56,.,.,.,0,0,2,-0.228156093,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.796,mg/L,11/20/2017 13:22,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1726,16,3,56.08472222,56,.,.,.,0,0,1,74.3,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.3,mg/L,11/20/2017 13:22,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1727,16,3,56.08472222,112,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,11/20/2017 13:22,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1728,16,3,56.08472222,112,.,.,.,0,0,5,201,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,201,u/ml,11/20/2017 13:22,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1729,16,3,56.08472222,112,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,11/20/2017 13:22,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1730,16,3,84.08819444,84,.,.,.,0,0,2,-1.398366942,1,0.078,2,0,StudyID,001-081,300 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.247,mg/L,12/18/2017 13:27,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1731,16,3,84.08819444,84,.,.,.,0,0,1,101,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,101,mg/L,12/18/2017 13:27,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1732,16,3,84.08819444,168,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,12/18/2017 13:27,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1733,16,3,84.08819444,168,.,.,.,0,0,5,212,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,212,u/ml,12/18/2017 13:27,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1734,16,3,84.08819444,168,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,12/18/2017 13:27,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1735,16,3,99.11597222,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-081,300 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,1/2/2018 14:07,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1736,16,3,99.11597222,98,.,.,.,0,0,1,77.4,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.4,mg/L,1/2/2018 14:07,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1737,16,3,99.11597222,196,.,.,.,0,0,4,109,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,109,u/ml,1/2/2018 14:07,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1738,16,3,99.11597222,196,.,.,.,0,0,5,234,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,234,u/ml,1/2/2018 14:07,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1739,16,3,99.11597222,196,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,1/2/2018 14:07,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1740,16,3,112.1013889,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-081,300 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,1/15/2018 13:46,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1741,16,3,112.1013889,112,.,.,.,0,0,1,78,0,0.0078,0,0,StudyID,001-081,300 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78,mg/L,1/15/2018 13:46,.,.,.,.,.,.,.,.,92.2,.,.,83.8,216
.,.,1742,16,3,112.1013889,224,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,1/15/2018 13:46,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1743,16,3,112.1013889,224,.,.,.,0,0,5,245,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,245,u/ml,1/15/2018 13:46,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
.,.,1744,16,3,112.1013889,224,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-081,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,1/15/2018 13:46,29,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.2,185,26.9,83.8,216
C,PRE-DOSE,1745,17,3,-78.81458333,0,.,.,.,0,0,4,134,.,.,0,0,StudyID,001-084,300 mg SC,VISIT NA,.,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,134,u/ml,6/28/2017 15:27,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
C,PRE-DOSE,1746,17,3,-78.81458333,0,.,.,.,0,0,5,270,.,.,0,0,StudyID,001-084,300 mg SC,VISIT NA,.,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,270,u/ml,6/28/2017 15:27,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
C,PRE-DOSE,1747,17,3,-78.81458333,0,.,.,.,0,0,6,79,.,.,0,0,StudyID,001-084,300 mg SC,VISIT NA,.,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,79,u/ml,6/28/2017 15:27,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
C,PRE-DOSE,1748,17,3,-0.899305556,-1,.,.,.,0,0,1,84.5,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.5,mg/L,9/14/2017 13:25,.,.,.,.,.,.,.,.,66,.,.,79.4,242
C,PRE-DOSE,1749,17,3,-0.899305556,0,.,.,.,0,0,4,102,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,102,u/ml,9/14/2017 13:25,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
C,PRE-DOSE,1750,17,3,-0.899305556,0,.,.,.,0,0,5,254,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,254,u/ml,9/14/2017 13:25,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
C,PRE-DOSE,1751,17,3,-0.899305556,0,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,9/14/2017 13:25,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
C,PRE-DOSE,1752,17,3,-0.154861111,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/15/2017 7:17,.,.,.,.,.,.,.,.,66,.,.,79.4,242
C,PRE-DOSE,1753,17,3,-0.154861111,0,.,.,.,0,0,1,79.4,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.4,mg/L,9/15/2017 7:17,.,.,.,.,.,.,.,.,66,.,.,79.4,242
C,PRE-DOSE,1754,17,3,-0.154861111,0,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,9/15/2017 7:17,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
C,PRE-DOSE,1755,17,3,-0.154861111,0,.,.,.,0,0,5,242,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,242,u/ml,9/15/2017 7:17,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
C,PRE-DOSE,1756,17,3,-0.154861111,0,.,.,.,0,0,6,64,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,64,u/ml,9/15/2017 7:17,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1757,17,3,0,.,.,300,.,1,1,0,.,.,.,1,1,StudyID,001-084,300 mg SC,VISIT 4 (DAY 1) BASELINE,1,.,0,300,mg,300,SUBCUTANEOUS,1505473200,1505473200,Dupilumab,.,.,.,.,,.,.,.,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1758,17,3,0.001388889,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/15/2017 11:02,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1759,17,3,0.001388889,0,.,.,.,0,0,1,82.9,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.9,mg/L,9/15/2017 11:02,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1760,17,3,0.001388889,0,.,.,.,0,0,4,97,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,97,u/ml,9/15/2017 11:02,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1761,17,3,0.001388889,0,.,.,.,0,0,5,251,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,251,u/ml,9/15/2017 11:02,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1762,17,3,0.001388889,0,.,.,.,0,0,6,66,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,66,u/ml,9/15/2017 11:02,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1763,17,3,0.010416667,0.010416667,.,.,.,0,0,2,-2.525728644,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.08,mg/L,9/15/2017 11:15,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1764,17,3,0.010416667,0.010416667,.,.,.,0,0,1,87,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87,mg/L,9/15/2017 11:15,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1765,17,3,0.010416667,0.010416667,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,9/15/2017 11:15,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1766,17,3,0.010416667,0.010416667,.,.,.,0,0,5,246,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,246,u/ml,9/15/2017 11:15,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1767,17,3,0.010416667,0.010416667,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,9/15/2017 11:15,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1768,17,3,0.020833333,0.020833333,.,.,.,0,0,2,-2.079441542,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.125,mg/L,9/15/2017 11:30,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1769,17,3,0.020833333,0.020833333,.,.,.,0,0,1,84.6,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.6,mg/L,9/15/2017 11:30,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1770,17,3,0.020833333,0.020833333,.,.,.,0,0,4,106,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,106,u/ml,9/15/2017 11:30,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1771,17,3,0.020833333,0.020833333,.,.,.,0,0,5,252,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,252,u/ml,9/15/2017 11:30,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1772,17,3,0.020833333,0.020833333,.,.,.,0,0,6,66,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,66,u/ml,9/15/2017 11:30,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1773,17,3,0.041666667,0.041666667,.,.,.,0,0,2,-1.331806176,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.264,mg/L,9/15/2017 12:00,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1774,17,3,0.041666667,0.041666667,.,.,.,0,0,1,82.9,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.9,mg/L,9/15/2017 12:00,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1775,17,3,0.041666667,0.041666667,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,9/15/2017 12:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1776,17,3,0.041666667,0.041666667,.,.,.,0,0,5,237,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,237,u/ml,9/15/2017 12:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1777,17,3,0.041666667,0.041666667,.,.,.,0,0,6,71,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,71,u/ml,9/15/2017 12:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1778,17,3,0.083333333,0.083333333,.,.,.,0,0,2,-0.125563223,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.882,mg/L,9/15/2017 13:00,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1779,17,3,0.083333333,0.083333333,.,.,.,0,0,1,79.3,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.3,mg/L,9/15/2017 13:00,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1780,17,3,0.083333333,0.083333333,.,.,.,0,0,4,101,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,101,u/ml,9/15/2017 13:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1781,17,3,0.083333333,0.083333333,.,.,.,0,0,5,219,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,219,u/ml,9/15/2017 13:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1782,17,3,0.083333333,0.083333333,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,9/15/2017 13:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1783,17,3,0.166666667,0.166666667,.,.,.,0,0,2,0.746687947,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.11,mg/L,9/15/2017 15:00,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1784,17,3,0.166666667,0.166666667,.,.,.,0,0,1,78.4,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.4,mg/L,9/15/2017 15:00,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1785,17,3,0.166666667,0.166666667,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,9/15/2017 15:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1786,17,3,0.166666667,0.166666667,.,.,.,0,0,5,229,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,229,u/ml,9/15/2017 15:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1787,17,3,0.166666667,0.166666667,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,9/15/2017 15:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1788,17,3,0.334027778,0.333333333,.,.,.,0,0,2,1.549687908,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,4.71,mg/L,9/15/2017 19:01,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1789,17,3,0.334027778,0.333333333,.,.,.,0,0,1,79.5,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.5,mg/L,9/15/2017 19:01,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1790,17,3,0.334027778,0.333333333,.,.,.,0,0,4,102,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,102,u/ml,9/15/2017 19:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1791,17,3,0.334027778,0.333333333,.,.,.,0,0,5,238,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,238,u/ml,9/15/2017 19:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1792,17,3,0.334027778,0.333333333,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,9/15/2017 19:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1793,17,3,0.5,0.5,.,.,.,0,0,2,1.795087259,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,6.02,mg/L,9/15/2017 23:00,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1794,17,3,0.5,0.5,.,.,.,0,0,1,74.6,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.6,mg/L,9/15/2017 23:00,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1795,17,3,0.5,0.5,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,9/15/2017 23:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1796,17,3,0.5,0.5,.,.,.,0,0,5,194,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,194,u/ml,9/15/2017 23:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1797,17,3,0.5,0.5,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,9/15/2017 23:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1798,17,3,1,1,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,9/16/2017 11:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1799,17,3,1,1,.,.,.,0,0,5,215,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,215,u/ml,9/16/2017 11:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1800,17,3,1,1,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,9/16/2017 11:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1801,17,3,1.070833333,0,.,.,.,0,0,2,2.424802726,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 997,997,U1,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,11.3,mg/L,9/16/2017 12:42,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1802,17,3,1.070833333,0,.,.,.,0,0,1,85.3,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 997,997,U1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.3,mg/L,9/16/2017 12:42,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1803,17,3,1.070833333,0,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-084,300 mg SC,VISIT NA,.,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,9/16/2017 12:42,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1804,17,3,3,3,.,.,.,0,0,2,3.493472658,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,32.9,mg/L,9/18/2017 11:00,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1805,17,3,3,3,.,.,.,0,0,1,87.3,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.3,mg/L,9/18/2017 11:00,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1806,17,3,3,3,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,9/18/2017 11:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1807,17,3,3,3,.,.,.,0,0,5,169,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,169,u/ml,9/18/2017 11:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1808,17,3,3,3,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,9/18/2017 11:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1809,17,3,7.088888889,7,.,.,.,0,0,2,3.73289634,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,41.8,mg/L,9/22/2017 13:08,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1810,17,3,7.088888889,7,.,.,.,0,0,1,89,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,89,mg/L,9/22/2017 13:08,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1811,17,3,7.088888889,14,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,9/22/2017 13:08,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1812,17,3,7.088888889,14,.,.,.,0,0,5,123,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,123,u/ml,9/22/2017 13:08,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1813,17,3,7.088888889,14,.,.,.,0,0,6,45,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,45,u/ml,9/22/2017 13:08,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1814,17,3,14.07569444,14,.,.,.,0,0,2,3.234749174,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,25.4,mg/L,9/29/2017 12:49,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1815,17,3,14.07569444,14,.,.,.,0,0,1,97.9,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,97.9,mg/L,9/29/2017 12:49,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1816,17,3,14.07569444,28,.,.,.,0,0,4,110,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,110,u/ml,9/29/2017 12:49,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1817,17,3,14.07569444,28,.,.,.,0,0,5,226,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,226,u/ml,9/29/2017 12:49,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1818,17,3,14.07569444,28,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,9/29/2017 12:49,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1819,17,3,21.08541667,21,.,.,.,0,0,2,2.564949357,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,13,mg/L,10/6/2017 13:03,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1820,17,3,21.08541667,21,.,.,.,0,0,1,94.7,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,94.7,mg/L,10/6/2017 13:03,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1821,17,3,21.08541667,42,.,.,.,0,0,4,115,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,115,u/ml,10/6/2017 13:03,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1822,17,3,21.08541667,42,.,.,.,0,0,5,281,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,281,u/ml,10/6/2017 13:03,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1823,17,3,21.08541667,42,.,.,.,0,0,6,72,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,72,u/ml,10/6/2017 13:03,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1824,17,3,28.08680556,28,.,.,.,0,0,2,1.969905655,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,7.17,mg/L,10/13/2017 13:05,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1825,17,3,28.08680556,28,.,.,.,0,0,1,99.9,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,99.9,mg/L,10/13/2017 13:05,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1826,17,3,28.08680556,56,.,.,.,0,0,4,112,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,112,u/ml,10/13/2017 13:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1827,17,3,28.08680556,56,.,.,.,0,0,5,276,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,276,u/ml,10/13/2017 13:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1828,17,3,28.08680556,56,.,.,.,0,0,6,75,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,75,u/ml,10/13/2017 13:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1829,17,3,42.10138889,42,.,.,.,0,0,2,0.712949808,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.04,mg/L,10/27/2017 13:26,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1830,17,3,42.10138889,42,.,.,.,0,0,1,79.3,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.3,mg/L,10/27/2017 13:26,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1831,17,3,42.10138889,84,.,.,.,0,0,4,119,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,119,u/ml,10/27/2017 13:26,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1832,17,3,42.10138889,84,.,.,.,0,0,5,212,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,212,u/ml,10/27/2017 13:26,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1833,17,3,42.10138889,84,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,10/27/2017 13:26,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1834,17,3,56.10069444,56,.,.,.,0,0,2,-0.486133011,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.615,mg/L,11/10/2017 13:25,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1835,17,3,56.10069444,56,.,.,.,0,0,1,136,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,136,mg/L,11/10/2017 13:25,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1836,17,3,56.10069444,112,.,.,.,0,0,4,128,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,128,u/ml,11/10/2017 13:25,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1837,17,3,56.10069444,112,.,.,.,0,0,5,271,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,271,u/ml,11/10/2017 13:25,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1838,17,3,56.10069444,112,.,.,.,0,0,6,92,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,92,u/ml,11/10/2017 13:25,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1839,17,3,84.09513889,84,.,.,.,0,0,2,-2.378386806,1,0.078,2,0,StudyID,001-084,300 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.0927,mg/L,12/8/2017 13:17,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1840,17,3,84.09513889,84,.,.,.,0,0,1,94.3,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,94.3,mg/L,12/8/2017 13:17,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1841,17,3,84.09513889,168,.,.,.,0,0,4,120,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,120,u/ml,12/8/2017 13:17,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1842,17,3,84.09513889,168,.,.,.,0,0,5,306,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,306,u/ml,12/8/2017 13:17,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1843,17,3,84.09513889,168,.,.,.,0,0,6,77,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,77,u/ml,12/8/2017 13:17,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1844,17,3,98.11597222,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-084,300 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,12/22/2017 13:47,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1845,17,3,98.11597222,98,.,.,.,0,0,1,81,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81,mg/L,12/22/2017 13:47,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1846,17,3,98.11597222,196,.,.,.,0,0,4,120,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,120,u/ml,12/22/2017 13:47,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1847,17,3,98.11597222,196,.,.,.,0,0,5,268,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,268,u/ml,12/22/2017 13:47,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1848,17,3,98.11597222,196,.,.,.,0,0,6,75,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,75,u/ml,12/22/2017 13:47,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1849,17,3,112.1125,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-084,300 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,1/5/2018 13:42,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1850,17,3,112.1125,112,.,.,.,0,0,1,71.6,0,0.0078,0,0,StudyID,001-084,300 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.6,mg/L,1/5/2018 13:42,.,.,.,.,.,.,.,.,66,.,.,79.4,242
.,.,1851,17,3,112.1125,224,.,.,.,0,0,4,119,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,119,u/ml,1/5/2018 13:42,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1852,17,3,112.1125,224,.,.,.,0,0,5,274,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,274,u/ml,1/5/2018 13:42,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
.,.,1853,17,3,112.1125,224,.,.,.,0,0,6,85,.,.,0,0,StudyID,001-084,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,85,u/ml,1/5/2018 13:42,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66,165,24.2,79.4,242
C,PRE-DOSE,1854,18,4,-45.825,0,.,.,.,0,0,1,89.3,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,89.3,mg/L,8/24/2017 14:12,.,.,.,.,.,.,.,.,79.5,.,.,106,394
C,PRE-DOSE,1855,18,4,-45.825,0,.,.,.,0,0,4,112,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,112,u/ml,8/24/2017 14:12,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
C,PRE-DOSE,1856,18,4,-45.825,0,.,.,.,0,0,5,333,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,333,u/ml,8/24/2017 14:12,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
C,PRE-DOSE,1857,18,4,-45.825,0,.,.,.,0,0,6,66,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,66,u/ml,8/24/2017 14:12,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
C,PRE-DOSE,1858,18,4,-0.845138889,-1,.,.,.,0,0,1,113,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,113,mg/L,10/8/2017 13:43,.,.,.,.,.,.,.,.,79.5,.,.,106,394
C,PRE-DOSE,1859,18,4,-0.845138889,0,.,.,.,0,0,4,127,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,127,u/ml,10/8/2017 13:43,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
C,PRE-DOSE,1860,18,4,-0.845138889,0,.,.,.,0,0,5,379,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,379,u/ml,10/8/2017 13:43,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
C,PRE-DOSE,1861,18,4,-0.845138889,0,.,.,.,0,0,6,90,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,90,u/ml,10/8/2017 13:43,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
C,PRE-DOSE,1862,18,4,-0.124305556,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/9/2017 7:01,.,.,.,.,.,.,.,.,79.5,.,.,106,394
C,PRE-DOSE,1863,18,4,-0.124305556,0,.,.,.,0,0,1,106,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,106,mg/L,10/9/2017 7:01,.,.,.,.,.,.,.,.,79.5,.,.,106,394
C,PRE-DOSE,1864,18,4,-0.124305556,0,.,.,.,0,0,4,126,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,126,u/ml,10/9/2017 7:01,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
C,PRE-DOSE,1865,18,4,-0.124305556,0,.,.,.,0,0,5,394,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,394,u/ml,10/9/2017 7:01,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
C,PRE-DOSE,1866,18,4,-0.124305556,0,.,.,.,0,0,6,90,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,90,u/ml,10/9/2017 7:01,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1867,18,4,0,.,.,800,16695.65217,1,2,0,.,.,.,2,1,StudyID,001-087,10 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.047916667,800,mg,800,INTRAVENOUS,1507543200,1507547340,Dupilumab,.,.,.,.,,.,.,.,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1868,18,4,0.047916667,0,.,.,.,0,0,2,5.80814249,0,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,333,mg/L,10/9/2017 11:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1869,18,4,0.047916667,0,.,.,.,0,0,1,91.1,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,91.1,mg/L,10/9/2017 11:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1870,18,4,0.047916667,0,.,.,.,0,0,4,56,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,56,u/ml,10/9/2017 11:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1871,18,4,0.047916667,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/9/2017 11:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1872,18,4,0.047916667,0,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,10/9/2017 11:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1873,18,4,0.058333333,0.010416667,.,.,.,0,0,2,5.826000107,0,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,339,mg/L,10/9/2017 11:24,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1874,18,4,0.058333333,0.010416667,.,.,.,0,0,1,99.9,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,99.9,mg/L,10/9/2017 11:24,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1875,18,4,0.058333333,0.010416667,.,.,.,0,0,4,39,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,39,u/ml,10/9/2017 11:24,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1876,18,4,0.058333333,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/9/2017 11:24,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1877,18,4,0.058333333,0.010416667,.,.,.,0,0,6,8,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,8,u/ml,10/9/2017 11:24,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1878,18,4,0.06875,0.020833333,.,.,.,0,0,2,5.752572639,0,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,315,mg/L,10/9/2017 11:39,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1879,18,4,0.06875,0.020833333,.,.,.,0,0,1,88,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88,mg/L,10/9/2017 11:39,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1880,18,4,0.06875,0.020833333,.,.,.,0,0,4,44,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,44,u/ml,10/9/2017 11:39,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1881,18,4,0.06875,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/9/2017 11:39,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1882,18,4,0.06875,0.020833333,.,.,.,0,0,6,8,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,8,u/ml,10/9/2017 11:39,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1883,18,4,0.089583333,0.041666667,.,.,.,0,0,2,5.783825182,0,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,325,mg/L,10/9/2017 12:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1884,18,4,0.089583333,0.041666667,.,.,.,0,0,1,97.7,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,97.7,mg/L,10/9/2017 12:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1885,18,4,0.089583333,0.041666667,.,.,.,0,0,4,43,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,43,u/ml,10/9/2017 12:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1886,18,4,0.089583333,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/9/2017 12:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1887,18,4,0.089583333,0.041666667,.,.,.,0,0,6,8,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,8,u/ml,10/9/2017 12:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1888,18,4,0.13125,0.083333333,.,.,.,0,0,2,5.726847748,0,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,307,mg/L,10/9/2017 13:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1889,18,4,0.13125,0.083333333,.,.,.,0,0,1,93.4,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,93.4,mg/L,10/9/2017 13:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1890,18,4,0.13125,0.083333333,.,.,.,0,0,4,30,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,30,u/ml,10/9/2017 13:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1891,18,4,0.13125,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/9/2017 13:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1892,18,4,0.13125,0.083333333,.,.,.,0,0,6,8,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,8,u/ml,10/9/2017 13:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1893,18,4,0.208333333,0.166666667,.,.,.,0,0,2,5.673323267,0,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,291,mg/L,10/9/2017 15:00,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1894,18,4,0.208333333,0.166666667,.,.,.,0,0,1,100,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,100,mg/L,10/9/2017 15:00,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1895,18,4,0.208333333,0.166666667,.,.,.,0,0,4,39,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,39,u/ml,10/9/2017 15:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1896,18,4,0.208333333,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/9/2017 15:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1897,18,4,0.208333333,0.166666667,.,.,.,0,0,6,8,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,8,u/ml,10/9/2017 15:00,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1898,18,4,0.38125,0.333333333,.,.,.,0,0,2,5.605802066,0,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,272,mg/L,10/9/2017 19:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1899,18,4,0.38125,0.333333333,.,.,.,0,0,1,102,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,102,mg/L,10/9/2017 19:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1900,18,4,0.38125,0.333333333,.,.,.,0,0,4,55,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,55,u/ml,10/9/2017 19:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1901,18,4,0.38125,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/9/2017 19:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1902,18,4,0.38125,0.333333333,.,.,.,0,0,6,9,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,9,u/ml,10/9/2017 19:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1903,18,4,0.547916667,0.5,.,.,.,0,0,2,5.730099783,0,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,308,mg/L,10/9/2017 23:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1904,18,4,0.547916667,0.5,.,.,.,0,0,1,103,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,103,mg/L,10/9/2017 23:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1905,18,4,0.547916667,0.5,.,.,.,0,0,4,45,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,45,u/ml,10/9/2017 23:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1906,18,4,0.547916667,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/9/2017 23:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1907,18,4,0.547916667,0.5,.,.,.,0,0,6,9,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,9,u/ml,10/9/2017 23:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1908,18,4,1.047916667,1,.,.,.,0,0,2,5.525452939,0,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,251,mg/L,10/10/2017 11:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1909,18,4,1.047916667,1,.,.,.,0,0,1,112,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,112,mg/L,10/10/2017 11:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1910,18,4,1.047916667,1,.,.,.,0,0,4,64,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,64,u/ml,10/10/2017 11:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1911,18,4,1.047916667,1,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/10/2017 11:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1912,18,4,1.047916667,1,.,.,.,0,0,6,10,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,10,u/ml,10/10/2017 11:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1913,18,4,3.047916667,3,.,.,.,0,0,2,5.023880521,0,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,152,mg/L,10/12/2017 11:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1914,18,4,3.047916667,3,.,.,.,0,0,1,130,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,130,mg/L,10/12/2017 11:09,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1915,18,4,3.047916667,3,.,.,.,0,0,4,74,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,74,u/ml,10/12/2017 11:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1916,18,4,3.047916667,3,.,.,.,0,0,5,2,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,2,u/ml,10/12/2017 11:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1917,18,4,3.047916667,3,.,.,.,0,0,6,13,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,13,u/ml,10/12/2017 11:09,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1918,18,4,7.153472222,7,.,.,.,0,0,2,4.672828834,0,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,107,mg/L,10/16/2017 13:41,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1919,18,4,7.153472222,7,.,.,.,0,0,1,120,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,120,mg/L,10/16/2017 13:41,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1920,18,4,7.153472222,14,.,.,.,0,0,4,63,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,63,u/ml,10/16/2017 13:41,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1921,18,4,7.153472222,14,.,.,.,0,0,5,6,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,6,u/ml,10/16/2017 13:41,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1922,18,4,7.153472222,14,.,.,.,0,0,6,14,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,14,u/ml,10/16/2017 13:41,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1923,18,4,14.14722222,14,.,.,.,0,0,2,4.239886868,1,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,69.4,mg/L,10/23/2017 13:32,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1924,18,4,14.14722222,14,.,.,.,0,0,1,98.9,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,98.9,mg/L,10/23/2017 13:32,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1925,18,4,14.14722222,28,.,.,.,0,0,4,90,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,90,u/ml,10/23/2017 13:32,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1926,18,4,14.14722222,28,.,.,.,0,0,5,76,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,76,u/ml,10/23/2017 13:32,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1927,18,4,14.14722222,28,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,10/23/2017 13:32,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1928,18,4,21.18194444,21,.,.,.,0,0,2,3.686376324,1,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,39.9,mg/L,10/30/2017 14:22,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1929,18,4,21.18194444,21,.,.,.,0,0,1,97.2,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,97.2,mg/L,10/30/2017 14:22,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1930,18,4,21.18194444,42,.,.,.,0,0,4,83,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,83,u/ml,10/30/2017 14:22,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1931,18,4,21.18194444,42,.,.,.,0,0,5,178,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,178,u/ml,10/30/2017 14:22,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1932,18,4,21.18194444,42,.,.,.,0,0,6,37,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,37,u/ml,10/30/2017 14:22,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1933,18,4,28.19305556,28,.,.,.,0,0,2,3.077312261,1,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,21.7,mg/L,11/6/2017 14:38,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1934,18,4,28.19305556,28,.,.,.,0,0,1,104,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,104,mg/L,11/6/2017 14:38,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1935,18,4,28.19305556,56,.,.,.,0,0,4,120,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,120,u/ml,11/6/2017 14:38,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1936,18,4,28.19305556,56,.,.,.,0,0,5,328,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,328,u/ml,11/6/2017 14:38,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1937,18,4,28.19305556,56,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,11/6/2017 14:38,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1938,18,4,42.17083333,42,.,.,.,0,0,2,3.493472658,1,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,32.9,mg/L,11/20/2017 14:06,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1939,18,4,42.17083333,42,.,.,.,0,0,1,94.4,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,94.4,mg/L,11/20/2017 14:06,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1940,18,4,42.17083333,84,.,.,.,0,0,4,116,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,116,u/ml,11/20/2017 14:06,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1941,18,4,42.17083333,84,.,.,.,0,0,5,349,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,349,u/ml,11/20/2017 14:06,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1942,18,4,42.17083333,84,.,.,.,0,0,6,69,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,69,u/ml,11/20/2017 14:06,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1943,18,4,56.16388889,56,.,.,.,0,0,2,0.90825856,1,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.48,mg/L,12/4/2017 13:56,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1944,18,4,56.16388889,56,.,.,.,0,0,1,75.8,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.8,mg/L,12/4/2017 13:56,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1945,18,4,56.16388889,112,.,.,.,0,0,4,101,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,101,u/ml,12/4/2017 13:56,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1946,18,4,56.16388889,112,.,.,.,0,0,5,212,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,212,u/ml,12/4/2017 13:56,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1947,18,4,56.16388889,112,.,.,.,0,0,6,66,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,66,u/ml,12/4/2017 13:56,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1948,18,4,86.17013889,84,.,.,.,0,0,2,-0.316081547,1,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.729,mg/L,1/3/2018 14:05,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1949,18,4,86.17013889,84,.,.,.,0,0,1,75.2,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.2,mg/L,1/3/2018 14:05,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1950,18,4,86.17013889,168,.,.,.,0,0,4,128,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,128,u/ml,1/3/2018 14:05,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1951,18,4,86.17013889,168,.,.,.,0,0,5,303,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,303,u/ml,1/3/2018 14:05,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1952,18,4,86.17013889,168,.,.,.,0,0,6,79,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,79,u/ml,1/3/2018 14:05,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1953,18,4,98.16180556,98,.,.,.,0,0,2,-0.809680997,1,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.445,mg/L,1/15/2018 13:53,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1954,18,4,98.16180556,98,.,.,.,0,0,1,70.5,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.5,mg/L,1/15/2018 13:53,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1955,18,4,98.16180556,196,.,.,.,0,0,4,117,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,117,u/ml,1/15/2018 13:53,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1956,18,4,98.16180556,196,.,.,.,0,0,5,310,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,310,u/ml,1/15/2018 13:53,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1957,18,4,98.16180556,196,.,.,.,0,0,6,74,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,74,u/ml,1/15/2018 13:53,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1958,18,4,112.1701389,112,.,.,.,0,0,2,-1.194022473,1,0.078,2,0,StudyID,001-087,10 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.303,mg/L,1/29/2018 14:05,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1959,18,4,112.1701389,112,.,.,.,0,0,1,74.9,0,0.0078,0,0,StudyID,001-087,10 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.9,mg/L,1/29/2018 14:05,.,.,.,.,.,.,.,.,79.5,.,.,106,394
.,.,1960,18,4,112.1701389,224,.,.,.,0,0,4,110,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,110,u/ml,1/29/2018 14:05,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1961,18,4,112.1701389,224,.,.,.,0,0,5,318,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,318,u/ml,1/29/2018 14:05,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
.,.,1962,18,4,112.1701389,224,.,.,.,0,0,6,82,.,.,0,0,StudyID,001-087,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,82,u/ml,1/29/2018 14:05,26,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,79.5,172,26.9,106,394
C,PRE-DOSE,1963,19,4,-45.91180556,0,.,.,.,0,0,1,70.5,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.5,mg/L,8/31/2017 12:27,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
C,PRE-DOSE,1964,19,4,-45.91180556,0,.,.,.,0,0,4,93,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,93,u/ml,8/31/2017 12:27,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
C,PRE-DOSE,1965,19,4,-45.91180556,0,.,.,.,0,0,5,242,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,242,u/ml,8/31/2017 12:27,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
C,PRE-DOSE,1966,19,4,-45.91180556,0,.,.,.,0,0,6,51,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,51,u/ml,8/31/2017 12:27,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
C,PRE-DOSE,1967,19,4,-0.859027778,-1,.,.,.,0,0,1,67.1,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.1,mg/L,10/15/2017 13:43,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
C,PRE-DOSE,1968,19,4,-0.859027778,0,.,.,.,0,0,4,102,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,102,u/ml,10/15/2017 13:43,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
C,PRE-DOSE,1969,19,4,-0.859027778,0,.,.,.,0,0,5,223,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,223,u/ml,10/15/2017 13:43,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
C,PRE-DOSE,1970,19,4,-0.859027778,0,.,.,.,0,0,6,51,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,51,u/ml,10/15/2017 13:43,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
C,PRE-DOSE,1971,19,4,-0.122916667,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/16/2017 7:23,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
C,PRE-DOSE,1972,19,4,-0.122916667,0,.,.,.,0,0,1,67.8,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.8,mg/L,10/16/2017 7:23,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
C,PRE-DOSE,1973,19,4,-0.122916667,0,.,.,.,0,0,4,98,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,98,u/ml,10/16/2017 7:23,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
C,PRE-DOSE,1974,19,4,-0.122916667,0,.,.,.,0,0,5,237,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,237,u/ml,10/16/2017 7:23,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
C,PRE-DOSE,1975,19,4,-0.122916667,0,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,10/16/2017 7:23,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1976,19,4,0,.,.,550,11647.05882,1,2,0,.,.,.,2,1,StudyID,001-097,10 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.047222222,550,mg,550,INTRAVENOUS,1508149200,1508153280,Dupilumab,.,.,.,.,,.,.,.,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1977,19,4,0.047222222,0,.,.,.,0,0,2,5.513428746,0,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,248,mg/L,10/16/2017 11:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,1978,19,4,0.047222222,0,.,.,.,0,0,1,55,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,55,mg/L,10/16/2017 11:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,1979,19,4,0.047222222,0,.,.,.,0,0,4,30,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,30,u/ml,10/16/2017 11:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1980,19,4,0.047222222,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 11:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1981,19,4,0.047222222,0,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,10/16/2017 11:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1982,19,4,0.057638889,0.010416667,.,.,.,0,0,2,5.537334267,0,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,254,mg/L,10/16/2017 11:43,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,1983,19,4,0.057638889,0.010416667,.,.,.,0,0,1,59.6,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,59.6,mg/L,10/16/2017 11:43,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,1984,19,4,0.057638889,0.010416667,.,.,.,0,0,4,34,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,34,u/ml,10/16/2017 11:43,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1985,19,4,0.057638889,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 11:43,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1986,19,4,0.057638889,0.010416667,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,10/16/2017 11:43,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1987,19,4,0.068055556,0.020833333,.,.,.,0,0,2,5.560681631,0,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,260,mg/L,10/16/2017 11:58,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,1988,19,4,0.068055556,0.020833333,.,.,.,0,0,1,56.4,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,56.4,mg/L,10/16/2017 11:58,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,1989,19,4,0.068055556,0.020833333,.,.,.,0,0,4,27,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,27,u/ml,10/16/2017 11:58,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1990,19,4,0.068055556,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 11:58,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1991,19,4,0.068055556,0.020833333,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,10/16/2017 11:58,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1992,19,4,0.088888889,0.041666667,.,.,.,0,0,2,5.497168225,0,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,244,mg/L,10/16/2017 12:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,1993,19,4,0.088888889,0.041666667,.,.,.,0,0,1,53.9,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,53.9,mg/L,10/16/2017 12:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,1994,19,4,0.088888889,0.041666667,.,.,.,0,0,4,29,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,29,u/ml,10/16/2017 12:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1995,19,4,0.088888889,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 12:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1996,19,4,0.088888889,0.041666667,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,10/16/2017 12:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,1997,19,4,0.130555556,0.083333333,.,.,.,0,0,2,5.463831805,0,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,236,mg/L,10/16/2017 13:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,1998,19,4,0.130555556,0.083333333,.,.,.,0,0,1,58.9,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,58.9,mg/L,10/16/2017 13:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,1999,19,4,0.130555556,0.083333333,.,.,.,0,0,4,28,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,28,u/ml,10/16/2017 13:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2000,19,4,0.130555556,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 13:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2001,19,4,0.130555556,0.083333333,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,10/16/2017 13:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2002,19,4,0.213888889,0.166666667,.,.,.,0,0,2,5.493061443,0,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,243,mg/L,10/16/2017 15:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2003,19,4,0.213888889,0.166666667,.,.,.,0,0,1,59.7,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,59.7,mg/L,10/16/2017 15:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2004,19,4,0.213888889,0.166666667,.,.,.,0,0,4,27,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,27,u/ml,10/16/2017 15:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2005,19,4,0.213888889,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 15:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2006,19,4,0.213888889,0.166666667,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,10/16/2017 15:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2007,19,4,0.380555556,0.333333333,.,.,.,0,0,2,5.459585514,0,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,235,mg/L,10/16/2017 19:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2008,19,4,0.380555556,0.333333333,.,.,.,0,0,1,60.4,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,60.4,mg/L,10/16/2017 19:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2009,19,4,0.380555556,0.333333333,.,.,.,0,0,4,26,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,26,u/ml,10/16/2017 19:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2010,19,4,0.380555556,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 19:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2011,19,4,0.380555556,0.333333333,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,10/16/2017 19:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2012,19,4,0.547222222,0.5,.,.,.,0,0,2,5.420534999,0,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,226,mg/L,10/16/2017 23:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2013,19,4,0.547222222,0.5,.,.,.,0,0,1,65.9,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.9,mg/L,10/16/2017 23:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2014,19,4,0.547222222,0.5,.,.,.,0,0,4,45,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,45,u/ml,10/16/2017 23:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2015,19,4,0.547222222,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 23:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2016,19,4,0.547222222,0.5,.,.,.,0,0,6,6,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,6,u/ml,10/16/2017 23:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2017,19,4,1.047222222,1,.,.,.,0,0,2,5.318119994,0,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,204,mg/L,10/17/2017 11:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2018,19,4,1.047222222,1,.,.,.,0,0,1,75.3,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.3,mg/L,10/17/2017 11:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2019,19,4,1.047222222,1,.,.,.,0,0,4,52,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,52,u/ml,10/17/2017 11:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2020,19,4,1.047222222,1,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/17/2017 11:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2021,19,4,1.047222222,1,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,10/17/2017 11:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2022,19,4,3.047222222,3,.,.,.,0,0,2,4.9698133,0,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,144,mg/L,10/19/2017 11:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2023,19,4,3.047222222,3,.,.,.,0,0,1,81.8,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.8,mg/L,10/19/2017 11:28,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2024,19,4,3.047222222,3,.,.,.,0,0,4,44,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,44,u/ml,10/19/2017 11:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2025,19,4,3.047222222,3,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/19/2017 11:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2026,19,4,3.047222222,3,.,.,.,0,0,6,9,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,9,u/ml,10/19/2017 11:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2027,19,4,7.139583333,7,.,.,.,0,0,2,4.624972813,0,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,102,mg/L,10/23/2017 13:41,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2028,19,4,7.139583333,7,.,.,.,0,0,1,82.7,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.7,mg/L,10/23/2017 13:41,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2029,19,4,7.139583333,14,.,.,.,0,0,4,58,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,58,u/ml,10/23/2017 13:41,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2030,19,4,7.139583333,14,.,.,.,0,0,5,8,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,8,u/ml,10/23/2017 13:41,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2031,19,4,7.139583333,14,.,.,.,0,0,6,9,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,9,u/ml,10/23/2017 13:41,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2032,19,4,14.14375,14,.,.,.,0,0,2,4.301358732,1,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,73.8,mg/L,10/30/2017 13:47,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2033,19,4,14.14375,14,.,.,.,0,0,1,89.4,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,89.4,mg/L,10/30/2017 13:47,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2034,19,4,14.14375,28,.,.,.,0,0,4,74,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,74,u/ml,10/30/2017 13:47,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2035,19,4,14.14375,28,.,.,.,0,0,5,20,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,20,u/ml,10/30/2017 13:47,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2036,19,4,14.14375,28,.,.,.,0,0,6,14,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,14,u/ml,10/30/2017 13:47,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2037,19,4,21.15555556,21,.,.,.,0,0,2,3.795489189,1,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,44.5,mg/L,11/6/2017 14:04,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2038,19,4,21.15555556,21,.,.,.,0,0,1,82.6,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.6,mg/L,11/6/2017 14:04,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2039,19,4,21.15555556,42,.,.,.,0,0,4,63,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,63,u/ml,11/6/2017 14:04,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2040,19,4,21.15555556,42,.,.,.,0,0,5,111,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,111,u/ml,11/6/2017 14:04,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2041,19,4,21.15555556,42,.,.,.,0,0,6,22,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,22,u/ml,11/6/2017 14:04,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2042,19,4,42.13819444,42,.,.,.,0,0,2,3.681351188,1,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,39.7,mg/L,11/27/2017 13:39,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2043,19,4,42.13819444,42,.,.,.,0,0,1,88.9,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88.9,mg/L,11/27/2017 13:39,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2044,19,4,42.13819444,84,.,.,.,0,0,4,100,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,100,u/ml,11/27/2017 13:39,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2045,19,4,42.13819444,84,.,.,.,0,0,5,188,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,188,u/ml,11/27/2017 13:39,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2046,19,4,42.13819444,84,.,.,.,0,0,6,51,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,51,u/ml,11/27/2017 13:39,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2047,19,4,56.12152778,56,.,.,.,0,0,2,1.172482137,1,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.23,mg/L,12/11/2017 13:15,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2048,19,4,56.12152778,56,.,.,.,0,0,1,64.9,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.9,mg/L,12/11/2017 13:15,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2049,19,4,56.12152778,112,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,12/11/2017 13:15,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2050,19,4,56.12152778,112,.,.,.,0,0,5,199,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,199,u/ml,12/11/2017 13:15,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2051,19,4,56.12152778,112,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,12/11/2017 13:15,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2052,19,4,84.15277778,84,.,.,.,0,0,2,-0.391562203,1,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.676,mg/L,1/8/2018 14:00,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2053,19,4,84.15277778,84,.,.,.,0,0,1,61.9,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,61.9,mg/L,1/8/2018 14:00,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2054,19,4,84.15277778,168,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,1/8/2018 14:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2055,19,4,84.15277778,168,.,.,.,0,0,5,219,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,219,u/ml,1/8/2018 14:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2056,19,4,84.15277778,168,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,1/8/2018 14:00,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2057,19,4,98.14236111,98,.,.,.,0,0,2,-1.044124103,1,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.352,mg/L,1/22/2018 13:45,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2058,19,4,98.14236111,98,.,.,.,0,0,1,62.7,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,62.7,mg/L,1/22/2018 13:45,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2059,19,4,98.14236111,196,.,.,.,0,0,4,93,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,93,u/ml,1/22/2018 13:45,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2060,19,4,98.14236111,196,.,.,.,0,0,5,233,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,233,u/ml,1/22/2018 13:45,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2061,19,4,98.14236111,196,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,1/22/2018 13:45,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2062,19,4,112.1569444,112,.,.,.,0,0,2,-1.692819521,1,0.078,2,0,StudyID,001-097,10 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.184,mg/L,2/5/2018 14:06,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2063,19,4,112.1569444,112,.,.,.,0,0,1,88.3,0,0.0078,0,0,StudyID,001-097,10 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88.3,mg/L,2/5/2018 14:06,.,.,.,.,.,.,.,.,55.8,.,.,67.8,237
.,.,2064,19,4,112.1569444,224,.,.,.,0,0,4,145,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,145,u/ml,2/5/2018 14:06,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2065,19,4,112.1569444,224,.,.,.,0,0,5,300,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,300,u/ml,2/5/2018 14:06,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
.,.,2066,19,4,112.1569444,224,.,.,.,0,0,6,86,.,.,0,0,StudyID,001-097,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,86,u/ml,2/5/2018 14:06,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55.8,159,22.1,67.8,237
C,PRE-DOSE,2067,20,4,-41.91597222,0,.,.,.,0,0,1,93.5,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,93.5,mg/L,9/4/2017 12:01,.,.,.,.,.,.,.,.,56.9,.,.,108,253
C,PRE-DOSE,2068,20,4,-41.91597222,0,.,.,.,0,0,4,128,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,128,u/ml,9/4/2017 12:01,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
C,PRE-DOSE,2069,20,4,-41.91597222,0,.,.,.,0,0,5,241,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,241,u/ml,9/4/2017 12:01,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
C,PRE-DOSE,2070,20,4,-41.91597222,0,.,.,.,0,0,6,91,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,91,u/ml,9/4/2017 12:01,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
C,PRE-DOSE,2071,20,4,-0.851388889,-1,.,.,.,0,0,1,103,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,103,mg/L,10/15/2017 13:34,.,.,.,.,.,.,.,.,56.9,.,.,108,253
C,PRE-DOSE,2072,20,4,-0.851388889,0,.,.,.,0,0,4,118,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,118,u/ml,10/15/2017 13:34,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
C,PRE-DOSE,2073,20,4,-0.851388889,0,.,.,.,0,0,5,281,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,281,u/ml,10/15/2017 13:34,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
C,PRE-DOSE,2074,20,4,-0.851388889,0,.,.,.,0,0,6,98,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,98,u/ml,10/15/2017 13:34,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
C,PRE-DOSE,2075,20,4,-0.120833333,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/16/2017 7:06,.,.,.,.,.,.,.,.,56.9,.,.,108,253
C,PRE-DOSE,2076,20,4,-0.120833333,0,.,.,.,0,0,1,108,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,108,mg/L,10/16/2017 7:06,.,.,.,.,.,.,.,.,56.9,.,.,108,253
C,PRE-DOSE,2077,20,4,-0.120833333,0,.,.,.,0,0,4,118,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,118,u/ml,10/16/2017 7:06,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
C,PRE-DOSE,2078,20,4,-0.120833333,0,.,.,.,0,0,5,253,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,253,u/ml,10/16/2017 7:06,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
C,PRE-DOSE,2079,20,4,-0.120833333,0,.,.,.,0,0,6,97,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,97,u/ml,10/16/2017 7:06,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2080,20,4,0,.,.,550,11820.89552,1,2,0,.,.,.,2,1,StudyID,001-099,10 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.046527778,550,mg,550,INTRAVENOUS,1508148000,1508152020,Dupilumab,.,.,.,.,,.,.,.,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2081,20,4,0.046527778,0,.,.,.,0,0,2,5.327876169,0,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,206,mg/L,10/16/2017 11:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2082,20,4,0.046527778,0,.,.,.,0,0,1,86.9,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,86.9,mg/L,10/16/2017 11:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2083,20,4,0.046527778,0,.,.,.,0,0,4,55,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,55,u/ml,10/16/2017 11:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2084,20,4,0.046527778,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 11:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2085,20,4,0.046527778,0,.,.,.,0,0,6,10,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,10,u/ml,10/16/2017 11:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2086,20,4,0.056944444,0.010416667,.,.,.,0,0,2,5.407171771,0,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,223,mg/L,10/16/2017 11:22,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2087,20,4,0.056944444,0.010416667,.,.,.,0,0,1,78.7,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.7,mg/L,10/16/2017 11:22,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2088,20,4,0.056944444,0.010416667,.,.,.,0,0,4,53,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,53,u/ml,10/16/2017 11:22,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2089,20,4,0.056944444,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 11:22,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2090,20,4,0.056944444,0.010416667,.,.,.,0,0,6,10,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,10,u/ml,10/16/2017 11:22,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2091,20,4,0.067361111,0.020833333,.,.,.,0,0,2,5.342334252,0,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,209,mg/L,10/16/2017 11:37,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2092,20,4,0.067361111,0.020833333,.,.,.,0,0,1,83.9,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.9,mg/L,10/16/2017 11:37,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2093,20,4,0.067361111,0.020833333,.,.,.,0,0,4,53,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,53,u/ml,10/16/2017 11:37,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2094,20,4,0.067361111,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 11:37,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2095,20,4,0.067361111,0.020833333,.,.,.,0,0,6,10,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,10,u/ml,10/16/2017 11:37,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2096,20,4,0.088194444,0.041666667,.,.,.,0,0,2,5.393627546,0,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,220,mg/L,10/16/2017 12:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2097,20,4,0.088194444,0.041666667,.,.,.,0,0,1,87.7,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.7,mg/L,10/16/2017 12:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2098,20,4,0.088194444,0.041666667,.,.,.,0,0,4,56,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,56,u/ml,10/16/2017 12:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2099,20,4,0.088194444,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 12:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2100,20,4,0.088194444,0.041666667,.,.,.,0,0,6,10,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,10,u/ml,10/16/2017 12:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2101,20,4,0.129861111,0.083333333,.,.,.,0,0,2,5.283203729,0,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,197,mg/L,10/16/2017 13:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2102,20,4,0.129861111,0.083333333,.,.,.,0,0,1,76.1,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.1,mg/L,10/16/2017 13:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2103,20,4,0.129861111,0.083333333,.,.,.,0,0,4,55,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,55,u/ml,10/16/2017 13:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2104,20,4,0.129861111,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 13:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2105,20,4,0.129861111,0.083333333,.,.,.,0,0,6,10,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,10,u/ml,10/16/2017 13:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2106,20,4,0.213194444,0.166666667,.,.,.,0,0,2,5.318119994,0,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,204,mg/L,10/16/2017 15:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2107,20,4,0.213194444,0.166666667,.,.,.,0,0,1,82.9,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.9,mg/L,10/16/2017 15:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2108,20,4,0.213194444,0.166666667,.,.,.,0,0,4,58,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,58,u/ml,10/16/2017 15:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2109,20,4,0.213194444,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 15:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2110,20,4,0.213194444,0.166666667,.,.,.,0,0,6,11,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,11,u/ml,10/16/2017 15:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2111,20,4,0.379861111,0.333333333,.,.,.,0,0,2,5.225746674,0,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,186,mg/L,10/16/2017 19:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2112,20,4,0.379861111,0.333333333,.,.,.,0,0,1,84.5,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.5,mg/L,10/16/2017 19:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2113,20,4,0.379861111,0.333333333,.,.,.,0,0,4,53,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,53,u/ml,10/16/2017 19:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2114,20,4,0.379861111,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 19:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2115,20,4,0.379861111,0.333333333,.,.,.,0,0,6,11,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,11,u/ml,10/16/2017 19:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2116,20,4,0.546527778,0.5,.,.,.,0,0,2,5.18178355,0,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,178,mg/L,10/16/2017 23:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2117,20,4,0.546527778,0.5,.,.,.,0,0,1,89.6,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,89.6,mg/L,10/16/2017 23:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2118,20,4,0.546527778,0.5,.,.,.,0,0,4,57,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,57,u/ml,10/16/2017 23:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2119,20,4,0.546527778,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/16/2017 23:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2120,20,4,0.546527778,0.5,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,10/16/2017 23:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2121,20,4,1.046527778,1,.,.,.,0,0,2,5.176149733,0,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,177,mg/L,10/17/2017 11:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2122,20,4,1.046527778,1,.,.,.,0,0,1,92.5,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,92.5,mg/L,10/17/2017 11:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2123,20,4,1.046527778,1,.,.,.,0,0,4,67,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,67,u/ml,10/17/2017 11:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2124,20,4,1.046527778,1,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,10/17/2017 11:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2125,20,4,1.046527778,1,.,.,.,0,0,6,13,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,13,u/ml,10/17/2017 11:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2126,20,4,3.046527778,3,.,.,.,0,0,2,4.890349128,0,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,133,mg/L,10/19/2017 11:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2127,20,4,3.046527778,3,.,.,.,0,0,1,99.9,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,99.9,mg/L,10/19/2017 11:07,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2128,20,4,3.046527778,3,.,.,.,0,0,4,72,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,72,u/ml,10/19/2017 11:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2129,20,4,3.046527778,3,.,.,.,0,0,5,6,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,6,u/ml,10/19/2017 11:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2130,20,4,3.046527778,3,.,.,.,0,0,6,17,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,17,u/ml,10/19/2017 11:07,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2131,20,4,7.174305556,7,.,.,.,0,0,2,4.548599834,0,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,94.5,mg/L,10/23/2017 14:11,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2132,20,4,7.174305556,7,.,.,.,0,0,1,88.8,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88.8,mg/L,10/23/2017 14:11,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2133,20,4,7.174305556,14,.,.,.,0,0,4,69,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,69,u/ml,10/23/2017 14:11,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2134,20,4,7.174305556,14,.,.,.,0,0,5,3,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,3,u/ml,10/23/2017 14:11,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2135,20,4,7.174305556,14,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,10/23/2017 14:11,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2136,20,4,14.17013889,14,.,.,.,0,0,2,4.213607983,1,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,67.6,mg/L,10/30/2017 14:05,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2137,20,4,14.17013889,14,.,.,.,0,0,1,85.7,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.7,mg/L,10/30/2017 14:05,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2138,20,4,14.17013889,28,.,.,.,0,0,4,89,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,89,u/ml,10/30/2017 14:05,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2139,20,4,14.17013889,28,.,.,.,0,0,5,41,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,41,u/ml,10/30/2017 14:05,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2140,20,4,14.17013889,28,.,.,.,0,0,6,26,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,26,u/ml,10/30/2017 14:05,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2141,20,4,21.15694444,21,.,.,.,0,0,2,3.747148362,1,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,42.4,mg/L,11/6/2017 13:46,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2142,20,4,21.15694444,21,.,.,.,0,0,1,84.9,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.9,mg/L,11/6/2017 13:46,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2143,20,4,21.15694444,42,.,.,.,0,0,4,83,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,83,u/ml,11/6/2017 13:46,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2144,20,4,21.15694444,42,.,.,.,0,0,5,47,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,47,u/ml,11/6/2017 13:46,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2145,20,4,21.15694444,42,.,.,.,0,0,6,42,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,42,u/ml,11/6/2017 13:46,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2146,20,4,28.14791667,28,.,.,.,0,0,2,3.401197382,1,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,30,mg/L,11/13/2017 13:33,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2147,20,4,28.14791667,28,.,.,.,0,0,1,91.9,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,91.9,mg/L,11/13/2017 13:33,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2148,20,4,28.14791667,56,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,11/13/2017 13:33,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2149,20,4,28.14791667,56,.,.,.,0,0,5,138,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,138,u/ml,11/13/2017 13:33,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2150,20,4,28.14791667,56,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,11/13/2017 13:33,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2151,20,4,42.15833333,42,.,.,.,0,0,2,2.379546134,1,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,10.8,mg/L,11/27/2017 13:48,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2152,20,4,42.15833333,42,.,.,.,0,0,1,87.3,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.3,mg/L,11/27/2017 13:48,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2153,20,4,42.15833333,84,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,11/27/2017 13:48,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2154,20,4,42.15833333,84,.,.,.,0,0,5,131,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,131,u/ml,11/27/2017 13:48,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2155,20,4,42.15833333,84,.,.,.,0,0,6,78,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,78,u/ml,11/27/2017 13:48,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2156,20,4,56.15486111,56,.,.,.,0,0,2,1.686398954,1,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,5.4,mg/L,12/11/2017 13:43,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2157,20,4,56.15486111,56,.,.,.,0,0,1,89.7,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,89.7,mg/L,12/11/2017 13:43,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2158,20,4,56.15486111,112,.,.,.,0,0,4,109,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,109,u/ml,12/11/2017 13:43,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2159,20,4,56.15486111,112,.,.,.,0,0,5,185,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,185,u/ml,12/11/2017 13:43,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2160,20,4,56.15486111,112,.,.,.,0,0,6,84,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,84,u/ml,12/11/2017 13:43,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2161,20,4,84.16875,84,.,.,.,0,0,2,0.438254931,1,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.55,mg/L,1/8/2018 14:03,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2162,20,4,84.16875,84,.,.,.,0,0,1,96.3,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,96.3,mg/L,1/8/2018 14:03,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2163,20,4,84.16875,168,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,1/8/2018 14:03,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2164,20,4,84.16875,168,.,.,.,0,0,5,203,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,203,u/ml,1/8/2018 14:03,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2165,20,4,84.16875,168,.,.,.,0,0,6,93,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,93,u/ml,1/8/2018 14:03,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2166,20,4,98.14930556,98,.,.,.,0,0,2,-0.116533816,1,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.89,mg/L,1/22/2018 13:35,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2167,20,4,98.14930556,98,.,.,.,0,0,1,72.3,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.3,mg/L,1/22/2018 13:35,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2168,20,4,98.14930556,196,.,.,.,0,0,4,102,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,102,u/ml,1/22/2018 13:35,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2169,20,4,98.14930556,196,.,.,.,0,0,5,197,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,197,u/ml,1/22/2018 13:35,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2170,20,4,98.14930556,196,.,.,.,0,0,6,93,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,93,u/ml,1/22/2018 13:35,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2171,20,4,112.1618056,112,.,.,.,0,0,2,-0.558616288,1,0.078,2,0,StudyID,001-099,10 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.572,mg/L,2/5/2018 13:53,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2172,20,4,112.1618056,112,.,.,.,0,0,1,75.6,0,0.0078,0,0,StudyID,001-099,10 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.6,mg/L,2/5/2018 13:53,.,.,.,.,.,.,.,.,56.9,.,.,108,253
.,.,2173,20,4,112.1618056,224,.,.,.,0,0,4,111,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,111,u/ml,2/5/2018 13:53,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2174,20,4,112.1618056,224,.,.,.,0,0,5,193,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,193,u/ml,2/5/2018 13:53,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
.,.,2175,20,4,112.1618056,224,.,.,.,0,0,6,92,.,.,0,0,StudyID,001-099,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,92,u/ml,2/5/2018 13:53,50,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,56.9,160,22.2,108,253
C,PRE-DOSE,2176,21,4,-48.91388889,0,.,.,.,0,0,1,88.5,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88.5,mg/L,9/11/2017 12:04,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
C,PRE-DOSE,2177,21,4,-48.91388889,0,.,.,.,0,0,4,138,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,138,u/ml,9/11/2017 12:04,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
C,PRE-DOSE,2178,21,4,-48.91388889,0,.,.,.,0,0,5,234,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,234,u/ml,9/11/2017 12:04,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
C,PRE-DOSE,2179,21,4,-48.91388889,0,.,.,.,0,0,6,86,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,86,u/ml,9/11/2017 12:04,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
C,PRE-DOSE,2180,21,4,-0.864583333,-1,.,.,.,0,0,1,85.2,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.2,mg/L,10/29/2017 13:15,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
C,PRE-DOSE,2181,21,4,-0.864583333,0,.,.,.,0,0,4,124,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,124,u/ml,10/29/2017 13:15,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
C,PRE-DOSE,2182,21,4,-0.864583333,0,.,.,.,0,0,5,222,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,222,u/ml,10/29/2017 13:15,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
C,PRE-DOSE,2183,21,4,-0.864583333,0,.,.,.,0,0,6,79,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,79,u/ml,10/29/2017 13:15,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
C,PRE-DOSE,2184,21,4,-0.118055556,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/30/2017 7:10,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
C,PRE-DOSE,2185,21,4,-0.118055556,0,.,.,.,0,0,1,84.8,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.8,mg/L,10/30/2017 7:10,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
C,PRE-DOSE,2186,21,4,-0.118055556,0,.,.,.,0,0,4,117,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,117,u/ml,10/30/2017 7:10,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
C,PRE-DOSE,2187,21,4,-0.118055556,0,.,.,.,0,0,5,251,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,251,u/ml,10/30/2017 7:10,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
C,PRE-DOSE,2188,21,4,-0.118055556,0,.,.,.,0,0,6,86,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,86,u/ml,10/30/2017 7:10,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2189,21,4,0,.,.,850,18545.45455,1,2,0,.,.,.,2,1,StudyID,001-103,10 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045833333,850,mg,850,INTRAVENOUS,1509357600,1509361560,Dupilumab,.,.,.,.,,.,.,.,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2190,21,4,0.045833333,0,.,.,.,0,0,2,5.552959585,0,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,258,mg/L,10/30/2017 11:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2191,21,4,0.045833333,0,.,.,.,0,0,1,73.9,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.9,mg/L,10/30/2017 11:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2192,21,4,0.045833333,0,.,.,.,0,0,4,42,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,42,u/ml,10/30/2017 11:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2193,21,4,0.045833333,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 11:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2194,21,4,0.045833333,0,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,10/30/2017 11:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2195,21,4,0.05625,0.010416667,.,.,.,0,0,2,5.572154032,0,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,263,mg/L,10/30/2017 11:21,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2196,21,4,0.05625,0.010416667,.,.,.,0,0,1,69.5,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.5,mg/L,10/30/2017 11:21,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2197,21,4,0.05625,0.010416667,.,.,.,0,0,4,61,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,61,u/ml,10/30/2017 11:21,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2198,21,4,0.05625,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 11:21,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2199,21,4,0.05625,0.010416667,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,10/30/2017 11:21,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2200,21,4,0.066666667,0.020833333,.,.,.,0,0,2,5.560681631,0,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,260,mg/L,10/30/2017 11:36,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2201,21,4,0.066666667,0.020833333,.,.,.,0,0,1,75,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75,mg/L,10/30/2017 11:36,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2202,21,4,0.066666667,0.020833333,.,.,.,0,0,4,63,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,63,u/ml,10/30/2017 11:36,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2203,21,4,0.066666667,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 11:36,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2204,21,4,0.066666667,0.020833333,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,10/30/2017 11:36,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2205,21,4,0.0875,0.041666667,.,.,.,0,0,2,5.529429088,0,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,252,mg/L,10/30/2017 12:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2206,21,4,0.0875,0.041666667,.,.,.,0,0,1,68.5,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.5,mg/L,10/30/2017 12:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2207,21,4,0.0875,0.041666667,.,.,.,0,0,4,25,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,25,u/ml,10/30/2017 12:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2208,21,4,0.0875,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 12:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2209,21,4,0.0875,0.041666667,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,10/30/2017 12:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2210,21,4,0.129861111,0.083333333,.,.,.,0,0,2,5.568344504,0,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,262,mg/L,10/30/2017 13:07,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2211,21,4,0.129861111,0.083333333,.,.,.,0,0,1,75.4,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.4,mg/L,10/30/2017 13:07,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2212,21,4,0.129861111,0.083333333,.,.,.,0,0,4,48,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,48,u/ml,10/30/2017 13:07,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2213,21,4,0.129861111,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 13:07,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2214,21,4,0.129861111,0.083333333,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,10/30/2017 13:07,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2215,21,4,0.2125,0.166666667,.,.,.,0,0,2,5.493061443,0,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,243,mg/L,10/30/2017 15:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2216,21,4,0.2125,0.166666667,.,.,.,0,0,1,71.8,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.8,mg/L,10/30/2017 15:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2217,21,4,0.2125,0.166666667,.,.,.,0,0,4,64,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,64,u/ml,10/30/2017 15:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2218,21,4,0.2125,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 15:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2219,21,4,0.2125,0.166666667,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,10/30/2017 15:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2220,21,4,0.379166667,0.333333333,.,.,.,0,0,2,5.38907173,0,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,219,mg/L,10/30/2017 19:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2221,21,4,0.379166667,0.333333333,.,.,.,0,0,1,73.2,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.2,mg/L,10/30/2017 19:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2222,21,4,0.379166667,0.333333333,.,.,.,0,0,4,67,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,67,u/ml,10/30/2017 19:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2223,21,4,0.379166667,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 19:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2224,21,4,0.379166667,0.333333333,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,10/30/2017 19:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2225,21,4,0.545833333,0.5,.,.,.,0,0,2,5.402677382,0,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,222,mg/L,10/30/2017 23:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2226,21,4,0.545833333,0.5,.,.,.,0,0,1,72.8,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.8,mg/L,10/30/2017 23:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2227,21,4,0.545833333,0.5,.,.,.,0,0,4,48,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,48,u/ml,10/30/2017 23:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2228,21,4,0.545833333,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 23:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2229,21,4,0.545833333,0.5,.,.,.,0,0,6,8,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,8,u/ml,10/30/2017 23:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2230,21,4,1.045833333,1,.,.,.,0,0,2,5.38907173,0,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,219,mg/L,10/31/2017 11:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2231,21,4,1.045833333,1,.,.,.,0,0,1,83.3,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.3,mg/L,10/31/2017 11:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2232,21,4,1.045833333,1,.,.,.,0,0,4,67,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,67,u/ml,10/31/2017 11:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2233,21,4,1.045833333,1,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/31/2017 11:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2234,21,4,1.045833333,1,.,.,.,0,0,6,10,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,10,u/ml,10/31/2017 11:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2235,21,4,3.045833333,3,.,.,.,0,0,2,5.087596335,0,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,162,mg/L,11/2/2017 11:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2236,21,4,3.045833333,3,.,.,.,0,0,1,102,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,102,mg/L,11/2/2017 11:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2237,21,4,3.045833333,3,.,.,.,0,0,4,77,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,77,u/ml,11/2/2017 11:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2238,21,4,3.045833333,3,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,11/2/2017 11:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2239,21,4,3.045833333,3,.,.,.,0,0,6,14,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,14,u/ml,11/2/2017 11:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2240,21,4,7.170833333,7,.,.,.,0,0,2,4.718498871,0,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,112,mg/L,11/6/2017 14:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2241,21,4,7.170833333,7,.,.,.,0,0,1,100,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,100,mg/L,11/6/2017 14:06,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2242,21,4,7.170833333,14,.,.,.,0,0,4,81,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,81,u/ml,11/6/2017 14:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2243,21,4,7.170833333,14,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/6/2017 14:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2244,21,4,7.170833333,14,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,11/6/2017 14:06,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2245,21,4,14.16666667,14,.,.,.,0,0,2,4.423648309,0,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,83.4,mg/L,11/13/2017 14:00,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2246,21,4,14.16666667,14,.,.,.,0,0,1,108,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,108,mg/L,11/13/2017 14:00,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2247,21,4,14.16666667,28,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,11/13/2017 14:00,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2248,21,4,14.16666667,28,.,.,.,0,0,5,12,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,12,u/ml,11/13/2017 14:00,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2249,21,4,14.16666667,28,.,.,.,0,0,6,24,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,24,u/ml,11/13/2017 14:00,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2250,21,4,21.16180556,21,.,.,.,0,0,2,3.979681654,1,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,53.5,mg/L,11/20/2017 13:53,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2251,21,4,21.16180556,21,.,.,.,0,0,1,100,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,100,mg/L,11/20/2017 13:53,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2252,21,4,21.16180556,42,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,11/20/2017 13:53,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2253,21,4,21.16180556,42,.,.,.,0,0,5,42,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,42,u/ml,11/20/2017 13:53,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2254,21,4,21.16180556,42,.,.,.,0,0,6,44,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,44,u/ml,11/20/2017 13:53,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2255,21,4,28.15,28,.,.,.,0,0,2,3.563882964,1,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,35.3,mg/L,11/27/2017 13:36,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2256,21,4,28.15,28,.,.,.,0,0,1,90.2,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.2,mg/L,11/27/2017 13:36,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2257,21,4,28.15,56,.,.,.,0,0,4,118,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,118,u/ml,11/27/2017 13:36,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2258,21,4,28.15,56,.,.,.,0,0,5,182,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,182,u/ml,11/27/2017 13:36,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2259,21,4,28.15,56,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,11/27/2017 13:36,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2260,21,4,42.17013889,42,.,.,.,0,0,2,3.280911216,1,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,26.6,mg/L,12/11/2017 14:05,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2261,21,4,42.17013889,42,.,.,.,0,0,1,113,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,113,mg/L,12/11/2017 14:05,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2262,21,4,42.17013889,84,.,.,.,0,0,4,134,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,134,u/ml,12/11/2017 14:05,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2263,21,4,42.17013889,84,.,.,.,0,0,5,187,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,187,u/ml,12/11/2017 14:05,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2264,21,4,42.17013889,84,.,.,.,0,0,6,80,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,80,u/ml,12/11/2017 14:05,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2265,21,4,54.16319444,56,.,.,.,0,0,2,1.654411278,1,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,5.23,mg/L,12/23/2017 13:55,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2266,21,4,54.16319444,56,.,.,.,0,0,1,78,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78,mg/L,12/23/2017 13:55,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2267,21,4,54.16319444,112,.,.,.,0,0,4,128,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,128,u/ml,12/23/2017 13:55,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2268,21,4,54.16319444,112,.,.,.,0,0,5,202,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,202,u/ml,12/23/2017 13:55,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2269,21,4,54.16319444,112,.,.,.,0,0,6,76,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,76,u/ml,12/23/2017 13:55,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2270,21,4,84.16597222,84,.,.,.,0,0,2,0.104360015,1,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.11,mg/L,1/22/2018 13:59,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2271,21,4,84.16597222,84,.,.,.,0,0,1,69.9,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.9,mg/L,1/22/2018 13:59,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2272,21,4,84.16597222,168,.,.,.,0,0,4,123,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,123,u/ml,1/22/2018 13:59,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2273,21,4,84.16597222,168,.,.,.,0,0,5,199,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,199,u/ml,1/22/2018 13:59,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2274,21,4,84.16597222,168,.,.,.,0,0,6,78,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,78,u/ml,1/22/2018 13:59,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2275,21,4,98.14166667,98,.,.,.,0,0,2,-0.491022996,1,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.612,mg/L,2/5/2018 13:24,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2276,21,4,98.14166667,98,.,.,.,0,0,1,91.8,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,91.8,mg/L,2/5/2018 13:24,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2277,21,4,98.14166667,196,.,.,.,0,0,4,149,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,149,u/ml,2/5/2018 13:24,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2278,21,4,98.14166667,196,.,.,.,0,0,5,254,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,254,u/ml,2/5/2018 13:24,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2279,21,4,98.14166667,196,.,.,.,0,0,6,99,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,99,u/ml,2/5/2018 13:24,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2280,21,4,112.1430556,112,.,.,.,0,0,2,-0.933945667,1,0.078,2,0,StudyID,001-103,10 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.393,mg/L,2/19/2018 13:26,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2281,21,4,112.1430556,112,.,.,.,0,0,1,87.1,0,0.0078,0,0,StudyID,001-103,10 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.1,mg/L,2/19/2018 13:26,.,.,.,.,.,.,.,.,86.4,.,.,84.8,251
.,.,2282,21,4,112.1430556,224,.,.,.,0,0,4,136,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,136,u/ml,2/19/2018 13:26,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2283,21,4,112.1430556,224,.,.,.,0,0,5,191,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,191,u/ml,2/19/2018 13:26,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
.,.,2284,21,4,112.1430556,224,.,.,.,0,0,6,86,.,.,0,0,StudyID,001-103,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,86,u/ml,2/19/2018 13:26,46,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,86.4,178,27.3,84.8,251
C,PRE-DOSE,2285,22,4,-46.81527778,0,.,.,.,0,0,1,66.4,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.4,mg/L,9/13/2017 14:36,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
C,PRE-DOSE,2286,22,4,-46.81527778,0,.,.,.,0,0,4,106,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,106,u/ml,9/13/2017 14:36,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
C,PRE-DOSE,2287,22,4,-46.81527778,0,.,.,.,0,0,5,204,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,204,u/ml,9/13/2017 14:36,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
C,PRE-DOSE,2288,22,4,-46.81527778,0,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,9/13/2017 14:36,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
C,PRE-DOSE,2289,22,4,-0.863194444,-1,.,.,.,0,0,1,79,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79,mg/L,10/29/2017 13:27,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
C,PRE-DOSE,2290,22,4,-0.863194444,0,.,.,.,0,0,4,116,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,116,u/ml,10/29/2017 13:27,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
C,PRE-DOSE,2291,22,4,-0.863194444,0,.,.,.,0,0,5,259,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,259,u/ml,10/29/2017 13:27,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
C,PRE-DOSE,2292,22,4,-0.863194444,0,.,.,.,0,0,6,73,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,73,u/ml,10/29/2017 13:27,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
C,PRE-DOSE,2293,22,4,-0.113888889,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,10/30/2017 7:26,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
C,PRE-DOSE,2294,22,4,-0.113888889,0,.,.,.,0,0,1,75.2,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.2,mg/L,10/30/2017 7:26,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
C,PRE-DOSE,2295,22,4,-0.113888889,0,.,.,.,0,0,4,110,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,110,u/ml,10/30/2017 7:26,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
C,PRE-DOSE,2296,22,4,-0.113888889,0,.,.,.,0,0,5,221,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,221,u/ml,10/30/2017 7:26,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
C,PRE-DOSE,2297,22,4,-0.113888889,0,.,.,.,0,0,6,73,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,73,u/ml,10/30/2017 7:26,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2298,22,4,0,.,.,750,16363.63636,1,2,0,.,.,.,2,1,StudyID,001-114,10 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045833333,750,mg,750,INTRAVENOUS,1509358200,1509362160,Dupilumab,.,.,.,.,,.,.,.,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2299,22,4,0.045833333,0,.,.,.,0,0,2,5.634789603,0,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,280,mg/L,10/30/2017 11:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2300,22,4,0.045833333,0,.,.,.,0,0,1,66.8,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.8,mg/L,10/30/2017 11:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2301,22,4,0.045833333,0,.,.,.,0,0,4,35,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,35,u/ml,10/30/2017 11:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2302,22,4,0.045833333,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 11:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2303,22,4,0.045833333,0,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,10/30/2017 11:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2304,22,4,0.05625,0.010416667,.,.,.,0,0,2,5.613128106,0,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,274,mg/L,10/30/2017 11:31,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2305,22,4,0.05625,0.010416667,.,.,.,0,0,1,64.3,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.3,mg/L,10/30/2017 11:31,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2306,22,4,0.05625,0.010416667,.,.,.,0,0,4,9,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,9,u/ml,10/30/2017 11:31,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2307,22,4,0.05625,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 11:31,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2308,22,4,0.05625,0.010416667,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,10/30/2017 11:31,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2309,22,4,0.066666667,0.020833333,.,.,.,0,0,2,5.572154032,0,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,263,mg/L,10/30/2017 11:46,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2310,22,4,0.066666667,0.020833333,.,.,.,0,0,1,62.5,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,62.5,mg/L,10/30/2017 11:46,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2311,22,4,0.066666667,0.020833333,.,.,.,0,0,4,48,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,48,u/ml,10/30/2017 11:46,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2312,22,4,0.066666667,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 11:46,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2313,22,4,0.066666667,0.020833333,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,10/30/2017 11:46,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2314,22,4,0.0875,0.041666667,.,.,.,0,0,2,5.620400866,0,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,276,mg/L,10/30/2017 12:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2315,22,4,0.0875,0.041666667,.,.,.,0,0,1,67,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67,mg/L,10/30/2017 12:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2316,22,4,0.0875,0.041666667,.,.,.,0,0,4,12,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,12,u/ml,10/30/2017 12:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2317,22,4,0.0875,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 12:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2318,22,4,0.0875,0.041666667,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,10/30/2017 12:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2319,22,4,0.129166667,0.083333333,.,.,.,0,0,2,5.575949103,0,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,264,mg/L,10/30/2017 13:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2320,22,4,0.129166667,0.083333333,.,.,.,0,0,1,63.3,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,63.3,mg/L,10/30/2017 13:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2321,22,4,0.129166667,0.083333333,.,.,.,0,0,4,9,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,9,u/ml,10/30/2017 13:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2322,22,4,0.129166667,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 13:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2323,22,4,0.129166667,0.083333333,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,10/30/2017 13:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2324,22,4,0.2125,0.166666667,.,.,.,0,0,2,5.529429088,0,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,252,mg/L,10/30/2017 15:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2325,22,4,0.2125,0.166666667,.,.,.,0,0,1,58.8,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,58.8,mg/L,10/30/2017 15:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2326,22,4,0.2125,0.166666667,.,.,.,0,0,4,33,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,33,u/ml,10/30/2017 15:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2327,22,4,0.2125,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 15:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2328,22,4,0.2125,0.166666667,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,10/30/2017 15:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2329,22,4,0.379166667,0.333333333,.,.,.,0,0,2,5.497168225,0,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,244,mg/L,10/30/2017 19:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2330,22,4,0.379166667,0.333333333,.,.,.,0,0,1,67.4,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.4,mg/L,10/30/2017 19:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2331,22,4,0.379166667,0.333333333,.,.,.,0,0,4,36,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,36,u/ml,10/30/2017 19:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2332,22,4,0.379166667,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 19:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2333,22,4,0.379166667,0.333333333,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,10/30/2017 19:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2334,22,4,0.545833333,0.5,.,.,.,0,0,2,5.429345629,0,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,228,mg/L,10/30/2017 23:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2335,22,4,0.545833333,0.5,.,.,.,0,0,1,62.5,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,62.5,mg/L,10/30/2017 23:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2336,22,4,0.545833333,0.5,.,.,.,0,0,4,34,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,34,u/ml,10/30/2017 23:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2337,22,4,0.545833333,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/30/2017 23:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2338,22,4,0.545833333,0.5,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,10/30/2017 23:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2339,22,4,1.046527778,1,.,.,.,0,0,2,5.411646052,0,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,224,mg/L,10/31/2017 11:17,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2340,22,4,1.046527778,1,.,.,.,0,0,1,74.4,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.4,mg/L,10/31/2017 11:17,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2341,22,4,1.046527778,1,.,.,.,0,0,4,43,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,43,u/ml,10/31/2017 11:17,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2342,22,4,1.046527778,1,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,10/31/2017 11:17,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2343,22,4,1.046527778,1,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,10/31/2017 11:17,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2344,22,4,3.045833333,3,.,.,.,0,0,2,5.123963979,0,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,168,mg/L,11/2/2017 11:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2345,22,4,3.045833333,3,.,.,.,0,0,1,86.2,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,86.2,mg/L,11/2/2017 11:16,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2346,22,4,3.045833333,3,.,.,.,0,0,4,52,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,52,u/ml,11/2/2017 11:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2347,22,4,3.045833333,3,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,11/2/2017 11:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2348,22,4,3.045833333,3,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,11/2/2017 11:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2349,22,4,7.16875,7,.,.,.,0,0,2,4.812184355,0,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,123,mg/L,11/6/2017 14:13,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2350,22,4,7.16875,7,.,.,.,0,0,1,76.2,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.2,mg/L,11/6/2017 14:13,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2351,22,4,7.16875,14,.,.,.,0,0,4,46,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,46,u/ml,11/6/2017 14:13,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2352,22,4,7.16875,14,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/6/2017 14:13,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2353,22,4,7.16875,14,.,.,.,0,0,6,9,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,9,u/ml,11/6/2017 14:13,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2354,22,4,14.15555556,14,.,.,.,0,0,2,4.476199805,0,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,87.9,mg/L,11/13/2017 13:54,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2355,22,4,14.15555556,14,.,.,.,0,0,1,82.2,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.2,mg/L,11/13/2017 13:54,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2356,22,4,14.15555556,28,.,.,.,0,0,4,78,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,78,u/ml,11/13/2017 13:54,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2357,22,4,14.15555556,28,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,11/13/2017 13:54,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2358,22,4,14.15555556,28,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,11/13/2017 13:54,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2359,22,4,21.16319444,21,.,.,.,0,0,2,4.203198967,1,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,66.9,mg/L,11/20/2017 14:05,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2360,22,4,21.16319444,21,.,.,.,0,0,1,77.5,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.5,mg/L,11/20/2017 14:05,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2361,22,4,21.16319444,42,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,11/20/2017 14:05,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2362,22,4,21.16319444,42,.,.,.,0,0,5,4,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,4,u/ml,11/20/2017 14:05,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2363,22,4,21.16319444,42,.,.,.,0,0,6,18,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,18,u/ml,11/20/2017 14:05,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2364,22,4,28.16805556,28,.,.,.,0,0,2,3.737669618,1,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,42,mg/L,11/27/2017 14:12,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2365,22,4,28.16805556,28,.,.,.,0,0,1,73,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73,mg/L,11/27/2017 14:12,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2366,22,4,28.16805556,56,.,.,.,0,0,4,101,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,101,u/ml,11/27/2017 14:12,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2367,22,4,28.16805556,56,.,.,.,0,0,5,81,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,81,u/ml,11/27/2017 14:12,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2368,22,4,28.16805556,56,.,.,.,0,0,6,31,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,31,u/ml,11/27/2017 14:12,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2369,22,4,42.16597222,42,.,.,.,0,0,2,2.778819272,1,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,16.1,mg/L,12/11/2017 14:09,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2370,22,4,42.16597222,42,.,.,.,0,0,1,73.9,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.9,mg/L,12/11/2017 14:09,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2371,22,4,42.16597222,84,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,12/11/2017 14:09,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2372,22,4,42.16597222,84,.,.,.,0,0,5,142,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,142,u/ml,12/11/2017 14:09,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2373,22,4,42.16597222,84,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,12/11/2017 14:09,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2374,22,4,54.14722222,56,.,.,.,0,0,2,1.736951233,1,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,5.68,mg/L,12/23/2017 13:42,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2375,22,4,54.14722222,56,.,.,.,0,0,1,61.5,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,61.5,mg/L,12/23/2017 13:42,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2376,22,4,54.14722222,112,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,12/23/2017 13:42,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2377,22,4,54.14722222,112,.,.,.,0,0,5,175,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,175,u/ml,12/23/2017 13:42,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2378,22,4,84.15,84,.,.,.,0,0,2,0.058268908,1,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.06,mg/L,1/22/2018 13:46,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2379,22,4,84.15,84,.,.,.,0,0,1,79.1,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.1,mg/L,1/22/2018 13:46,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2380,22,4,84.15,168,.,.,.,0,0,4,117,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,117,u/ml,1/22/2018 13:46,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2381,22,4,84.15,168,.,.,.,0,0,5,188,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,188,u/ml,1/22/2018 13:46,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2382,22,4,84.15,168,.,.,.,0,0,6,86,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,86,u/ml,1/22/2018 13:46,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2383,22,4,98.14305556,98,.,.,.,0,0,2,-0.761426021,1,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.467,mg/L,2/5/2018 13:36,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2384,22,4,98.14305556,98,.,.,.,0,0,1,69.3,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.3,mg/L,2/5/2018 13:36,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2385,22,4,98.14305556,196,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,2/5/2018 13:36,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2386,22,4,98.14305556,196,.,.,.,0,0,5,226,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,226,u/ml,2/5/2018 13:36,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2387,22,4,98.14305556,196,.,.,.,0,0,6,81,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,81,u/ml,2/5/2018 13:36,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2388,22,4,112.1409722,112,.,.,.,0,0,2,-1.276543497,1,0.078,2,0,StudyID,001-114,10 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.279,mg/L,2/19/2018 13:33,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2389,22,4,112.1409722,112,.,.,.,0,0,1,68.2,0,0.0078,0,0,StudyID,001-114,10 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.2,mg/L,2/19/2018 13:33,.,.,.,.,.,.,.,.,73.2,.,.,75.2,221
.,.,2390,22,4,112.1409722,224,.,.,.,0,0,4,125,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,125,u/ml,2/19/2018 13:33,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2391,22,4,112.1409722,224,.,.,.,0,0,5,141,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,141,u/ml,2/19/2018 13:33,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
.,.,2392,22,4,112.1409722,224,.,.,.,0,0,6,78,.,.,0,0,StudyID,001-114,10 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,78,u/ml,2/19/2018 13:33,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,73.2,171,25,75.2,221
C,PRE-DOSE,2393,23,3,-10.94583333,0,.,.,.,0,0,1,90.2,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.2,mg/L,9/14/2017 12:18,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
C,PRE-DOSE,2394,23,3,-10.94583333,0,.,.,.,0,0,4,170,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,170,u/ml,9/14/2017 12:18,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
C,PRE-DOSE,2395,23,3,-10.94583333,0,.,.,.,0,0,5,259,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,259,u/ml,9/14/2017 12:18,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
C,PRE-DOSE,2396,23,3,-10.94583333,0,.,.,.,0,0,6,109,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,109,u/ml,9/14/2017 12:18,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
C,PRE-DOSE,2397,23,3,-0.899305556,-1,.,.,.,0,0,1,85.2,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.2,mg/L,9/24/2017 13:25,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
C,PRE-DOSE,2398,23,3,-0.899305556,0,.,.,.,0,0,4,135,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,135,u/ml,9/24/2017 13:25,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
C,PRE-DOSE,2399,23,3,-0.899305556,0,.,.,.,0,0,5,226,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,226,u/ml,9/24/2017 13:25,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
C,PRE-DOSE,2400,23,3,-0.899305556,0,.,.,.,0,0,6,108,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,108,u/ml,9/24/2017 13:25,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
C,PRE-DOSE,2401,23,3,-0.159722222,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,9/25/2017 7:10,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
C,PRE-DOSE,2402,23,3,-0.159722222,0,.,.,.,0,0,1,87.3,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.3,mg/L,9/25/2017 7:10,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
C,PRE-DOSE,2403,23,3,-0.159722222,0,.,.,.,0,0,4,152,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,152,u/ml,9/25/2017 7:10,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
C,PRE-DOSE,2404,23,3,-0.159722222,0,.,.,.,0,0,5,213,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,213,u/ml,9/25/2017 7:10,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
C,PRE-DOSE,2405,23,3,-0.159722222,0,.,.,.,0,0,6,104,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,104,u/ml,9/25/2017 7:10,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2406,23,3,0,.,.,300,.,1,1,0,.,.,.,1,1,StudyID,001-116,300 mg SC,VISIT 4 (DAY 1) BASELINE,1,.,0.000694444,300,mg,300,SUBCUTANEOUS,1506337200,1506337260,Dupilumab,.,.,.,.,,.,.,.,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2407,23,3,0.000694444,0,.,.,.,0,0,2,-2.128631786,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.119,mg/L,9/25/2017 11:01,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2408,23,3,0.000694444,0,.,.,.,0,0,1,81.9,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.9,mg/L,9/25/2017 11:01,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2409,23,3,0.000694444,0,.,.,.,0,0,4,129,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,129,u/ml,9/25/2017 11:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2410,23,3,0.000694444,0,.,.,.,0,0,5,203,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,203,u/ml,9/25/2017 11:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2411,23,3,0.000694444,0,.,.,.,0,0,6,100,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,100,u/ml,9/25/2017 11:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2412,23,3,0.011111111,0.010416667,.,.,.,0,0,2,-1.565421027,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.209,mg/L,9/25/2017 11:16,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2413,23,3,0.011111111,0.010416667,.,.,.,0,0,1,80.7,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.7,mg/L,9/25/2017 11:16,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2414,23,3,0.011111111,0.010416667,.,.,.,0,0,4,133,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,133,u/ml,9/25/2017 11:16,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2415,23,3,0.011111111,0.010416667,.,.,.,0,0,5,197,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,197,u/ml,9/25/2017 11:16,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2416,23,3,0.011111111,0.010416667,.,.,.,0,0,6,92,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,92,u/ml,9/25/2017 11:16,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2417,23,3,0.021527778,0.020833333,.,.,.,0,0,2,-1.26940061,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.281,mg/L,9/25/2017 11:31,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2418,23,3,0.021527778,0.020833333,.,.,.,0,0,1,79.2,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.2,mg/L,9/25/2017 11:31,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2419,23,3,0.021527778,0.020833333,.,.,.,0,0,4,153,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,153,u/ml,9/25/2017 11:31,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2420,23,3,0.021527778,0.020833333,.,.,.,0,0,5,212,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,212,u/ml,9/25/2017 11:31,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2421,23,3,0.021527778,0.020833333,.,.,.,0,0,6,102,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,102,u/ml,9/25/2017 11:31,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2422,23,3,0.042361111,0.041666667,.,.,.,0,0,2,-1.136314156,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.321,mg/L,9/25/2017 12:01,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2423,23,3,0.042361111,0.041666667,.,.,.,0,0,1,80.2,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.2,mg/L,9/25/2017 12:01,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2424,23,3,0.042361111,0.041666667,.,.,.,0,0,4,134,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,134,u/ml,9/25/2017 12:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2425,23,3,0.042361111,0.041666667,.,.,.,0,0,5,220,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,220,u/ml,9/25/2017 12:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2426,23,3,0.042361111,0.041666667,.,.,.,0,0,6,99,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,99,u/ml,9/25/2017 12:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2427,23,3,0.084027778,0.083333333,.,.,.,0,0,2,-0.785262469,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.456,mg/L,9/25/2017 13:01,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2428,23,3,0.084027778,0.083333333,.,.,.,0,0,1,85.8,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.8,mg/L,9/25/2017 13:01,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2429,23,3,0.084027778,0.083333333,.,.,.,0,0,4,130,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,130,u/ml,9/25/2017 13:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2430,23,3,0.084027778,0.083333333,.,.,.,0,0,5,222,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,222,u/ml,9/25/2017 13:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2431,23,3,0.084027778,0.083333333,.,.,.,0,0,6,101,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,101,u/ml,9/25/2017 13:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2432,23,3,0.168055556,0.166666667,.,.,.,0,0,2,0.488580015,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.63,mg/L,9/25/2017 15:02,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2433,23,3,0.168055556,0.166666667,.,.,.,0,0,1,80.1,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.1,mg/L,9/25/2017 15:02,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2434,23,3,0.168055556,0.166666667,.,.,.,0,0,4,144,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,144,u/ml,9/25/2017 15:02,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2435,23,3,0.168055556,0.166666667,.,.,.,0,0,5,211,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,211,u/ml,9/25/2017 15:02,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2436,23,3,0.168055556,0.166666667,.,.,.,0,0,6,101,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,101,u/ml,9/25/2017 15:02,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2437,23,3,0.334027778,0.333333333,.,.,.,0,0,2,1.587192303,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,4.89,mg/L,9/25/2017 19:01,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2438,23,3,0.334027778,0.333333333,.,.,.,0,0,1,77.7,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.7,mg/L,9/25/2017 19:01,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2439,23,3,0.334027778,0.333333333,.,.,.,0,0,4,127,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,127,u/ml,9/25/2017 19:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2440,23,3,0.334027778,0.333333333,.,.,.,0,0,5,177,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,177,u/ml,9/25/2017 19:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2441,23,3,0.334027778,0.333333333,.,.,.,0,0,6,93,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,93,u/ml,9/25/2017 19:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2442,23,3,0.500694444,0.5,.,.,.,0,0,2,2.085672091,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,8.05,mg/L,9/25/2017 23:01,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2443,23,3,0.500694444,0.5,.,.,.,0,0,1,76.8,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.8,mg/L,9/25/2017 23:01,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2444,23,3,0.500694444,0.5,.,.,.,0,0,4,130,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,130,u/ml,9/25/2017 23:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2445,23,3,0.500694444,0.5,.,.,.,0,0,5,193,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,193,u/ml,9/25/2017 23:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2446,23,3,0.500694444,0.5,.,.,.,0,0,6,89,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,89,u/ml,9/25/2017 23:01,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2447,23,3,1.004861111,1,.,.,.,0,0,2,2.772588722,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,16,mg/L,9/26/2017 11:07,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2448,23,3,1.004861111,1,.,.,.,0,0,1,82.3,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.3,mg/L,9/26/2017 11:07,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2449,23,3,1.004861111,1,.,.,.,0,0,4,141,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,141,u/ml,9/26/2017 11:07,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2450,23,3,1.004861111,1,.,.,.,0,0,5,164,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,164,u/ml,9/26/2017 11:07,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2451,23,3,1.004861111,1,.,.,.,0,0,6,88,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,88,u/ml,9/26/2017 11:07,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2452,23,3,3.004861111,3,.,.,.,0,0,2,3.356897123,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.7,mg/L,9/28/2017 11:07,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2453,23,3,3.004861111,3,.,.,.,0,0,1,85.8,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.8,mg/L,9/28/2017 11:07,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2454,23,3,3.004861111,3,.,.,.,0,0,4,135,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,135,u/ml,9/28/2017 11:07,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2455,23,3,3.004861111,3,.,.,.,0,0,5,107,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,107,u/ml,9/28/2017 11:07,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2456,23,3,3.004861111,3,.,.,.,0,0,6,84,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,84,u/ml,9/28/2017 11:07,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2457,23,3,7.135416667,7,.,.,.,0,0,2,3.47506723,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,32.3,mg/L,10/2/2017 14:15,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2458,23,3,7.135416667,7,.,.,.,0,0,1,93.3,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,93.3,mg/L,10/2/2017 14:15,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2459,23,3,7.135416667,14,.,.,.,0,0,4,140,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,140,u/ml,10/2/2017 14:15,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2460,23,3,7.135416667,14,.,.,.,0,0,5,198,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,198,u/ml,10/2/2017 14:15,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2461,23,3,7.135416667,14,.,.,.,0,0,6,87,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,87,u/ml,10/2/2017 14:15,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2462,23,3,14.12083333,14,.,.,.,0,0,2,2.785011242,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,16.2,mg/L,10/9/2017 13:54,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2463,23,3,14.12083333,14,.,.,.,0,0,1,86.3,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,86.3,mg/L,10/9/2017 13:54,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2464,23,3,14.12083333,28,.,.,.,0,0,4,131,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,131,u/ml,10/9/2017 13:54,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2465,23,3,14.12083333,28,.,.,.,0,0,5,194,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,194,u/ml,10/9/2017 13:54,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2466,23,3,14.12083333,28,.,.,.,0,0,6,85,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,85,u/ml,10/9/2017 13:54,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2467,23,3,21.11875,21,.,.,.,0,0,2,1.948763218,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,7.02,mg/L,10/16/2017 13:51,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2468,23,3,21.11875,21,.,.,.,0,0,1,73.3,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.3,mg/L,10/16/2017 13:51,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2469,23,3,21.11875,42,.,.,.,0,0,4,115,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,115,u/ml,10/16/2017 13:51,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2470,23,3,21.11875,42,.,.,.,0,0,5,228,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,228,u/ml,10/16/2017 13:51,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2471,23,3,21.11875,42,.,.,.,0,0,6,78,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,78,u/ml,10/16/2017 13:51,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2472,23,3,28.11805556,28,.,.,.,0,0,2,1.486139696,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,4.42,mg/L,10/23/2017 13:50,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2473,23,3,28.11805556,28,.,.,.,0,0,1,99.2,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,99.2,mg/L,10/23/2017 13:50,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2474,23,3,28.11805556,56,.,.,.,0,0,4,170,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,170,u/ml,10/23/2017 13:50,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2475,23,3,28.11805556,56,.,.,.,0,0,5,316,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,316,u/ml,10/23/2017 13:50,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2476,23,3,28.11805556,56,.,.,.,0,0,6,115,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,115,u/ml,10/23/2017 13:50,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2477,23,3,42.11527778,42,.,.,.,0,0,2,-0.002002003,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.998,mg/L,11/6/2017 13:46,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2478,23,3,42.11527778,42,.,.,.,0,0,1,85.6,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.6,mg/L,11/6/2017 13:46,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2479,23,3,42.11527778,84,.,.,.,0,0,4,134,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,134,u/ml,11/6/2017 13:46,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2480,23,3,42.11527778,84,.,.,.,0,0,5,205,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,205,u/ml,11/6/2017 13:46,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2481,23,3,42.11527778,84,.,.,.,0,0,6,88,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,88,u/ml,11/6/2017 13:46,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2482,23,3,56.12152778,56,.,.,.,0,0,2,-1.276543497,1,0.078,2,0,StudyID,001-116,300 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.279,mg/L,11/20/2017 13:55,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2483,23,3,56.12152778,56,.,.,.,0,0,1,81.3,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.3,mg/L,11/20/2017 13:55,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2484,23,3,56.12152778,112,.,.,.,0,0,4,136,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,136,u/ml,11/20/2017 13:55,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2485,23,3,56.12152778,112,.,.,.,0,0,5,223,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,223,u/ml,11/20/2017 13:55,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2486,23,3,56.12152778,112,.,.,.,0,0,6,112,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,112,u/ml,11/20/2017 13:55,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2487,23,3,84.14513889,84,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-116,300 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,12/18/2017 14:29,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2488,23,3,84.14513889,84,.,.,.,0,0,1,90.9,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,90.9,mg/L,12/18/2017 14:29,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2489,23,3,84.14513889,168,.,.,.,0,0,4,136,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,136,u/ml,12/18/2017 14:29,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2490,23,3,84.14513889,168,.,.,.,0,0,5,178,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,178,u/ml,12/18/2017 14:29,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2491,23,3,84.14513889,168,.,.,.,0,0,6,92,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,92,u/ml,12/18/2017 14:29,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2492,23,3,99.11944444,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-116,300 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,1/2/2018 13:52,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2493,23,3,99.11944444,98,.,.,.,0,0,1,65.5,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.5,mg/L,1/2/2018 13:52,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2494,23,3,99.11944444,196,.,.,.,0,0,4,127,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,127,u/ml,1/2/2018 13:52,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2495,23,3,99.11944444,196,.,.,.,0,0,5,219,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,219,u/ml,1/2/2018 13:52,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2496,23,3,99.11944444,196,.,.,.,0,0,6,87,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,87,u/ml,1/2/2018 13:52,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2497,23,3,112.1083333,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-116,300 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,1/15/2018 13:36,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2498,23,3,112.1083333,112,.,.,.,0,0,1,70.9,0,0.0078,0,0,StudyID,001-116,300 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.9,mg/L,1/15/2018 13:36,.,.,.,.,.,.,.,.,85.7,.,.,87.3,213
.,.,2499,23,3,112.1083333,224,.,.,.,0,0,4,159,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,159,u/ml,1/15/2018 13:36,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2500,23,3,112.1083333,224,.,.,.,0,0,5,221,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,221,u/ml,1/15/2018 13:36,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
.,.,2501,23,3,112.1083333,224,.,.,.,0,0,6,103,.,.,0,0,StudyID,001-116,300 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,103,u/ml,1/15/2018 13:36,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,85.7,170,29.7,87.3,213
C,PRE-DOSE,2502,24,5,-46.95069444,0,.,.,.,0,0,1,67.9,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.9,mg/L,9/15/2017 12:31,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
C,PRE-DOSE,2503,24,5,-46.95069444,0,.,.,.,0,0,4,111,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,111,u/ml,9/15/2017 12:31,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
C,PRE-DOSE,2504,24,5,-46.95069444,0,.,.,.,0,0,5,208,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,208,u/ml,9/15/2017 12:31,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
C,PRE-DOSE,2505,24,5,-46.95069444,0,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,9/15/2017 12:31,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
C,PRE-DOSE,2506,24,5,-0.886805556,-1,.,.,.,0,0,1,71.6,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.6,mg/L,10/31/2017 14:03,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
C,PRE-DOSE,2507,24,5,-0.886805556,0,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,10/31/2017 14:03,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
C,PRE-DOSE,2508,24,5,-0.886805556,0,.,.,.,0,0,5,202,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,202,u/ml,10/31/2017 14:03,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
C,PRE-DOSE,2509,24,5,-0.886805556,0,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,10/31/2017 14:03,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
C,PRE-DOSE,2510,24,5,-0.161111111,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/1/2017 7:28,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
C,PRE-DOSE,2511,24,5,-0.161111111,0,.,.,.,0,0,1,69.8,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.8,mg/L,11/1/2017 7:28,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
C,PRE-DOSE,2512,24,5,-0.161111111,0,.,.,.,0,0,4,98,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,98,u/ml,11/1/2017 7:28,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
C,PRE-DOSE,2513,24,5,-0.161111111,0,.,.,.,0,0,5,208,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,208,u/ml,11/1/2017 7:28,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
C,PRE-DOSE,2514,24,5,-0.161111111,0,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,11/1/2017 7:28,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2515,24,5,0,.,.,600,.,1,1,0,.,.,.,1,1,StudyID,001-119,600 mg SC,VISIT 4 (DAY 1) BASELINE,1,.,0.001388889,600,mg,600,SUBCUTANEOUS,1509535200,1509535320,Dupilumab,.,.,.,.,,.,.,.,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2516,24,5,0.001388889,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/1/2017 11:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2517,24,5,0.001388889,0,.,.,.,0,0,1,61.9,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,61.9,mg/L,11/1/2017 11:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2518,24,5,0.001388889,0,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,11/1/2017 11:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2519,24,5,0.001388889,0,.,.,.,0,0,5,155,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,155,u/ml,11/1/2017 11:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2520,24,5,0.001388889,0,.,.,.,0,0,6,61,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,61,u/ml,11/1/2017 11:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2521,24,5,0.011805556,0.010416667,.,.,.,0,0,2,-1.505077897,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.222,mg/L,11/1/2017 11:37,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2522,24,5,0.011805556,0.010416667,.,.,.,0,0,1,64.6,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.6,mg/L,11/1/2017 11:37,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2523,24,5,0.011805556,0.010416667,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,11/1/2017 11:37,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2524,24,5,0.011805556,0.010416667,.,.,.,0,0,5,176,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,176,u/ml,11/1/2017 11:37,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2525,24,5,0.011805556,0.010416667,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,11/1/2017 11:37,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2526,24,5,0.022222222,0.020833333,.,.,.,0,0,2,-1.347073648,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.26,mg/L,11/1/2017 11:52,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2527,24,5,0.022222222,0.020833333,.,.,.,0,0,1,67.9,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.9,mg/L,11/1/2017 11:52,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2528,24,5,0.022222222,0.020833333,.,.,.,0,0,4,91,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,91,u/ml,11/1/2017 11:52,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2529,24,5,0.022222222,0.020833333,.,.,.,0,0,5,208,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,208,u/ml,11/1/2017 11:52,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2530,24,5,0.022222222,0.020833333,.,.,.,0,0,6,66,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,66,u/ml,11/1/2017 11:52,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2531,24,5,0.043055556,0.041666667,.,.,.,0,0,2,-1.081755172,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.339,mg/L,11/1/2017 12:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2532,24,5,0.043055556,0.041666667,.,.,.,0,0,1,68.6,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.6,mg/L,11/1/2017 12:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2533,24,5,0.043055556,0.041666667,.,.,.,0,0,4,101,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,101,u/ml,11/1/2017 12:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2534,24,5,0.043055556,0.041666667,.,.,.,0,0,5,193,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,193,u/ml,11/1/2017 12:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2535,24,5,0.043055556,0.041666667,.,.,.,0,0,6,66,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,66,u/ml,11/1/2017 12:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2536,24,5,0.084722222,0.083333333,.,.,.,0,0,2,-0.404965233,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.667,mg/L,11/1/2017 13:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2537,24,5,0.084722222,0.083333333,.,.,.,0,0,1,64.4,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.4,mg/L,11/1/2017 13:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2538,24,5,0.084722222,0.083333333,.,.,.,0,0,4,101,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,101,u/ml,11/1/2017 13:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2539,24,5,0.084722222,0.083333333,.,.,.,0,0,5,175,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,175,u/ml,11/1/2017 13:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2540,24,5,0.084722222,0.083333333,.,.,.,0,0,6,62,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,62,u/ml,11/1/2017 13:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2541,24,5,0.168055556,0.166666667,.,.,.,0,0,2,1.141033005,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.13,mg/L,11/1/2017 15:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2542,24,5,0.168055556,0.166666667,.,.,.,0,0,1,67.2,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.2,mg/L,11/1/2017 15:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2543,24,5,0.168055556,0.166666667,.,.,.,0,0,4,91,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,91,u/ml,11/1/2017 15:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2544,24,5,0.168055556,0.166666667,.,.,.,0,0,5,165,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,165,u/ml,11/1/2017 15:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2545,24,5,0.168055556,0.166666667,.,.,.,0,0,6,64,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,64,u/ml,11/1/2017 15:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2546,24,5,0.334722222,0.333333333,.,.,.,0,0,2,2.193885676,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,8.97,mg/L,11/1/2017 19:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2547,24,5,0.334722222,0.333333333,.,.,.,0,0,1,64,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64,mg/L,11/1/2017 19:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2548,24,5,0.334722222,0.333333333,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,11/1/2017 19:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2549,24,5,0.334722222,0.333333333,.,.,.,0,0,5,165,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,165,u/ml,11/1/2017 19:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2550,24,5,0.334722222,0.333333333,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,11/1/2017 19:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2551,24,5,0.501388889,0.5,.,.,.,0,0,2,2.803360381,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,16.5,mg/L,11/1/2017 23:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2552,24,5,0.501388889,0.5,.,.,.,0,0,1,65.4,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.4,mg/L,11/1/2017 23:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2553,24,5,0.501388889,0.5,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,11/1/2017 23:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2554,24,5,0.501388889,0.5,.,.,.,0,0,5,180,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,180,u/ml,11/1/2017 23:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2555,24,5,0.501388889,0.5,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,11/1/2017 23:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2556,24,5,1.001388889,1,.,.,.,0,0,2,3.387774361,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,29.6,mg/L,11/2/2017 11:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2557,24,5,1.001388889,1,.,.,.,0,0,1,64,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64,mg/L,11/2/2017 11:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2558,24,5,1.001388889,1,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,11/2/2017 11:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2559,24,5,1.001388889,1,.,.,.,0,0,5,145,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,145,u/ml,11/2/2017 11:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2560,24,5,1.001388889,1,.,.,.,0,0,6,44,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,44,u/ml,11/2/2017 11:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2561,24,5,2.976388889,3,.,.,.,0,0,2,4.010962953,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,55.2,mg/L,11/4/2017 10:46,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2562,24,5,2.976388889,3,.,.,.,0,0,1,70.3,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.3,mg/L,11/4/2017 10:46,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2563,24,5,2.976388889,3,.,.,.,0,0,4,64,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,64,u/ml,11/4/2017 10:46,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2564,24,5,2.976388889,3,.,.,.,0,0,5,18,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,18,u/ml,11/4/2017 10:46,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2565,24,5,2.976388889,3,.,.,.,0,0,6,19,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,19,u/ml,11/4/2017 10:46,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2566,24,5,7.082638889,7,.,.,.,0,0,2,4.149463861,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,63.4,mg/L,11/8/2017 13:19,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2567,24,5,7.082638889,7,.,.,.,0,0,1,75.8,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.8,mg/L,11/8/2017 13:19,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2568,24,5,7.082638889,14,.,.,.,0,0,4,54,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,54,u/ml,11/8/2017 13:19,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2569,24,5,7.082638889,14,.,.,.,0,0,5,6,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,6,u/ml,11/8/2017 13:19,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2570,24,5,7.082638889,14,.,.,.,0,0,6,19,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,19,u/ml,11/8/2017 13:19,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2571,24,5,15.07222222,14,.,.,.,0,0,2,3.78191432,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,43.9,mg/L,11/16/2017 13:04,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2572,24,5,15.07222222,14,.,.,.,0,0,1,71.9,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.9,mg/L,11/16/2017 13:04,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2573,24,5,15.07222222,28,.,.,.,0,0,4,65,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,65,u/ml,11/16/2017 13:04,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2574,24,5,15.07222222,28,.,.,.,0,0,5,60,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,60,u/ml,11/16/2017 13:04,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2575,24,5,15.07222222,28,.,.,.,0,0,6,33,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,33,u/ml,11/16/2017 13:04,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2576,24,5,21.07430556,21,.,.,.,0,0,2,3.346389145,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.4,mg/L,11/22/2017 13:07,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2577,24,5,21.07430556,21,.,.,.,0,0,1,78,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78,mg/L,11/22/2017 13:07,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2578,24,5,21.07430556,42,.,.,.,0,0,4,115,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,115,u/ml,11/22/2017 13:07,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2579,24,5,21.07430556,42,.,.,.,0,0,5,138,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,138,u/ml,11/22/2017 13:07,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2580,24,5,21.07430556,42,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,11/22/2017 13:07,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2581,24,5,28.10763889,28,.,.,.,0,0,2,2.667228207,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,14.4,mg/L,11/29/2017 13:55,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2582,24,5,28.10763889,28,.,.,.,0,0,1,72.8,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.8,mg/L,11/29/2017 13:55,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2583,24,5,28.10763889,56,.,.,.,0,0,4,115,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,115,u/ml,11/29/2017 13:55,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2584,24,5,28.10763889,56,.,.,.,0,0,5,190,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,190,u/ml,11/29/2017 13:55,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2585,24,5,28.10763889,56,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,11/29/2017 13:55,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2586,24,5,42.08472222,42,.,.,.,0,0,2,1.581038438,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,4.86,mg/L,12/13/2017 13:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2587,24,5,42.08472222,42,.,.,.,0,0,1,71.1,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.1,mg/L,12/13/2017 13:22,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2588,24,5,42.08472222,84,.,.,.,0,0,4,102,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,102,u/ml,12/13/2017 13:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2589,24,5,42.08472222,84,.,.,.,0,0,5,193,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,193,u/ml,12/13/2017 13:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2590,24,5,42.08472222,84,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,12/13/2017 13:22,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2591,24,5,58.08958333,56,.,.,.,0,0,2,0.524728529,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.69,mg/L,12/29/2017 13:29,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2592,24,5,58.08958333,56,.,.,.,0,0,1,67.9,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.9,mg/L,12/29/2017 13:29,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2593,24,5,58.08958333,112,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,12/29/2017 13:29,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2594,24,5,58.08958333,112,.,.,.,0,0,5,191,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,191,u/ml,12/29/2017 13:29,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2595,24,5,58.08958333,112,.,.,.,0,0,6,76,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,76,u/ml,12/29/2017 13:29,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2596,24,5,84.10486111,84,.,.,.,0,0,2,-0.877070019,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.416,mg/L,1/24/2018 13:51,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2597,24,5,84.10486111,84,.,.,.,0,0,1,70.1,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.1,mg/L,1/24/2018 13:51,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2598,24,5,84.10486111,168,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,1/24/2018 13:51,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2599,24,5,84.10486111,168,.,.,.,0,0,5,217,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,217,u/ml,1/24/2018 13:51,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2600,24,5,84.10486111,168,.,.,.,0,0,6,87,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,87,u/ml,1/24/2018 13:51,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2601,24,5,98.10208333,98,.,.,.,0,0,2,-1.57987911,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.206,mg/L,2/7/2018 13:47,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2602,24,5,98.10208333,98,.,.,.,0,0,1,65.5,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.5,mg/L,2/7/2018 13:47,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2603,24,5,98.10208333,196,.,.,.,0,0,6,72,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,72,u/ml,2/7/2018 13:47,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2604,24,5,112.0902778,112,.,.,.,0,0,2,-2.103734234,1,0.078,2,0,StudyID,001-119,600 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.122,mg/L,2/21/2018 13:30,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2605,24,5,112.0902778,112,.,.,.,0,0,1,74.7,0,0.0078,0,0,StudyID,001-119,600 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.7,mg/L,2/21/2018 13:30,.,.,.,.,.,.,.,.,62.8,.,.,69.8,208
.,.,2606,24,5,112.0902778,224,.,.,.,0,0,4,122,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,122,u/ml,2/21/2018 13:30,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2607,24,5,112.0902778,224,.,.,.,0,0,5,160,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,160,u/ml,2/21/2018 13:30,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
.,.,2608,24,5,112.0902778,224,.,.,.,0,0,6,74,.,.,0,0,StudyID,001-119,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,74,u/ml,2/21/2018 13:30,49,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.8,173,21,69.8,208
C,PRE-DOSE,2609,25,5,-46.81319444,0,.,.,.,0,0,1,91.8,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,91.8,mg/L,9/15/2017 15:39,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
C,PRE-DOSE,2610,25,5,-46.81319444,0,.,.,.,0,0,4,112,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,112,u/ml,9/15/2017 15:39,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
C,PRE-DOSE,2611,25,5,-46.81319444,0,.,.,.,0,0,5,265,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,265,u/ml,9/15/2017 15:39,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
C,PRE-DOSE,2612,25,5,-46.81319444,0,.,.,.,0,0,6,88,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,88,u/ml,9/15/2017 15:39,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
C,PRE-DOSE,2613,25,5,-0.884722222,-1,.,.,.,0,0,1,86.1,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,86.1,mg/L,10/31/2017 13:56,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
C,PRE-DOSE,2614,25,5,-0.884722222,0,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,10/31/2017 13:56,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
C,PRE-DOSE,2615,25,5,-0.884722222,0,.,.,.,0,0,5,291,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,291,u/ml,10/31/2017 13:56,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
C,PRE-DOSE,2616,25,5,-0.884722222,0,.,.,.,0,0,6,79,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,79,u/ml,10/31/2017 13:56,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
C,PRE-DOSE,2617,25,5,-0.15625,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/1/2017 7:25,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
C,PRE-DOSE,2618,25,5,-0.15625,0,.,.,.,0,0,1,79.3,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.3,mg/L,11/1/2017 7:25,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
C,PRE-DOSE,2619,25,5,-0.15625,0,.,.,.,0,0,4,116,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,116,u/ml,11/1/2017 7:25,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
C,PRE-DOSE,2620,25,5,-0.15625,0,.,.,.,0,0,5,267,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,267,u/ml,11/1/2017 7:25,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
C,PRE-DOSE,2621,25,5,-0.15625,0,.,.,.,0,0,6,77,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,77,u/ml,11/1/2017 7:25,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2622,25,5,0,.,.,600,.,1,1,0,.,.,.,1,1,StudyID,001-123,600 mg SC,VISIT 4 (DAY 1) BASELINE,1,.,0.002083333,600,mg,600,SUBCUTANEOUS,1509534600,1509534780,Dupilumab,.,.,.,.,,.,.,.,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2623,25,5,0.007638889,0,.,.,.,0,0,2,-2.391416307,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.0915,mg/L,11/1/2017 11:21,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2624,25,5,0.007638889,0,.,.,.,0,0,1,81.7,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.7,mg/L,11/1/2017 11:21,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2625,25,5,0.007638889,0,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,11/1/2017 11:21,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2626,25,5,0.007638889,0,.,.,.,0,0,5,274,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,274,u/ml,11/1/2017 11:21,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2627,25,5,0.007638889,0,.,.,.,0,0,6,78,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,78,u/ml,11/1/2017 11:21,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2628,25,5,0.017361111,0.010416667,.,.,.,0,0,2,-2.071473372,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.126,mg/L,11/1/2017 11:35,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2629,25,5,0.017361111,0.010416667,.,.,.,0,0,1,83.2,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.2,mg/L,11/1/2017 11:35,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2630,25,5,0.017361111,0.010416667,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,11/1/2017 11:35,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2631,25,5,0.017361111,0.010416667,.,.,.,0,0,5,289,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,289,u/ml,11/1/2017 11:35,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2632,25,5,0.017361111,0.010416667,.,.,.,0,0,6,76,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,76,u/ml,11/1/2017 11:35,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2633,25,5,0.023611111,0.020833333,.,.,.,0,0,2,-2.071473372,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.126,mg/L,11/1/2017 11:44,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2634,25,5,0.023611111,0.020833333,.,.,.,0,0,1,80.5,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.5,mg/L,11/1/2017 11:44,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2635,25,5,0.023611111,0.020833333,.,.,.,0,0,4,111,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,111,u/ml,11/1/2017 11:44,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2636,25,5,0.023611111,0.020833333,.,.,.,0,0,5,261,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,261,u/ml,11/1/2017 11:44,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2637,25,5,0.023611111,0.020833333,.,.,.,0,0,6,76,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,76,u/ml,11/1/2017 11:44,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2638,25,5,0.04375,0.041666667,.,.,.,0,0,2,-1.505077897,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.222,mg/L,11/1/2017 12:13,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2639,25,5,0.04375,0.041666667,.,.,.,0,0,1,74.2,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.2,mg/L,11/1/2017 12:13,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2640,25,5,0.04375,0.041666667,.,.,.,0,0,4,98,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,98,u/ml,11/1/2017 12:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2641,25,5,0.04375,0.041666667,.,.,.,0,0,5,222,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,222,u/ml,11/1/2017 12:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2642,25,5,0.04375,0.041666667,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,11/1/2017 12:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2643,25,5,0.085416667,0.083333333,.,.,.,0,0,2,0.231111721,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.26,mg/L,11/1/2017 13:13,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2644,25,5,0.085416667,0.083333333,.,.,.,0,0,1,74.2,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.2,mg/L,11/1/2017 13:13,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2645,25,5,0.085416667,0.083333333,.,.,.,0,0,4,86,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,86,u/ml,11/1/2017 13:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2646,25,5,0.085416667,0.083333333,.,.,.,0,0,5,247,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,247,u/ml,11/1/2017 13:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2647,25,5,0.085416667,0.083333333,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,11/1/2017 13:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2648,25,5,0.16875,0.166666667,.,.,.,0,0,2,1.566530411,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,4.79,mg/L,11/1/2017 15:13,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2649,25,5,0.16875,0.166666667,.,.,.,0,0,1,74.8,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.8,mg/L,11/1/2017 15:13,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2650,25,5,0.16875,0.166666667,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,11/1/2017 15:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2651,25,5,0.16875,0.166666667,.,.,.,0,0,5,252,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,252,u/ml,11/1/2017 15:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2652,25,5,0.16875,0.166666667,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,11/1/2017 15:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2653,25,5,0.335416667,0.333333333,.,.,.,0,0,2,2.424802726,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,11.3,mg/L,11/1/2017 19:13,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2654,25,5,0.335416667,0.333333333,.,.,.,0,0,1,69.5,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.5,mg/L,11/1/2017 19:13,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2655,25,5,0.335416667,0.333333333,.,.,.,0,0,4,83,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,83,u/ml,11/1/2017 19:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2656,25,5,0.335416667,0.333333333,.,.,.,0,0,5,217,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,217,u/ml,11/1/2017 19:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2657,25,5,0.335416667,0.333333333,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,11/1/2017 19:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2658,25,5,0.502083333,0.5,.,.,.,0,0,2,2.772588722,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,16,mg/L,11/1/2017 23:13,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2659,25,5,0.502083333,0.5,.,.,.,0,0,1,65.4,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.4,mg/L,11/1/2017 23:13,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2660,25,5,0.502083333,0.5,.,.,.,0,0,4,82,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,82,u/ml,11/1/2017 23:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2661,25,5,0.502083333,0.5,.,.,.,0,0,5,198,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,198,u/ml,11/1/2017 23:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2662,25,5,0.502083333,0.5,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,11/1/2017 23:13,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2663,25,5,1.003472222,1,.,.,.,0,0,2,3.424262655,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,30.7,mg/L,11/2/2017 11:15,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2664,25,5,1.003472222,1,.,.,.,0,0,1,80.1,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.1,mg/L,11/2/2017 11:15,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2665,25,5,1.003472222,1,.,.,.,0,0,4,86,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,86,u/ml,11/2/2017 11:15,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2666,25,5,1.003472222,1,.,.,.,0,0,5,175,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,175,u/ml,11/2/2017 11:15,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2667,25,5,1.003472222,1,.,.,.,0,0,6,50,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,50,u/ml,11/2/2017 11:15,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2668,25,5,2.978472222,3,.,.,.,0,0,2,4.147885329,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,63.3,mg/L,11/4/2017 10:39,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2669,25,5,2.978472222,3,.,.,.,0,0,1,88.5,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88.5,mg/L,11/4/2017 10:39,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2670,25,5,2.978472222,3,.,.,.,0,0,4,66,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,66,u/ml,11/4/2017 10:39,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2671,25,5,2.978472222,3,.,.,.,0,0,5,30,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,30,u/ml,11/4/2017 10:39,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2672,25,5,2.978472222,3,.,.,.,0,0,6,22,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,22,u/ml,11/4/2017 10:39,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2673,25,5,7.11875,7,.,.,.,0,0,2,4.509760001,0,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,90.9,mg/L,11/8/2017 14:01,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2674,25,5,7.11875,7,.,.,.,0,0,1,105,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,105,mg/L,11/8/2017 14:01,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2675,25,5,7.11875,14,.,.,.,0,0,4,57,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,57,u/ml,11/8/2017 14:01,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2676,25,5,7.11875,14,.,.,.,0,0,5,14,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,14,u/ml,11/8/2017 14:01,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2677,25,5,7.11875,14,.,.,.,0,0,6,18,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,18,u/ml,11/8/2017 14:01,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2678,25,5,14.11111111,14,.,.,.,0,0,2,4.348986781,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,77.4,mg/L,11/15/2017 13:50,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2679,25,5,14.11111111,14,.,.,.,0,0,1,115,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,115,mg/L,11/15/2017 13:50,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2680,25,5,14.11111111,28,.,.,.,0,0,4,79,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,79,u/ml,11/15/2017 13:50,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2681,25,5,14.11111111,28,.,.,.,0,0,5,7,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,7,u/ml,11/15/2017 13:50,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2682,25,5,14.11111111,28,.,.,.,0,0,6,22,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,22,u/ml,11/15/2017 13:50,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2683,25,5,21.11736111,21,.,.,.,0,0,2,4.136765278,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,62.6,mg/L,11/22/2017 13:59,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2684,25,5,21.11736111,21,.,.,.,0,0,1,104,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,104,mg/L,11/22/2017 13:59,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2685,25,5,21.11736111,42,.,.,.,0,0,4,65,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,65,u/ml,11/22/2017 13:59,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2686,25,5,21.11736111,42,.,.,.,0,0,5,94,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,94,u/ml,11/22/2017 13:59,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2687,25,5,21.11736111,42,.,.,.,0,0,6,28,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,28,u/ml,11/22/2017 13:59,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2688,25,5,28.10833333,28,.,.,.,0,0,2,3.824284091,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,45.8,mg/L,11/29/2017 13:46,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2689,25,5,28.10833333,28,.,.,.,0,0,1,105,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,105,mg/L,11/29/2017 13:46,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2690,25,5,28.10833333,56,.,.,.,0,0,4,92,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,92,u/ml,11/29/2017 13:46,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2691,25,5,28.10833333,56,.,.,.,0,0,5,203,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,203,u/ml,11/29/2017 13:46,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2692,25,5,28.10833333,56,.,.,.,0,0,6,49,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,49,u/ml,11/29/2017 13:46,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2693,25,5,42.09930556,42,.,.,.,0,0,2,2.890371758,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,18,mg/L,12/13/2017 13:33,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2694,25,5,42.09930556,42,.,.,.,0,0,1,94.4,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,94.4,mg/L,12/13/2017 13:33,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2695,25,5,42.09930556,84,.,.,.,0,0,4,90,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,90,u/ml,12/13/2017 13:33,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2696,25,5,42.09930556,84,.,.,.,0,0,5,167,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,167,u/ml,12/13/2017 13:33,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2697,25,5,42.09930556,84,.,.,.,0,0,6,61,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,61,u/ml,12/13/2017 13:33,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2698,25,5,59.025,56,.,.,.,0,0,2,1.916922612,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,6.8,mg/L,12/30/2017 11:46,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2699,25,5,59.025,56,.,.,.,0,0,1,78.4,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.4,mg/L,12/30/2017 11:46,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2700,25,5,59.025,112,.,.,.,0,0,4,103,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,103,u/ml,12/30/2017 11:46,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2701,25,5,59.025,112,.,.,.,0,0,5,251,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,251,u/ml,12/30/2017 11:46,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2702,25,5,59.025,112,.,.,.,0,0,6,74,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,74,u/ml,12/30/2017 11:46,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2703,25,5,84.10486111,84,.,.,.,0,0,2,0.636576829,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.89,mg/L,1/24/2018 13:41,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2704,25,5,84.10486111,84,.,.,.,0,0,1,79.8,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.8,mg/L,1/24/2018 13:41,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2705,25,5,84.10486111,168,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,1/24/2018 13:41,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2706,25,5,84.10486111,168,.,.,.,0,0,5,272,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,272,u/ml,1/24/2018 13:41,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2707,25,5,84.10486111,168,.,.,.,0,0,6,90,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,90,u/ml,1/24/2018 13:41,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2708,25,5,98.10347222,98,.,.,.,0,0,2,0.039220713,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.04,mg/L,2/7/2018 13:39,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2709,25,5,98.10347222,98,.,.,.,0,0,1,72.8,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.8,mg/L,2/7/2018 13:39,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2710,25,5,98.10347222,196,.,.,.,0,0,6,79,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,79,u/ml,2/7/2018 13:39,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2711,25,5,112.1055556,112,.,.,.,0,0,2,-0.482886255,1,0.078,2,0,StudyID,001-123,600 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.617,mg/L,2/21/2018 13:42,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2712,25,5,112.1055556,112,.,.,.,0,0,1,87.6,0,0.0078,0,0,StudyID,001-123,600 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.6,mg/L,2/21/2018 13:42,.,.,.,.,.,.,.,.,58.5,.,.,79.3,267
.,.,2713,25,5,112.1055556,224,.,.,.,0,0,4,97,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,97,u/ml,2/21/2018 13:42,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2714,25,5,112.1055556,224,.,.,.,0,0,5,228,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,228,u/ml,2/21/2018 13:42,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
.,.,2715,25,5,112.1055556,224,.,.,.,0,0,6,78,.,.,0,0,StudyID,001-123,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,78,u/ml,2/21/2018 13:42,27,YEARS,F,2,ASIAN,3,Not Hispanic or Latino,.,58.5,157,23.7,79.3,267
C,PRE-DOSE,2716,26,5,-47.95347222,0,.,.,.,0,0,1,57.9,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,57.9,mg/L,9/26/2017 12:07,.,.,.,.,.,.,.,.,55,.,.,55.1,193
C,PRE-DOSE,2717,26,5,-47.95347222,0,.,.,.,0,0,4,84,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,84,u/ml,9/26/2017 12:07,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
C,PRE-DOSE,2718,26,5,-47.95347222,0,.,.,.,0,0,5,158,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,158,u/ml,9/26/2017 12:07,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
C,PRE-DOSE,2719,26,5,-47.95347222,0,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,9/26/2017 12:07,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
C,PRE-DOSE,2720,26,5,-0.885416667,-1,.,.,.,0,0,1,60.5,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,60.5,mg/L,11/12/2017 13:45,.,.,.,.,.,.,.,.,55,.,.,55.1,193
C,PRE-DOSE,2721,26,5,-0.885416667,0,.,.,.,0,0,4,89,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,89,u/ml,11/12/2017 13:45,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
C,PRE-DOSE,2722,26,5,-0.885416667,0,.,.,.,0,0,5,183,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,183,u/ml,11/12/2017 13:45,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
C,PRE-DOSE,2723,26,5,-0.885416667,0,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,11/12/2017 13:45,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
C,PRE-DOSE,2724,26,5,-0.161111111,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/13/2017 7:08,.,.,.,.,.,.,.,.,55,.,.,55.1,193
C,PRE-DOSE,2725,26,5,-0.161111111,0,.,.,.,0,0,1,55.1,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,55.1,mg/L,11/13/2017 7:08,.,.,.,.,.,.,.,.,55,.,.,55.1,193
C,PRE-DOSE,2726,26,5,-0.161111111,0,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,11/13/2017 7:08,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
C,PRE-DOSE,2727,26,5,-0.161111111,0,.,.,.,0,0,5,193,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,193,u/ml,11/13/2017 7:08,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
C,PRE-DOSE,2728,26,5,-0.161111111,0,.,.,.,0,0,6,52,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,52,u/ml,11/13/2017 7:08,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2729,26,5,0,.,.,600,.,1,1,0,.,.,.,1,1,StudyID,001-130,600 mg SC,VISIT 4 (DAY 1) BASELINE,1,.,0.000694444,600,mg,600,SUBCUTANEOUS,1510570800,1510570860,Dupilumab,.,.,.,.,,.,.,.,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2730,26,5,0.001388889,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/13/2017 11:02,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2731,26,5,0.001388889,0,.,.,.,0,0,1,54.9,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,54.9,mg/L,11/13/2017 11:02,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2732,26,5,0.001388889,0,.,.,.,0,0,4,85,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,85,u/ml,11/13/2017 11:02,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2733,26,5,0.001388889,0,.,.,.,0,0,5,209,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,209,u/ml,11/13/2017 11:02,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2734,26,5,0.001388889,0,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,11/13/2017 11:02,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2735,26,5,0.011111111,0.010416667,.,.,.,0,0,2,-1.604450371,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.201,mg/L,11/13/2017 11:16,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2736,26,5,0.011111111,0.010416667,.,.,.,0,0,1,55.7,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,55.7,mg/L,11/13/2017 11:16,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2737,26,5,0.011111111,0.010416667,.,.,.,0,0,4,80,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,80,u/ml,11/13/2017 11:16,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2738,26,5,0.011111111,0.010416667,.,.,.,0,0,5,214,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,214,u/ml,11/13/2017 11:16,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2739,26,5,0.011111111,0.010416667,.,.,.,0,0,6,52,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,52,u/ml,11/13/2017 11:16,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2740,26,5,0.021527778,0.020833333,.,.,.,0,0,2,-1.509592577,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.221,mg/L,11/13/2017 11:31,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2741,26,5,0.021527778,0.020833333,.,.,.,0,0,1,50.9,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,50.9,mg/L,11/13/2017 11:31,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2742,26,5,0.021527778,0.020833333,.,.,.,0,0,4,79,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,79,u/ml,11/13/2017 11:31,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2743,26,5,0.021527778,0.020833333,.,.,.,0,0,5,137,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,137,u/ml,11/13/2017 11:31,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2744,26,5,0.021527778,0.020833333,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,11/13/2017 11:31,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2745,26,5,0.042361111,0.041666667,.,.,.,0,0,2,-0.93140437,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.394,mg/L,11/13/2017 12:01,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2746,26,5,0.042361111,0.041666667,.,.,.,0,0,1,60.6,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,60.6,mg/L,11/13/2017 12:01,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2747,26,5,0.042361111,0.041666667,.,.,.,0,0,4,89,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,89,u/ml,11/13/2017 12:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2748,26,5,0.042361111,0.041666667,.,.,.,0,0,5,204,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,204,u/ml,11/13/2017 12:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2749,26,5,0.042361111,0.041666667,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,11/13/2017 12:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2750,26,5,0.084027778,0.083333333,.,.,.,0,0,2,0.587786665,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.8,mg/L,11/13/2017 13:01,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2751,26,5,0.084027778,0.083333333,.,.,.,0,0,1,52.8,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,52.8,mg/L,11/13/2017 13:01,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2752,26,5,0.084027778,0.083333333,.,.,.,0,0,4,79,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,79,u/ml,11/13/2017 13:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2753,26,5,0.084027778,0.083333333,.,.,.,0,0,5,188,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,188,u/ml,11/13/2017 13:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2754,26,5,0.084027778,0.083333333,.,.,.,0,0,6,51,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,51,u/ml,11/13/2017 13:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2755,26,5,0.170833333,0.166666667,.,.,.,0,0,2,1.667706821,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,5.3,mg/L,11/13/2017 15:06,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2756,26,5,0.170833333,0.166666667,.,.,.,0,0,1,55.7,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,55.7,mg/L,11/13/2017 15:06,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2757,26,5,0.170833333,0.166666667,.,.,.,0,0,4,81,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,81,u/ml,11/13/2017 15:06,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2758,26,5,0.170833333,0.166666667,.,.,.,0,0,5,198,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,198,u/ml,11/13/2017 15:06,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2759,26,5,0.170833333,0.166666667,.,.,.,0,0,6,52,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,52,u/ml,11/13/2017 15:06,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2760,26,5,0.334722222,0.333333333,.,.,.,0,0,2,2.660259537,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,14.3,mg/L,11/13/2017 19:02,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2761,26,5,0.334722222,0.333333333,.,.,.,0,0,1,53.2,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,53.2,mg/L,11/13/2017 19:02,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2762,26,5,0.334722222,0.333333333,.,.,.,0,0,4,91,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,91,u/ml,11/13/2017 19:02,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2763,26,5,0.334722222,0.333333333,.,.,.,0,0,5,164,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,164,u/ml,11/13/2017 19:02,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2764,26,5,0.334722222,0.333333333,.,.,.,0,0,6,43,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,43,u/ml,11/13/2017 19:02,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2765,26,5,0.500694444,0.5,.,.,.,0,0,2,3.034952987,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,20.8,mg/L,11/13/2017 23:01,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2766,26,5,0.500694444,0.5,.,.,.,0,0,1,47.3,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,47.3,mg/L,11/13/2017 23:01,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2767,26,5,0.500694444,0.5,.,.,.,0,0,4,75,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,75,u/ml,11/13/2017 23:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2768,26,5,0.500694444,0.5,.,.,.,0,0,5,68,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,68,u/ml,11/13/2017 23:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2769,26,5,0.500694444,0.5,.,.,.,0,0,6,29,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,29,u/ml,11/13/2017 23:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2770,26,5,1.000694444,1,.,.,.,0,0,2,3.349904087,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,28.5,mg/L,11/14/2017 11:01,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2771,26,5,1.000694444,1,.,.,.,0,0,1,53,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,53,mg/L,11/14/2017 11:01,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2772,26,5,1.000694444,1,.,.,.,0,0,4,43,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,43,u/ml,11/14/2017 11:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2773,26,5,1.000694444,1,.,.,.,0,0,5,25,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,25,u/ml,11/14/2017 11:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2774,26,5,1.000694444,1,.,.,.,0,0,6,20,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,20,u/ml,11/14/2017 11:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2775,26,5,3.000694444,3,.,.,.,0,0,2,4.005513349,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,54.9,mg/L,11/16/2017 11:01,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2776,26,5,3.000694444,3,.,.,.,0,0,1,56,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,56,mg/L,11/16/2017 11:01,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2777,26,5,3.000694444,3,.,.,.,0,0,4,29,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,29,u/ml,11/16/2017 11:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2778,26,5,3.000694444,3,.,.,.,0,0,5,8,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,8,u/ml,11/16/2017 11:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2779,26,5,3.000694444,3,.,.,.,0,0,6,9,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,9,u/ml,11/16/2017 11:01,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2780,26,5,7.113194444,7,.,.,.,0,0,2,4.206184044,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,67.1,mg/L,11/20/2017 13:43,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2781,26,5,7.113194444,7,.,.,.,0,0,1,58.7,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,58.7,mg/L,11/20/2017 13:43,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2782,26,5,7.113194444,14,.,.,.,0,0,4,22,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,22,u/ml,11/20/2017 13:43,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2783,26,5,7.113194444,14,.,.,.,0,0,5,6,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,6,u/ml,11/20/2017 13:43,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2784,26,5,7.113194444,14,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,11/20/2017 13:43,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2785,26,5,14.13263889,14,.,.,.,0,0,2,4.131961426,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,62.3,mg/L,11/27/2017 14:11,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2786,26,5,14.13263889,14,.,.,.,0,0,1,51.6,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,51.6,mg/L,11/27/2017 14:11,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2787,26,5,14.13263889,28,.,.,.,0,0,4,53,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,53,u/ml,11/27/2017 14:11,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2788,26,5,14.13263889,28,.,.,.,0,0,5,2,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,2,u/ml,11/27/2017 14:11,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2789,26,5,14.13263889,28,.,.,.,0,0,6,9,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,9,u/ml,11/27/2017 14:11,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2790,26,5,21.12708333,21,.,.,.,0,0,2,3.640214282,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,38.1,mg/L,12/4/2017 14:03,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2791,26,5,21.12708333,21,.,.,.,0,0,1,49.1,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,49.1,mg/L,12/4/2017 14:03,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2792,26,5,21.12708333,42,.,.,.,0,0,4,36,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,36,u/ml,12/4/2017 14:03,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2793,26,5,21.12708333,42,.,.,.,0,0,5,3,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,3,u/ml,12/4/2017 14:03,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2794,26,5,21.12708333,42,.,.,.,0,0,6,11,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,11,u/ml,12/4/2017 14:03,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2795,26,5,28.10694444,28,.,.,.,0,0,2,3.380994674,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,29.4,mg/L,12/11/2017 13:34,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2796,26,5,28.10694444,28,.,.,.,0,0,1,61.8,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,61.8,mg/L,12/11/2017 13:34,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2797,26,5,28.10694444,56,.,.,.,0,0,4,78,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,78,u/ml,12/11/2017 13:34,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2798,26,5,28.10694444,56,.,.,.,0,0,5,95,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,95,u/ml,12/11/2017 13:34,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2799,26,5,28.10694444,56,.,.,.,0,0,6,26,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,26,u/ml,12/11/2017 13:34,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2800,26,5,40.12847222,42,.,.,.,0,0,2,2.312535424,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,10.1,mg/L,12/23/2017 14:05,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2801,26,5,40.12847222,42,.,.,.,0,0,1,51.9,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,51.9,mg/L,12/23/2017 14:05,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2802,26,5,40.12847222,84,.,.,.,0,0,4,81,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,81,u/ml,12/23/2017 14:05,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2803,26,5,40.12847222,84,.,.,.,0,0,5,148,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,148,u/ml,12/23/2017 14:05,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2804,26,5,40.12847222,84,.,.,.,0,0,6,47,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,47,u/ml,12/23/2017 14:05,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2805,26,5,56.13541667,56,.,.,.,0,0,2,1.261297871,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.53,mg/L,1/8/2018 14:15,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2806,26,5,56.13541667,56,.,.,.,0,0,1,56.9,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,56.9,mg/L,1/8/2018 14:15,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2807,26,5,56.13541667,112,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,1/8/2018 14:15,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2808,26,5,56.13541667,112,.,.,.,0,0,5,165,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,165,u/ml,1/8/2018 14:15,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2809,26,5,56.13541667,112,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,1/8/2018 14:15,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2810,26,5,84.12986111,84,.,.,.,0,0,2,-0.438504962,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.645,mg/L,2/5/2018 14:07,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2811,26,5,84.12986111,84,.,.,.,0,0,1,57.7,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,57.7,mg/L,2/5/2018 14:07,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2812,26,5,84.12986111,168,.,.,.,0,0,4,86,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,86,u/ml,2/5/2018 14:07,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2813,26,5,84.12986111,168,.,.,.,0,0,5,197,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,197,u/ml,2/5/2018 14:07,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2814,26,5,84.12986111,168,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,2/5/2018 14:07,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2815,26,5,98.08611111,98,.,.,.,0,0,2,-1.190727578,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.304,mg/L,2/19/2018 13:04,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2816,26,5,98.08611111,98,.,.,.,0,0,1,59,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,59,mg/L,2/19/2018 13:04,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2817,26,5,98.08611111,196,.,.,.,0,0,4,82,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,82,u/ml,2/19/2018 13:04,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2818,26,5,98.08611111,196,.,.,.,0,0,5,100,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,100,u/ml,2/19/2018 13:04,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2819,26,5,98.08611111,196,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,2/19/2018 13:04,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2820,26,5,112.1173611,112,.,.,.,0,0,2,-1.720369473,1,0.078,2,0,StudyID,001-130,600 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.179,mg/L,3/5/2018 13:49,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2821,26,5,112.1173611,112,.,.,.,0,0,1,54.3,0,0.0078,0,0,StudyID,001-130,600 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,54.3,mg/L,3/5/2018 13:49,.,.,.,.,.,.,.,.,55,.,.,55.1,193
.,.,2822,26,5,112.1173611,224,.,.,.,0,0,4,80,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,80,u/ml,3/5/2018 13:49,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2823,26,5,112.1173611,224,.,.,.,0,0,5,124,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,124,u/ml,3/5/2018 13:49,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
.,.,2824,26,5,112.1173611,224,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-130,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,3/5/2018 13:49,29,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,55,155,22.9,55.1,193
C,PRE-DOSE,2825,27,5,-41.99097222,0,.,.,.,0,0,1,60.5,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,60.5,mg/L,9/27/2017 11:13,.,.,.,.,.,.,.,.,76,.,.,68.7,224
C,PRE-DOSE,2826,27,5,-41.99097222,0,.,.,.,0,0,4,103,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,103,u/ml,9/27/2017 11:13,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
C,PRE-DOSE,2827,27,5,-41.99097222,0,.,.,.,0,0,5,160,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,160,u/ml,9/27/2017 11:13,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
C,PRE-DOSE,2828,27,5,-41.99097222,0,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,9/27/2017 11:13,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
C,PRE-DOSE,2829,27,5,-0.891666667,-1,.,.,.,0,0,1,73.1,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.1,mg/L,11/7/2017 13:36,.,.,.,.,.,.,.,.,76,.,.,68.7,224
C,PRE-DOSE,2830,27,5,-0.891666667,0,.,.,.,0,0,4,119,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,119,u/ml,11/7/2017 13:36,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
C,PRE-DOSE,2831,27,5,-0.891666667,0,.,.,.,0,0,5,223,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,223,u/ml,11/7/2017 13:36,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
C,PRE-DOSE,2832,27,5,-0.891666667,0,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,11/7/2017 13:36,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
C,PRE-DOSE,2833,27,5,-0.157638889,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/8/2017 7:13,.,.,.,.,.,.,.,.,76,.,.,68.7,224
C,PRE-DOSE,2834,27,5,-0.157638889,0,.,.,.,0,0,1,68.7,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.7,mg/L,11/8/2017 7:13,.,.,.,.,.,.,.,.,76,.,.,68.7,224
C,PRE-DOSE,2835,27,5,-0.157638889,0,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,11/8/2017 7:13,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
C,PRE-DOSE,2836,27,5,-0.157638889,0,.,.,.,0,0,5,224,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,224,u/ml,11/8/2017 7:13,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
C,PRE-DOSE,2837,27,5,-0.157638889,0,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,11/8/2017 7:13,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2838,27,5,0,.,.,600,.,1,1,0,.,.,.,1,1,StudyID,001-131,600 mg SC,VISIT 4 (DAY 1) BASELINE,1,.,0.000694444,600,mg,600,SUBCUTANEOUS,1510138800,1510138860,Dupilumab,.,.,.,.,,.,.,.,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2839,27,5,0.001388889,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/8/2017 11:02,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2840,27,5,0.001388889,0,.,.,.,0,0,1,71.3,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.3,mg/L,11/8/2017 11:02,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2841,27,5,0.001388889,0,.,.,.,0,0,4,102,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,102,u/ml,11/8/2017 11:02,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2842,27,5,0.001388889,0,.,.,.,0,0,5,216,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,216,u/ml,11/8/2017 11:02,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2843,27,5,0.001388889,0,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,11/8/2017 11:02,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2844,27,5,0.011111111,0.010416667,.,.,.,0,0,2,-2.017406151,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.133,mg/L,11/8/2017 11:16,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2845,27,5,0.011111111,0.010416667,.,.,.,0,0,1,69.1,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.1,mg/L,11/8/2017 11:16,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2846,27,5,0.011111111,0.010416667,.,.,.,0,0,4,109,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,109,u/ml,11/8/2017 11:16,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2847,27,5,0.011111111,0.010416667,.,.,.,0,0,5,227,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,227,u/ml,11/8/2017 11:16,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2848,27,5,0.011111111,0.010416667,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,11/8/2017 11:16,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2849,27,5,0.021527778,0.020833333,.,.,.,0,0,2,-1.832581464,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.16,mg/L,11/8/2017 11:31,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2850,27,5,0.021527778,0.020833333,.,.,.,0,0,1,74.1,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.1,mg/L,11/8/2017 11:31,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2851,27,5,0.021527778,0.020833333,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,11/8/2017 11:31,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2852,27,5,0.021527778,0.020833333,.,.,.,0,0,5,207,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,207,u/ml,11/8/2017 11:31,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2853,27,5,0.021527778,0.020833333,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,11/8/2017 11:31,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2854,27,5,0.041666667,0.041666667,.,.,.,0,0,2,-1.265848208,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.282,mg/L,11/8/2017 12:00,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2855,27,5,0.041666667,0.041666667,.,.,.,0,0,1,65.9,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.9,mg/L,11/8/2017 12:00,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2856,27,5,0.041666667,0.041666667,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,11/8/2017 12:00,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2857,27,5,0.041666667,0.041666667,.,.,.,0,0,5,208,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,208,u/ml,11/8/2017 12:00,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2858,27,5,0.041666667,0.041666667,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,11/8/2017 12:00,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2859,27,5,0.084027778,0.083333333,.,.,.,0,0,2,-0.102032726,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.903,mg/L,11/8/2017 13:01,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2860,27,5,0.084027778,0.083333333,.,.,.,0,0,1,69.5,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.5,mg/L,11/8/2017 13:01,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2861,27,5,0.084027778,0.083333333,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,11/8/2017 13:01,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2862,27,5,0.084027778,0.083333333,.,.,.,0,0,5,228,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,228,u/ml,11/8/2017 13:01,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2863,27,5,0.084027778,0.083333333,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,11/8/2017 13:01,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2864,27,5,0.166666667,0.166666667,.,.,.,0,0,2,0.712949808,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.04,mg/L,11/8/2017 15:00,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2865,27,5,0.166666667,0.166666667,.,.,.,0,0,1,76.6,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.6,mg/L,11/8/2017 15:00,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2866,27,5,0.166666667,0.166666667,.,.,.,0,0,4,106,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,106,u/ml,11/8/2017 15:00,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2867,27,5,0.166666667,0.166666667,.,.,.,0,0,5,211,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,211,u/ml,11/8/2017 15:00,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2868,27,5,0.166666667,0.166666667,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,11/8/2017 15:00,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2869,27,5,0.334027778,0.333333333,.,.,.,0,0,2,1.78339122,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,5.95,mg/L,11/8/2017 19:01,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2870,27,5,0.334027778,0.333333333,.,.,.,0,0,1,68.1,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.1,mg/L,11/8/2017 19:01,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2871,27,5,0.334027778,0.333333333,.,.,.,0,0,4,98,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,98,u/ml,11/8/2017 19:01,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2872,27,5,0.334027778,0.333333333,.,.,.,0,0,5,237,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,237,u/ml,11/8/2017 19:01,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2873,27,5,0.334027778,0.333333333,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,11/8/2017 19:01,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2874,27,5,0.500694444,0.5,.,.,.,0,0,2,2.200552367,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,9.03,mg/L,11/8/2017 23:01,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2875,27,5,0.500694444,0.5,.,.,.,0,0,1,65.4,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.4,mg/L,11/8/2017 23:01,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2876,27,5,0.500694444,0.5,.,.,.,0,0,4,93,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,93,u/ml,11/8/2017 23:01,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2877,27,5,0.500694444,0.5,.,.,.,0,0,5,171,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,171,u/ml,11/8/2017 23:01,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2878,27,5,0.500694444,0.5,.,.,.,0,0,6,48,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,48,u/ml,11/8/2017 23:01,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2879,27,5,1,1,.,.,.,0,0,2,2.856470206,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,17.4,mg/L,11/9/2017 11:00,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2880,27,5,1,1,.,.,.,0,0,1,65.5,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.5,mg/L,11/9/2017 11:00,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2881,27,5,1,1,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,11/9/2017 11:00,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2882,27,5,1,1,.,.,.,0,0,5,163,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,163,u/ml,11/9/2017 11:00,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2883,27,5,1,1,.,.,.,0,0,6,49,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,49,u/ml,11/9/2017 11:00,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2884,27,5,3.000694444,3,.,.,.,0,0,2,3.502549876,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,33.2,mg/L,11/11/2017 11:01,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2885,27,5,3.000694444,3,.,.,.,0,0,1,66.9,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.9,mg/L,11/11/2017 11:01,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2886,27,5,3.000694444,3,.,.,.,0,0,4,85,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,85,u/ml,11/11/2017 11:01,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2887,27,5,3.000694444,3,.,.,.,0,0,5,91,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,91,u/ml,11/11/2017 11:01,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2888,27,5,3.000694444,3,.,.,.,0,0,6,31,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,31,u/ml,11/11/2017 11:01,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2889,27,5,7.102083333,7,.,.,.,0,0,2,3.770459441,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,43.4,mg/L,11/15/2017 13:27,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2890,27,5,7.102083333,7,.,.,.,0,0,1,69.9,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.9,mg/L,11/15/2017 13:27,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2891,27,5,7.102083333,14,.,.,.,0,0,4,56,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,56,u/ml,11/15/2017 13:27,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2892,27,5,7.102083333,14,.,.,.,0,0,5,21,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,21,u/ml,11/15/2017 13:27,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2893,27,5,7.102083333,14,.,.,.,0,0,6,20,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,20,u/ml,11/15/2017 13:27,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2894,27,5,14.11666667,14,.,.,.,0,0,2,3.711130063,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,40.9,mg/L,11/22/2017 13:48,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2895,27,5,14.11666667,14,.,.,.,0,0,1,68,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68,mg/L,11/22/2017 13:48,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2896,27,5,14.11666667,28,.,.,.,0,0,4,64,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,64,u/ml,11/22/2017 13:48,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2897,27,5,14.11666667,28,.,.,.,0,0,5,25,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,25,u/ml,11/22/2017 13:48,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2898,27,5,14.11666667,28,.,.,.,0,0,6,27,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,27,u/ml,11/22/2017 13:48,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2899,27,5,21.14375,21,.,.,.,0,0,2,3.317815773,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,27.6,mg/L,11/29/2017 14:27,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2900,27,5,21.14375,21,.,.,.,0,0,1,69.6,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.6,mg/L,11/29/2017 14:27,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2901,27,5,21.14375,42,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,11/29/2017 14:27,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2902,27,5,21.14375,42,.,.,.,0,0,5,146,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,146,u/ml,11/29/2017 14:27,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2903,27,5,21.14375,42,.,.,.,0,0,6,52,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,52,u/ml,11/29/2017 14:27,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2904,27,5,28.13402778,28,.,.,.,0,0,2,2.879198457,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,17.8,mg/L,12/6/2017 14:13,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2905,27,5,28.13402778,28,.,.,.,0,0,1,66.8,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.8,mg/L,12/6/2017 14:13,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2906,27,5,28.13402778,56,.,.,.,0,0,4,110,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,110,u/ml,12/6/2017 14:13,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2907,27,5,28.13402778,56,.,.,.,0,0,5,183,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,183,u/ml,12/6/2017 14:13,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2908,27,5,28.13402778,56,.,.,.,0,0,6,48,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,48,u/ml,12/6/2017 14:13,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2909,27,5,42.13333333,42,.,.,.,0,0,2,1.816452082,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,6.15,mg/L,12/20/2017 14:12,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2910,27,5,42.13333333,42,.,.,.,0,0,1,65.6,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.6,mg/L,12/20/2017 14:12,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2911,27,5,42.13333333,84,.,.,.,0,0,4,95,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,95,u/ml,12/20/2017 14:12,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2912,27,5,42.13333333,84,.,.,.,0,0,5,137,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,137,u/ml,12/20/2017 14:12,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2913,27,5,42.13333333,84,.,.,.,0,0,6,48,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,48,u/ml,12/20/2017 14:12,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2914,27,5,56.125,56,.,.,.,0,0,2,1.040276712,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.83,mg/L,1/3/2018 14:00,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2915,27,5,56.125,56,.,.,.,0,0,1,65.2,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.2,mg/L,1/3/2018 14:00,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2916,27,5,56.125,112,.,.,.,0,0,4,109,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,109,u/ml,1/3/2018 14:00,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2917,27,5,56.125,112,.,.,.,0,0,5,195,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,195,u/ml,1/3/2018 14:00,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2918,27,5,56.125,112,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,1/3/2018 14:00,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2919,27,5,84.10972222,84,.,.,.,0,0,2,-0.345311185,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.708,mg/L,1/31/2018 13:38,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2920,27,5,84.10972222,84,.,.,.,0,0,1,65.9,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.9,mg/L,1/31/2018 13:38,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2921,27,5,84.10972222,168,.,.,.,0,0,4,98,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,98,u/ml,1/31/2018 13:38,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2922,27,5,84.10972222,168,.,.,.,0,0,5,235,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,235,u/ml,1/31/2018 13:38,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2923,27,5,84.10972222,168,.,.,.,0,0,6,73,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,73,u/ml,1/31/2018 13:38,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2924,27,5,98.10972222,98,.,.,.,0,0,2,-0.869884359,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.419,mg/L,2/14/2018 13:38,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2925,27,5,98.10972222,98,.,.,.,0,0,1,59.9,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,59.9,mg/L,2/14/2018 13:38,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2926,27,5,98.10972222,196,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,2/14/2018 13:38,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2927,27,5,112.1138889,112,.,.,.,0,0,2,-1.474033275,1,0.078,2,0,StudyID,001-131,600 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.229,mg/L,2/28/2018 13:44,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2928,27,5,112.1138889,112,.,.,.,0,0,1,64,0,0.0078,0,0,StudyID,001-131,600 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64,mg/L,2/28/2018 13:44,.,.,.,.,.,.,.,.,76,.,.,68.7,224
.,.,2929,27,5,112.1138889,224,.,.,.,0,0,4,106,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,106,u/ml,2/28/2018 13:44,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2930,27,5,112.1138889,224,.,.,.,0,0,5,145,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,145,u/ml,2/28/2018 13:44,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
.,.,2931,27,5,112.1138889,224,.,.,.,0,0,6,66,.,.,0,0,StudyID,001-131,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,66,u/ml,2/28/2018 13:44,23,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,76,170,26.3,68.7,224
C,PRE-DOSE,2932,28,5,-44.825,0,.,.,.,0,0,1,82,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82,mg/L,9/29/2017 15:22,.,.,.,.,.,.,.,.,108,.,.,72.9,380
C,PRE-DOSE,2933,28,5,-44.825,0,.,.,.,0,0,4,125,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,125,u/ml,9/29/2017 15:22,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
C,PRE-DOSE,2934,28,5,-44.825,0,.,.,.,0,0,5,344,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,344,u/ml,9/29/2017 15:22,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
C,PRE-DOSE,2935,28,5,-44.825,0,.,.,.,0,0,6,73,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,73,u/ml,9/29/2017 15:22,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
C,PRE-DOSE,2936,28,5,-0.9,-1,.,.,.,0,0,1,71.8,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.8,mg/L,11/12/2017 13:34,.,.,.,.,.,.,.,.,108,.,.,72.9,380
C,PRE-DOSE,2937,28,5,-0.9,0,.,.,.,0,0,4,115,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,115,u/ml,11/12/2017 13:34,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
C,PRE-DOSE,2938,28,5,-0.9,0,.,.,.,0,0,5,341,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,341,u/ml,11/12/2017 13:34,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
C,PRE-DOSE,2939,28,5,-0.9,0,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,11/12/2017 13:34,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
C,PRE-DOSE,2940,28,5,-0.161111111,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/13/2017 7:18,.,.,.,.,.,.,.,.,108,.,.,72.9,380
C,PRE-DOSE,2941,28,5,-0.161111111,0,.,.,.,0,0,1,72.9,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.9,mg/L,11/13/2017 7:18,.,.,.,.,.,.,.,.,108,.,.,72.9,380
C,PRE-DOSE,2942,28,5,-0.161111111,0,.,.,.,0,0,4,133,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,133,u/ml,11/13/2017 7:18,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
C,PRE-DOSE,2943,28,5,-0.161111111,0,.,.,.,0,0,5,380,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,380,u/ml,11/13/2017 7:18,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
C,PRE-DOSE,2944,28,5,-0.161111111,0,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,11/13/2017 7:18,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2945,28,5,0,.,.,600,.,1,1,0,.,.,.,1,1,StudyID,001-139,600 mg SC,VISIT 4 (DAY 1) BASELINE,1,.,0.000694444,600,mg,600,SUBCUTANEOUS,1510571400,1510571460,Dupilumab,.,.,.,.,,.,.,.,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2946,28,5,0.001388889,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/13/2017 11:12,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2947,28,5,0.001388889,0,.,.,.,0,0,1,71.6,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.6,mg/L,11/13/2017 11:12,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2948,28,5,0.001388889,0,.,.,.,0,0,4,134,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,134,u/ml,11/13/2017 11:12,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2949,28,5,0.001388889,0,.,.,.,0,0,5,355,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,355,u/ml,11/13/2017 11:12,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2950,28,5,0.001388889,0,.,.,.,0,0,6,52,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,52,u/ml,11/13/2017 11:12,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2951,28,5,0.011111111,0.010416667,.,.,.,0,0,2,-1.771956842,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.17,mg/L,11/13/2017 11:26,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2952,28,5,0.011111111,0.010416667,.,.,.,0,0,1,67.9,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.9,mg/L,11/13/2017 11:26,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2953,28,5,0.011111111,0.010416667,.,.,.,0,0,4,131,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,131,u/ml,11/13/2017 11:26,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2954,28,5,0.011111111,0.010416667,.,.,.,0,0,5,309,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,309,u/ml,11/13/2017 11:26,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2955,28,5,0.011111111,0.010416667,.,.,.,0,0,6,49,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,49,u/ml,11/13/2017 11:26,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2956,28,5,0.021527778,0.020833333,.,.,.,0,0,2,-1.500583508,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.223,mg/L,11/13/2017 11:41,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2957,28,5,0.021527778,0.020833333,.,.,.,0,0,1,74.9,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.9,mg/L,11/13/2017 11:41,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2958,28,5,0.021527778,0.020833333,.,.,.,0,0,4,134,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,134,u/ml,11/13/2017 11:41,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2959,28,5,0.021527778,0.020833333,.,.,.,0,0,5,385,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,385,u/ml,11/13/2017 11:41,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2960,28,5,0.021527778,0.020833333,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,11/13/2017 11:41,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2961,28,5,0.042361111,0.041666667,.,.,.,0,0,2,-0.972861083,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.378,mg/L,11/13/2017 12:11,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2962,28,5,0.042361111,0.041666667,.,.,.,0,0,1,72.5,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.5,mg/L,11/13/2017 12:11,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2963,28,5,0.042361111,0.041666667,.,.,.,0,0,4,124,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,124,u/ml,11/13/2017 12:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2964,28,5,0.042361111,0.041666667,.,.,.,0,0,5,342,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,342,u/ml,11/13/2017 12:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2965,28,5,0.042361111,0.041666667,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,11/13/2017 12:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2966,28,5,0.084027778,0.083333333,.,.,.,0,0,2,0.553885113,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.74,mg/L,11/13/2017 13:11,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2967,28,5,0.084027778,0.083333333,.,.,.,0,0,1,68.8,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.8,mg/L,11/13/2017 13:11,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2968,28,5,0.084027778,0.083333333,.,.,.,0,0,4,119,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,119,u/ml,11/13/2017 13:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2969,28,5,0.084027778,0.083333333,.,.,.,0,0,5,290,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,290,u/ml,11/13/2017 13:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2970,28,5,0.084027778,0.083333333,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,11/13/2017 13:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2971,28,5,0.166666667,0.166666667,.,.,.,0,0,2,1.704748092,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,5.5,mg/L,11/13/2017 15:10,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2972,28,5,0.166666667,0.166666667,.,.,.,0,0,1,66.3,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.3,mg/L,11/13/2017 15:10,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2973,28,5,0.166666667,0.166666667,.,.,.,0,0,4,126,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,126,u/ml,11/13/2017 15:10,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2974,28,5,0.166666667,0.166666667,.,.,.,0,0,5,311,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,311,u/ml,11/13/2017 15:10,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2975,28,5,0.166666667,0.166666667,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,11/13/2017 15:10,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2976,28,5,0.336111111,0.333333333,.,.,.,0,0,2,2.442347035,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,11.5,mg/L,11/13/2017 19:14,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2977,28,5,0.336111111,0.333333333,.,.,.,0,0,1,57.7,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,57.7,mg/L,11/13/2017 19:14,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2978,28,5,0.336111111,0.333333333,.,.,.,0,0,4,103,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,103,u/ml,11/13/2017 19:14,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2979,28,5,0.336111111,0.333333333,.,.,.,0,0,5,304,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,304,u/ml,11/13/2017 19:14,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2980,28,5,0.336111111,0.333333333,.,.,.,0,0,6,50,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,50,u/ml,11/13/2017 19:14,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2981,28,5,0.500694444,0.5,.,.,.,0,0,2,2.714694744,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,15.1,mg/L,11/13/2017 23:11,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2982,28,5,0.500694444,0.5,.,.,.,0,0,1,63.8,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,63.8,mg/L,11/13/2017 23:11,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2983,28,5,0.500694444,0.5,.,.,.,0,0,4,114,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,114,u/ml,11/13/2017 23:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2984,28,5,0.500694444,0.5,.,.,.,0,0,5,319,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,319,u/ml,11/13/2017 23:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2985,28,5,0.500694444,0.5,.,.,.,0,0,6,50,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,50,u/ml,11/13/2017 23:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2986,28,5,1.000694444,1,.,.,.,0,0,2,3.058707073,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,21.3,mg/L,11/14/2017 11:11,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2987,28,5,1.000694444,1,.,.,.,0,0,1,69.1,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.1,mg/L,11/14/2017 11:11,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2988,28,5,1.000694444,1,.,.,.,0,0,4,112,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,112,u/ml,11/14/2017 11:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2989,28,5,1.000694444,1,.,.,.,0,0,5,260,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,260,u/ml,11/14/2017 11:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2990,28,5,1.000694444,1,.,.,.,0,0,6,40,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,40,u/ml,11/14/2017 11:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2991,28,5,3.000694444,3,.,.,.,0,0,2,3.61361697,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,37.1,mg/L,11/16/2017 11:11,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2992,28,5,3.000694444,3,.,.,.,0,0,1,71.4,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.4,mg/L,11/16/2017 11:11,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2993,28,5,3.000694444,3,.,.,.,0,0,4,64,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,64,u/ml,11/16/2017 11:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2994,28,5,3.000694444,3,.,.,.,0,0,5,92,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,92,u/ml,11/16/2017 11:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2995,28,5,3.000694444,3,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,11/16/2017 11:11,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2996,28,5,7.106944444,7,.,.,.,0,0,2,3.742420221,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,42.2,mg/L,11/20/2017 13:44,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2997,28,5,7.106944444,7,.,.,.,0,0,1,75.8,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.8,mg/L,11/20/2017 13:44,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,2998,28,5,7.106944444,14,.,.,.,0,0,4,81,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,81,u/ml,11/20/2017 13:44,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,2999,28,5,7.106944444,14,.,.,.,0,0,5,117,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,117,u/ml,11/20/2017 13:44,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3000,28,5,7.106944444,14,.,.,.,0,0,6,21,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,21,u/ml,11/20/2017 13:44,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3001,28,5,14.11319444,14,.,.,.,0,0,2,3.374168709,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,29.2,mg/L,11/27/2017 13:53,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3002,28,5,14.11319444,14,.,.,.,0,0,1,68.7,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.7,mg/L,11/27/2017 13:53,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3003,28,5,14.11319444,28,.,.,.,0,0,4,118,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,118,u/ml,11/27/2017 13:53,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3004,28,5,14.11319444,28,.,.,.,0,0,5,208,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,208,u/ml,11/27/2017 13:53,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3005,28,5,14.11319444,28,.,.,.,0,0,6,42,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,42,u/ml,11/27/2017 13:53,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3006,28,5,21.125,21,.,.,.,0,0,2,2.714694744,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,15.1,mg/L,12/4/2017 14:10,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3007,28,5,21.125,21,.,.,.,0,0,1,64.4,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.4,mg/L,12/4/2017 14:10,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3008,28,5,21.125,42,.,.,.,0,0,4,117,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,117,u/ml,12/4/2017 14:10,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3009,28,5,21.125,42,.,.,.,0,0,5,240,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,240,u/ml,12/4/2017 14:10,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3010,28,5,21.125,42,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,12/4/2017 14:10,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3011,28,5,28.11666667,28,.,.,.,0,0,2,2.060513532,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,7.85,mg/L,12/11/2017 13:58,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3012,28,5,28.11666667,28,.,.,.,0,0,1,71.7,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.7,mg/L,12/11/2017 13:58,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3013,28,5,28.11666667,56,.,.,.,0,0,4,114,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,114,u/ml,12/11/2017 13:58,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3014,28,5,28.11666667,56,.,.,.,0,0,5,274,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,274,u/ml,12/11/2017 13:58,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3015,28,5,28.11666667,56,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,12/11/2017 13:58,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3016,28,5,40.13472222,42,.,.,.,0,0,2,0.850150929,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.34,mg/L,12/23/2017 14:24,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3017,28,5,40.13472222,42,.,.,.,0,0,1,67,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67,mg/L,12/23/2017 14:24,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3018,28,5,40.13472222,84,.,.,.,0,0,4,127,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,127,u/ml,12/23/2017 14:24,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3019,28,5,40.13472222,84,.,.,.,0,0,5,398,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,398,u/ml,12/23/2017 14:24,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3020,28,5,40.13472222,84,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,12/23/2017 14:24,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3021,28,5,56.12986111,56,.,.,.,0,0,2,-0.507497834,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.602,mg/L,1/8/2018 14:17,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3022,28,5,56.12986111,56,.,.,.,0,0,1,68.3,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.3,mg/L,1/8/2018 14:17,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3023,28,5,56.12986111,112,.,.,.,0,0,4,131,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,131,u/ml,1/8/2018 14:17,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3024,28,5,56.12986111,112,.,.,.,0,0,5,392,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,392,u/ml,1/8/2018 14:17,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3025,28,5,56.12986111,112,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,1/8/2018 14:17,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3026,28,5,84.11319444,84,.,.,.,0,0,2,-2.225624052,1,0.078,2,0,StudyID,001-139,600 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.108,mg/L,2/5/2018 13:53,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3027,28,5,84.11319444,84,.,.,.,0,0,1,60.6,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,60.6,mg/L,2/5/2018 13:53,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3028,28,5,84.11319444,168,.,.,.,0,0,4,101,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,101,u/ml,2/5/2018 13:53,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3029,28,5,84.11319444,168,.,.,.,0,0,5,352,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,352,u/ml,2/5/2018 13:53,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3030,28,5,84.11319444,168,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,2/5/2018 13:53,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3031,28,5,97.16597222,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-139,600 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,2/18/2018 15:09,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3032,28,5,97.16597222,98,.,.,.,0,0,1,61.4,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,61.4,mg/L,2/18/2018 15:09,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3033,28,5,97.16597222,196,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,2/18/2018 15:09,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3034,28,5,112.09375,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-139,600 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,3/5/2018 13:25,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3035,28,5,112.09375,112,.,.,.,0,0,1,60.2,0,0.0078,0,0,StudyID,001-139,600 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,60.2,mg/L,3/5/2018 13:25,.,.,.,.,.,.,.,.,108,.,.,72.9,380
.,.,3036,28,5,112.09375,224,.,.,.,0,0,4,132,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,132,u/ml,3/5/2018 13:25,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3037,28,5,112.09375,224,.,.,.,0,0,5,291,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,291,u/ml,3/5/2018 13:25,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
.,.,3038,28,5,112.09375,224,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-139,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,3/5/2018 13:25,32,YEARS,M,1,BLACK OR AFRICAN AMERICAN,2,Not Hispanic or Latino,.,108,195,28.4,72.9,380
C,PRE-DOSE,3039,29,6,-49.84513889,0,.,.,.,0,0,1,97.9,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,97.9,mg/L,10/3/2017 14:13,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
C,PRE-DOSE,3040,29,6,-49.84513889,0,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,10/3/2017 14:13,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
C,PRE-DOSE,3041,29,6,-49.84513889,0,.,.,.,0,0,5,295,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,295,u/ml,10/3/2017 14:13,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
C,PRE-DOSE,3042,29,6,-49.84513889,0,.,.,.,0,0,6,71,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,71,u/ml,10/3/2017 14:13,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
C,PRE-DOSE,3043,29,6,-0.852083333,-1,.,.,.,0,0,1,80.2,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.2,mg/L,11/21/2017 14:03,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
C,PRE-DOSE,3044,29,6,-0.852083333,0,.,.,.,0,0,4,90,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,90,u/ml,11/21/2017 14:03,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
C,PRE-DOSE,3045,29,6,-0.852083333,0,.,.,.,0,0,5,237,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,237,u/ml,11/21/2017 14:03,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
C,PRE-DOSE,3046,29,6,-0.852083333,0,.,.,.,0,0,6,64,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,64,u/ml,11/21/2017 14:03,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
C,PRE-DOSE,3047,29,6,-0.128472222,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/22/2017 7:25,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
C,PRE-DOSE,3048,29,6,-0.128472222,0,.,.,.,0,0,1,80.8,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.8,mg/L,11/22/2017 7:25,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
C,PRE-DOSE,3049,29,6,-0.128472222,0,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,11/22/2017 7:25,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
C,PRE-DOSE,3050,29,6,-0.128472222,0,.,.,.,0,0,5,255,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,255,u/ml,11/22/2017 7:25,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
C,PRE-DOSE,3051,29,6,-0.128472222,0,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,11/22/2017 7:25,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3052,29,6,0,.,.,1950,43875,1,2,0,.,.,.,2,1,StudyID,001-142,30 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.044444444,1950,mg,1950,INTRAVENOUS,1511346600,1511350440,Dupilumab,.,.,.,.,,.,.,.,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3053,29,6,0.044444444,0,.,.,.,0,0,2,6.621405652,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,751,mg/L,11/22/2017 11:34,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3054,29,6,0.044444444,0,.,.,.,0,0,1,78.1,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.1,mg/L,11/22/2017 11:34,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3055,29,6,0.044444444,0,.,.,.,0,0,4,21,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,21,u/ml,11/22/2017 11:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3056,29,6,0.044444444,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 11:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3057,29,6,0.044444444,0,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 11:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3058,29,6,0.054861111,0.010416667,.,.,.,0,0,2,6.692083743,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,806,mg/L,11/22/2017 11:49,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3059,29,6,0.054861111,0.010416667,.,.,.,0,0,1,78,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78,mg/L,11/22/2017 11:49,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3060,29,6,0.054861111,0.010416667,.,.,.,0,0,4,20,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,20,u/ml,11/22/2017 11:49,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3061,29,6,0.054861111,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 11:49,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3062,29,6,0.054861111,0.010416667,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 11:49,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3063,29,6,0.065277778,0.020833333,.,.,.,0,0,2,6.679599186,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,796,mg/L,11/22/2017 12:04,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3064,29,6,0.065277778,0.020833333,.,.,.,0,0,1,74.3,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.3,mg/L,11/22/2017 12:04,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3065,29,6,0.065277778,0.020833333,.,.,.,0,0,4,14,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,14,u/ml,11/22/2017 12:04,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3066,29,6,0.065277778,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 12:04,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3067,29,6,0.065277778,0.020833333,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 12:04,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3068,29,6,0.085416667,0.041666667,.,.,.,0,0,2,6.689599269,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,804,mg/L,11/22/2017 12:33,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3069,29,6,0.085416667,0.041666667,.,.,.,0,0,1,79.1,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.1,mg/L,11/22/2017 12:33,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3070,29,6,0.085416667,0.041666667,.,.,.,0,0,4,38,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,38,u/ml,11/22/2017 12:33,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3071,29,6,0.085416667,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 12:33,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3072,29,6,0.085416667,0.041666667,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 12:33,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3073,29,6,0.127777778,0.083333333,.,.,.,0,0,2,6.520621128,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,679,mg/L,11/22/2017 13:34,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3074,29,6,0.127777778,0.083333333,.,.,.,0,0,1,73.5,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.5,mg/L,11/22/2017 13:34,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3075,29,6,0.127777778,0.083333333,.,.,.,0,0,4,32,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,32,u/ml,11/22/2017 13:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3076,29,6,0.127777778,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 13:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3077,29,6,0.127777778,0.083333333,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 13:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3078,29,6,0.211111111,0.166666667,.,.,.,0,0,2,6.598509029,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,734,mg/L,11/22/2017 15:34,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3079,29,6,0.211111111,0.166666667,.,.,.,0,0,1,77.9,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.9,mg/L,11/22/2017 15:34,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3080,29,6,0.211111111,0.166666667,.,.,.,0,0,4,36,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,36,u/ml,11/22/2017 15:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3081,29,6,0.211111111,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 15:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3082,29,6,0.211111111,0.166666667,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 15:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3083,29,6,0.377777778,0.333333333,.,.,.,0,0,2,6.445719819,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,630,mg/L,11/22/2017 19:34,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3084,29,6,0.377777778,0.333333333,.,.,.,0,0,1,75.1,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.1,mg/L,11/22/2017 19:34,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3085,29,6,0.377777778,0.333333333,.,.,.,0,0,4,28,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,28,u/ml,11/22/2017 19:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3086,29,6,0.377777778,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 19:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3087,29,6,0.377777778,0.333333333,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 19:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3088,29,6,0.544444444,0.5,.,.,.,0,0,2,6.398594935,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,601,mg/L,11/22/2017 23:34,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3089,29,6,0.544444444,0.5,.,.,.,0,0,1,73.5,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.5,mg/L,11/22/2017 23:34,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3090,29,6,0.544444444,0.5,.,.,.,0,0,4,32,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,32,u/ml,11/22/2017 23:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3091,29,6,0.544444444,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 23:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3092,29,6,0.544444444,0.5,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/22/2017 23:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3093,29,6,1.044444444,1,.,.,.,0,0,2,6.393590754,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,598,mg/L,11/23/2017 11:34,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3094,29,6,1.044444444,1,.,.,.,0,0,1,89,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,89,mg/L,11/23/2017 11:34,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3095,29,6,1.044444444,1,.,.,.,0,0,4,42,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,42,u/ml,11/23/2017 11:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3096,29,6,1.044444444,1,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/23/2017 11:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3097,29,6,1.044444444,1,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/23/2017 11:34,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3098,29,6,3.031944444,3,.,.,.,0,0,2,6.133398043,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,461,mg/L,11/25/2017 11:16,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3099,29,6,3.031944444,3,.,.,.,0,0,1,101,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,101,mg/L,11/25/2017 11:16,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3100,29,6,3.031944444,3,.,.,.,0,0,4,25,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,25,u/ml,11/25/2017 11:16,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3101,29,6,3.031944444,3,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/25/2017 11:16,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3102,29,6,3.031944444,3,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,11/25/2017 11:16,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3103,29,6,7.159722222,7,.,.,.,0,0,2,5.823045895,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,338,mg/L,11/29/2017 14:20,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3104,29,6,7.159722222,7,.,.,.,0,0,1,116,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,116,mg/L,11/29/2017 14:20,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3105,29,6,7.159722222,14,.,.,.,0,0,4,31,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,31,u/ml,11/29/2017 14:20,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3106,29,6,7.159722222,14,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/29/2017 14:20,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3107,29,6,7.159722222,14,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,11/29/2017 14:20,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3108,29,6,14.13402778,14,.,.,.,0,0,2,5.513428746,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,248,mg/L,12/6/2017 13:43,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3109,29,6,14.13402778,14,.,.,.,0,0,1,111,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,111,mg/L,12/6/2017 13:43,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3110,29,6,14.13402778,28,.,.,.,0,0,4,19,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,19,u/ml,12/6/2017 13:43,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3111,29,6,14.13402778,28,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,12/6/2017 13:43,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3112,29,6,14.13402778,28,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,12/6/2017 13:43,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3113,29,6,21.15347222,21,.,.,.,0,0,2,5.241747015,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,189,mg/L,12/13/2017 14:11,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3114,29,6,21.15347222,21,.,.,.,0,0,1,136,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,136,mg/L,12/13/2017 14:11,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3115,29,6,21.15347222,42,.,.,.,0,0,4,47,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,47,u/ml,12/13/2017 14:11,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3116,29,6,21.15347222,42,.,.,.,0,0,5,3,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,3,u/ml,12/13/2017 14:11,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3117,29,6,21.15347222,42,.,.,.,0,0,6,7,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,7,u/ml,12/13/2017 14:11,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3118,29,6,28.13333333,28,.,.,.,0,0,2,4.997212274,0,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,148,mg/L,12/20/2017 13:42,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3119,29,6,28.13333333,28,.,.,.,0,0,1,133,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,133,mg/L,12/20/2017 13:42,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3120,29,6,28.13333333,56,.,.,.,0,0,4,36,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,36,u/ml,12/20/2017 13:42,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3121,29,6,28.13333333,56,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,12/20/2017 13:42,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3122,29,6,28.13333333,56,.,.,.,0,0,6,6,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,6,u/ml,12/20/2017 13:42,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3123,29,6,42.12083333,42,.,.,.,0,0,2,4.102643365,1,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,60.5,mg/L,1/3/2018 13:24,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3124,29,6,42.12083333,42,.,.,.,0,0,1,126,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,126,mg/L,1/3/2018 13:24,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3125,29,6,42.12083333,84,.,.,.,0,0,4,62,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,62,u/ml,1/3/2018 13:24,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3126,29,6,42.12083333,84,.,.,.,0,0,5,104,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,104,u/ml,1/3/2018 13:24,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3127,29,6,42.12083333,84,.,.,.,0,0,6,21,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,21,u/ml,1/3/2018 13:24,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3128,29,6,56.11875,56,.,.,.,0,0,2,3.380994674,1,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,29.4,mg/L,1/17/2018 13:21,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3129,29,6,56.11875,56,.,.,.,0,0,1,99.1,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,99.1,mg/L,1/17/2018 13:21,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3130,29,6,56.11875,112,.,.,.,0,0,4,90,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,90,u/ml,1/17/2018 13:21,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3131,29,6,56.11875,112,.,.,.,0,0,5,253,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,253,u/ml,1/17/2018 13:21,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3132,29,6,56.11875,112,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,1/17/2018 13:21,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3133,29,6,84.15,84,.,.,.,0,0,2,1.32972401,1,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.78,mg/L,2/14/2018 14:06,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3134,29,6,84.15,168,.,.,.,0,0,4,68,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,68,u/ml,2/14/2018 14:06,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3135,29,6,84.15,168,.,.,.,0,0,5,231,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,231,u/ml,2/14/2018 14:06,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3136,29,6,84.15,168,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,2/14/2018 14:06,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3137,29,6,101.0361111,98,.,.,.,0,0,2,0.576613364,1,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.78,mg/L,3/3/2018 11:22,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3138,29,6,101.0361111,98,.,.,.,0,0,1,76.5,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.5,mg/L,3/3/2018 11:22,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3139,29,6,101.0361111,196,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,3/3/2018 11:22,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3140,29,6,101.0361111,196,.,.,.,0,0,5,199,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,199,u/ml,3/3/2018 11:22,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3141,29,6,101.0361111,196,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,3/3/2018 11:22,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3142,29,6,112.1402778,112,.,.,.,0,0,2,0.139761942,1,0.078,2,0,StudyID,001-142,30 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.15,mg/L,3/14/2018 13:52,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3143,29,6,112.1402778,112,.,.,.,0,0,1,87.3,0,0.0078,0,0,StudyID,001-142,30 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.3,mg/L,3/14/2018 13:52,.,.,.,.,.,.,.,.,65.4,.,.,80.8,255
.,.,3144,29,6,112.1402778,224,.,.,.,0,0,4,82,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,82,u/ml,3/14/2018 13:52,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3145,29,6,112.1402778,224,.,.,.,0,0,5,246,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,246,u/ml,3/14/2018 13:52,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
.,.,3146,29,6,112.1402778,224,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-142,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,3/14/2018 13:52,34,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,65.4,173,21.9,80.8,255
C,PRE-DOSE,3147,30,6,-44.91388889,0,.,.,.,0,0,1,71,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71,mg/L,10/6/2017 12:05,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
C,PRE-DOSE,3148,30,6,-44.91388889,0,.,.,.,0,0,4,63,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,63,u/ml,10/6/2017 12:05,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
C,PRE-DOSE,3149,30,6,-44.91388889,0,.,.,.,0,0,5,231,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,231,u/ml,10/6/2017 12:05,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
C,PRE-DOSE,3150,30,6,-44.91388889,0,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,10/6/2017 12:05,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
C,PRE-DOSE,3151,30,6,-0.857638889,-1,.,.,.,0,0,1,83.7,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.7,mg/L,11/19/2017 13:26,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
C,PRE-DOSE,3152,30,6,-0.857638889,0,.,.,.,0,0,4,75,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,75,u/ml,11/19/2017 13:26,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
C,PRE-DOSE,3153,30,6,-0.857638889,0,.,.,.,0,0,5,285,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,285,u/ml,11/19/2017 13:26,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
C,PRE-DOSE,3154,30,6,-0.857638889,0,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,11/19/2017 13:26,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
C,PRE-DOSE,3155,30,6,-0.120138889,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/20/2017 7:08,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
C,PRE-DOSE,3156,30,6,-0.120138889,0,.,.,.,0,0,1,84.3,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,84.3,mg/L,11/20/2017 7:08,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
C,PRE-DOSE,3157,30,6,-0.120138889,0,.,.,.,0,0,4,63,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,63,u/ml,11/20/2017 7:08,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
C,PRE-DOSE,3158,30,6,-0.120138889,0,.,.,.,0,0,5,262,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,262,u/ml,11/20/2017 7:08,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
C,PRE-DOSE,3159,30,6,-0.120138889,0,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,11/20/2017 7:08,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3160,30,6,0,.,.,2000,44307.69231,1,2,0,.,.,.,2,1,StudyID,001-147,30 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045138889,2000,mg,2000,INTRAVENOUS,1511172060,1511175960,Dupilumab,.,.,.,.,,.,.,.,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3161,30,6,0.045138889,0,.,.,.,0,0,2,6.66440902,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,784,mg/L,11/20/2017 11:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3162,30,6,0.045138889,0,.,.,.,0,0,1,66.2,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.2,mg/L,11/20/2017 11:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3163,30,6,0.045138889,0,.,.,.,0,0,4,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,3,u/ml,11/20/2017 11:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3164,30,6,0.045138889,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 11:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3165,30,6,0.045138889,0,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 11:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3166,30,6,0.055555556,0.010416667,.,.,.,0,0,2,6.70930434,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,820,mg/L,11/20/2017 11:21,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3167,30,6,0.055555556,0.010416667,.,.,.,0,0,1,67.8,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.8,mg/L,11/20/2017 11:21,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3168,30,6,0.055555556,0.010416667,.,.,.,0,0,4,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,3,u/ml,11/20/2017 11:21,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3169,30,6,0.055555556,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 11:21,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3170,30,6,0.055555556,0.010416667,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 11:21,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3171,30,6,0.065972222,0.020833333,.,.,.,0,0,2,6.679599186,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,796,mg/L,11/20/2017 11:36,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3172,30,6,0.065972222,0.020833333,.,.,.,0,0,1,64.7,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.7,mg/L,11/20/2017 11:36,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3173,30,6,0.065972222,0.020833333,.,.,.,0,0,4,2,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,2,u/ml,11/20/2017 11:36,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3174,30,6,0.065972222,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 11:36,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3175,30,6,0.065972222,0.020833333,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 11:36,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3176,30,6,0.086805556,0.041666667,.,.,.,0,0,2,6.7310181,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,838,mg/L,11/20/2017 12:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3177,30,6,0.086805556,0.041666667,.,.,.,0,0,1,64.2,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.2,mg/L,11/20/2017 12:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3178,30,6,0.086805556,0.041666667,.,.,.,0,0,4,6,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,6,u/ml,11/20/2017 12:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3179,30,6,0.086805556,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 12:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3180,30,6,0.086805556,0.041666667,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 12:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3181,30,6,0.128472222,0.083333333,.,.,.,0,0,2,6.629363253,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,757,mg/L,11/20/2017 13:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3182,30,6,0.128472222,0.083333333,.,.,.,0,0,1,63.8,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,63.8,mg/L,11/20/2017 13:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3183,30,6,0.128472222,0.083333333,.,.,.,0,0,4,4,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,4,u/ml,11/20/2017 13:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3184,30,6,0.128472222,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 13:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3185,30,6,0.128472222,0.083333333,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 13:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3186,30,6,0.211805556,0.166666667,.,.,.,0,0,2,6.606650186,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,740,mg/L,11/20/2017 15:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3187,30,6,0.211805556,0.166666667,.,.,.,0,0,1,71.2,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.2,mg/L,11/20/2017 15:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3188,30,6,0.211805556,0.166666667,.,.,.,0,0,4,20,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,20,u/ml,11/20/2017 15:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3189,30,6,0.211805556,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 15:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3190,30,6,0.211805556,0.166666667,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 15:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3191,30,6,0.378472222,0.333333333,.,.,.,0,0,2,6.573680167,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,716,mg/L,11/20/2017 19:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3192,30,6,0.378472222,0.333333333,.,.,.,0,0,1,69,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69,mg/L,11/20/2017 19:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3193,30,6,0.378472222,0.333333333,.,.,.,0,0,4,1,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,1,u/ml,11/20/2017 19:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3194,30,6,0.378472222,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 19:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3195,30,6,0.378472222,0.333333333,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 19:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3196,30,6,0.545138889,0.5,.,.,.,0,0,2,6.403574198,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,604,mg/L,11/20/2017 23:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3197,30,6,0.545138889,0.5,.,.,.,0,0,1,66.6,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.6,mg/L,11/20/2017 23:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3198,30,6,0.545138889,0.5,.,.,.,0,0,4,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,0,u/ml,11/20/2017 23:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3199,30,6,0.545138889,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 23:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3200,30,6,0.545138889,0.5,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 23:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3201,30,6,1.045138889,1,.,.,.,0,0,2,6.391917113,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,597,mg/L,11/21/2017 11:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3202,30,6,1.045138889,1,.,.,.,0,0,1,73.3,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.3,mg/L,11/21/2017 11:06,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3203,30,6,1.045138889,1,.,.,.,0,0,4,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,3,u/ml,11/21/2017 11:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3204,30,6,1.045138889,1,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/21/2017 11:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3205,30,6,1.045138889,1,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/21/2017 11:06,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3206,30,6,3.074305556,3,.,.,.,0,0,2,6.159095388,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,473,mg/L,11/23/2017 11:48,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3207,30,6,3.074305556,3,.,.,.,0,0,1,80,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80,mg/L,11/23/2017 11:48,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3208,30,6,3.074305556,3,.,.,.,0,0,4,4,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,4,u/ml,11/23/2017 11:48,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3209,30,6,3.074305556,3,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/23/2017 11:48,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3210,30,6,3.074305556,3,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,11/23/2017 11:48,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3211,30,6,7.172916667,7,.,.,.,0,0,2,5.598421959,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,270,mg/L,11/27/2017 14:10,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3212,30,6,7.172916667,7,.,.,.,0,0,1,79.4,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.4,mg/L,11/27/2017 14:10,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3213,30,6,7.172916667,14,.,.,.,0,0,4,3,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,3,u/ml,11/27/2017 14:10,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3214,30,6,7.172916667,14,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/27/2017 14:10,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3215,30,6,7.172916667,14,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,11/27/2017 14:10,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3216,30,6,14.17708333,14,.,.,.,0,0,2,5.407171771,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,223,mg/L,12/4/2017 14:16,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3217,30,6,14.17708333,14,.,.,.,0,0,1,89.7,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,89.7,mg/L,12/4/2017 14:16,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3218,30,6,14.17708333,28,.,.,.,0,0,4,7,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,7,u/ml,12/4/2017 14:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3219,30,6,14.17708333,28,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,12/4/2017 14:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3220,30,6,14.17708333,28,.,.,.,0,0,6,6,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,6,u/ml,12/4/2017 14:16,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3221,30,6,21.18125,21,.,.,.,0,0,2,5.365976015,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,214,mg/L,12/11/2017 14:22,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3222,30,6,21.18125,21,.,.,.,0,0,1,95.2,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,95.2,mg/L,12/11/2017 14:22,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3223,30,6,21.18125,42,.,.,.,0,0,4,11,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,11,u/ml,12/11/2017 14:22,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3224,30,6,21.18125,42,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,12/11/2017 14:22,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3225,30,6,21.18125,42,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,12/11/2017 14:22,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3226,30,6,28.15347222,28,.,.,.,0,0,2,5.099866428,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,164,mg/L,12/18/2017 13:42,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3227,30,6,28.15347222,28,.,.,.,0,0,1,98.1,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,98.1,mg/L,12/18/2017 13:42,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3228,30,6,28.15347222,56,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,12/18/2017 13:42,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3229,30,6,28.15347222,56,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,12/18/2017 13:42,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3230,30,6,28.15347222,56,.,.,.,0,0,6,6,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,6,u/ml,12/18/2017 13:42,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3231,30,6,44.14027778,42,.,.,.,0,0,2,4.49980967,0,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,90,mg/L,1/3/2018 13:23,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3232,30,6,44.14027778,42,.,.,.,0,0,1,88,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88,mg/L,1/3/2018 13:23,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3233,30,6,44.14027778,84,.,.,.,0,0,4,15,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,15,u/ml,1/3/2018 13:23,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3234,30,6,44.14027778,84,.,.,.,0,0,5,15,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,15,u/ml,1/3/2018 13:23,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3235,30,6,44.14027778,84,.,.,.,0,0,6,9,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,9,u/ml,1/3/2018 13:23,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3236,30,6,56.1625,56,.,.,.,0,0,2,4.289088639,1,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,72.9,mg/L,1/15/2018 13:55,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3237,30,6,56.1625,56,.,.,.,0,0,1,77.4,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.4,mg/L,1/15/2018 13:55,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3238,30,6,56.1625,112,.,.,.,0,0,4,17,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,17,u/ml,1/15/2018 13:55,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3239,30,6,56.1625,112,.,.,.,0,0,5,55,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,55,u/ml,1/15/2018 13:55,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3240,30,6,56.1625,112,.,.,.,0,0,6,17,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,17,u/ml,1/15/2018 13:55,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3241,30,6,84.15277778,84,.,.,.,0,0,2,2.890371758,1,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,18,mg/L,2/12/2018 13:41,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3242,30,6,84.15277778,84,.,.,.,0,0,1,70.9,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.9,mg/L,2/12/2018 13:41,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3243,30,6,84.15277778,168,.,.,.,0,0,4,4,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,4,u/ml,2/12/2018 13:41,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3244,30,6,84.15277778,168,.,.,.,0,0,5,209,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,209,u/ml,2/12/2018 13:41,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3245,30,6,84.15277778,168,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,2/12/2018 13:41,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3246,30,6,98.13194444,98,.,.,.,0,0,2,2.17702187,1,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,8.82,mg/L,2/26/2018 13:11,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3247,30,6,98.13194444,98,.,.,.,0,0,1,73.9,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.9,mg/L,2/26/2018 13:11,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3248,30,6,98.13194444,196,.,.,.,0,0,4,0,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,0,u/ml,2/26/2018 13:11,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3249,30,6,98.13194444,196,.,.,.,0,0,5,185,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,185,u/ml,2/26/2018 13:11,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3250,30,6,98.13194444,196,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,2/26/2018 13:11,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3251,30,6,112.1527778,112,.,.,.,0,0,2,1.386294361,1,0.078,2,0,StudyID,001-147,30 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,4,mg/L,3/12/2018 13:41,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3252,30,6,112.1527778,112,.,.,.,0,0,1,76.2,0,0.0078,0,0,StudyID,001-147,30 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.2,mg/L,3/12/2018 13:41,.,.,.,.,.,.,.,.,66.8,.,.,84.3,262
.,.,3253,30,6,112.1527778,224,.,.,.,0,0,4,40,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,40,u/ml,3/12/2018 13:41,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3254,30,6,112.1527778,224,.,.,.,0,0,5,232,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,232,u/ml,3/12/2018 13:41,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
.,.,3255,30,6,112.1527778,224,.,.,.,0,0,6,50,.,.,0,0,StudyID,001-147,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,50,u/ml,3/12/2018 13:41,48,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,66.8,171,22.8,84.3,262
C,PRE-DOSE,3256,31,6,-46.8875,0,.,.,.,0,0,1,69.2,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.2,mg/L,10/6/2017 12:42,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
C,PRE-DOSE,3257,31,6,-46.8875,0,.,.,.,0,0,4,80,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,80,u/ml,10/6/2017 12:42,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
C,PRE-DOSE,3258,31,6,-46.8875,0,.,.,.,0,0,5,170,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,170,u/ml,10/6/2017 12:42,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
C,PRE-DOSE,3259,31,6,-46.8875,0,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,10/6/2017 12:42,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
C,PRE-DOSE,3260,31,6,-0.842361111,-1,.,.,.,0,0,1,82.2,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.2,mg/L,11/21/2017 13:47,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
C,PRE-DOSE,3261,31,6,-0.842361111,0,.,.,.,0,0,4,109,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,109,u/ml,11/21/2017 13:47,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
C,PRE-DOSE,3262,31,6,-0.842361111,0,.,.,.,0,0,5,231,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,231,u/ml,11/21/2017 13:47,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
C,PRE-DOSE,3263,31,6,-0.842361111,0,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,11/21/2017 13:47,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
C,PRE-DOSE,3264,31,6,-0.121527778,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/22/2017 7:05,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
C,PRE-DOSE,3265,31,6,-0.121527778,0,.,.,.,0,0,1,78.9,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.9,mg/L,11/22/2017 7:05,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
C,PRE-DOSE,3266,31,6,-0.121527778,0,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,11/22/2017 7:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
C,PRE-DOSE,3267,31,6,-0.121527778,0,.,.,.,0,0,5,243,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,243,u/ml,11/22/2017 7:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
C,PRE-DOSE,3268,31,6,-0.121527778,0,.,.,.,0,0,6,62,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,62,u/ml,11/22/2017 7:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3269,31,6,0,.,.,1850,40984.61538,1,2,0,.,.,.,2,1,StudyID,001-148,30 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045138889,1850,mg,1850,INTRAVENOUS,1511344800,1511348700,Dupilumab,.,.,.,.,,.,.,.,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3270,31,6,0.045138889,0,.,.,.,0,0,2,6.525029658,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,682,mg/L,11/22/2017 11:05,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3271,31,6,0.045138889,0,.,.,.,0,0,1,71.6,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.6,mg/L,11/22/2017 11:05,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3272,31,6,0.045138889,0,.,.,.,0,0,4,20,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,20,u/ml,11/22/2017 11:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3273,31,6,0.045138889,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 11:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3274,31,6,0.045138889,0,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/22/2017 11:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3275,31,6,0.055555556,0.010416667,.,.,.,0,0,2,6.552507887,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,701,mg/L,11/22/2017 11:20,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3276,31,6,0.055555556,0.010416667,.,.,.,0,0,1,68.6,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.6,mg/L,11/22/2017 11:20,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3277,31,6,0.055555556,0.010416667,.,.,.,0,0,4,26,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,26,u/ml,11/22/2017 11:20,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3278,31,6,0.055555556,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 11:20,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3279,31,6,0.055555556,0.010416667,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/22/2017 11:20,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3280,31,6,0.065972222,0.020833333,.,.,.,0,0,2,6.563855527,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,709,mg/L,11/22/2017 11:35,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3281,31,6,0.065972222,0.020833333,.,.,.,0,0,1,70,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70,mg/L,11/22/2017 11:35,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3282,31,6,0.065972222,0.020833333,.,.,.,0,0,4,29,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,29,u/ml,11/22/2017 11:35,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3283,31,6,0.065972222,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 11:35,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3284,31,6,0.065972222,0.020833333,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/22/2017 11:35,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3285,31,6,0.086805556,0.041666667,.,.,.,0,0,2,6.629363253,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,757,mg/L,11/22/2017 12:05,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3286,31,6,0.086805556,0.041666667,.,.,.,0,0,1,73.6,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.6,mg/L,11/22/2017 12:05,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3287,31,6,0.086805556,0.041666667,.,.,.,0,0,4,44,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,44,u/ml,11/22/2017 12:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3288,31,6,0.086805556,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 12:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3289,31,6,0.086805556,0.041666667,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/22/2017 12:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3290,31,6,0.129861111,0.083333333,.,.,.,0,0,2,6.573680167,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,716,mg/L,11/22/2017 13:07,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3291,31,6,0.129861111,0.083333333,.,.,.,0,0,1,68.3,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.3,mg/L,11/22/2017 13:07,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3292,31,6,0.129861111,0.083333333,.,.,.,0,0,4,40,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,40,u/ml,11/22/2017 13:07,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3293,31,6,0.129861111,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 13:07,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3294,31,6,0.129861111,0.083333333,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/22/2017 13:07,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3295,31,6,0.214583333,0.166666667,.,.,.,0,0,2,6.463029457,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,641,mg/L,11/22/2017 15:09,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3296,31,6,0.214583333,0.166666667,.,.,.,0,0,1,74.8,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.8,mg/L,11/22/2017 15:09,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3297,31,6,0.214583333,0.166666667,.,.,.,0,0,4,45,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,45,u/ml,11/22/2017 15:09,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3298,31,6,0.214583333,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 15:09,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3299,31,6,0.214583333,0.166666667,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/22/2017 15:09,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3300,31,6,0.378472222,0.333333333,.,.,.,0,0,2,6.388561406,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,595,mg/L,11/22/2017 19:05,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3301,31,6,0.378472222,0.333333333,.,.,.,0,0,1,70.8,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.8,mg/L,11/22/2017 19:05,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3302,31,6,0.378472222,0.333333333,.,.,.,0,0,4,44,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,44,u/ml,11/22/2017 19:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3303,31,6,0.378472222,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 19:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3304,31,6,0.378472222,0.333333333,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/22/2017 19:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3305,31,6,0.545138889,0.5,.,.,.,0,0,2,6.403574198,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,604,mg/L,11/22/2017 23:05,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3306,31,6,0.545138889,0.5,.,.,.,0,0,1,73.8,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.8,mg/L,11/22/2017 23:05,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3307,31,6,0.545138889,0.5,.,.,.,0,0,4,48,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,48,u/ml,11/22/2017 23:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3308,31,6,0.545138889,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 23:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3309,31,6,0.545138889,0.5,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/22/2017 23:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3310,31,6,1.045138889,1,.,.,.,0,0,2,6.311734809,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,551,mg/L,11/23/2017 11:05,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3311,31,6,1.045138889,1,.,.,.,0,0,1,78.7,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.7,mg/L,11/23/2017 11:05,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3312,31,6,1.045138889,1,.,.,.,0,0,4,54,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,54,u/ml,11/23/2017 11:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3313,31,6,1.045138889,1,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/23/2017 11:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3314,31,6,1.045138889,1,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/23/2017 11:05,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3315,31,6,3.031944444,3,.,.,.,0,0,2,6.107022888,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,449,mg/L,11/25/2017 10:46,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3316,31,6,3.031944444,3,.,.,.,0,0,1,87.7,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.7,mg/L,11/25/2017 10:46,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3317,31,6,3.031944444,3,.,.,.,0,0,4,56,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,56,u/ml,11/25/2017 10:46,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3318,31,6,3.031944444,3,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/25/2017 10:46,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3319,31,6,3.031944444,3,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,11/25/2017 10:46,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3320,31,6,7.204861111,7,.,.,.,0,0,2,5.97126184,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,392,mg/L,11/29/2017 14:55,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3321,31,6,7.204861111,7,.,.,.,0,0,1,82.7,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.7,mg/L,11/29/2017 14:55,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3322,31,6,7.204861111,14,.,.,.,0,0,4,51,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,51,u/ml,11/29/2017 14:55,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3323,31,6,7.204861111,14,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/29/2017 14:55,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3324,31,6,7.204861111,14,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,11/29/2017 14:55,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3325,31,6,14.16388889,14,.,.,.,0,0,2,5.446737372,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,232,mg/L,12/6/2017 13:56,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3326,31,6,14.16388889,14,.,.,.,0,0,1,85.2,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,85.2,mg/L,12/6/2017 13:56,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3327,31,6,14.16388889,28,.,.,.,0,0,4,45,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,45,u/ml,12/6/2017 13:56,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3328,31,6,14.16388889,28,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,12/6/2017 13:56,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3329,31,6,14.16388889,28,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,12/6/2017 13:56,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3330,31,6,21.16458333,21,.,.,.,0,0,2,5.18178355,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,178,mg/L,12/13/2017 13:57,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3331,31,6,21.16458333,21,.,.,.,0,0,1,78.7,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.7,mg/L,12/13/2017 13:57,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3332,31,6,21.16458333,42,.,.,.,0,0,4,48,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,48,u/ml,12/13/2017 13:57,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3333,31,6,21.16458333,42,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,12/13/2017 13:57,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3334,31,6,21.16458333,42,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,12/13/2017 13:57,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3335,31,6,28.16805556,28,.,.,.,0,0,2,4.836281907,0,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,126,mg/L,12/20/2017 14:02,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3336,31,6,28.16805556,28,.,.,.,0,0,1,80.8,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.8,mg/L,12/20/2017 14:02,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3337,31,6,28.16805556,56,.,.,.,0,0,4,58,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,58,u/ml,12/20/2017 14:02,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3338,31,6,28.16805556,56,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,12/20/2017 14:02,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3339,31,6,28.16805556,56,.,.,.,0,0,6,6,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,6,u/ml,12/20/2017 14:02,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3340,31,6,42.18611111,42,.,.,.,0,0,2,4.009149716,1,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,55.1,mg/L,1/3/2018 14:28,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3341,31,6,42.18611111,42,.,.,.,0,0,1,81.3,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.3,mg/L,1/3/2018 14:28,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3342,31,6,42.18611111,84,.,.,.,0,0,4,45,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,45,u/ml,1/3/2018 14:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3343,31,6,42.18611111,84,.,.,.,0,0,5,26,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,26,u/ml,1/3/2018 14:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3344,31,6,42.18611111,84,.,.,.,0,0,6,14,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,14,u/ml,1/3/2018 14:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3345,31,6,56.18125,56,.,.,.,0,0,2,3.063390922,1,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,21.4,mg/L,1/17/2018 14:21,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3346,31,6,56.18125,56,.,.,.,0,0,1,75,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75,mg/L,1/17/2018 14:21,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3347,31,6,56.18125,112,.,.,.,0,0,4,104,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,104,u/ml,1/17/2018 14:21,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3348,31,6,56.18125,112,.,.,.,0,0,5,194,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,194,u/ml,1/17/2018 14:21,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3349,31,6,56.18125,112,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,1/17/2018 14:21,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3350,31,6,84.20347222,84,.,.,.,0,0,2,1.047318994,1,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.85,mg/L,2/14/2018 14:53,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3351,31,6,84.20347222,84,.,.,.,0,0,1,73.8,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.8,mg/L,2/14/2018 14:53,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3352,31,6,84.20347222,168,.,.,.,0,0,4,97,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,97,u/ml,2/14/2018 14:53,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3353,31,6,84.20347222,168,.,.,.,0,0,5,263,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,263,u/ml,2/14/2018 14:53,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3354,31,6,84.20347222,168,.,.,.,0,0,6,69,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,69,u/ml,2/14/2018 14:53,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3355,31,6,98.26944444,98,.,.,.,0,0,2,0.086177696,1,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.09,mg/L,2/28/2018 16:28,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3356,31,6,98.26944444,98,.,.,.,0,0,1,81.6,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.6,mg/L,2/28/2018 16:28,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3357,31,6,98.26944444,196,.,.,.,0,0,4,117,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,117,u/ml,2/28/2018 16:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3358,31,6,98.26944444,196,.,.,.,0,0,5,170,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,170,u/ml,2/28/2018 16:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3359,31,6,98.26944444,196,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,2/28/2018 16:28,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3360,31,6,112.1486111,112,.,.,.,0,0,2,-0.772190388,1,0.078,2,0,StudyID,001-148,30 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.462,mg/L,3/14/2018 13:34,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3361,31,6,112.1486111,112,.,.,.,0,0,1,80.1,0,0.0078,0,0,StudyID,001-148,30 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.1,mg/L,3/14/2018 13:34,.,.,.,.,.,.,.,.,62.2,.,.,78.9,243
.,.,3362,31,6,112.1486111,224,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,3/14/2018 13:34,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3363,31,6,112.1486111,224,.,.,.,0,0,5,210,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,210,u/ml,3/14/2018 13:34,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
.,.,3364,31,6,112.1486111,224,.,.,.,0,0,6,69,.,.,0,0,StudyID,001-148,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,69,u/ml,3/14/2018 13:34,22,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,62.2,171,21.3,78.9,243
C,PRE-DOSE,3365,32,6,-43.92638889,0,.,.,.,0,0,1,77.9,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.9,mg/L,10/9/2017 12:06,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
C,PRE-DOSE,3366,32,6,-43.92638889,0,.,.,.,0,0,4,84,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,84,u/ml,10/9/2017 12:06,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
C,PRE-DOSE,3367,32,6,-43.92638889,0,.,.,.,0,0,5,302,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,302,u/ml,10/9/2017 12:06,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
C,PRE-DOSE,3368,32,6,-43.92638889,0,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,10/9/2017 12:06,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
C,PRE-DOSE,3369,32,6,-0.849305556,-1,.,.,.,0,0,1,77.2,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.2,mg/L,11/21/2017 13:57,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
C,PRE-DOSE,3370,32,6,-0.849305556,0,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,11/21/2017 13:57,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
C,PRE-DOSE,3371,32,6,-0.849305556,0,.,.,.,0,0,5,312,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,312,u/ml,11/21/2017 13:57,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
C,PRE-DOSE,3372,32,6,-0.849305556,0,.,.,.,0,0,6,61,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,61,u/ml,11/21/2017 13:57,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
C,PRE-DOSE,3373,32,6,-0.127083333,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/22/2017 7:17,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
C,PRE-DOSE,3374,32,6,-0.127083333,0,.,.,.,0,0,1,78.2,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.2,mg/L,11/22/2017 7:17,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
C,PRE-DOSE,3375,32,6,-0.127083333,0,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,11/22/2017 7:17,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
C,PRE-DOSE,3376,32,6,-0.127083333,0,.,.,.,0,0,5,285,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,285,u/ml,11/22/2017 7:17,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
C,PRE-DOSE,3377,32,6,-0.127083333,0,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,11/22/2017 7:17,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3378,32,6,0,.,.,1850,41625,1,2,0,.,.,.,2,1,StudyID,001-150,30 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.044444444,1850,mg,1850,INTRAVENOUS,1511346000,1511349840,Dupilumab,.,.,.,.,,.,.,.,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3379,32,6,0.044444444,0,.,.,.,0,0,2,6.704414355,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,816,mg/L,11/22/2017 11:24,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3380,32,6,0.044444444,0,.,.,.,0,0,1,63.4,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,63.4,mg/L,11/22/2017 11:24,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3381,32,6,0.044444444,0,.,.,.,0,0,4,22,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,22,u/ml,11/22/2017 11:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3382,32,6,0.044444444,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 11:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3383,32,6,0.044444444,0,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 11:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3384,32,6,0.054861111,0.010416667,.,.,.,0,0,2,6.723832441,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,832,mg/L,11/22/2017 11:39,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3385,32,6,0.054861111,0.010416667,.,.,.,0,0,1,69.2,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.2,mg/L,11/22/2017 11:39,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3386,32,6,0.054861111,0.010416667,.,.,.,0,0,4,27,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,27,u/ml,11/22/2017 11:39,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3387,32,6,0.054861111,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 11:39,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3388,32,6,0.054861111,0.010416667,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 11:39,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3389,32,6,0.065277778,0.020833333,.,.,.,0,0,2,6.73459166,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,841,mg/L,11/22/2017 11:54,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3390,32,6,0.065277778,0.020833333,.,.,.,0,0,1,65.5,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.5,mg/L,11/22/2017 11:54,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3391,32,6,0.065277778,0.020833333,.,.,.,0,0,4,18,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,18,u/ml,11/22/2017 11:54,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3392,32,6,0.065277778,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 11:54,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3393,32,6,0.065277778,0.020833333,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 11:54,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3394,32,6,0.086111111,0.041666667,.,.,.,0,0,2,6.774223886,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,875,mg/L,11/22/2017 12:24,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3395,32,6,0.086111111,0.041666667,.,.,.,0,0,1,66.4,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.4,mg/L,11/22/2017 12:24,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3396,32,6,0.086111111,0.041666667,.,.,.,0,0,4,29,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,29,u/ml,11/22/2017 12:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3397,32,6,0.086111111,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 12:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3398,32,6,0.086111111,0.041666667,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 12:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3399,32,6,0.127777778,0.083333333,.,.,.,0,0,2,6.799055862,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,897,mg/L,11/22/2017 13:24,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3400,32,6,0.127777778,0.083333333,.,.,.,0,0,1,70,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70,mg/L,11/22/2017 13:24,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3401,32,6,0.127777778,0.083333333,.,.,.,0,0,4,31,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,31,u/ml,11/22/2017 13:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3402,32,6,0.127777778,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 13:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3403,32,6,0.127777778,0.083333333,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 13:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3404,32,6,0.211111111,0.166666667,.,.,.,0,0,2,6.65929392,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,780,mg/L,11/22/2017 15:24,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3405,32,6,0.211111111,0.166666667,.,.,.,0,0,1,68.6,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.6,mg/L,11/22/2017 15:24,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3406,32,6,0.211111111,0.166666667,.,.,.,0,0,4,23,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,23,u/ml,11/22/2017 15:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3407,32,6,0.211111111,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 15:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3408,32,6,0.211111111,0.166666667,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 15:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3409,32,6,0.377777778,0.333333333,.,.,.,0,0,2,6.605297921,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,739,mg/L,11/22/2017 19:24,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3410,32,6,0.377777778,0.333333333,.,.,.,0,0,1,67.7,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.7,mg/L,11/22/2017 19:24,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3411,32,6,0.377777778,0.333333333,.,.,.,0,0,4,36,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,36,u/ml,11/22/2017 19:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3412,32,6,0.377777778,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 19:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3413,32,6,0.377777778,0.333333333,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 19:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3414,32,6,0.547916667,0.5,.,.,.,0,0,2,6.507277712,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,670,mg/L,11/22/2017 23:29,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3415,32,6,0.547916667,0.5,.,.,.,0,0,1,73.1,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.1,mg/L,11/22/2017 23:29,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3416,32,6,0.547916667,0.5,.,.,.,0,0,4,25,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,25,u/ml,11/22/2017 23:29,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3417,32,6,0.547916667,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/22/2017 23:29,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3418,32,6,0.547916667,0.5,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/22/2017 23:29,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3419,32,6,1.044444444,1,.,.,.,0,0,2,6.486160789,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,656,mg/L,11/23/2017 11:24,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3420,32,6,1.044444444,1,.,.,.,0,0,1,88.2,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88.2,mg/L,11/23/2017 11:24,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3421,32,6,1.044444444,1,.,.,.,0,0,4,40,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,40,u/ml,11/23/2017 11:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3422,32,6,1.044444444,1,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/23/2017 11:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3423,32,6,1.044444444,1,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/23/2017 11:24,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3424,32,6,3.031944444,3,.,.,.,0,0,2,6.150602768,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,469,mg/L,11/25/2017 11:06,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3425,32,6,3.031944444,3,.,.,.,0,0,1,92.5,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,92.5,mg/L,11/25/2017 11:06,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3426,32,6,3.031944444,3,.,.,.,0,0,4,40,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,40,u/ml,11/25/2017 11:06,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3427,32,6,3.031944444,3,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/25/2017 11:06,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3428,32,6,3.031944444,3,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/25/2017 11:06,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3429,32,6,7.165972222,7,.,.,.,0,0,2,5.888877958,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,361,mg/L,11/29/2017 14:19,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3430,32,6,7.165972222,7,.,.,.,0,0,1,93.6,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,93.6,mg/L,11/29/2017 14:19,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3431,32,6,7.165972222,14,.,.,.,0,0,4,32,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,32,u/ml,11/29/2017 14:19,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3432,32,6,7.165972222,14,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/29/2017 14:19,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3433,32,6,7.165972222,14,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/29/2017 14:19,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3434,32,6,14.14166667,14,.,.,.,0,0,2,5.564520407,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,261,mg/L,12/6/2017 13:44,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3435,32,6,14.14166667,14,.,.,.,0,0,1,102,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,102,mg/L,12/6/2017 13:44,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3436,32,6,14.14166667,28,.,.,.,0,0,4,32,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,32,u/ml,12/6/2017 13:44,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3437,32,6,14.14166667,28,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,12/6/2017 13:44,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3438,32,6,14.14166667,28,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,12/6/2017 13:44,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3439,32,6,24.12013889,21,.,.,.,0,0,2,5.198497031,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,181,mg/L,12/16/2017 13:13,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3440,32,6,24.12013889,21,.,.,.,0,0,1,100,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,100,mg/L,12/16/2017 13:13,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3441,32,6,24.12013889,42,.,.,.,0,0,4,22,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,22,u/ml,12/16/2017 13:13,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3442,32,6,24.12013889,42,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,12/16/2017 13:13,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3443,32,6,24.12013889,42,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,12/16/2017 13:13,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3444,32,6,28.12916667,28,.,.,.,0,0,2,5.093750201,0,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,163,mg/L,12/20/2017 13:26,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3445,32,6,28.12916667,28,.,.,.,0,0,1,108,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,108,mg/L,12/20/2017 13:26,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3446,32,6,28.12916667,56,.,.,.,0,0,4,44,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,44,u/ml,12/20/2017 13:26,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3447,32,6,28.12916667,56,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,12/20/2017 13:26,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3448,32,6,28.12916667,56,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,12/20/2017 13:26,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3449,32,6,43.12569444,42,.,.,.,0,0,2,4.286341385,1,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,72.7,mg/L,1/4/2018 13:21,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3450,32,6,43.12569444,42,.,.,.,0,0,1,86,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,86,mg/L,1/4/2018 13:21,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3451,32,6,43.12569444,84,.,.,.,0,0,4,63,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,63,u/ml,1/4/2018 13:21,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3452,32,6,43.12569444,84,.,.,.,0,0,5,56,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,56,u/ml,1/4/2018 13:21,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3453,32,6,43.12569444,84,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,1/4/2018 13:21,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3454,32,6,56.15069444,56,.,.,.,0,0,2,3.538056564,1,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,34.4,mg/L,1/17/2018 13:57,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3455,32,6,56.15069444,56,.,.,.,0,0,1,81.1,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.1,mg/L,1/17/2018 13:57,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3456,32,6,56.15069444,112,.,.,.,0,0,4,83,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,83,u/ml,1/17/2018 13:57,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3457,32,6,56.15069444,112,.,.,.,0,0,5,213,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,213,u/ml,1/17/2018 13:57,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3458,32,6,56.15069444,112,.,.,.,0,0,6,38,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,38,u/ml,1/17/2018 13:57,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3459,32,6,84.13888889,84,.,.,.,0,0,2,1.029619417,1,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.8,mg/L,2/14/2018 13:40,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3460,32,6,84.13888889,84,.,.,.,0,0,1,77.4,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.4,mg/L,2/14/2018 13:40,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3461,32,6,84.13888889,168,.,.,.,0,0,4,79,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,79,u/ml,2/14/2018 13:40,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3462,32,6,84.13888889,168,.,.,.,0,0,5,312,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,312,u/ml,2/14/2018 13:40,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3463,32,6,84.13888889,168,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,2/14/2018 13:40,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3464,32,6,98.12847222,98,.,.,.,0,0,2,0.285178942,1,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.33,mg/L,2/28/2018 13:25,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3465,32,6,98.12847222,98,.,.,.,0,0,1,66.8,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.8,mg/L,2/28/2018 13:25,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3466,32,6,98.12847222,196,.,.,.,0,0,4,81,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,81,u/ml,2/28/2018 13:25,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3467,32,6,98.12847222,196,.,.,.,0,0,5,293,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,293,u/ml,2/28/2018 13:25,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3468,32,6,98.12847222,196,.,.,.,0,0,6,50,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,50,u/ml,2/28/2018 13:25,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3469,32,6,112.1409722,112,.,.,.,0,0,2,-0.40947313,1,0.078,2,0,StudyID,001-150,30 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.664,mg/L,3/14/2018 13:43,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3470,32,6,112.1409722,112,.,.,.,0,0,1,86.1,0,0.0078,0,0,StudyID,001-150,30 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,86.1,mg/L,3/14/2018 13:43,.,.,.,.,.,.,.,.,61.3,.,.,78.2,285
.,.,3471,32,6,112.1409722,224,.,.,.,0,0,4,60,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,60,u/ml,3/14/2018 13:43,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3472,32,6,112.1409722,224,.,.,.,0,0,5,308,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,308,u/ml,3/14/2018 13:43,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
.,.,3473,32,6,112.1409722,224,.,.,.,0,0,6,59,.,.,0,0,StudyID,001-150,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,59,u/ml,3/14/2018 13:43,20,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,61.3,163,23.1,78.2,285
C,PRE-DOSE,3474,33,6,-41.81180556,0,.,.,.,0,0,1,73.9,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.9,mg/L,10/9/2017 14:41,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
C,PRE-DOSE,3475,33,6,-41.81180556,0,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,10/9/2017 14:41,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
C,PRE-DOSE,3476,33,6,-41.81180556,0,.,.,.,0,0,5,187,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,187,u/ml,10/9/2017 14:41,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
C,PRE-DOSE,3477,33,6,-41.81180556,0,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,10/9/2017 14:41,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
C,PRE-DOSE,3478,33,6,-0.858333333,-1,.,.,.,0,0,1,69.6,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69.6,mg/L,11/19/2017 13:34,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
C,PRE-DOSE,3479,33,6,-0.858333333,0,.,.,.,0,0,4,86,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,86,u/ml,11/19/2017 13:34,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
C,PRE-DOSE,3480,33,6,-0.858333333,0,.,.,.,0,0,5,244,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,244,u/ml,11/19/2017 13:34,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
C,PRE-DOSE,3481,33,6,-0.858333333,0,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,11/19/2017 13:34,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
C,PRE-DOSE,3482,33,6,-0.119444444,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/20/2017 7:18,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
C,PRE-DOSE,3483,33,6,-0.119444444,0,.,.,.,0,0,1,67.9,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.9,mg/L,11/20/2017 7:18,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
C,PRE-DOSE,3484,33,6,-0.119444444,0,.,.,.,0,0,4,97,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,97,u/ml,11/20/2017 7:18,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
C,PRE-DOSE,3485,33,6,-0.119444444,0,.,.,.,0,0,5,220,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,220,u/ml,11/20/2017 7:18,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
C,PRE-DOSE,3486,33,6,-0.119444444,0,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,11/20/2017 7:18,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3487,33,6,0,.,.,2050,45415.38462,1,2,0,.,.,.,2,1,StudyID,001-152,30 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.045138889,2050,mg,2050,INTRAVENOUS,1511172600,1511176500,Dupilumab,.,.,.,.,,.,.,.,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3488,33,6,0.045138889,0,.,.,.,0,0,2,6.722629795,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,831,mg/L,11/20/2017 11:15,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3489,33,6,0.045138889,0,.,.,.,0,0,1,60.4,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,60.4,mg/L,11/20/2017 11:15,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3490,33,6,0.045138889,0,.,.,.,0,0,4,16,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,16,u/ml,11/20/2017 11:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3491,33,6,0.045138889,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 11:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3492,33,6,0.045138889,0,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 11:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3493,33,6,0.055555556,0.010416667,.,.,.,0,0,2,6.694562059,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,808,mg/L,11/20/2017 11:30,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3494,33,6,0.055555556,0.010416667,.,.,.,0,0,1,59.2,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,59.2,mg/L,11/20/2017 11:30,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3495,33,6,0.055555556,0.010416667,.,.,.,0,0,4,16,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,16,u/ml,11/20/2017 11:30,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3496,33,6,0.055555556,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 11:30,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3497,33,6,0.055555556,0.010416667,.,.,.,0,0,6,2,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,2,u/ml,11/20/2017 11:30,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3498,33,6,0.065972222,0.020833333,.,.,.,0,0,2,6.704414355,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,816,mg/L,11/20/2017 11:45,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3499,33,6,0.065972222,0.020833333,.,.,.,0,0,1,58.9,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,58.9,mg/L,11/20/2017 11:45,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3500,33,6,0.065972222,0.020833333,.,.,.,0,0,4,15,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,15,u/ml,11/20/2017 11:45,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3501,33,6,0.065972222,0.020833333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 11:45,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3502,33,6,0.065972222,0.020833333,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 11:45,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3503,33,6,0.086805556,0.041666667,.,.,.,0,0,2,6.720220155,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,829,mg/L,11/20/2017 12:15,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3504,33,6,0.086805556,0.041666667,.,.,.,0,0,1,59.9,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,59.9,mg/L,11/20/2017 12:15,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3505,33,6,0.086805556,0.041666667,.,.,.,0,0,4,4,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,4,u/ml,11/20/2017 12:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3506,33,6,0.086805556,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 12:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3507,33,6,0.086805556,0.041666667,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 12:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3508,33,6,0.128472222,0.083333333,.,.,.,0,0,2,6.684611728,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,800,mg/L,11/20/2017 13:15,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3509,33,6,0.128472222,0.083333333,.,.,.,0,0,1,56.6,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,56.6,mg/L,11/20/2017 13:15,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3510,33,6,0.128472222,0.083333333,.,.,.,0,0,4,2,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,2,u/ml,11/20/2017 13:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3511,33,6,0.128472222,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 13:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3512,33,6,0.128472222,0.083333333,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 13:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3513,33,6,0.2125,0.166666667,.,.,.,0,0,2,6.673297968,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,791,mg/L,11/20/2017 15:16,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3514,33,6,0.2125,0.166666667,.,.,.,0,0,1,66.6,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.6,mg/L,11/20/2017 15:16,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3515,33,6,0.2125,0.166666667,.,.,.,0,0,4,4,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,4,u/ml,11/20/2017 15:16,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3516,33,6,0.2125,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 15:16,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3517,33,6,0.2125,0.166666667,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 15:16,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3518,33,6,0.378472222,0.333333333,.,.,.,0,0,2,6.562444094,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,708,mg/L,11/20/2017 19:15,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3519,33,6,0.378472222,0.333333333,.,.,.,0,0,1,62.4,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,62.4,mg/L,11/20/2017 19:15,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3520,33,6,0.378472222,0.333333333,.,.,.,0,0,4,21,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,21,u/ml,11/20/2017 19:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3521,33,6,0.378472222,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 19:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3522,33,6,0.378472222,0.333333333,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 19:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3523,33,6,0.545138889,0.5,.,.,.,0,0,2,6.508769137,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,671,mg/L,11/20/2017 23:15,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3524,33,6,0.545138889,0.5,.,.,.,0,0,1,58.7,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,58.7,mg/L,11/20/2017 23:15,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3525,33,6,0.545138889,0.5,.,.,.,0,0,4,12,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,12,u/ml,11/20/2017 23:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3526,33,6,0.545138889,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 23:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3527,33,6,0.545138889,0.5,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 23:15,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3528,33,6,1.047222222,1,.,.,.,0,0,2,6.452048954,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,634,mg/L,11/21/2017 11:18,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3529,33,6,1.047222222,1,.,.,.,0,0,1,68.5,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.5,mg/L,11/21/2017 11:18,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3530,33,6,1.047222222,1,.,.,.,0,0,4,24,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,24,u/ml,11/21/2017 11:18,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3531,33,6,1.047222222,1,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/21/2017 11:18,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3532,33,6,1.047222222,1,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/21/2017 11:18,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3533,33,6,3.031944444,3,.,.,.,0,0,2,6.226536669,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,506,mg/L,11/23/2017 10:56,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3534,33,6,3.031944444,3,.,.,.,0,0,1,75.1,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,75.1,mg/L,11/23/2017 10:56,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3535,33,6,3.031944444,3,.,.,.,0,0,4,19,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,19,u/ml,11/23/2017 10:56,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3536,33,6,3.031944444,3,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/23/2017 10:56,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3537,33,6,3.031944444,3,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,11/23/2017 10:56,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3538,33,6,7.157638889,7,.,.,.,0,0,2,5.991464547,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,400,mg/L,11/27/2017 13:57,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3539,33,6,7.157638889,7,.,.,.,0,0,1,79.8,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,79.8,mg/L,11/27/2017 13:57,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3540,33,6,7.157638889,14,.,.,.,0,0,4,19,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,19,u/ml,11/27/2017 13:57,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3541,33,6,7.157638889,14,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/27/2017 13:57,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3542,33,6,7.157638889,14,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,11/27/2017 13:57,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3543,33,6,14.17638889,14,.,.,.,0,0,2,5.624017506,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,277,mg/L,12/4/2017 14:24,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3544,33,6,14.17638889,14,.,.,.,0,0,1,83.1,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.1,mg/L,12/4/2017 14:24,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3545,33,6,14.17638889,28,.,.,.,0,0,4,18,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,18,u/ml,12/4/2017 14:24,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3546,33,6,14.17638889,28,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,12/4/2017 14:24,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3547,33,6,14.17638889,28,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,12/4/2017 14:24,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3548,33,6,21.17638889,21,.,.,.,0,0,2,5.407171771,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,223,mg/L,12/11/2017 14:24,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3549,33,6,21.17638889,21,.,.,.,0,0,1,86.4,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,86.4,mg/L,12/11/2017 14:24,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3550,33,6,21.17638889,42,.,.,.,0,0,4,28,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,28,u/ml,12/11/2017 14:24,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3551,33,6,21.17638889,42,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,12/11/2017 14:24,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3552,33,6,21.17638889,42,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,12/11/2017 14:24,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3553,33,6,28.15833333,28,.,.,.,0,0,2,5.220355825,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,185,mg/L,12/18/2017 13:58,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3554,33,6,28.15833333,28,.,.,.,0,0,1,88.8,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88.8,mg/L,12/18/2017 13:58,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3555,33,6,28.15833333,56,.,.,.,0,0,4,25,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,25,u/ml,12/18/2017 13:58,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3556,33,6,28.15833333,56,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,12/18/2017 13:58,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3557,33,6,28.15833333,56,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,12/18/2017 13:58,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3558,33,6,44.15416667,42,.,.,.,0,0,2,4.443827036,0,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,85.1,mg/L,1/3/2018 13:52,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3559,33,6,44.15416667,42,.,.,.,0,0,1,89,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,89,mg/L,1/3/2018 13:52,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3560,33,6,44.15416667,84,.,.,.,0,0,4,42,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,42,u/ml,1/3/2018 13:52,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3561,33,6,44.15416667,84,.,.,.,0,0,5,3,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,3,u/ml,1/3/2018 13:52,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3562,33,6,44.15416667,84,.,.,.,0,0,6,8,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,8,u/ml,1/3/2018 13:52,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3563,33,6,56.15138889,56,.,.,.,0,0,2,4.122283931,1,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,61.7,mg/L,1/15/2018 13:48,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3564,33,6,56.15138889,56,.,.,.,0,0,1,80.2,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.2,mg/L,1/15/2018 13:48,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3565,33,6,56.15138889,112,.,.,.,0,0,4,52,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,52,u/ml,1/15/2018 13:48,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3566,33,6,56.15138889,112,.,.,.,0,0,5,27,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,27,u/ml,1/15/2018 13:48,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3567,33,6,56.15138889,112,.,.,.,0,0,6,18,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,18,u/ml,1/15/2018 13:48,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3568,33,6,84.14791667,84,.,.,.,0,0,2,1.95160817,1,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,7.04,mg/L,2/12/2018 13:43,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3569,33,6,84.14791667,84,.,.,.,0,0,1,77,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77,mg/L,2/12/2018 13:43,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3570,33,6,84.14791667,168,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,2/12/2018 13:43,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3571,33,6,84.14791667,168,.,.,.,0,0,5,259,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,259,u/ml,2/12/2018 13:43,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3572,33,6,84.14791667,168,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,2/12/2018 13:43,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3573,33,6,98.13958333,98,.,.,.,0,0,2,1.371180723,1,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.94,mg/L,2/26/2018 13:31,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3574,33,6,98.13958333,98,.,.,.,0,0,1,66.7,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.7,mg/L,2/26/2018 13:31,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3575,33,6,98.13958333,196,.,.,.,0,0,4,91,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,91,u/ml,2/26/2018 13:31,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3576,33,6,98.13958333,196,.,.,.,0,0,5,176,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,176,u/ml,2/26/2018 13:31,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3577,33,6,98.13958333,196,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,2/26/2018 13:31,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3578,33,6,112.1534722,112,.,.,.,0,0,2,0.819779831,1,0.078,2,0,StudyID,001-152,30 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.27,mg/L,3/12/2018 13:51,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3579,33,6,112.1534722,112,.,.,.,0,0,1,77.8,0,0.0078,0,0,StudyID,001-152,30 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.8,mg/L,3/12/2018 13:51,.,.,.,.,.,.,.,.,69.1,.,.,67.9,220
.,.,3580,33,6,112.1534722,224,.,.,.,0,0,4,91,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,91,u/ml,3/12/2018 13:51,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3581,33,6,112.1534722,224,.,.,.,0,0,5,197,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,197,u/ml,3/12/2018 13:51,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
.,.,3582,33,6,112.1534722,224,.,.,.,0,0,6,64,.,.,0,0,StudyID,001-152,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,64,u/ml,3/12/2018 13:51,40,YEARS,F,2,WHITE,1,Not Hispanic or Latino,.,69.1,164,25.7,67.9,220
C,PRE-DOSE,3583,34,6,-41.83055556,0,.,.,.,0,0,1,82.6,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.6,mg/L,10/9/2017 14:34,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
C,PRE-DOSE,3584,34,6,-41.83055556,0,.,.,.,0,0,4,76,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,76,u/ml,10/9/2017 14:34,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
C,PRE-DOSE,3585,34,6,-41.83055556,0,.,.,.,0,0,5,144,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,144,u/ml,10/9/2017 14:34,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
C,PRE-DOSE,3586,34,6,-41.83055556,0,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,10/9/2017 14:34,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
C,PRE-DOSE,3587,34,6,-0.855555556,-1,.,.,.,0,0,1,87.2,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.2,mg/L,11/19/2017 13:58,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
C,PRE-DOSE,3588,34,6,-0.855555556,0,.,.,.,0,0,4,85,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,85,u/ml,11/19/2017 13:58,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
C,PRE-DOSE,3589,34,6,-0.855555556,0,.,.,.,0,0,5,242,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,242,u/ml,11/19/2017 13:58,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
C,PRE-DOSE,3590,34,6,-0.855555556,0,.,.,.,0,0,6,49,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,49,u/ml,11/19/2017 13:58,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
C,PRE-DOSE,3591,34,6,-0.104166667,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/20/2017 8:00,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
C,PRE-DOSE,3592,34,6,-0.104166667,0,.,.,.,0,0,1,91.5,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,91.5,mg/L,11/20/2017 8:00,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
C,PRE-DOSE,3593,34,6,-0.104166667,0,.,.,.,0,0,4,93,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,93,u/ml,11/20/2017 8:00,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
C,PRE-DOSE,3594,34,6,-0.104166667,0,.,.,.,0,0,5,205,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,205,u/ml,11/20/2017 8:00,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
C,PRE-DOSE,3595,34,6,-0.104166667,0,.,.,.,0,0,6,55,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,55,u/ml,11/20/2017 8:00,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3596,34,6,0,.,.,1850,41625,1,2,0,.,.,.,2,1,StudyID,001-153,30 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.044444444,1850,mg,1850,INTRAVENOUS,1511173800,1511177640,Dupilumab,.,.,.,.,,.,.,.,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3597,34,6,0.044444444,0,.,.,.,0,0,2,6.767343125,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,869,mg/L,11/20/2017 11:34,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3598,34,6,0.044444444,0,.,.,.,0,0,1,72.9,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.9,mg/L,11/20/2017 11:34,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3599,34,6,0.044444444,0,.,.,.,0,0,4,2,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,2,u/ml,11/20/2017 11:34,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3600,34,6,0.044444444,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 11:34,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3601,34,6,0.044444444,0,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 11:34,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3602,34,6,0.055555556,0.010416667,.,.,.,0,0,2,6.726233402,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,834,mg/L,11/20/2017 11:50,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3603,34,6,0.055555556,0.010416667,.,.,.,0,0,1,76.2,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.2,mg/L,11/20/2017 11:50,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3604,34,6,0.055555556,0.010416667,.,.,.,0,0,4,10,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,10,u/ml,11/20/2017 11:50,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3605,34,6,0.055555556,0.010416667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 11:50,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3606,34,6,0.055555556,0.010416667,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 11:50,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3607,34,6,0.065972222,0.020833333,.,.,.,0,0,2,6.807934944,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,905,mg/L,11/20/2017 12:05,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3608,34,6,0.065972222,0.020833333,.,.,.,0,0,1,78.5,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.5,mg/L,11/20/2017 12:05,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3609,34,6,0.065972222,0.020833333,.,.,.,0,0,4,96,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,96,u/ml,11/20/2017 12:05,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3610,34,6,0.065972222,0.020833333,.,.,.,0,0,5,230,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,230,u/ml,11/20/2017 12:05,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3611,34,6,0.065972222,0.020833333,.,.,.,0,0,6,57,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,57,u/ml,11/20/2017 12:05,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3612,34,6,0.086805556,0.041666667,.,.,.,0,0,2,6.752270376,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,856,mg/L,11/20/2017 12:35,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3613,34,6,0.086805556,0.041666667,.,.,.,0,0,1,80.3,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.3,mg/L,11/20/2017 12:35,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3614,34,6,0.086805556,0.041666667,.,.,.,0,0,4,34,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,34,u/ml,11/20/2017 12:35,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3615,34,6,0.086805556,0.041666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 12:35,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3616,34,6,0.086805556,0.041666667,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 12:35,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3617,34,6,0.128472222,0.083333333,.,.,.,0,0,2,6.735780014,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,842,mg/L,11/20/2017 13:35,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3618,34,6,0.128472222,0.083333333,.,.,.,0,0,1,77.5,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,77.5,mg/L,11/20/2017 13:35,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3619,34,6,0.128472222,0.083333333,.,.,.,0,0,4,21,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,21,u/ml,11/20/2017 13:35,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3620,34,6,0.128472222,0.083333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 13:35,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3621,34,6,0.128472222,0.083333333,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 13:35,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3622,34,6,0.211805556,0.166666667,.,.,.,0,0,2,6.705639095,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,817,mg/L,11/20/2017 15:35,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3623,34,6,0.211805556,0.166666667,.,.,.,0,0,1,83.1,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,83.1,mg/L,11/20/2017 15:35,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3624,34,6,0.211805556,0.166666667,.,.,.,0,0,4,33,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,33,u/ml,11/20/2017 15:35,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3625,34,6,0.211805556,0.166666667,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 15:35,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3626,34,6,0.211805556,0.166666667,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 15:35,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3627,34,6,0.377777778,0.333333333,.,.,.,0,0,2,6.647688374,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,771,mg/L,11/20/2017 19:34,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3628,34,6,0.377777778,0.333333333,.,.,.,0,0,1,76.4,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,76.4,mg/L,11/20/2017 19:34,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3629,34,6,0.377777778,0.333333333,.,.,.,0,0,4,27,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,27,u/ml,11/20/2017 19:34,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3630,34,6,0.377777778,0.333333333,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 19:34,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3631,34,6,0.377777778,0.333333333,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 19:34,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3632,34,6,0.544444444,0.5,.,.,.,0,0,2,6.555356892,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,703,mg/L,11/20/2017 23:34,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3633,34,6,0.544444444,0.5,.,.,.,0,0,1,73.1,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.1,mg/L,11/20/2017 23:34,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3634,34,6,0.544444444,0.5,.,.,.,0,0,4,20,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,20,u/ml,11/20/2017 23:34,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3635,34,6,0.544444444,0.5,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/20/2017 23:34,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3636,34,6,0.544444444,0.5,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/20/2017 23:34,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3637,34,6,1.045833333,1,.,.,.,0,0,2,6.475432717,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,649,mg/L,11/21/2017 11:36,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3638,34,6,1.045833333,1,.,.,.,0,0,1,88.3,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,88.3,mg/L,11/21/2017 11:36,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3639,34,6,1.045833333,1,.,.,.,0,0,4,3,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,3,u/ml,11/21/2017 11:36,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3640,34,6,1.045833333,1,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/21/2017 11:36,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3641,34,6,1.045833333,1,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/21/2017 11:36,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3642,34,6,3.031944444,3,.,.,.,0,0,2,6.257667588,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,522,mg/L,11/23/2017 11:16,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3643,34,6,3.031944444,3,.,.,.,0,0,1,109,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,109,mg/L,11/23/2017 11:16,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3644,34,6,3.031944444,3,.,.,.,0,0,4,19,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,19,u/ml,11/23/2017 11:16,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3645,34,6,3.031944444,3,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/23/2017 11:16,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3646,34,6,3.031944444,3,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,11/23/2017 11:16,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3647,34,6,7.148611111,7,.,.,.,0,0,2,5.998936562,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,403,mg/L,11/27/2017 14:04,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3648,34,6,7.148611111,7,.,.,.,0,0,1,122,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,122,mg/L,11/27/2017 14:04,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3649,34,6,7.148611111,14,.,.,.,0,0,4,38,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,38,u/ml,11/27/2017 14:04,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3650,34,6,7.148611111,14,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/27/2017 14:04,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3651,34,6,7.148611111,14,.,.,.,0,0,6,3,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,3,u/ml,11/27/2017 14:04,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3652,34,6,14.16041667,14,.,.,.,0,0,2,5.497168225,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,244,mg/L,12/4/2017 14:21,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3653,34,6,14.16041667,14,.,.,.,0,0,1,108,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,108,mg/L,12/4/2017 14:21,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3654,34,6,14.16041667,28,.,.,.,0,0,4,41,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,41,u/ml,12/4/2017 14:21,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3655,34,6,14.16041667,28,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,12/4/2017 14:21,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3656,34,6,14.16041667,28,.,.,.,0,0,6,4,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,4,u/ml,12/4/2017 14:21,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3657,34,6,21.16458333,21,.,.,.,0,0,2,5.308267697,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,202,mg/L,12/11/2017 14:27,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3658,34,6,21.16458333,21,.,.,.,0,0,1,121,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,121,mg/L,12/11/2017 14:27,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3659,34,6,21.16458333,42,.,.,.,0,0,4,43,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,43,u/ml,12/11/2017 14:27,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3660,34,6,21.16458333,42,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,12/11/2017 14:27,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3661,34,6,21.16458333,42,.,.,.,0,0,6,5,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,5,u/ml,12/11/2017 14:27,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3662,34,6,28.15902778,28,.,.,.,0,0,2,4.8978398,0,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,134,mg/L,12/18/2017 14:19,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3663,34,6,28.15902778,28,.,.,.,0,0,1,114,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,114,mg/L,12/18/2017 14:19,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3664,34,6,28.15902778,56,.,.,.,0,0,4,57,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,57,u/ml,12/18/2017 14:19,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3665,34,6,28.15902778,56,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,12/18/2017 14:19,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3666,34,6,28.15902778,56,.,.,.,0,0,6,6,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,6,u/ml,12/18/2017 14:19,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3667,34,6,44.13402778,42,.,.,.,0,0,2,4.079230924,1,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,59.1,mg/L,1/3/2018 13:43,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3668,34,6,44.13402778,42,.,.,.,0,0,1,100,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,100,mg/L,1/3/2018 13:43,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3669,34,6,44.13402778,84,.,.,.,0,0,4,45,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,45,u/ml,1/3/2018 13:43,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3670,34,6,44.13402778,84,.,.,.,0,0,5,10,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,10,u/ml,1/3/2018 13:43,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3671,34,6,44.13402778,84,.,.,.,0,0,6,13,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,13,u/ml,1/3/2018 13:43,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3672,34,6,56.14375,56,.,.,.,0,0,2,3.481240089,1,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,32.5,mg/L,1/15/2018 13:57,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3673,34,6,56.14375,56,.,.,.,0,0,1,92.9,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,92.9,mg/L,1/15/2018 13:57,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3674,34,6,56.14375,112,.,.,.,0,0,4,81,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,81,u/ml,1/15/2018 13:57,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3675,34,6,56.14375,112,.,.,.,0,0,5,109,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,109,u/ml,1/15/2018 13:57,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3676,34,6,56.14375,112,.,.,.,0,0,6,46,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,46,u/ml,1/15/2018 13:57,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3677,34,6,84.14722222,84,.,.,.,0,0,2,1.678963975,1,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,5.36,mg/L,2/12/2018 14:02,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3678,34,6,84.14722222,84,.,.,.,0,0,1,89.3,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,89.3,mg/L,2/12/2018 14:02,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3679,34,6,84.14722222,168,.,.,.,0,0,4,80,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,80,u/ml,2/12/2018 14:02,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3680,34,6,84.14722222,168,.,.,.,0,0,5,244,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,244,u/ml,2/12/2018 14:02,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3681,34,6,84.14722222,168,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,2/12/2018 14:02,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3682,34,6,98.13541667,98,.,.,.,0,0,2,0.966983846,1,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,2.63,mg/L,2/26/2018 13:45,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3683,34,6,98.13541667,98,.,.,.,0,0,1,91.6,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,91.6,mg/L,2/26/2018 13:45,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3684,34,6,98.13541667,196,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,2/26/2018 13:45,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3685,34,6,98.13541667,196,.,.,.,0,0,5,176,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,176,u/ml,2/26/2018 13:45,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3686,34,6,98.13541667,196,.,.,.,0,0,6,53,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,53,u/ml,2/26/2018 13:45,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3687,34,6,112.1465278,112,.,.,.,0,0,2,0.364643114,1,0.078,2,0,StudyID,001-153,30 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.44,mg/L,3/12/2018 14:01,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3688,34,6,112.1465278,112,.,.,.,0,0,1,98.8,0,0.0078,0,0,StudyID,001-153,30 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,98.8,mg/L,3/12/2018 14:01,.,.,.,.,.,.,.,.,62.1,.,.,91.5,205
.,.,3689,34,6,112.1465278,224,.,.,.,0,0,4,101,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,101,u/ml,3/12/2018 14:01,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3690,34,6,112.1465278,224,.,.,.,0,0,5,177,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,177,u/ml,3/12/2018 14:01,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
.,.,3691,34,6,112.1465278,224,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-153,30 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,3/12/2018 14:01,48,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,62.1,172,21,91.5,205
C,PRE-DOSE,3692,35,5,-43.89513889,0,.,.,.,0,0,1,66.3,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.3,mg/L,10/9/2017 14:15,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
C,PRE-DOSE,3693,35,5,-43.89513889,0,.,.,.,0,0,4,97,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,97,u/ml,10/9/2017 14:15,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
C,PRE-DOSE,3694,35,5,-43.89513889,0,.,.,.,0,0,5,143,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,143,u/ml,10/9/2017 14:15,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
C,PRE-DOSE,3695,35,5,-43.89513889,0,.,.,.,0,0,6,69,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,69,u/ml,10/9/2017 14:15,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
C,PRE-DOSE,3696,35,5,-0.922916667,-1,.,.,.,0,0,1,67.7,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.7,mg/L,11/21/2017 13:35,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
C,PRE-DOSE,3697,35,5,-0.922916667,0,.,.,.,0,0,4,114,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,114,u/ml,11/21/2017 13:35,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
C,PRE-DOSE,3698,35,5,-0.922916667,0,.,.,.,0,0,5,0,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,0,u/ml,11/21/2017 13:35,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
C,PRE-DOSE,3699,35,5,-0.922916667,0,.,.,.,0,0,6,81,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,81,u/ml,11/21/2017 13:35,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
C,PRE-DOSE,3700,35,5,-0.177083333,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/22/2017 7:29,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
C,PRE-DOSE,3701,35,5,-0.177083333,0,.,.,.,0,0,1,72.3,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.3,mg/L,11/22/2017 7:29,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
C,PRE-DOSE,3702,35,5,-0.177083333,0,.,.,.,0,0,4,128,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,128,u/ml,11/22/2017 7:29,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
C,PRE-DOSE,3703,35,5,-0.177083333,0,.,.,.,0,0,5,163,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,163,u/ml,11/22/2017 7:29,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
C,PRE-DOSE,3704,35,5,-0.177083333,0,.,.,.,0,0,6,74,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,74,u/ml,11/22/2017 7:29,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3705,35,5,0,.,.,600,.,1,1,0,.,.,.,1,1,StudyID,001-154,600 mg SC,VISIT 4 (DAY 1) BASELINE,1,.,0.000694444,600,mg,600,SUBCUTANEOUS,1511351040,1511351100,Dupilumab,.,.,.,.,,.,.,.,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3706,35,5,0.000694444,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,11/22/2017 11:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3707,35,5,0.000694444,0,.,.,.,0,0,1,71.5,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.5,mg/L,11/22/2017 11:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3708,35,5,0.000694444,0,.,.,.,0,0,4,123,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,123,u/ml,11/22/2017 11:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3709,35,5,0.000694444,0,.,.,.,0,0,5,163,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,163,u/ml,11/22/2017 11:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3710,35,5,0.000694444,0,.,.,.,0,0,6,72,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,72,u/ml,11/22/2017 11:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3711,35,5,0.011111111,0.010416667,.,.,.,0,0,2,-2.162823151,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.115,mg/L,11/22/2017 12:00,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3712,35,5,0.011111111,0.010416667,.,.,.,0,0,1,68.5,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.5,mg/L,11/22/2017 12:00,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3713,35,5,0.011111111,0.010416667,.,.,.,0,0,4,109,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,109,u/ml,11/22/2017 12:00,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3714,35,5,0.011111111,0.010416667,.,.,.,0,0,5,159,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,159,u/ml,11/22/2017 12:00,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3715,35,5,0.011111111,0.010416667,.,.,.,0,0,6,76,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,76,u/ml,11/22/2017 12:00,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3716,35,5,0.021527778,0.020833333,.,.,.,0,0,2,-2.009915479,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.134,mg/L,11/22/2017 12:15,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3717,35,5,0.021527778,0.020833333,.,.,.,0,0,1,65.5,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.5,mg/L,11/22/2017 12:15,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3718,35,5,0.021527778,0.020833333,.,.,.,0,0,4,106,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,106,u/ml,11/22/2017 12:15,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3719,35,5,0.021527778,0.020833333,.,.,.,0,0,5,200,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,200,u/ml,11/22/2017 12:15,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3720,35,5,0.021527778,0.020833333,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,11/22/2017 12:15,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3721,35,5,0.042361111,0.041666667,.,.,.,0,0,2,-1.760260802,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.172,mg/L,11/22/2017 12:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3722,35,5,0.042361111,0.041666667,.,.,.,0,0,1,65.5,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.5,mg/L,11/22/2017 12:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3723,35,5,0.042361111,0.041666667,.,.,.,0,0,4,110,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,110,u/ml,11/22/2017 12:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3724,35,5,0.042361111,0.041666667,.,.,.,0,0,5,141,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,141,u/ml,11/22/2017 12:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3725,35,5,0.042361111,0.041666667,.,.,.,0,0,6,71,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,71,u/ml,11/22/2017 12:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3726,35,5,0.084027778,0.083333333,.,.,.,0,0,2,-0.114289146,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.892,mg/L,11/22/2017 13:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3727,35,5,0.084027778,0.083333333,.,.,.,0,0,1,68.3,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.3,mg/L,11/22/2017 13:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3728,35,5,0.084027778,0.083333333,.,.,.,0,0,4,97,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,97,u/ml,11/22/2017 13:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3729,35,5,0.084027778,0.083333333,.,.,.,0,0,5,128,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,128,u/ml,11/22/2017 13:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3730,35,5,0.084027778,0.083333333,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,11/22/2017 13:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3731,35,5,0.167361111,0.166666667,.,.,.,0,0,2,1.184789985,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.27,mg/L,11/22/2017 15:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3732,35,5,0.167361111,0.166666667,.,.,.,0,0,1,65.1,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.1,mg/L,11/22/2017 15:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3733,35,5,0.167361111,0.166666667,.,.,.,0,0,4,99,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,99,u/ml,11/22/2017 15:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3734,35,5,0.167361111,0.166666667,.,.,.,0,0,5,129,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,129,u/ml,11/22/2017 15:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3735,35,5,0.167361111,0.166666667,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,11/22/2017 15:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3736,35,5,0.334027778,0.333333333,.,.,.,0,0,2,2.199444334,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,9.02,mg/L,11/22/2017 19:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3737,35,5,0.334027778,0.333333333,.,.,.,0,0,1,60.4,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,60.4,mg/L,11/22/2017 19:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3738,35,5,0.334027778,0.333333333,.,.,.,0,0,4,97,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,97,u/ml,11/22/2017 19:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3739,35,5,0.334027778,0.333333333,.,.,.,0,0,5,93,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,93,u/ml,11/22/2017 19:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3740,35,5,0.334027778,0.333333333,.,.,.,0,0,6,54,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,54,u/ml,11/22/2017 19:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3741,35,5,0.500694444,0.5,.,.,.,0,0,2,2.714694744,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,15.1,mg/L,11/22/2017 23:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3742,35,5,0.500694444,0.5,.,.,.,0,0,1,58.4,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,58.4,mg/L,11/22/2017 23:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3743,35,5,0.500694444,0.5,.,.,.,0,0,4,101,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,101,u/ml,11/22/2017 23:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3744,35,5,0.500694444,0.5,.,.,.,0,0,5,132,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,132,u/ml,11/22/2017 23:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3745,35,5,0.500694444,0.5,.,.,.,0,0,6,47,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,47,u/ml,11/22/2017 23:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3746,35,5,1.000694444,1,.,.,.,0,0,2,3.284663565,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,26.7,mg/L,11/23/2017 11:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3747,35,5,1.000694444,1,.,.,.,0,0,1,59.8,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,59.8,mg/L,11/23/2017 11:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3748,35,5,1.000694444,1,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,11/23/2017 11:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3749,35,5,1.000694444,1,.,.,.,0,0,5,54,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,54,u/ml,11/23/2017 11:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3750,35,5,1.000694444,1,.,.,.,0,0,6,48,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,48,u/ml,11/23/2017 11:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3751,35,5,2.9875,3,.,.,.,0,0,2,4.032469159,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,56.4,mg/L,11/25/2017 11:26,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3752,35,5,2.9875,3,.,.,.,0,0,1,64.3,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.3,mg/L,11/25/2017 11:26,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3753,35,5,2.9875,3,.,.,.,0,0,4,66,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,66,u/ml,11/25/2017 11:26,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3754,35,5,2.9875,3,.,.,.,0,0,5,9,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,9,u/ml,11/25/2017 11:26,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3755,35,5,2.9875,3,.,.,.,0,0,6,20,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,20,u/ml,11/25/2017 11:26,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3756,35,5,7.0875,7,.,.,.,0,0,2,4.062165664,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,58.1,mg/L,11/29/2017 13:50,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3757,35,5,7.0875,7,.,.,.,0,0,1,70.3,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.3,mg/L,11/29/2017 13:50,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3758,35,5,7.0875,14,.,.,.,0,0,4,68,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,68,u/ml,11/29/2017 13:50,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3759,35,5,7.0875,14,.,.,.,0,0,5,6,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,6,u/ml,11/29/2017 13:50,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3760,35,5,7.0875,14,.,.,.,0,0,6,20,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,20,u/ml,11/29/2017 13:50,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3761,35,5,14.075,14,.,.,.,0,0,2,3.650658241,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,38.5,mg/L,12/6/2017 13:32,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3762,35,5,14.075,14,.,.,.,0,0,1,73.3,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.3,mg/L,12/6/2017 13:32,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3763,35,5,14.075,28,.,.,.,0,0,4,73,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,73,u/ml,12/6/2017 13:32,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3764,35,5,14.075,28,.,.,.,0,0,5,25,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,25,u/ml,12/6/2017 13:32,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3765,35,5,14.075,28,.,.,.,0,0,6,32,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,32,u/ml,12/6/2017 13:32,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3766,35,5,21.08055556,21,.,.,.,0,0,2,3.234749174,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,25.4,mg/L,12/13/2017 13:40,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3767,35,5,21.08055556,21,.,.,.,0,0,1,80.8,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,80.8,mg/L,12/13/2017 13:40,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3768,35,5,21.08055556,42,.,.,.,0,0,4,118,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,118,u/ml,12/13/2017 13:40,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3769,35,5,21.08055556,42,.,.,.,0,0,5,119,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,119,u/ml,12/13/2017 13:40,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3770,35,5,21.08055556,42,.,.,.,0,0,6,70,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,70,u/ml,12/13/2017 13:40,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3771,35,5,28.09930556,28,.,.,.,0,0,2,2.509599262,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,12.3,mg/L,12/20/2017 14:07,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3772,35,5,28.09930556,28,.,.,.,0,0,1,73.6,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.6,mg/L,12/20/2017 14:07,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3773,35,5,28.09930556,56,.,.,.,0,0,4,107,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,107,u/ml,12/20/2017 14:07,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3774,35,5,28.09930556,56,.,.,.,0,0,5,141,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,141,u/ml,12/20/2017 14:07,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3775,35,5,28.09930556,56,.,.,.,0,0,6,60,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,60,u/ml,12/20/2017 14:07,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3776,35,5,42.07430556,42,.,.,.,0,0,2,1.269760545,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,3.56,mg/L,1/3/2018 13:31,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3777,35,5,42.07430556,42,.,.,.,0,0,1,87.5,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.5,mg/L,1/3/2018 13:31,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3778,35,5,42.07430556,84,.,.,.,0,0,4,100,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,100,u/ml,1/3/2018 13:31,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3779,35,5,42.07430556,84,.,.,.,0,0,5,166,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,166,u/ml,1/3/2018 13:31,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3780,35,5,42.07430556,84,.,.,.,0,0,6,58,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,58,u/ml,1/3/2018 13:31,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3781,35,5,56.08402778,56,.,.,.,0,0,2,0.3074847,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.36,mg/L,1/17/2018 13:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3782,35,5,56.08402778,56,.,.,.,0,0,1,92.5,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,92.5,mg/L,1/17/2018 13:45,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3783,35,5,56.08402778,112,.,.,.,0,0,4,103,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,103,u/ml,1/17/2018 13:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3784,35,5,56.08402778,112,.,.,.,0,0,5,184,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,184,u/ml,1/17/2018 13:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3785,35,5,56.08402778,112,.,.,.,0,0,6,74,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,74,u/ml,1/17/2018 13:45,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3786,35,5,84.09375,84,.,.,.,0,0,2,-1.15518264,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.315,mg/L,2/14/2018 13:59,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3787,35,5,84.09375,84,.,.,.,0,0,1,55.6,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,55.6,mg/L,2/14/2018 13:59,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3788,35,5,84.09375,168,.,.,.,0,0,4,88,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,88,u/ml,2/14/2018 13:59,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3789,35,5,84.09375,168,.,.,.,0,0,5,199,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,199,u/ml,2/14/2018 13:59,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3790,35,5,84.09375,168,.,.,.,0,0,6,64,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,64,u/ml,2/14/2018 13:59,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3791,35,5,98.07708333,98,.,.,.,0,0,2,-1.737271284,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.176,mg/L,2/28/2018 13:35,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3792,35,5,98.07708333,98,.,.,.,0,0,1,64.5,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,64.5,mg/L,2/28/2018 13:35,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3793,35,5,98.07708333,196,.,.,.,0,0,4,105,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,105,u/ml,2/28/2018 13:35,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3794,35,5,98.07708333,196,.,.,.,0,0,5,178,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,178,u/ml,2/28/2018 13:35,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3795,35,5,98.07708333,196,.,.,.,0,0,6,66,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,66,u/ml,2/28/2018 13:35,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3796,35,5,112.1055556,112,.,.,.,0,0,2,-2.137070655,1,0.078,2,0,StudyID,001-154,600 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.118,mg/L,3/14/2018 14:16,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3797,35,5,112.1055556,112,.,.,.,0,0,1,71.1,0,0.0078,0,0,StudyID,001-154,600 mg SC,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,71.1,mg/L,3/14/2018 14:16,.,.,.,.,.,.,.,.,92.7,.,.,72.3,163
.,.,3798,35,5,112.1055556,224,.,.,.,0,0,4,94,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,94,u/ml,3/14/2018 14:16,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3799,35,5,112.1055556,224,.,.,.,0,0,5,128,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,128,u/ml,3/14/2018 14:16,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
.,.,3800,35,5,112.1055556,224,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-154,600 mg SC,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,3/14/2018 14:16,35,YEARS,M,1,WHITE,1,Not Hispanic or Latino,.,92.7,182,28,72.3,163
C,PRE-DOSE,3801,36,2,-4.020833333,0,.,.,.,0,0,1,78.4,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 1,1,SCR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,78.4,mg/L,12/11/2017 10:10,.,.,.,.,.,.,.,.,74,.,.,72.6,179
C,PRE-DOSE,3802,36,2,-4.020833333,0,.,.,.,0,0,4,123,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,123,u/ml,12/11/2017 10:10,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
C,PRE-DOSE,3803,36,2,-4.020833333,0,.,.,.,0,0,5,197,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,197,u/ml,12/11/2017 10:10,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
C,PRE-DOSE,3804,36,2,-4.020833333,0,.,.,.,0,0,6,73,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 1,1,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,73,u/ml,12/11/2017 10:10,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
C,PRE-DOSE,3805,36,2,-0.872222222,-1,.,.,.,0,0,1,73.9,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 3,3,DAY -1,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.9,mg/L,12/14/2017 13:44,.,.,.,.,.,.,.,.,74,.,.,72.6,179
C,PRE-DOSE,3806,36,2,-0.872222222,0,.,.,.,0,0,4,124,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,124,u/ml,12/14/2017 13:44,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
C,PRE-DOSE,3807,36,2,-0.872222222,0,.,.,.,0,0,5,198,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,198,u/ml,12/14/2017 13:44,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
C,PRE-DOSE,3808,36,2,-0.872222222,0,.,.,.,0,0,6,67,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 3,3,.,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,67,u/ml,12/14/2017 13:44,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
C,PRE-DOSE,3809,36,2,-0.127777778,0,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,12/15/2017 7:36,.,.,.,.,.,.,.,.,74,.,.,72.6,179
C,PRE-DOSE,3810,36,2,-0.127777778,0,.,.,.,0,0,1,72.6,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 PRE,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.6,mg/L,12/15/2017 7:36,.,.,.,.,.,.,.,.,74,.,.,72.6,179
C,PRE-DOSE,3811,36,2,-0.127777778,0,.,.,.,0,0,4,117,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,117,u/ml,12/15/2017 7:36,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
C,PRE-DOSE,3812,36,2,-0.127777778,0,.,.,.,0,0,5,179,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,179,u/ml,12/15/2017 7:36,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
C,PRE-DOSE,3813,36,2,-0.127777778,0,.,.,.,0,0,6,65,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,BASELINE,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,65,u/ml,12/15/2017 7:36,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3814,36,2,0,.,.,220,4658.823529,1,2,0,.,.,.,2,1,StudyID,001-158,3 mg/kg IV,VISIT 4 (DAY 1) BASELINE,1,.,0.047222222,220,mg,220,INTRAVENOUS,1513334400,1513338480,Dupilumab,.,.,.,.,,.,.,.,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3815,36,2,0.047222222,0,.,.,.,0,0,2,4.33073334,1,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,76,mg/L,12/15/2017 11:48,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3816,36,2,0.047222222,0,.,.,.,0,0,1,65.9,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 0HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,65.9,mg/L,12/15/2017 11:48,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3817,36,2,0.047222222,0,.,.,.,0,0,4,74,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,74,u/ml,12/15/2017 11:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3818,36,2,0.047222222,0,.,.,.,0,0,5,5,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,5,u/ml,12/15/2017 11:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3819,36,2,0.047222222,0,.,.,.,0,0,6,10,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 EOI,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,10,u/ml,12/15/2017 11:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3820,36,2,0.057638889,0.010416667,.,.,.,0,0,2,4.352855257,1,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,77.7,mg/L,12/15/2017 12:03,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3821,36,2,0.057638889,0.010416667,.,.,.,0,0,1,67,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67,mg/L,12/15/2017 12:03,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3822,36,2,0.057638889,0.010416667,.,.,.,0,0,4,76,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,76,u/ml,12/15/2017 12:03,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3823,36,2,0.057638889,0.010416667,.,.,.,0,0,5,1,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,1,u/ml,12/15/2017 12:03,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3824,36,2,0.057638889,0.010416667,.,.,.,0,0,6,10,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 15MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,10,u/ml,12/15/2017 12:03,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3825,36,2,0.068055556,0.020833333,.,.,.,0,0,2,4.360547603,0,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,78.3,mg/L,12/15/2017 12:18,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3826,36,2,0.068055556,0.020833333,.,.,.,0,0,1,63.3,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,63.3,mg/L,12/15/2017 12:18,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3827,36,2,0.068055556,0.020833333,.,.,.,0,0,4,69,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,69,u/ml,12/15/2017 12:18,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3828,36,2,0.068055556,0.020833333,.,.,.,0,0,5,4,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,4,u/ml,12/15/2017 12:18,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3829,36,2,0.068055556,0.020833333,.,.,.,0,0,6,11,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 30MIN,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,11,u/ml,12/15/2017 12:18,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3830,36,2,0.088888889,0.041666667,.,.,.,0,0,2,4.359269648,0,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,78.2,mg/L,12/15/2017 12:48,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3831,36,2,0.088888889,0.041666667,.,.,.,0,0,1,74.2,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.2,mg/L,12/15/2017 12:48,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3832,36,2,0.088888889,0.041666667,.,.,.,0,0,4,77,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,77,u/ml,12/15/2017 12:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3833,36,2,0.088888889,0.041666667,.,.,.,0,0,5,4,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,4,u/ml,12/15/2017 12:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3834,36,2,0.088888889,0.041666667,.,.,.,0,0,6,11,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 1HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,11,u/ml,12/15/2017 12:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3835,36,2,0.130555556,0.083333333,.,.,.,0,0,2,4.374498368,0,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,79.4,mg/L,12/15/2017 13:48,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3836,36,2,0.130555556,0.083333333,.,.,.,0,0,1,70.6,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,70.6,mg/L,12/15/2017 13:48,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3837,36,2,0.130555556,0.083333333,.,.,.,0,0,4,80,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,80,u/ml,12/15/2017 13:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3838,36,2,0.130555556,0.083333333,.,.,.,0,0,5,2,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,2,u/ml,12/15/2017 13:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3839,36,2,0.130555556,0.083333333,.,.,.,0,0,6,11,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 2HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,11,u/ml,12/15/2017 13:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3840,36,2,0.213888889,0.166666667,.,.,.,0,0,2,4.385769621,0,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,80.3,mg/L,12/15/2017 15:48,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3841,36,2,0.213888889,0.166666667,.,.,.,0,0,1,68.8,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,68.8,mg/L,12/15/2017 15:48,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3842,36,2,0.213888889,0.166666667,.,.,.,0,0,4,74,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,74,u/ml,12/15/2017 15:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3843,36,2,0.213888889,0.166666667,.,.,.,0,0,5,5,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,5,u/ml,12/15/2017 15:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3844,36,2,0.213888889,0.166666667,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 4HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,12/15/2017 15:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3845,36,2,0.382638889,0.333333333,.,.,.,0,0,2,4.209160237,1,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,67.3,mg/L,12/15/2017 19:51,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3846,36,2,0.382638889,0.333333333,.,.,.,0,0,1,67.8,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.8,mg/L,12/15/2017 19:51,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3847,36,2,0.382638889,0.333333333,.,.,.,0,0,4,75,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,75,u/ml,12/15/2017 19:51,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3848,36,2,0.382638889,0.333333333,.,.,.,0,0,5,3,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,3,u/ml,12/15/2017 19:51,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3849,36,2,0.382638889,0.333333333,.,.,.,0,0,6,12,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 8HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,12,u/ml,12/15/2017 19:51,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3850,36,2,0.547222222,0.5,.,.,.,0,0,2,4.197201948,1,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,66.5,mg/L,12/15/2017 23:48,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3851,36,2,0.547222222,0.5,.,.,.,0,0,1,73.3,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,73.3,mg/L,12/15/2017 23:48,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3852,36,2,0.547222222,0.5,.,.,.,0,0,4,67,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,67,u/ml,12/15/2017 23:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3853,36,2,0.547222222,0.5,.,.,.,0,0,5,8,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,8,u/ml,12/15/2017 23:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3854,36,2,0.547222222,0.5,.,.,.,0,0,6,14,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 4,4,DAY 1 12HR,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,14,u/ml,12/15/2017 23:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3855,36,2,1.047222222,1,.,.,.,0,0,2,4.075841091,1,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,58.9,mg/L,12/16/2017 11:48,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3856,36,2,1.047222222,1,.,.,.,0,0,1,69,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69,mg/L,12/16/2017 11:48,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3857,36,2,1.047222222,1,.,.,.,0,0,4,78,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,78,u/ml,12/16/2017 11:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3858,36,2,1.047222222,1,.,.,.,0,0,5,12,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,12,u/ml,12/16/2017 11:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3859,36,2,1.047222222,1,.,.,.,0,0,6,16,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 5,5,DAY 2,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,16,u/ml,12/16/2017 11:48,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3860,36,2,3.047916667,3,.,.,.,0,0,2,3.725693427,1,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,41.5,mg/L,12/18/2017 11:49,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3861,36,2,3.047916667,3,.,.,.,0,0,1,82.7,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,82.7,mg/L,12/18/2017 11:49,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3862,36,2,3.047916667,3,.,.,.,0,0,4,111,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,111,u/ml,12/18/2017 11:49,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3863,36,2,3.047916667,3,.,.,.,0,0,5,51,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,51,u/ml,12/18/2017 11:49,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3864,36,2,3.047916667,3,.,.,.,0,0,6,37,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 6,6,DAY 4,.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,37,u/ml,12/18/2017 11:49,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3865,36,2,7.027777778,7,.,.,.,0,0,2,3.417726684,1,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,30.5,mg/L,12/22/2017 11:20,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3866,36,2,7.027777778,7,.,.,.,0,0,1,94.8,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 7,7,DAY 8,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,94.8,mg/L,12/22/2017 11:20,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3867,36,2,7.027777778,14,.,.,.,0,0,4,127,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,127,u/ml,12/22/2017 11:20,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3868,36,2,7.027777778,14,.,.,.,0,0,5,171,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,171,u/ml,12/22/2017 11:20,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3869,36,2,7.027777778,14,.,.,.,0,0,6,56,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 7,7,WEEK 1 (DAY 8),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,56,u/ml,12/22/2017 11:20,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3870,36,2,13.16041667,14,.,.,.,0,0,2,3.117949906,1,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,22.6,mg/L,12/28/2017 14:31,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3871,36,2,13.16041667,14,.,.,.,0,0,1,74.7,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 8,8,DAY 15,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,74.7,mg/L,12/28/2017 14:31,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3872,36,2,13.16041667,28,.,.,.,0,0,4,124,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,124,u/ml,12/28/2017 14:31,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3873,36,2,13.16041667,28,.,.,.,0,0,5,189,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,189,u/ml,12/28/2017 14:31,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3874,36,2,13.16041667,28,.,.,.,0,0,6,61,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 8,8,WEEK 2 (DAY 15),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,61,u/ml,12/28/2017 14:31,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3875,36,2,21.13680556,21,.,.,.,0,0,2,1.857859271,1,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,6.41,mg/L,1/5/2018 13:57,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3876,36,2,21.13680556,21,.,.,.,0,0,1,67.5,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 9,9,DAY 22,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,67.5,mg/L,1/5/2018 13:57,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3877,36,2,21.13680556,42,.,.,.,0,0,4,113,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,113,u/ml,1/5/2018 13:57,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3878,36,2,21.13680556,42,.,.,.,0,0,5,203,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,203,u/ml,1/5/2018 13:57,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3879,36,2,21.13680556,42,.,.,.,0,0,6,69,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 9,9,WEEK 3 (DAY 22),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,69,u/ml,1/5/2018 13:57,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3880,36,2,28.12430556,28,.,.,.,0,0,2,1.742219024,1,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,5.71,mg/L,1/12/2018 13:39,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3881,36,2,28.12430556,28,.,.,.,0,0,1,81.6,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 10,10,DAY 29,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.6,mg/L,1/12/2018 13:39,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3882,36,2,28.12430556,56,.,.,.,0,0,4,108,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,108,u/ml,1/12/2018 13:39,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3883,36,2,28.12430556,56,.,.,.,0,0,5,202,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,202,u/ml,1/12/2018 13:39,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3884,36,2,28.12430556,56,.,.,.,0,0,6,68,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 10,10,WEEK 4 (DAY 29),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,68,u/ml,1/12/2018 13:39,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3885,36,2,42.10625,42,.,.,.,0,0,2,0.009950331,1,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,1.01,mg/L,1/26/2018 13:13,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3886,36,2,42.10625,42,.,.,.,0,0,1,69,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 11,11,DAY 43,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,69,mg/L,1/26/2018 13:13,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3887,36,2,42.10625,84,.,.,.,0,0,4,113,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,113,u/ml,1/26/2018 13:13,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3888,36,2,42.10625,84,.,.,.,0,0,5,246,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,246,u/ml,1/26/2018 13:13,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3889,36,2,42.10625,84,.,.,.,0,0,6,86,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 11,11,WEEK 6 (DAY 43),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,86,u/ml,1/26/2018 13:13,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3890,36,2,56.1125,56,.,.,.,0,0,2,-1.46967597,1,0.078,2,0,StudyID,001-158,3 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0.23,mg/L,2/9/2018 13:22,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3891,36,2,56.1125,56,.,.,.,0,0,1,66.9,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 12,12,DAY 57,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,66.9,mg/L,2/9/2018 13:22,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3892,36,2,56.1125,112,.,.,.,0,0,4,114,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,114,u/ml,2/9/2018 13:22,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3893,36,2,56.1125,112,.,.,.,0,0,5,275,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,275,u/ml,2/9/2018 13:22,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3894,36,2,56.1125,112,.,.,.,0,0,6,82,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 12,12,WEEK 8 (DAY 57),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,82,u/ml,2/9/2018 13:22,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3895,36,2,84.11875,84,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-158,3 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,3/9/2018 13:31,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3896,36,2,84.11875,84,.,.,.,0,0,1,72.9,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 13,13,DAY 85,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,72.9,mg/L,3/9/2018 13:31,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3897,36,2,84.11875,168,.,.,.,0,0,4,137,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,137,u/ml,3/9/2018 13:31,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3898,36,2,84.11875,168,.,.,.,0,0,5,195,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,195,u/ml,3/9/2018 13:31,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3899,36,2,84.11875,168,.,.,.,0,0,6,77,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 13,13,WEEK 12 (DAY 85),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,77,u/ml,3/9/2018 13:31,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3900,36,2,98.1125,98,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-158,3 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,3/23/2018 13:22,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3901,36,2,98.1125,98,.,.,.,0,0,1,81.4,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 14,14,DAY 99,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,81.4,mg/L,3/23/2018 13:22,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3902,36,2,98.1125,196,.,.,.,0,0,4,128,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,128,u/ml,3/23/2018 13:22,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3903,36,2,98.1125,196,.,.,.,0,0,5,231,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,231,u/ml,3/23/2018 13:22,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3904,36,2,98.1125,196,.,.,.,0,0,6,77,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 14,14,WEEK 14 (DAY 99),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,77,u/ml,3/23/2018 13:22,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3905,36,2,109.0611111,112,.,.,.,0,0,2,.,1,0.078,2,1,StudyID,001-158,3 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,total dupilumab,total dupilumab,Concentration of Total Dupilumab,PK,,0,.,4/3/2018 12:08,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3906,36,2,109.0611111,112,.,.,.,0,0,1,87.2,0,0.0078,0,0,StudyID,001-158,3 mg/kg IV,VISIT 15,15,DAY 113,.,.,.,.,.,.,.,Dupilumab,IL-13,IL-13,Concentration of Total IL-13,TARGET,,87.2,mg/L,4/3/2018 12:08,.,.,.,.,.,.,.,.,74,.,.,72.6,179
.,.,3907,36,2,109.0611111,224,.,.,.,0,0,4,130,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,NRS,NRS,NRS Score,RESP3,,130,u/ml,4/3/2018 12:08,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3908,36,2,109.0611111,224,.,.,.,0,0,5,205,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,EASI,EASI,EASI Score,RESP1,,205,u/ml,4/3/2018 12:08,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
.,.,3909,36,2,109.0611111,224,.,.,.,0,0,6,63,.,.,0,0,StudyID,001-158,3 mg/kg IV,VISIT 15,15,WEEK 16 (DAY 113),.,.,.,.,.,.,.,Dupilumab,IGA,IGA,IGA Score,RESP2,,63,u/ml,4/3/2018 12:08,42,YEARS,M,1,AMERICAN INDIAN OR ALASKA NATIVE,4,Hispanic or Latino,.,74,169,25.9,72.6,179
